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Thesis structure 
 
 
This thesis is divided into eight chapters. The introduction comprises chapters 1-5, and 
while somewhat detailed, represents work submitted as a current peer review on the 
functional analysis of the von Hippel-Lindau tumour suppressor and its role in 
tumourigenesis. It summarises the current worldwide literature concerning VHL biology. 
 
Chapter 1 details VHL disease with respect to tumour formation, diagnosis and 
clinical management. Each lesion is described. This chapter, while lacking in its 
molecular biological content, was deemed important as it demonstrates the disease that 
stems from VHL inactivation. This is the ultimate reason why familial cancer syndromes 
like VHL disease are studied - so as to obtain insights into how they function and the 
consequence of their deregulation that may result in a pathological outcome. Chapter 2 
describes the molecular aspects of the VHL gene, and its gene product. It summarises 
work related to the biochemical structure of the VCB complex, and discusses what can 
be learned from evolutionary conservation of the VHL locus. Chapter 3 details current 
concepts of VHL mutational analysis with an emphasis on the role of VHL in sporadic 
tumours of the same tissue origin as those seen in VHL disease. Chapter 4 discusses 
the role of pVHL as a component of an E3 ligase, and the consequence of Hif-α 
regulation. It also highlights other pVHL-protein interactions that are believed to be 
additional ligase substrates, or which represent novel functions of pVHL. Finally, chapter 
5 discusses the role of pVHL in tumour formation and tumour progression. It describes 
current in vivo tumour models in which VHL function can be studied, and documents the 
evidence available for the involvement of pVHL in tumour growth, invasion and 
metastasis. 
 
Chapter 7 represents the results of work undertaken as partial fulfilment of this 
doctoral study. It is divided into three parts. Part I describes the results obtained from a 
novel proteomics approach that was developed in an attempt to identify new pVHL 
interactions. Part II outlines work contributed to an article published in Nature Cell 
Biology corresponding to pVHL intracellular localisation and dynamics. Finally part III 
describes work pertaining to the targeting of endogenous pVHL by RNA interference. 
 
Chapter 8 discusses the observations and findings related to chapters 1 through 7. It is 
divided into two main parts. The first is the peer review currently in press, which 
represents a summary and critical discussion of work outlined in chapters 1-5. The 
second part of the discussion is a brief discussion of the work documented in chapter 7. 
Particular emphasis is given to future perspectives intended to develop those results 
obtained from the proteomics approach. 
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ABSTRACT 
 
 
Complex genotype-phenotype relations are a hallmark of VHL disease. Patients develop 
a wide range of tumours depending on how and where pVHL malfunctions. Thus it 
appears that the VHL tumour suppressor gene product must have multiple and tissue 
specific functions. 
  
 pVHL interacts with the proteins Elongin C, Elongin B, and Cullin 2 in a complex 
referred to as the VCB-Cul2 complex. This complex displays structural analogy to the 
Skp1-Cdc53/Cul1-F-box protein (SCF) complex. As with its SCF counterparts, the VCB-
Cul2 complex has been shown to constitute an E3 ligase, which serves to recruit protein 
substrates for degradation by the 26S proteasome. To date, only one such target has 
been firmly established, the transcription factor Hif-α (hypoxia inducible factor). 
Proteolytic degradation of Hif-α reflects a key cellular mechanism in the control of 
adaptive gene expression in response to changes in oxygen levels. While identification of 
Hif-α as a substrate for the VCB-Cul2 complex proves to be a crucial milestone in VHL 
biology, isolation of other proteins that are targeted for ubiquitination by VHL represent a 
major challenge. 
  
 A proteomics approach was developed in an effort to expose unknown pVHL 
protein interactions, and thereby highlighting novel functions of the VHL tumour 
suppressor. One candidate protein is a 97-kDa ATPase called p97. p97 is a member of 
the AAA family of ATPase’s and is involved in a myriad of distinct cellular functions, 
interestingly among which include binding to poly-ubiquitin chains and facilitating 
substrate presentation to the proteasome. We show that p97 binds pVHL both in vitro 
and in vivo, and propose a model whereby p97 may facilitate presentation of 
ubiquitinated Hif-α to the 26S proteasome for subsequent degradation. We also 
demonstrate that, similar to pVHL, p97 can promote microtubule stability, and propose a 
model through binding to HDAC6, a histone deacetylase known to bind p97 and shown 
here to bind pVHL in vitro, that these proteins might be involved in the malfolded protein 
response, and that this potential function could be microtubule dependent. 
 
 
 The proteomics approach also uncovered additional protein interactions, namely 
two uncharacterised proteins with homologues in S.Cerevisiae known to complex and 
constitute a critical RNA methyltransferase. We suggest that this co-precipitating 
complex is the mammalian orthologue and we provide preliminary data showing, in 
addition to the endogenous interaction, in vitro binding to pVHL. Finally we propose a 
model where, by means of its ability to negatively regulate the activity of this complex, 
  11
pVHL could be involved in the mammalian stress-responsive pathway, thereby helping to 
explain, in part, the observation that the inability of renal cell carcinoma cells lacking VHL 
to exit the cell cycle upon serum withdrawal can be restored upon reintroduction of pVHL 
into these cells.  
 
 In a second part to this thesis, pVHL intracellular dynamics have been studied. We 
demonstrate that pVHl19 and pVHL30 exhibit different localisation patterns, with pVHL30 
residing primarily in the cytoplasm, and pVHl19 in the nucleus. We show that when 
pVHL30 is in the cytoplasm, it co-localises with microtubules, and that this localisation is 
altered upon microtubule destabilisation, which renders a strong nuclear signal for 
pVHL30. We conclude that pVHL intracellular dynamics are reflective, in part, by the 
stability of the microtubule network. This work contributed to an article in Nature Cell 
Biology. 
 
 The third part of the results outlines the targeting of endogenous pVHL by RNA 
interference. Optimal conditions for VHL RNAi and a study on the cellular affects are 
presented. Hif-α regulation is investigated in the presence of VHL siRNA oligos, and the 
lack of Hif-α up-regulation discussed. Finally, positive regulation of phospho-cofilin, an 
important component in actin ctyoskeleton rearrangements, is demonstrated as the only 
positive read-out for VHL RNAi to date, and the implications this regulation by pVHL 
might have an cell shape changes and movement is briefly discussed. 
Chapter 1 – VHL Disease 
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CHAPTER 1 
VHL Disease 
 
1.1 Background and clinical features of VHL disease 
 
Von Hippel-Lindau disease is an autosomal dominantly inherited, multi-system, family 
cancer syndrome predisposing individuals to a defined pattern of tumours. It has been 
estimated that the birth incidence of VHL disease is between 1 in 36,000 - 45,500 live 
births [10]. The tumours are of specific histological types: retinal, cerebellar, and spinal 
haemangioblastomas, clear-cell type (non-papillary) renal cell carcinoma (RCC), 
phaeochromocytoma, pancreatic islet tumours and endolymphatic sac tumours of the 
inner ear. In addition, multiple renal, pancreatic, epididymal and broad ligament cysts 
occur. In this chapter a concise overview will be outlined defining each malignancy 
associated with VHL disease, their means of detection and available treatment. While 
this chapter does not contain molecular detail, it was considered important in order to 
gain a comprehensive understanding of VHL biology, and represents the justification for 
studying this disease, and for studying familial cancer syndromes in general. 
 
Figure 1. Location of principal neoplasma associated with von Hippel-Lindau disease. 
Chapter 1 – VHL Disease 
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Von Hippel-Lindau (VHL) disease is named after the German ophthalmologist Eugene 
von Hippel, who described retinal haemangioblastoma in 1904, and the Swedish 
pathologist Arvid Lindau who associated retinal and central nervous system (CNS) 
haemangioblastoma with cysts of the kidneys, pancreas and epididymis in 1926 [14] [15]. 
The first report on phaeochromocytoma in VHL disease appeared in 1953 [16]. The most 
recently discovered VHL-related tumours are the endolymphatic sac tumours of the inner 
ear and the adnexal papillary tumour of probable mesonephric origin (AMPO), otherwise 
known as lesions of the broad ligament [18]. 
 
The mean age at symptomatic diagnosis varies: 24.5 years for retinal angioma, 29 
years for haemangioblastoma, and 44 years in renal cell carcinoma (RCC). Due to the 
early onset of retinal angioma and cerebellar haemangioblastoma, these complications 
appear more frequent than RCC in cross-sectional studies and are the most common 
first manifestations of the disease. VHL disease may manifest in childhood or old age, 
but most patients present in the second and third decade, and penetrance is almost 
complete by age 60 years [21, 22]. These results are summarised in tables 1 and 2, 
which compare clinical data from several large independent studies. 
 
 Table 1. Cause of death in VHL disease 
 
Author Lamiell et al.  Maher et al.  Maddock et al.  Richard et al.
 
Deceased patients 182   51               44   13 
 
Age at death(years)  36.9±14 (13-67)     41±14 (13-67)      40.9±14.6 (12-65)         47±16 (24-81) 
 
Cause of death 
    CNS Haemangioblastoma 55%   41%           52.30%              61.50% 
     Renal cell carcinoma 13%   47%           27.30%              30.80% 
     Others   32%   12%           28.40%               7.70% 
Adapted from Richard et al. 2000 
Table 2. Clinical data from three large series of VHL patients 
Author  Maher et al.  Maddock et al.  Richard et al. 
Patients (n) 152  83  215 
CNS Haemangioblastoma 
      Frequency 72%  63.80%  72% 
      Multilpe tumours 38%  ND  43% 
 Age at diagnosis in yrs (range) 29±10 (11-61)  30±12 (4-76)  30±11.5 (13-70) 
Other Manifestations of VHL 
      Retinal Haemangioblastoma 59%  41%  44% 
      Renal cell carcinoma 28%  14.50%  36.70% 
      Pheochromocytoma 7%  14.50%  17.20% 
      Pancreatic lesions ND  22%  53% 
Presenting manifestations 
     CNS Haemangioblastoma 41%  38.50%  38.80% 
      Retinal Haemangioblastoma 43%  25.30%  23.70% 
      Others 13%  36.20%  37.50% 
ND not detailed. Adapted from Richard et al 2000 
Chapter 1 – VHL Disease 
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1.2 Diagnosis, surveillance and clinical classification of VHL disease 
 
Metastases from renal cell carcinoma and neurological complications from cerebellar 
haemangioblastoma (Hb) are the most common causes of death in VHL disease. 
However, improved surveillance through early detection of tumours by intensive 
radiological and clinical screening, together with advanced operation techniques are 
helping to reduce both morbidity and mortality in VHL disease [24-26]. 
 
Diagnosis of von Hippel-
Lindau disease is often based on 
clinical criteria. Patients with a family 
history, and a CNS 
Haemangioblastoma, including 
retinal angioma, 
phaeochromocytoma (Phaeo), or 
RCC are diagnosed with the 
disease. To meet the diagnostic 
criteria, those with no relevant family 
history must have two or more CNS 
Hb’s, or one CNS Hb and a visceral 
tumour, with the exception of 
epididymal and renal cysts, which 
are frequent in the general 
population [29-31]. Table 3 
summarises standard screening 
procedures for at-risk individuals. 
 
Specific correlations of genotype 
and phenotype have emerged in affected 
families. As outlined in table 4, several 
familial phenotypes of von Hippel-Lindau 
disease are now recognised, providing 
useful information to screen and counsel 
affected individuals [32]. Clinically, VHL 
disease can be subdivided into two main 
classes. Type 1 families have a greatly 
reduced risk of phaeochromocytoma's, but 
can develop all the other tumour types 
generally associated with the disease. Type 2 families have phaeochromocytoma’s, but 
have either a low-risk (type 2A) or high-risk (type 2B) for renal cell carcinomas. Type 2C 
families have phaeochromocytoma’s only, with no other neoplastic findings characteristic 
of VHL disease [33].  
Table 3. Recommended intervals for 
screening in at-risk individuals 
Adapted from Choyke et al. 1995 
Test Start age (frequency) 
 
Ophthalmoscopy Infancy (early) 
 
Plasma or 24 h urinary  2 years of age (yearly  
catecholamines and  and when blood pressure  
metanephrines  is raised) 
  
 
MRI of cranio-spinal axis 11 years of age (yearly) 
 
CT and MRI of internal Onset of symptoms  
auditory canals  (hearing, loss, tinnitus, vertigo, or 
unexplained difficulties of balance)
 
Ultrasound of abdomen 18 years of age or  
earlier if clinically indicated (yearly)
 
Audiological function tests When clinically indicated 
Table 4.  Clinical sub-divisions in VHL  
disease 
Class  Tumour types observed in families 
Haem. RCC Phaeochr. 
Type 1 + + − 
Type 2A + − + 
Type 2B + + + 
Type 2C − − + 
Chapter 1 – VHL Disease 
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Advances in genetic testing for the disease include qualitative and quantitative 
Southern blotting, which has been added to DNA sequence analysis. This improved 
testing has increased the detection rate of DNA mutations in peripheral blood leucocytes 
from 75% to nearly 100% [34]. In 1996, there were more than 137 distinct intragenic 
germ-line mutations reported in affected families in North America, Europe, and Japan 
[35]. Mutation types included missense, non-sense, micro-deletion, insertion, deletion, 
and splice site [35]. Known mutations of von Hippel-Lindau disease are now stored 
online (www.umd.be), where some 834 somatic mutations have been collected. Since 
genetic testing detects mutations in nearly 100% of documented affected families, serial 
clinical surveillance studies are recommended for family members with mutations. A 
more detailed mutational analysis of the VHL locus will be discussed in chapter 3. 
 
A diagnostic challenge arises in de novo cases (i.e. the first affected member of a 
family) of von Hippel-Lindau disease. These cases arise in as many as 20% of kindred’s 
[36]. The initial mutation in a de novo case might result in disease mosaicism. This 
means that some, but not all, tissues could carry the new disease mutation. Thus, such 
patients might have clinical signs of the disease, but test negative genetically, because 
the VHL mutation is not carried in all peripheral leucocytes. The earlier the new mutation 
arises in embryogenesis, the more numerous and varied the types of cells that will carry 
the mutation.  
 
1.3 Central nervous system lesions 
 
1.3.1 CNS Haemangioblastoma 
 
Haemangioblastoma manifests in early 
adulthood and is the most common presenting 
manifestation of VHL, revealing the disease in 
30-50% of cases (Table 1). CNS 
haemangioblastoma arise preferentially in the 
cerebellum (∼37%), brain stem (∼10%) and 
spinal cord (∼50%), but are rare in the cerebrum 
(∼1%) [37]. Haemangioblastoma are benign 
tumours mainly found in the brain stem, with a 
heterogeneous histology comprising endothelial 
cells, pericytes and interstitial stromal cells. 
About 60% are cystic and 40% are solid. They 
are the most common brain stem tumour in the 
adult, comprising about 7% of all brain stem 
tumours. Haemangioblastoma may be multiple, 
particularly in VHL disease and when located in the spinal cord. On gross pathology, they 
Figure 2. Basic anatomy of the brain. The 
image illustrates the brain, viewed from the side, 
showing the major lobes (frontal, parietal, 
temporal and occipital) and the brain stem 
structures. The brainstem is the portion of the 
brain connecting the cerebral hemispheres with 
the spinal cord. It contains the midbrain, pons, 
and medulla oblongata. 
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are well demarcated, highly vascularised nodules frequently associated with a cyst 
whose walls are usually composed of gliotic tissue (see Fig.3A). Although they can be 
easily diagnosed by CT (computed tomography), MRI (magnetic resonance imaging) is 
the most effective non-invasive modality to diagnose haemangioblastoma's (Figs. 3, 4).  
 
The three specific elements that allow an almost certain diagnosis of 
haemangioblastoma are, however, the brain stem location, the cystic nature, a peripheral 
enhancing nodule and the presence of large vessels at the periphery or within the mass. 
Angiography is, however, necessary not only to definitely depict the lesion which clearly 
appears as a highly vascular nodule with a prolonged stain and a draining vein, but also 
to identify small nodules that can be missed on MRI.  
 
 
 
Figure 4. Haemangioblastoma 
A, B. MRI images. An inhomogeneous nodule surrounded by 
oedema1 is seen in the right superior cerebellar hemisphere. 
C, D. Coronal image, without and with gadolinium2 (Gd). The 
nodule is poorly seen in the non-enhanced imaged and 
enhances markedly and homogeneously following Gd 
injection. E, F. Axial and sagittal images, following Gd 
injection. Enhancement and position of the nodule are well 
seen. G, H. AP and lateral projection angiogram 
demonstrating nodule being fed by the superior cerebellar 
artery. 
Adapted from The Encycl. of Med. Imaging Vol. VI:1 
 
                                                 
1 Oedema is an abnormal excess accumulation of serous fluid in connective tissue or in a serous cavity 
2 Gadolinium is a magnetic metallic element of the rare-earth group used for contrast medium in imaging procedures like MRI 
Figure 3. MRI and histological features of CNS haemangioblastoma
(A). MRI of a cerebellar haemangioblastoma (arrow) with an associated cyst (homogenous associated dark region) in 
a 40-year old woman. (B). MRI of medullary haemangioblastoma (arrow) in a 12-year old girl. (C). MRI of the spinal 
cord of a 50-year old man. The haemangioblastoma is located in the posterior portion of the spinal cord at C5 and C6 
(arrow). (D). Haematoxylin and eosin staining of a haemangioblastoma showing the stromal cells (arrows) distributed 
within a capillary network (arrowheads). 
Adapted from Lonser et al.2003 
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Patient outcome has been greatly ameliorated by microsurgery and progress in 
intensive care, but the possibility of other tumours developing is still a major problem. 
Postoperative mortality is 7-10% and is higher in brainstem-associated lesions [38].  
 
1.3.2 Retinal Angioma 
 
Retinal angioma is a benign vascular tumour of 
the retina, which in VHL disease usually occurs 
as a clinically observable fundus3 lesion in the 
20 to 40-year old age group. They may be 
present at birth but are frequently not detected 
until this time because of the usual small size 
and peripheral location of the tumours. Although 
they may develop anywhere in the retina, they 
tend to be most prevalent in the temporal mid-
periphery of the eye.  
 
Retinal angioma begin as a proliferation 
of endothelial cells between arterioles and 
venules in the capillary bed [39]. The angioma 
gradually enlarges and the surrounding capillary 
network develops into a large fistular single 
arteriolar and venous channel, which serves to 
feed and drain the tumour [40] (Figure 6). Micro-
vasculopathy4 occurs in the capillary bed, as 
blood is shunted to the tumour from the 
surrounding retina. The non-perfused area may 
then develop intra-retinal oedema through 
leakage of plasma and other blood constituents 
into the retinal tissue, which leads to hard exudates and eventual involvement of the 
macula via cystoid maculopathy (Figure 4). Macular oedema represents the major cause 
of vision loss in VHL disease. The maculopathy first presents as early oedema or 
discrete exudates in a star-shaped pattern and can occur with peripheral angioma in the 
presence of normal intervening retina [41]. If unrecognised and untreated at this early 
stage, the majority of these angioma will eventually haemorrhage, resulting in massive 
exudation, retinal detachment and ultimately, neo-vascular glaucoma and blindness. 
 
Treatment of retinal angioma is dependent on the presence of tumour exudation 
and macular involvement. Angioma's that are small, stable and asymptomatic may be 
followed by photo-documentation. Treatment becomes necessary when there is a threat 
                                                 
3 Fundus refers to the bottom of or part opposite the aperture of the internal surface of a hollow organ, in this case the part of the eye 
opposite the pupil 
4 Vasculopathy refers to any pathological condition regarding vasculature 
Figure 5. (A) Basic anatomy of the eye. 
This graphic lists many of the essential 
components of the eye's optical system in 
an aid to help understand the text. (B). The 
macula is the highly sensitive area of the 
retina.  It is responsible for critical focusing 
vision.  It is the part of the retina most used. 
We use our macula to read or to stare 
intently at an object. 
Adapted from www. stlukeseye.com 
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to macular function by exudation. Argon laser photocoagulation is the treatment of choice 
in tumours less than 2.5 disc diameters in size [41]. Laser is applied to the tumour itself, 
leaving a pigmented scar and involuted feeder vessels. Tumours larger than 2.5 disc 
diameters and those with sub-retinal fluid are more effectively treated with cryotherapy5 
[42].  Eye wall resection, which involves the surgical removal of the tumour through a cut 
in the sclera, has been successful for treating larger tumours (greater than 4.5mm) where 
photocoagulation and cyrotherapy modalities are not an option, however, this procedure 
is not without significant risk [41].  
 
 There are several treatment 
strategies on the horizon that show 
promise for the ocular management of 
this disease and include the use of 
radiotherapy, such as brachytherapy6 
or linear-accelerated based radio-
surgery [43, 44]. Molecular biological 
and pharmaceutical advances also 
offer interesting therapeutic potential. 
Active research is ongoing to devise 
drugs designed to target specific bio-
molecules. In the case of VHL 
disease, it is known that mutations in 
the VHL tumour suppressor gene 
result in changes in the oxygen-
regulation factor, hypoxia inducible 
factor, HIF. This factor subsequently 
binds to specific enhancer elements 
of the VEGF gene and stimulate 
angiogenesis7 (regulation of these 
factors by VHL and it’s consequence will be dealt with in more detail at a later stage). 
This increase in angiogenesis under normoxic (normal oxygen levels) conditions in key 
target organs such as the brain, kidney and eye leads to high morbidity and reduced life 
expectancy. Interestingly, Aiello et al. [45] reported a case of rapid and durable recovery 
of visual function in a patient with VHL disease and optic nerve head angioma after 
systemic administration of a VEGF receptor inhibitor SU5416.  VEGF is a homo-dimeric 
cytokine that was originally identified for its effects on endothelial cell proliferation and 
vascular permeability. Since it’s discovery, VEGF has been shown to bind on the surface 
of epithelial cells to tyrosine kinase receptors, Flt-1 and KDR (or VEGFR-1 and -2 
respectively), which regulate VEGF-induced physiologic and patho-physiologic 
                                                 
5 Cryotherapy, also known as cryosurgery, is a commonly used procedure for the treatment of a variety of benign and malignant 
lesions. The mechanism of destruction is necrosis, which results from the freezing and thawing of cells. Treated areas re-epithelialise. 
Adverse effects are usually minor and short-lived 
6 Brachytherapy is radiotherapy in which the source of radiation is placed (as by implantation) in or close to the area being treated 
7 Angiogenesis is the formation and differentiation of blood vessels 
Figure 6. Opthalmoscopic view of retinal angioma. (A) 
Peripheral retinal angioma (arrow) with an enlarged vessel in 
a 22-year-old woman. (B) Peripheral retinal angioma (arrow) 
with fibrous changes, hard exudates and retinal oedema in the 
surrounding region in a 24-year-old man. (C) Retinal angioma 
(arrow) on the optic nerve head with yellow retinal hard 
exudates below it in a 32-year-old-man. (D) The vascular 
tumour is seen as a mass of blood vessels. (E) After injection 
of fluorescein dye to identify the blood vessels, the highly 
vascular nature of the tumour is apparent.  
Adapted from references Kaelin et al. 1998 and Lonser et al. 2003 
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angiogenesis. Overproduction of VEGF in the mouse brain causes lesions that are 
reminiscent of haemangioblastoma. Therefore, increased expression of VEGF could 
explain the highly vascular nature of VHL-related tumours, and hence represent a target 
for systemic therapy. In recent years, a number of VEGF-targeted strategies have been 
tested in clinical trials, including anti-VEGF antibodies and small molecule inhibitors of 
VEGFR-1 and -2. Among these is SU5416.  Although caution is warranted in drawing 
conclusions from an isolated case report, the clear association between the initiation of 
treatment and marked improvement in numerous visual function parameters in a 
condition where spontaneous resolution is extremely rare, coupled with a plausible 
mechanism of action, suggests that systemic inhibition of VEGF should be considered as 
a potential therapeutic method for VHL disease. 
 
 
1.3.3 Endolymphatic Sac Tumours 
 
Endolymphatic sac tumour 
(ELST) [46] is a rare neoplasm 
arising from the temporal petrous 
region8. The origin of this tumour 
is thought to be the endolymphatic 
sac [46, 47]. ELST histologically 
shows epithelial features, such as 
papillary architecture, glandular 
formation and a colloid-like 
structure. The tumour is believed 
to be an epithelial tumour [47, 48].  
These tumours, while rare, are 
frequently associated with von 
Hippel-Lindau disease [18].  MRI revealed evidence of these tumours, as demonstrated 
by systematic radiological study of 121 patients with VHL, and showed an incidence of 
11% [18]. ELST are highly vascular, and often erode or expand the surrounding temporal 
bone. Histologically, ELST’s form papillary cystic regions filled with proteinaceous 
material (Fig.8D) characterised by a simple cuboidal epithelium covering highly 
vascularised stroma with blood capillaries in close contact with the surrounding 
epithelium.  
 
Diagnosis is easily made by CT scan and MRI (fig.6). On CT scan, ELST is seen 
as a destructive lesion lysing temporal bone, medial mastoid9 and auditory canal (Fig. 
6B). With MRI, ELST appears as a heterogeneous lesion and is markedly enhanced after 
contrast medium injection, e.g. godolinium (Fig. 8A).  Early radiological detection is 
                                                 
8 Petrous region is of, relates to, or constitutes the exceptionally hard and dense portion of the human temporal bone that contains the 
internal auditory organs 
9 Mastoid refers to part of the temporal bone behind the ear 
Figure 7.  The basic anatomy of the external, middle and inner ear. 
The inner ear consists of (A) the endolymphatic sac, (B) the semicircular 
canals, (C) the cochlea and (D) the auditory nerve.  The endolymphatic 
duct originates from the connecting duct between saccule and utricle. It 
consists of three parts: the shorter inner portion, the highly convoluted 
intermediate (or ‘rugose’) portion and the distal portion that is 
ensheathed by two layers of the dura. The intermediate part supposedly 
is the origin of ELST. 
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Figure 9. Gross anatomy of the kidney. 
Pathologically, renal cell carcinoma is a malignant
epithelial tumour of the renal parenchyma and is often
found in the renal cortex. The most common cellular
pattern is clear cell carcinoma, arising from cells of the
proximal tubuli [1]. 
crucial because timely therapy 
will prevent hearing deficits 
from progressing. Surgery is 
curative for completely 
excised tumours, and the 
preoperative level of hearing 
is usually preserved. The 
importance of adjunctive 
radiation remains unclear, but 
inoperable tumours have been 
radiated [49]. ELST are not 
known to metastasise [50]. 
 
1.4 Visceral Lesions 
 
1.4.1 Renal Cell Carcinoma and Renal Cysts 
 
Renal cell carcinomas (RCC) account for 
80-85% of all primary renal neoplasm’s. 
RCC is the major malignant neoplasm in 
the von Hippel-Lindau disease and the 
primary cause of inherited renal cancer. 
Almost half the number of patients 
diagnosed with RCC have metastatic 
disease on presentation [51]. Metastatic 
RCC has an extremely poor prognosis, 
with a median survival of less than 1 
year. The classification of RCCs reflects 
the morphology, cell of origin, and 
molecular basis of the different types of 
renal carcinomas [52]. Table 5 outlines 
the five distinct types. 
  
Similar to the colon and breast 
cancer fields, studies in the renal cancer 
area have identified several tumour 
suppressor genes and oncogenes 
involved in the pathogenesis of 
hereditary renal cancer syndromes. 
These same genes have been implicated 
in the pathogenesis of the majority of 
Table 5. Renal Cell Carcinoma Classification 
Type Frequency 
1. Clear cell renal carcinomas 80% 
2. Papillary or chromophillic 15% 
3. Chromophobic 5% 
4. Oncocytic <1% 
5. Collecting duct carcinomas Very rare 
Figure 8. A) MRI showing a enolymphatic sac 
tumour. B) CT showing destruction of the left 
temporal bone. C) Three-dimensional CT showing 
deformity of the left temporal bone. D, ELST 
showing papillary structure composed of cuboidal 
cells. Histological appearance of the endolymphatic 
sac tumour exhibits a highly vascularised papillary 
pattern. 
Adapted from Horiguchi et al. 2001 
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sporadic renal cancers and have helped define new targets for therapy. Among those 
genes identified is the VHL tumour suppressor gene. VHL syndrome is the most common 
familial syndrome with clear cell renal carcinoma as one of its features. Proximal tubular 
epithelium is thought to be the cell of origin for clear cell RCC (fig.7). 
  
Contrast-enhanced abdominal CT is the standard for detection of renal 
involvement in the disease (fig.8). CT allows detection and quantification by size and 
number of renal cell carcinomas and cysts, allowing serial monitoring of individual 
lesions. MRI is an alternative method of detection for patients who have reduced renal 
function. Histologically, they are always of the clear-cell subtype (fig.10), and small 
carcinomas tend to be low grade [53]. Treatment recommendations can depend on 
tumour size. 
 
 Options for treatment range 
from bilateral nephrectomy, nephron-
sparing surgery10 to follow-up 
investigations only [54]. If both kidneys 
are affected with multiple cysts and 
tumours, a difficult decision has to be 
made between radical nephrectomy or 
nephron-sparing surgery. This 
decision depends on risk factors for 
metastatic spread (size, progression, capsule involvement and whether the tumour is 
symptomatic). Management of metastatic lesions is a difficult problem, since their 
response to chemotherapy and radiotherapy is poor. A prospective analysis on treatment 
of renal cell carcinoma in VHL patients demonstrated that, using a 3 cm renal tumour 
diameter as an indication for renal surgery, no patient with renal cancer and VHL disease 
has metastatic disease regardless of the number of tumours [55]. At the third 
International meeting on VHL disease a consensus was reached to use a 3 cm threshold 
as the lower limit to perform renal surgery and whenever feasible preferably using 
nephron-sparing surgery [56]. This approach may help to prevent metastases, and avoid 
unnecessary renal damage due to frequent surgery, necessitating renal dialysis or 
transplantation. 
 
Percutaneous11 radio-frequency ablation or cryoablation of small carcinomas are 
experimental treatments and hold promise of being less invasive than other treatments. 
Pavlovich and colleagues [57] have reported early results of an ongoing trial of 
percutaneous radio-frequency ablation for small renal tumours, but it remains 
experimental until procedural and imaging parameters that correlate with tumour 
destruction are validated. 
                                                 
10 Nephron-sparing surgery refers to partial nephrectomy 
11 Percutaneous approaches are those effected or performed through the skin 
Figure 10. (A) CT image and (B) Histology of RCC and renal 
cysts. Bilateral multifocal RCC with both solid (arrows) and 
cystic (arrowheads) disease in a 22-year-old man. 
Adapted from Lonser et al 2003 
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1.4.2 Phaeochromocytoma 
 
Phaeochromocytoma and paraganglioma are terms 
describing a neoplasm of chromaffin cells12 found in 
the adrenal medulla or elsewhere within the 
sympathetic paraganglionic axis. The adrenal 
tumours are usually referred to as 
phaeochromocytoma’s, whereas an extra-adrenal 
tumour is often termed extra-adrenal 
phaeochromocytoma or paraganglioma, the latter 
usually reserved for a non-functional (i.e. non-
catecholamine secreting) neoplasm. This 
terminology is based on historical histopathological 
techniques, and since these neoplasms are 
otherwise indistinguishable, the terminology may be 
confusing. Furthermore, extra-paraganglioma may 
also arise from special structures in the neck, 
referred to as chemodectomas, glomus jugulare, or 
carotid body tumours. While phaeochromocytoma is 
the tumour type of discussion here, it is important to note that in contrast to other familial 
phaeochromocytoma syndromes such as multiple endocrine neoplasia type II (MEN 2) 
and neurofibromatosis type I (NF 1), it has been reported that up to 12% of VHL patients 
present extra-adrenal paraganglioma [58-61].  Phaeochromocytoma’s can be benign or 
malignant, sporadic or familial tumours. In one study performed by Walther and 
colleagues [61], a series of 246 patients with VHL syndrome were studied. 64 patients 
were found to have a phaeochromocytoma, the mean age at diagnosis being 29 years 
with a range from age 6 to age 54. Bilateral tumours in this group were found in 39% of 
patients. 
 
As already mentioned, and a topic that will be discussed in more detail in chapter 
3, genotype-phenotype correlations have emerged in VHL disease. Clinical classification 
of VHL disease groups families which manifest low-risk (Type 1) or high-risk (Type 2) of 
phaeochromocytoma, and some VHL families (Type 2C) present as familial 
phaeochromocytoma without haemangioblastoma or renal carcinoma [62-66]. These 
studies show strong evidence that the presence or absence of phaeochromocytoma is 
correlated with the type of VHL germ-line mutation. 
 
The first diagnostic step is represented by the measurement of catecholamines 
and their metabolites (metanephrines) in urine and plasma. Localisation and staging of 
                                                 
12 Chromaffin cells, so called due to the fact that they stain deeply with chromium salts, are characteristically located in the adrenal 
medulla and paraganglia (paraganglia, chromaffin) of the sympathetic nervous system. They store catecholamine secretory vesicles, 
e.g. adrenaline, which is released upon stumuli 
Figure 11. Anatomical location of the 
adrenal gland. (A). Simplified 
diagrammatic Cross section through an 
adrenal gland illustrating the chromaffin 
cell-containing adrenal medulla from 
which phaeochromocytomas arise. (B). 
Gross anatomy of the adrenal glands 
with respect to the kidney. 
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phaeochromocytoma is based on MRI, and metaiodobenzylguanidine (MIBG) 
scintigraphy is useful to confirm the catecholamine-producing nature of the tumour and 
reveal extra-adrenal tumours [4, 67]. Scintigraphy after administration of radio-labelled 
octreotide, a somatostatin analogue, has had only limited success, depending on 
anatomic factors, expression of somatostatin receptors, and delivery of the radio-
pharmaceutical to the tumour cells [68]. Preliminary results presented by Pacak et al. 
show that 6-[18F]-fluorodopamine PET scanning can detect and localise 
phaeochromocytoma, not only as a primary tumour in the adrenal gland but also as a 
recurrent extra-adrenal or metastatic tumour and is superior to MIBG scanning [69].   
 
Operative treatment can be considered in symptomatic phaeochromocytoma or if 
a growing mass in the adrenal gland is present. Satisfactory results have been reported 
from laparoscopic13 removal of adrenal tumours in VHL patients [70, 71]. Since bilateral 
tumours develop in 47% of VHL patients with phaeochromocytoma, most patients 
become independent on steroids after bilateral adrenalectomy [70]. Enucleation14 rather 
than adrenalectomy is therefore recommended by an increasing number of surgeons. 
Adrenal-sparing surgery is safe, effective and can preserve adrenal function in VHL 
patients. 
 
1.4.3 Pancreatic cysts and tumours 
 
Pancreatic involvement is frequent in 
VHL disease, presenting in up to 70% 
of affected patients, but in most cases 
is limited to isolated or multiple benign 
cysts [72]. Serous cystadenomas are 
benign multi-cystic calcified tumours 
and less frequently encountered. 
Cystic manifestations commonly have 
no clinical implications but abdominal 
pain and cholestatic jaundice15 can 
result from compression by enlarged 
cysts. Neuroendocrine tumours, islet 
cell tumours, frequently multi-focal, are observed in 10-15% of VHL patients. These 
tumours tend to be slow growing but have the potential of a truly malignant course.  
 
Endocrine tumours of the pancreas are very rare, accounting for only 5% of all pancreatic 
cancers. There are several types of islet cells and each produces its own hormone. 
                                                 
13 Laparoscopy refers to a fiber-optic instrument that is inserted through an incision in the abdominal wall and is used to examine 
visually the interior of the abdomen cavity 
14 Enucleation refers to removing, in this case the tumour, but without cutting into the vital organ, in this case the adrenal gland 
15 Cholestatic jaundice, or cholestasis, refers to impairment of bile flow due to obstruction in small bile ducts (intrahepatic cholestasis) 
or obstruction in large bile ducts (extrahepatic cholestasis) 
Figure 13. The pancreas has endocrine and exocrine 
functional components. Islet of Langerhan cells are 
components of the endoocrine system. These are cells of the 
pancreas that produce and secrete hormones into the 
bloodstream. 
Adapted from John Hopkins Pathology Homepage 
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Functional endocrine tumours are named after the hormone they secrete, e.g. insulinoma 
is the most common tumour of the endocrine pancreas. 10-15% of VHL patients will 
develop islet cell cancer. Symptoms vary among the different islet cell cancer types.  
 
Surgery and chemotherapy have been shown 
to improve the outcome of patients even if 
they have metastatic disease. Most patients 
with metastasis do not survive five years. Islet 
cell cancer tends to spread to the surrounding 
lymph nodes, stomach, small intestine, and 
liver. There are no known risk factors 
associated with sporadic islet cell cancer. 
Therefore, it is not clear how to prevent its 
occurrence. Individuals with VHL disease or 
MEN syndrome, however, have a genetic 
predisposition to developing islet cell cancer 
and should be screened regularly in an effort 
to catch the disease early.  
 
1.4.4 Epididymal cysts and cystadenoma 
 
Two types of lesions are encountered: 
simple cysts without specificity, and 
papillary cystadenomas with columnar 
clear cells lining a highly vascular 
stroma, a pattern sometimes 
confused with metastasis of renal cell 
carcinoma. Papillary cystadenomas of 
the epididymis (PCE), are seen in 
approximately 10-26% of men with 
VHL [29, 73, 74]. PCE’s are rarely 
found as unilateral lesions in the 
general population but when they are 
bilateral they are virtually 
pathognomonic of VHL disease. Epididymal cysts with no solid component are also 
commonly reported in VHL but are seen in 23% of the general population making 
epididymal cysts an unreliable diagnostic characteristic for VHL [75]. The PCE can be 
unilateral or bilateral and is most often found in the globus major, the head of the 
epididymis. PCE may involve the spermatic cord as well [76]. The lesions are typically 2-
3cm. PCE’s are firm and easily palpable but can contain cystic spaces with clear yellow 
or hemorrhagic fluid [75]. Histologically, PCE resembles endolymphatic sac cysts and 
renal cysts lined by clear cells containing fat and glycogen with tubular and papillary 
Figure 14. Patient with phaeochromocytoma
and islet cell tumour of the pancreas. (P)
phaeochromocytoma with a necrotic center. (I)
islet cell tumour  present in the neck of the
pancreas. Two small pancreatic cysts are also
observed.  
Adapted from Choyke et al. 1995 
Figure 15. The epididymis is a coiled, microscopic tubule
that carries sperm from the testicle into the vas deferens.
This 20-foot long tubule is coiled up into the length of about
one inch and is very fragile. 
Adapted from: www.drpadron.com  
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structures, a fibrous stroma and surrounding pseudo-capsule of dense collagenous 
tissue [76].  
 
The probable origin of these lesions is from 
epididymal duct epithelium that arises from the 
embryonic mesonephric duct (NB. Mesonephric duct 
is an embryological term given to a pair of long ducts 
— and a smaller set of tubules attached to each duct 
— that will, by the time we are born, form important 
parts of the reproductive system in both males and 
females) [77].  The lesions are generally 
asymptomatic and detected by manual examination 
or ultrasound (fig.16). Infertility, presumably due to 
obstructive azoospermia16 has been reported and 
atrophy of the seminiferous tubules of the testicle 
may be seen [29, 78]. Because these lesions are benign and typically symptomless, they 
are managed conservatively and treatment is reserved for the rare occurrence of 
symptoms. Ultrasonography can be used to monitor their growth over time. 
 
1.4.5 Adnexal papillary tumour of probable mesonephric origin (APMO) 
 
Papillary cystadenomas in the 
broad ligament have rarely been 
reported and are unrecognised in 
many women with VHL disease. 
These lesions are regarded as 
the female counterpart of the 
cystadenoma of the epididymis. 
The papillary cystadenoma of 
mesonephric origin is commonly 
called the "broad ligament cyst" 
because most of them form in 
remnant mesonephric duct tissue 
that happens to be embedded in the broad ligament. However the cystadenomas that are 
important in VHL are not all in the broad ligament (some are below it), and they are 
cystadenomas, not cysts. The broad ligament is a large area of tissue that lies on top of 
the reproductive organs. The broad ligament lies in folds and creases on top of both 
ovaries and uterine tubes, connecting these structures to the larger body of the uterus.  
Some papillary cystadenoma of mesonephric duct origin that can help in diagnosing VHL 
will be found attached to adnexal (adjoining) tissue that is not part of the broad ligament. 
                                                 
16 Azoospermia refers to absence of spermatozoa from the seminal fluid 
Figure 16. Ultrasonography of papillary 
cystadenoma of the epididymis. This 
lesion was palpable as a firm mass in the 
globus of the epididymis (arrow). E is the 
epididymal mass, T is the testicle. 
Adapted from Choyke et al [4] 
Figure 17. Sites of Mesonephric Duct Remnants in Females. It
is in tissue associated with these parts of the old mesonephric duct
that APMOs can be found. 
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Gaffey et al. coined the more appropriate name adnexal papillary cystadenoma of 
probable mesonephric origin (APMO) [79].  
 
Papillary cystadenoma in men are found throughout this duct system. In women, 
the mesonephric duct system is a remnant system. Although it is made up of the same 
set of tubules and ducts that are found in men, only short segments of the embryonic 
system, called "remnants", remain by the time a female is born. None of these segments 
performs any function. It is in tissue associated with these parts of the old mesonephric 
duct that APMOs can be found.  
 
In 1997, a comprehensive study of the literature showed that all cases with AMPO 
described thus far arose in VHL patients [79]. This association indicates that the AMPO 
may represent a pathognomonic visceral manifestation of VHL disease. These lesions 
can be diagnosed by CT-imaging or ultrasonography. The tumours are grossly similar to 
epididymal cystadenomas. Because they are benign and typically asymptomatic, they 
can be managed conservatively. Treatment is reserved for the rare occurrences of 
symptoms and CT or ultrasonography can be used to document their size over time. 
 
 
Concluding Remarks 
 
 
von Hippel-Lindau disease is a hereditary cancer syndrome predisposing carriers to the 
development of a wide spectrum of highly vascularised tumours present in both the CNS 
and visceral organs. The disease is the foremost cause of inherited renal cell carcinomas 
(RCC), which is induced by germline mutations of the VHL tumour-suppressor gene also 
inactivated in most sporadic RCC. VHL disease is a potentially life-threatening disorder, 
however, most of the associated tumours are accessible to effective medical 
management on condition of an early diagnosis and the multidisciplinary concerted 
actions of the medical profession. Identification of the VHL gene and genotype-
phenotype correlations might allow predictions of the risk of developing particular tumour 
types, so that personalised screening protocols can be designed for each patient once 
the mutation is known. A close surveillance of patients and gene carriers is imperative in 
order to detect manifestations early and to avoid complications. The concerted co-
ordinated effort of various medical disciplines is indispensable for optimal management 
of patients and national medical VHL networks have been established in many countries 
[21, 43]. Regular surveillance includes periodic CNS gadolinium enhanced MRI, 
abdominal MRI, CT scan or ultrasound, urinary metanephrines measurement and 
opthalmoscopy, both for early diagnosis and follow-up of different manifestations. 
Periodicity depends on age, number and type of manifestations in each patient. 
Chapter 2 – The VHL Gene 
 27
 
 
CHAPTER 2 
The VHL Gene 
 
 
 
2.1 Introduction 
 
This chapter discusses the identification, mapping and cloning of the VHL gene. It looks 
at the gene structure, including promoter and 3’-UTR regions, and summarises studies to 
date that outline expression profiles of VHL mRNA and subsequent protein species. In 
addition, biochemical structural analysis with respect to specific protein interactions and 
the consequence of mutations in VHL are detailed. Finally consideration is given to 
sequence homology at both the DNA and amino acid levels and how this can help in our 
understanding of VHL biology. 
 
2.2 Mapping, identification, and cloning of the VHL gene 
 
The VHL gene was mapped to the short arm of chromosome 3 in 1988 
by Seizinger et al [80],  and subsequent analysis localised it to a small 
region of 3p25-p26. The gene was isolated by positional cloning in 
1993 by Latif et al. [81] and intragenic germline mutations in members 
of VHL kindreds have confirmed the authenticity of the gene [43].   
 
2.3 VHL gene structure and sequence 
 
The VHL gene consists of three exons encoding a 4.7kb mRNA, covering less than 20kb 
of genomic DNA (Fig.18). The 642 nucleotide coding region encodes a polypeptide of 
213 amino acids. As a result of internal initiation of translation at a downstream 
methionine, a second mRNA species of 480 nucleotides gives rise to another polypeptide 
of 160 amino acids. The protein products have molecular weights of approximately 
30kDa and 19kDa, and will be from here on referred to as pVHL30 and pVHL19 
respectively. 
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2.4 Promoter Analysis 
 
Despite the importance of VHL 
in oncogenesis and 
development, little is known 
about the regulation of VHL 
expression. To date, only three 
studies exist regarding the VHL 
promoter. Kuzmin et al. mapped 
a minimal VHL promoter by 
deletion analysis, but putative 
transcription factor binding sites were not investigated [82]. The VHL gene promoter has 
been subsequently sequenced (Genbank Accession No. AF010238).  In 1999 evidence 
was reported for E2F1 activation of the VHL promoter, although an E2F1 binding site 
was not identified [83]. Finally in 2002, Zatyka et al. attempted to identify, in silico, 
candidate regulatory regions by defining regions of evolutionary conservation, and then 
proceeded to investigate these regions and specific putative transcription factor binding 
sites by electro-mobility shift (EMSA) and promoter activity assays (Fig.19). This latest 
study led to the identification of 4 regions of conservation between human, primate, and 
rodent sequences [84]. Sequence conservation over 100 million years of evolution 
suggests that these regions are of functional significance.  
 
Analysis of specific putative transcription factor binding sites (outlined in table 6 
above and figure 19 below) identified a functional Sp1 site at nucleotide position +1 to 
+11, which was shown to be a regulatory element. Overlapping Sp1/AP2 sites located at 
nucleotide position +72 to +87 were also identified. A further positive regulatory element 
Figure 18. VHL gene structure and protein domains. The VHL protein product is encoded by three exons located 
on chromosome 3p25-p26. The protein product encodes a 213 amino acid poly-peptide. Internal initiation of 
translation at methionine 54 gives rise to a second protein product of 160 amino acids. The N-terminal region is 
characterised by eight acidic pentameric repeats. pVHL can be divided structurally into an α and a β domain. 
Table 6.  In silico identification of candidate 
transcription factor binding sites 
 
Conserved Region Putative Transcription Factor 
 
1  GATA2, GATA3, NF-1, Barbie Box 
2  cRel, Nfkappa 
3  Sp1, Egr, AhR/Ar, GATA2, AP2, AP4
4  cRel, Nfkappa, Sp1, MZF1, AP2 
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CR2 
CR3
between nucleotide position –49 and –19 was identified. This region was specifically 
shown to bind as yet unidentified factors which were confirmed not to be E2F1. Upstream 
of the VHL minimal promoter another region, -114 to –91, was identified as being 
capable of binding yet another unknown factor. Although a second best candidate E2F1 
site spans this region, this unknown factor was confirmed again not to be E2F1. Zaytka 
et al. refer to these unknown factors as VHL-TF1, -TF2, and –TF3, and further studies 
are required to characterise their identity. 
 
actttataag cgtgatgatt gggtgttccc gtgtgagatg ccccaccctc gaaccttgtt -560 
aggacgtcgg cacattgcgc gtctgacatg aagaaaaaaa aattcagtta gtccaccagg -500 
 
 
 
cacagtggct aaggcctgta atccctgcac tttgagaggc caaggcggga ggatcacttg -440 
   
aacccaggag ttcgagacca gcctaggcaa cagagcgaga ctccgtttca aacaacaaat -380  
aaagataatt atcgggcaag gtggtgcgcg cctacagtac caactactcg ggaggctgag -320 
gcgagacgat cgcttgagcc agggaggtca aggctgcatg agccaagctc gcgccactgc -260 
actccagccc gggcgacaga gtgggaccct gtctcaaaaa aaaaaaacaa acaaccaaac –200 
cttagagggg tgaaaaaaaa ttttatagtg gaaatccagt aacgagttgg cctagcctcg –140 
cctccgttac aacagcctgg tgctggagga tccttttgcg cacgcgcaca gcctccggcc –80 
 
 
ggctatttcc gcgagcgcgt tccatcctca accgagcgcg cgcgaagact acggaggtcg –20 
 
 
 
   
 
actcgggagc gcgcacgcag ctccgccccg cgtccgaccc gcggatcccg cggcgtccgg +41 
 
      
 
cccgggtggt ctggaccgcg gagggaatgc cccggagggc ggagaactgg acgaggccga +101 
 
 
CR4
CR1 
AP2
Sp1 
Sp1
GATA 2,3 NF1
E2F
AP4 
AP2Egr 
AhR/Ar 
GATA 2
+1 
cRel,NFkappa
GATA 2cRel,NFkappa 
BARBIE BOX 
Figure 19. VHL promoter sequence. Underlined and in bold, CR1-CR4, the regions of conservation between human 
and rat as defined by Zatyka et al. 2002.  Promoter sequences are the in silico predicted putative binding sites for 
transcription factors. The candidate sites are only shown in regions of conservation. Studies have shown a functional 
Sp1 site and overlapping Sp1/AP2 sites. Other factors remain unidentified. 
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Sp1 is a zinc finger transcription factor which binds to GC rich sequences known 
as ‘GC’ boxes, which have been identified in 5’ regions of many genes [85]. Sp1 sites are 
reported often to regulate initiation of transcription in TATA-less promoters (the VHL 
promoter is TATA-less). Although generally considered to be ubiquitous, Sp1 has also 
been implicated in regulation of tissue specific gene expression [86-88]. It was reported 
that Sp1 is a critical regulator of the Wilms tumour suppressor gene, WT1, and that Sp1 
expression is temporally and spatially regulated during nephrogenesis [89]. Thus Sp1 
has been implicated in renal development. As VHL mRNA foetal expression patterns are 
consistent with a role in nephrogenesis, Zatyka et al. speculate that Sp1, WT1, and VHL 
may have interrelated roles in nephrogenesis [90]. 
 
2.5 3’ untranslated region of the VHL gene 
The 3' untranslated region (3'UTR) of the human VHL was isolated by Renbaum et al. in 
1996 [91]. Several putative non-canonical (ATTAAA) poly(A) signals were identified, and 
the functional significance of these signals was examined. Use of VHL transgene 
deletion mutants indicated that an ATTAAA sequence located between nucleotide +4237 
and +4379 most likely serves as an active poly(A) signal in renal carcinoma cells, 
yielding a 3.6-kb 3'UTR. Sequence analysis revealed a 300- to 600-bp region conserved 
in human, murine, and rat VHL UTRs. In addition, the human 3'UTR was extremely rich 
in Alu repetitive elements. 
Interspersed repetitive sequences have traditionally been dismissed as non-
functional, however, more evidence is accumulating that suggests that these sequences 
can play a role in gene expression and neoplastic transformation [92]. Alu repeat 
sequences are estimated to account for 5% of human genomic DNA, and are found in 
5% of fully spliced cDNAs, usually in the 3’UTR [93]. The region of the VHL gene that 
includes the 3’UTR contains 11 Alu repeat elements in a 4.5-kb DNA segment. 
Interestingly, the Wilms’ tumour gene was found to be regulated by a 460-bp 
transcriptional silencer that contains a full-length Alu repeat and an Alu-mediated 
recombination event has been implicated in a founding mutation in the MLH117 gene of 
hereditary colon cancer. At present no evidence exists that suggests a VHL-related 
functional role for these repeats. However, the high concentration of Alu sequences 
identified in this region (1 per 400-bp) may indicate a mechanism for different types of 
deletions, duplication, and inversions based on Alu-mediated recombination, both in 
germ-line and somatic tissue. 
                                                 
17 MLH1 - Human Mul L Homologue (MLH1) is homologous to the bacterial DNA mismatch repair Mult L gene. Mutations in the 
hMLH1 gene are associated with hereditary non-polyposis colon cancer and various other cancers. 
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2.6 VHL Expression 
 
2.6.1 Expression pattern of VHL mRNA 
 
Latif et al. identified the VHL gene and 
showed Northern blot analysis of VHL 
gene expression in foetal and adult kidney 
and brain as well as in adult adrenal and 
prostate [81]. However the first 
comprehensive study addressing 
expression of the von Hippel-Lindau 
tumour suppressor gene was undertaken 
by Kessler et al. and published in 1995 
[94]. Here the author’s investigated 
expression of the VHL gene in human 
foetal kidney, and during mouse 
embryogenesis using in situ hybridisation 
with 35S-labelled anti-sense VHL probes 
derived from human and mouse cDNAs 
on cryosections of human foetal kidney 
and paraffin sections of murine embryos. 
The results concluded that in human foetal 
kidney, the enhanced epithelial expression 
of the VHL gene is consistent with the role 
of this gene in renal cell carcinoma. 
Furthermore, the report showed 
widespread expression of the VHL gene 
during embryogenesis. An interesting 
observation apparent from the in situ 
investigation was the differential 
developmental VHL expression within 
epithelial cells derived from mesoderm 
(kidney and epididymis), endoderm (lung 
and pancreas), and ectoderm (eye). In 
addition, the localisation of VHL 
expression in human and mouse 
nephrogenesis was consistent with the 
histo-pathologic studies of the origin of the 
clear cell phenotype of renal cell 
carcinoma and their associated VHL 
mutations [95]. To complement this work, 
Table 7. Summary of VHL mRNA expression during 
human embryogenesis 
Germ 
Layer Tissue 
VHL 
Expression 
Endoderm 
Gut 
Pancreas 
Lung 
Pharyngeal pouches 
- 
- 
++ 
- 
Ectoderm 
Dorsal root ganglia 
Periderm 
Brain 
Cranial ganglia (V, VII, VIII) 
Vestibular apparatus 
Eye 
Cephalic mesenchyme 
+ 
(+) 
++ 
+++ 
+++ 
+ 
+ 
Mesoderm 
Heart 
Indifferent gonad 
Mesonephric duct 
Paramesonephric duct 
Bowman’s capsule 
Loop of Henle 
Nephrogenic cord 
Metanephric collecting ducts 
Proximal convoluted tubule 
Perichondrium 
Liver (haematopoietic tissue) 
Adrenal 
Striated muscle 
(+) 
++++ 
++ 
++ 
+ 
++++ 
+ 
++ 
++ 
(+) 
+ 
(+) 
+ 
Figure 20. Quantitative RT-PCR of GAPDH and VHL 
mRNA in 8-10 week human foetal tissues. VHL(1) = 
wt-VHL; VHL(2) = ∆Exon2 VHL; Li=liver; Ki=kidney; 
Br=brain; Ey=eye; SC=spinal cord; Ad=adrenal; 
In=intestine; Pa=pancreas; He=heart; Te=testis; 
Lu=lung; Lm=limbs; Pl=placenta; Tu=adult proximal 
renal tubule cell culture. 
Adapted from Richards et al.1996 
Adapted from Richards et al.1996
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Richards et al. investigated the expression of VHL mRNA during human embryogenesis 
again by in situ hybridisation studies at 4, 6 and 10 weeks post conception. Although 
VHL mRNA was expressed in all three germ layers, they noted strong expression in the 
central nervous system, kidneys, testis and lung. Within the kidney, VHL mRNA was 
differentially expressed within renal tubules, and the authors reiterated the previous 
findings by suggesting that the VHL gene product may have a specific role in kidney 
development.  
 
Moreover, two alternatively spliced VHL mRNAs characterised by inclusion 
(isoform I) or exclusion (isoform II) of exon 2 were transcribed in adult tissues. To 
investigate if the two isoforms were differentially expressed during embryogenesis, VHL 
mRNA was reverse transcribed from 13 foetal tissues (8-10 weeks gestation). The 
quantitative distribution of VHL mRNA within foetal tissues reflected that seen by in situ 
hybridisation and the ratio of the two VHL isoforms was similar between tissues (Fig.20).  
 
2.6.2 Expression pattern of pVHL 
 
Los et al. [96] first addressed expression of VHL protein in human tissues in 1996. The 
VHL protein was widely expressed in normal human tissue. The authors recorded a 
cellular distribution of the protein that was confined to the cytoplasm of specific cell types. 
Immuno-histochemistry did not facilitate the discrimination of tumours obtained from VHL 
patients or tumours unrelated to the VHL disease. Renal cell carcinomas, 
haemangioblastomas, and phaeochromocytomas, either VHL-related or sporadic, 
demonstrated positive staining for the VHL protein, which suggests that the antibody 
used recognised mutated VHL protein. However, no consideration was given to 
alternative pVHL species, e.g. pVHL19. The antibodies used were unexplained, the 
epitopes not described, and no proof of specificity in terms of western blot analysis or 
immuno-precipitation of endogenous pVHL was demonstrated. Without such pertinent 
data, drawing conclusions is difficult. 
 
A year later, Corless et al. re-addressed the issue of pVHL expression in normal 
and neoplastic tissues [3]. At this time, epitope-tagged pVHL had been observed in either 
the nucleus or the cytoplasm of cultured cells, depending on the density of the cell 
culture [97-99]. In this article, the cellular localisation of pVHL in normal and neoplastic 
human tissues was documented using three different monoclonal antibodies, one being a 
commercially available antibody widely used and characterised, Ig32. This monoclonal 
antibody recognises both pVHL30 and pVHL19. The other two antibodies had epitopes 
mapped to a region of amino acids 72-120, hence total pVHL was being detected. Strong 
expression of pVHL was observed in the epithelial cells of all organs examined, 
particularly in renal tubules, and was exclusively cytoplasmic. Lesser degrees of staining, 
also cytoplasmic, were observed in other cell types. 
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A variety of carcinomas (lung, prostate, colon, breast, bladder, and thyroid) 
showed strong cytoplasmic staining for pVHL including four of five sporadic clear cell 
RCC. Of the non-epithelial neoplasms examined, only one tumour, an embryonal 
rhabdomyosarcoma18, failed to stain for pVHL. The findings established widespread 
expression of VHL at the protein level and the authors state that it provided strong 
evidence that most, if not all, pVHL is localised to the cytoplasm of cells in vivo. We now 
know that this is in fact not the case, and pVHL can be both nuclear and cytoplasmic 
(see results).  
  
 
From these studies we can conclude that the areas of highest expression do not 
completely correlate with the tissues that are involved in VHL disease. The tissue 
specificity of VHL disease therefore cannot be entirely explained by tissue-specific 
expression during either foetal development or adulthood. However, the antibodies used 
would not distinguish between the different sized pVHL’s generated by alternative 
translation initiation sites. It is interesting to note that subsequent studies like those 
mentioned have documented VHL mRNA in a wide variety of tissues in a pattern similar 
to the generalised expression of other tumour suppressor genes including retinoblastoma 
and p53 [100, 101]. 
                                                 
18 Rhabdomysarcome is a malignant tumor composed of striated muscle fibers 
Table 8. Summary of normal human tissues positive for pVHL immunostaining 
Epithelial Cells Muscle Cells Lymphoid Cells Other 
Renal tubule 
Renal 
glomerulus 
Colon 
Ileum 
Endometrium 
Bladder 
Prostate 
Thyroid follicle 
Bile duct 
Uterine smooth muscle 
Intestinal smooth muscle 
Vascular smooth muscle 
Skeletal muscle 
Lymphocytes 
Endothelial cells 
Sertoli cells 
Leydig cells 
Spermatogonia / 
spermatocytes 
Peripheral nerve and 
ganglion cells 
Adrenal cortical cells 
Table 9. Summary of human tumours positive for pVHL immunostaining 
Renal Tumours Other Tumours Other Carcinomas Germ Cell Tumours 
Clear cell 
carcinoma 
Papillary carcinoma 
Wilms’ tumour 
Phaeochromocytoma 
Malignant mesothelioma   
   (pleural) 
Islet cell tumour 
Epithelioid 
haemangioendothelioma 
Leiomyoma, uterus 
Sex cord stromal tumour  
    (ovary) 
Thymoma 
Squamous cell carcinoma  
   (lung, oral cavity) 
Small cell carcinoma (lung) 
Adenocarcinoma (lung) 
Adenocarcinoma (prostate) 
Transitional cell carcinoma  
   (bladder) 
Cholangiocarcinoma (liver) 
Ductal carcinoma (breast) 
Papillary thyroid carcinoma 
Seminoma (testis) 
Teratoma (testis) 
Embryonal carcinoma 
(testis) 
Adaped from Corless et al. 1997 
Adaped from Corless et al. 1997 
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2.7 The VHL protein product 
 
Iliopoulos et al. 
demonstrated that the 
product of the VHL gene 
is an approximately 30-
kD protein [97]. In 
addition, they showed 
that the renal cell 
carcinoma cell line 786-
O, which is known to 
harbour a VHL mutation, 
fails to produce a wild-type VHL protein. Reintroduction of wild-type, but not mutant, VHL 
into these cells had no demonstrable effect on their growth in vitro but inhibited their 
ability to form tumours in nude mice. 
 
To understand the mechanisms by which VHL mediates tumour suppression, 
biochemical analyses of VHL gene products were necessary. However, the translation 
start site was not evident from the initial cloning of the human VHL gene [81]. The first 
AUG in the human VHL open reading frame (ORF) was designated as the translation 
start site, i.e., amino acid 1, on the basis of homology between the mouse, rat, and 
human VHL sequences, and a product initiated at this start site was detected in cell lines. 
This site, however, contains a sub-optimal Kozak consensus sequence. A second AUG 
is present in the VHL ORF at codon 54. This region contains a more conserved Kozak 
consensus sequence, and thus serves as a second, internal, translation initiation site. 
The significance of a second translation start site is underscored by the lack of mutations 
found between the first and second methionine codons of the VHL gene in both sporadic 
and VHL-associated renal carcinomas. This observation suggested that mutation in this 
region may not lead to VHL inactivation if translation could be initiated at the second 
methionine codon, producing a functional VHL protein. Furthermore, both the rat and 
mouse contain only 19 of the 53 amino acids present in this region in the human VHL 
ORF. Thus, this 53-amino acid region was thought to make little or no contribution to the 
biologic activity of VHL protein. However, as will be outlined throughout this thesis, subtle 
differences in these two protein products are beginning to emerge, most notably in their 
intra-cellular localisation, the topic of discussion in the following section.  
 
The two distinct native products of the human VHL gene exist with apparent 
molecular weights of 19- and 30-kDa. These protein products are referred to as pVHL19 
and pVHL30 respectively. Schoenfeld et al. were the first to report what at the time they 
termed 18-kDa VHL [102]. They reported the relative abundance of both VHL protein 
species, and demonstrated that that the shorter species was far more abundant in all cell 
lines tested as compared to its full-length counterpart. Importantly, they also 
Figure 21. The VHL protein product. pVHL30 has 213 amino acids, and pVHL19  
160 amino acids. pVHL19 results from translation at codon 54. The N-terminal 
region contains eight copies of an acidic pentameric repeat sequence (GxEEx). 
The tertiary structure is divided into an α and a β domain. Both forms of pVHL 
suppress tumour formation in nude mice experiments. 
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demonstrated that reintroduction of pVHL19 into renal cell carcinoma cells lacking 
functional pVHL (786-0) down-regulated vascular endothelial growth factor (VEGF) and 
glucose transporter 1 (GLUT1), two genes regulated by hypoxia inducible factor (HIF), a 
transcription factor itself regulated by pVHL (see chapter 4). This result suggested that 
pVHL19 may exhibit tumour suppressor activity, a suggestion confirmed by reintroducing 
this species into nude mice which resulted in the suppression of tumour formation. In 
addition, they demonstrated that pVHL19 bound Elongins B and C, previously established 
pVHL30 binding partners. 
 
2.8 Intracellular localisation of pVHL 
 
pVHL sub-cellular localisation has 
been represented somewhat 
confusingly in the literature. 
Several reports demonstrated both 
nuclear and cytoplasmic signals. 
pVHL has also been mapped to 
endoplasmic reticulum and 
mitochondria. Localisation patterns 
may be effected by changes in the 
cell cycle, cell density, and 
mutations in pVHL [98, 99, 103-
105]. Localisation studies began in 
1995 when Duan et al. reported 
FLAG-tagged pVHL30 over-
expressed in COS-7 cells exhibit a 
nuclear, nuclear/cytoplasmic or 
cytoplasmic signal in immuno-
fluorescence. A follow up paper by 
Lee et al. a year later supported this observation and developed it further by stating that 
the localisation pattern of rat pVHL is cell density dependent. They observed that in cells 
that are confluent, pVHL localises uniquely to the nucleus of NRK cells when stably over-
expressed, whereas in cells that are sparse, the localisation is rendered cytoplasmic. 
They also identified a domain that represents a putative bipartite nuclear localisation 
signal (NLS) they mapped to a region within the first 60 amino acids of human VHL 
sequence and the first 28 in rat VHL (PR[R/K]…RPRPV). This sequence is in good 
agreement with known NLS consensus sequences, i.e. hepta-peptide rich in lysine and 
arginine (fig.22) [105, 106]. However, the functional significance of this NLS remains 
unclear because no thorough mutational inactivation of this sequence has been 
analysed. Nonetheless, these data provided the initial indication of a cell density-
dependent pathway that could in part be responsible for the regulation of pVHL cellular 
Exon: 1 2 3
PRR(X)53RPRPV : 
PRRRPRPV  : Human 
PRKRPRPV  : Rat 
   RKRPRP     : PVLTP 
     KRPRP     : AV E1a 
PKKKRK–V : SV40 LTA 
A)
B)
Figure 22. A) Putative bipartite nuclear localization signal in the first 
60 amino acids in human VHL. Shaded box represent the acidic N-
terminal repeats. B) Comparison of the bipartite NLS of human, rat, 
polyomavirus large tumour antigen (PVLTP), adenovirus E1a protein 
(AVE1a), and a simian virus 40 large tumour antigen (SV40 LTA). 
Adapted from Lee et al. 1996 
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localisation. Understanding the molecular signalling generated upon cell contact that 
culminates in a localisation shift of pVHL is needed. 
 
 Studies by Ye et al. demonstrated that sub-cellular localisation of pVHL is 
regulated in a cell cycle dependent manner [103]. They illustrated exclusive VHL nuclear 
accumulation in cells that are in the G1/Go phase of the cell cycle, whereas the majority of 
cells in S-phase also showed a diffuse cytoplasmic staining. This study was the first to 
examine endogenously expessed pVHL. However antibodies used were raised against 
the N-terminus and C-terminal regions, but no attempts were made to differenciate 
between pVHL30 and pVHL19. While differences in localisation were observed, they may 
have reflected changes in one or other species, and not shifts in total pVHL. Subsequent 
work presented in this thesis shows a strong nuclear localisation with some cytoplasmic 
staining for pVHL19, while pVHL30 localises predominantly to the cytoplasm of 
logarhythmically growing cells (Fig.23). 
 
 Other reports have localised pVHL to 
cellular organelles including mitochondria and 
endoplasmic reticulum. Shiao et al. 
demonstrated that immuno-gold electron 
microscopy localised GFP-tagged pVHL30 to 
the mitochondrion [104]. VEGF, TGF-β1 and 
ubiquitination-associated enzymes have all 
been localised to the mitochondrion. In addition 
the mitochondrion plays a key role in glucose 
and lipid metabolism, and alteration in these 
processes as a result of abnormal VHL could 
lead to accumulation of glycogen and lipid in 
the cytosol, as seen in clear cell renal 
carcinoma [1].  For these reasons, the authors 
justify a mitochondrial localisation. Despite the 
tempting assumption, no endogenous data is 
shown, and no biochemical evidence is given in 
support of the above statement. Furthermore, 
attempts to reproduce similar findings with 
endogenous pVHL cast doubt on this finding 
(Barry and Krek; data not shown). 
 
 In 2001, Schoenfeld et al. claimed to have mapped a 64 amino acid region in VHL 
responsible for its association with the endoplasmic reticulum (ER) [105]. They report 
that native and exogenous VHL products co-localise with markers of the ER in renal cell 
lines, and that sub-cellular fractionation of both native and exogenously expressed pVHL 
are found predominantly in the cytosolic compartment. Schoenfeld and colleagues 
GFPVHL30 
GFPVHL19 
Figure 23. Mouse NIH3T3 fibroblasts stably 
expressing GFP-VHL30 and GFP-VHL19 
following retro-viral transduction. Dapi 
represents nuclear staining; GFP represents 
VHL localisation with respect to alternative 
translation products, pVHL30 and pVHL19. 
Adapted from chapter 7, Results. 
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mapped the region 114-177 as the site necessary for pVHL cytosolic sub-cellular 
localisation as well as ER association. The authors attempted to reinforce their findings 
by analysing this region for mutational events. It is true that this region is a region of 
frequent mutation, and the author’s use this to suggest that proper pVHL sub-cellular 
localisation with respect to the ER may be necessary for pVHL-mediated tumour 
suppression. This group originally published the finding of a second native pVHL product, 
pVHL19. Surprisingly there is no mention of differences between the localisation patterns 
of alternative translation products.  
 
 Work published by our laboratory, some of which will be detailed in the results 
section of this thesis, demonstrates that pVHL30 and pVHL19 show different localisation 
patterns (fig.22) [107]. Moreover, while pVHL19 is predominantly nuclear, pVHL30 may 
reside in both the nucleus and cytosol, and when in the cytosol it can associate with the 
microtubule network. The microtubule-binding domain has been mapped and lies 
between residues 95-123, a mutational hot spot in VHL disease. The consequence of 
pVHL binding to microtubules is to stabilise them. Interestingly, mutations associated 
with type 2C disease fail to stabilise the microtubule array, while mutations associated 
with other VHL clinical types do. This data has identified a role for pVHL in the regulation 
of microtubule dynamics, and provides insights into the function of pVHL in the 
pathogenesis of type 2C malignancies, namely haemangioblastoma and 
phaeochromocytoma. 
 
To summarise, pVHL has been shown to exhibit intra-cellular dynamics by 
shuttling in and out of the nucleus, for as yet, unexplained reasons. pVHL30 and pVHL19 
exhibit different localisation patterns, with pVH30 residing predominantly in the cytoplasm 
of logarythmically growing cells, and pVHL19 in the nucleus.  pVHL can partially localise 
to the ER mediated by a region in pVHL corresponding to ∆114-177. It has also been 
shown to bind microtubules in vivo, and that the region of pVHL responsible for this 
interaction is ∆95-123. Evidence exists that pVHL localisation can be affected by stimuli 
including cell cycle changes, cell density and stress signalling including serum 
deprivation, hypoxia, UV radiation and microtubule destabilising drug treatment. 
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2.9 Structure of VHL 
 
Biochemical studies revealed that VHL forms a ternary complex with the Elongin C and 
Elongin B proteins [98, 108]. The VHL-Elongin C-Elongin B complex (henceforth VCB 
complex) has a central role in VHL function because most of the tumour-derived 
mutations destabilise this complex [98, 108, 109]. Furthermore, peptide mapping studies 
showed that a 12-amino acid region of VHL that contains nearly a quarter of the tumour-
derived mutations makes key interactions with Elongin C [109], tightly linking the Elongin 
C binding and tumour suppression functions of VHL. The following section outlines the 
biochemical structural analysis of a pVHL–Elongin C and pVHL-HIF1α interaction. 
 
2.9.1 Structural analysis of Elongin C- pVHL interaction 
 
Stebbins et al. first solved the crystal 
structure of pVHL in 1999.  They showed 
that VHL has two domains: a roughly 100-
residue NH2-terminal domain rich in β sheet 
(β domain) and a smaller α-helical domain 
(α-domain), held together by two linkers and 
a polar interface (Fig.24). A large portion of 
the α-domain surface, and a small portion of 
the β domain, interacts with Elongin C. 
About half of the tumourigenic mutations 
map to the α domain and its residues that 
contact Elongin C [2]. The remaining 
mutations map to the β domain, and 
significantly, the author’s noted to a 
β domain surface patch uninvolved in 
Elongin C binding. This suggested that two 
macromolecular binding sites might be 
required for the tumour suppressor effects of 
VHL. At this time HIF had not yet been 
identified as a VHL binding protein. 
 
The β domain of VHL consists of a seven-stranded β sandwich (residues 63 to 
154) and an α helix (H4; residues 193 to 204) that packs against one of the β sheets 
through hydrophobic interactions  (Figs. 24 and 25). The α domain of VHL (residues 
155 to 192) consists of three α helices (H1, H2, and H3). A helix from ElonginC (H4) 
completes the four-helix cluster arrangement, giving two pairs of helices packing at a 
perpendicular angle (Fig.24). The α and β domains are connected by two short 
α domain β domain 
Figure 24. The VCB ternary complex. On the left is a ribbon 
diagram illustrating the secondary structure of the VCB complex. 
On the right is a topology diagram in which circles indicate 
helices and wide arrows indicate strands. C, COOH-terminus; N, 
NH2-terminus. 
Adapted from Stebbins et al. 1999
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polypeptide linkers (residues 154 to 156 and 189 to 194) and by a polar interface that is 
stabilised by hydrogen-bond networks from the H1 helix, the β sandwich, and Elongin C. 
Several of the residues at the inter-domain interface have been found mutated in 
tumours. 
 
The H1 helix of the VHL α domain 
coincides with the 12-amino acid segment shown 
to be important for Elongin C binding, and the 
structure reveals that it makes extensive contacts 
to Elongin C. The most significant van der Waals 
contacts are made by Leu158, which protrudes 
from the H1 helix and fits into an Elongin C 
pocket, and by Cys162 and Arg161 (Fig.26). These 
are augmented by contacts from the Lys159, 
Val165, Val166, and Leu169 side chains of VHL. The 
other two helices of the α-domain also contribute 
contacts (Leu178, Ile180, and Leu184), with Leu184 
making the most extensive ones in this region. 
Additional contacts are made by residues in the 
first α-β linker (Leu153 and Val155) and by Arg82 
from the β domain. The hydrogen bonds made by 
Arg82, together with those made by Lys159 and 
Arg161 from the H1 helix, represent the few 
significant hydrogen-bond contacts made at the 
VHL-Elongin C interface. The arginine side chains 
are also anchored in the hydrogen-bond networks 
of the VHL α-β domain interface.  
 
Figure 26. The VHL-Elongin C interface consists of an 
intermolecular hydrophobic four-helix cluster 
augmented by additional contacts. VHL and Elongin C 
secondary structural elements are shown in red and blue, 
respectively. VHL amino acids are in yellow and those of 
Elongin C are in cyan. Hydrogen bonds are indicated by 
white dashed lines. Red atoms indicate oxygen and blue, 
nitrogen. A red circle with the letter "M" indicates a 
residue that is one of the six most frequently mutated in 
cancer. The Elongin C pocket where the VHL Leu158 
binds is made up of Tyr76, Phe93, Leu103, and Ala107, and 
Cys112. 
Adapted from Stebbins et al. 1999 
Figure 25. Sequence of VHL demonstrating that tumour-derived missense mutations are divided between the α
and β domains of VHL, whereas residues contacting ElonginC cluster in the α domain. The histogram represents 
279 mis-sense mutations in the database (Beraud et al. 1998). The six most frequently mutated amino acids are 
labelled. Shaded squares above each residue describe the relative solvent exposure of a residue in a hypothetical VHL 
monomer. Blue boxes indicate residues that make hydrogen bonds or van der Waals contacts with Elongin C. 
Adapted from Stebbins et al.1999 
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In addition the 40-amino acid SOCS (suppressor of cytokine signalling) -box 
sequence motif was shown to bind Elongin C and to contain sequence homology with the 
H1 helix of VHL. When the sequence of the SOCS1 SOCS box was compared to a 
library of 1,925 structures, the VHL α-domain ranked first [110, 111]. In this alignment, 
the pattern of hydrophobic residues in SOCS-1 and the SOCS-box consensus matches 
that of the entire VHL α-domain (Fig.27). These findings, in conjunction with the reported 
SOCS box-Elongin C binding data [110], indicate that the SOCS box and VHL α-domain 
represent a common structural and functional motif. Growing evidence suggests that the 
SOCS box, similar to the F-box of the SCF (Skp1-Cul1-F-box protein) complex, acts as a 
bridge between specific 
substrate-binding domains 
and the more generic 
proteins comprise a large 
family of E3 ubiquitin 
protein ligases [112]. As 
discussed again in chapter 
4, this sequence and 
structural homology 
helped unveil the first 
known function of pVHL as 
a component of an E3 
ubiquitin ligase complex. 
 
2.9.2 Structural analysis of HIF1α - pVHL interaction 
 
The proposed model by Stebbins et al. that residues located within the β domain, a 
domain to which many mutations have been attributed, is an alternative macromolecular 
binding site required for tumour suppressor effects by VHL was confirmed structurally in 
a follow up paper by the Pavletich group in 2002 [113]. In this paper, Min et al. 
demonstrated that pVHL binds Hypoxia Inducible factor-1α (HIF-1α), and that this 
interaction is dependent on a modification involving molecular oxygen which results in 
the hydroxylation of a conserved Proline residue at position 564 within the HIF1α 
sequence [113, 114]. The consequence of this interaction is targeting of HIF-1α for 
ubiquitin-mediated proteasomal degradation [114]. It is now also appreciated that a 
second proline hydroxylation event occurs at Pro-402 of HIF-1α. These sites contain a 
conserved LxxLAP motif and are targeted by a newly defined prolyl hydroxylase activity 
that in mammalian cells is provided by three isoforms termed PHD (prolyl hydroxylase 
domain) 1–3 (see chapter 4). 
 
The structure illustrated in figure 28 shows that a 15-amino acid portion of HIF-1α 
(residues 561 to 575) adopts an extended, β strand-like conformation. It binds pVHL in a 
bipartite manner, with two discontinuous HIF-1α segments interacting with a continuous 
Figure 27. Alignment of the VHL α-domain, the SOCS1 and SOCS-box 
consensus, and the Skp2 and F-box consensus sequence. The VHL secondary 
structure is shown above the alignment and the α-domain is indicated.  Residues 
that stabilise the four-helix cluster are indicted in blue. Regions predicted to be α-
helical are underlined in red.  
Adapted from Stebbins et al 1999 
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site on pVHL. A six-residue 
N-terminal segment (residues 
561 to 566) that is centred on 
Hyp564 (Hyp is the three-letter 
code for hydroxyproline), and 
a four-residue C-terminal 
segment (residues 571 to 
574) are separated by a four-
amino acid bulge that does 
not contact pVHL (Fig.28.B).  
HIF-1α interacts exclusively 
with the β domain of pVHL. It 
binds alongside the 
β sandwich, making five 
backbone-backbone 
hydrogen bonds. The side of 
the pVHL β sandwich where 
HIF-1α binds has the 
hydrophobic core partially 
exposed. This exposed hydrophobic patch, together with several partially buried polar 
residues, makes up the binding site of the hydroxyproline. The hydroxyproline has a 
central role in complex formation. It is nearly entirely buried, with 96% of its accessible 
surface area in a hypothetical free peptide covered by pVHL. The pyrrolidine ring inserts 
toward the partially exposed hydrophobic core of the pVHL β domain, making multiple 
van der Waals contacts with Trp88, Tyr98, and Trp117 of pVHL (Fig.29). The 4-hydroxyl 
group inserts farthest into pVHL and forms 
hydrogen bonds with the Nδ of His115 and the 
OH group of Ser111, both of which also form 
hydrogen bonds with other pVHL groups. The 
pVHL residues that interact with Hyp564 are 
highly conserved in the human, mouse, frog, 
fly, and worm pVHL orthologues (Fig.28.B). 
Trp88, Tyr98, His115, and Trp117 are among the 
11 β domain residues that are invariant in the 
five orthologues, and Ser111 is replaced with a 
threonine in the frog, fly, and worm. Mutations 
of Tyr98, Ser111, and Trp117 of pVHL have been 
shown to abolish HIF1α binding [115]. 
Compared with Hyp564, the other N-segment 
residues make significantly fewer contacts. 
Among them, Ile566 makes the most contacts, 
Figure 29. The contacts made by the N segment, and in 
particular by Hyp564, are central to the binding of HIF1α 
to pVHL. The side chains of HIF1α and pVHL are coloured 
in light blue and yellow, respectively. The backbones of 
HIF1α and pVHL are in medium blue and red, respectively. 
The dotted lines indicate hydrogen bonds between the Gln67 
Oδ1, Tyr98 Oη, His110 NH, and His110 CO groups of pVHL, 
and the Leu562 NH, Hyp564 CO, Tyr565 NH, and Tyr565 CO 
groups of HIF1α.  
Adapted Min et al.2002 
Figure 28. The HIF1α 
destruction sequence binds 
the β domain of pVHL. (A) 
Schematic representation of the 
15-residue portion of the HIF-1α 
destruction sequence bound to 
the β domain of pVHL in the 
pVHL-ElonginB-ElonginC 
complex. HIF1α is in blue, Hyp564
in yellow, pVHL in red, ElonginB 
in magenta, and ElonginC in 
green. (B) Alignment of the first 
destruction sequence (containing 
Hyp564) in the ODDs of HIF1α 
orthologues and HIF2α and 
HIF3α paralogues, highlighting 
residues identical in seven of the 
nine sequences. The putative N 
and C segments of the second 
destruction sequences 
(containing Hyp402) of HIF1α and 
HIF2α orthologues are aligned 
below. The reported second 
destruction sequence is 
38 residues long, and only a 23-
residue region containing the 
conserved LxxLAP motif  that 
aligns with the first destruction 
sequence is shown. 
Adapted from Min et al. 2002 
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interacting with Pro99 and Ile109 of pVHL. Met561 packs with Phe91 of pVHL, Leu562 with 
Tyr112 and Arg69, Ala563 with Trp88, and Tyr565 with His110 (Fig.29). These side-chain 
contacts occur on the surface of the complex, however, and are unlikely to make a major 
contribution to specificity and affinity compared with Hyp564.  
A second, independent destruction sequence containing Hyp402 within the HIF-1α 
ODD interacts with pVHL in a similar mode assuming seven instead of four residues in 
the bulge between its putative hydroxyproline-containing N-segment- and C-segment-like 
sequences (Fig.28.B) [7].  This awaits further structural determination. 
 
2.10 Sequence Homology 
 
Comparative genome analysis can provide novel insights into gene evolution and 
function. The VHL gene is highly conserved in primates, rodents, flies and worms [116]. 
In the fly, Drosophila Melanogaster, an overall 50% similarity between fly and human was 
calculated, and 76% similarity in the elongin C binding site [117, 118]. Figure 30 
illustrates the nucleotide sequence alignment of the VHL open reading frame for human, 
rat and mouse.   
 
 
H.Sapiens         ATGCCCCGGAGGGCGGAGAACTGGGACGAGGCCGAGGTAGGCGCGGAGGAGGCAGGCGTC 
R.Norvegicas      ATGCCCCGGAAGGC--------------------AGCTAGTC-CAGAGGAGGCAG----- 
M.Musculus        ATGCCCCGGAAGGC--------------------AGCCAGTC-CAGAGGAGGCGG----- 
                  ********** ***                    **  ** * * ******** *      
 
H.Sapiens         GAAGAGTACGGCCCTGAAGAAGACGGCGGGGAGGAGTCGGGCGCCGAGGAGTCCGGCCCG 
R.Norvegicas      --AAAG---------------------------------GATGCCG--------GGCTCT 
M.Musculus        --CGGG---------------------------------GGAGCCC--------GGTCCT 
                       *                                 *  ***         **  *  
 
H.Sapiens         GAAGAGTCCGGCCCGGAGGAACTGGGCGCCGAGGAGGAGATGGAGGCCGGGCGGCCGCGG 
R.Norvegicas      GAAGAG---------------------------------ATAGAGGCTGGGCGGCCGCGG 
M.Musculus        GAGGAG---------------------------------ATGGAGGCTGGGCGGCCGCGG 
                  ** ***                                 ** ***** ************ 
 
H.Sapiens         CCCGTGCTGCGCTCGGTGAACTCGCGCGAGCCCTCCCAGGTCATCTTCTGCAATCGCAGT 
R.Norvegicas      CCGGTTTTACGCTCTGTGAACTCGCGCGAACCCTCTCAGGTCATCTTCTGCAACCGCAGC 
M.Musculus        CCGGTGCTGCGCTCGGTGAACTCGCGCGAGCCCTCTCAGGTCATCTTCTGCAACCGCAGC 
                  ** **  * ***** ************** ***** ***************** *****  
 
H.Sapiens         CCGCGCGTCGTGCTGCCCGTATGGCTCAACTTCGACGGCGAGCCGCAGCCCTACCCAACG 
R.Norvegicas      CCGCGCGTCGTGCTGCCTTTGTGGCTCAACTTTGATGGTGAGCCTCAGCCCTACCCGACC 
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M.Musculus        CCGCGCGTCGTGCTGCCTTTGTGGCTCAACTTCGACGGCGAGCCTCAGCCCTACCCGATC 
                  *****************  * *********** ** ** ***** *********** *   
 
H.Sapiens         CTGCCGCCTGGCACGGGCCGCCGCATCCACAGCTACCGAGGTCACCTTTGGCTCTTCAGA 
R.Norvegicas      TTACCACCGGGCACCGGCCGCCGCATCCACAGCTACCGAGGTCACCTTTGGCTCTTCAGG 
M.Musculus        TTACCACCGGGCACCGGCCGCCGCATCCACAGCTACCGAGGTCATCTTTGGCTCTTCAGG 
                   * ** ** ***** ***************************** **************  
 
H.Sapiens         GATGCAGGGACACACGATGGGCTTCTGGTTAACCAAACTGAATTATTTGTGCCATCTCTC 
R.Norvegicas      GATGCGGGGACCCATGATGGACTTCTGGTTAACCAAACGGAACTGTTTGTGCCATCCCTC 
M.Musculus        GATGCGGGGACCCATGATGGACTTCTGGTTAACCAAACGGAGCTGTTTGTGCCATCCCTC 
                  ***** ***** ** ***** ***************** **  * *********** *** 
 
H.Sapiens         AATGTTGACGGACAGCCTATTTTTGCCAATATCACACTGCCAGTGTATACTCTGAAAGAG 
R.Norvegicas      AATGTTGATGGACAGCCTATTTTTGCCAACATCACATTGCCAGTGTATACCCTGAAAGAG 
M.Musculus        AATGTCGATGGACAGCCTATTTTTGCCAACATCACATTGCCAGTGTATACCCTGAAAGAG 
                  ***** ** ******************** ****** ************* ********* 
 
H.Sapiens         CGATGCCTCCAGGTTGTCCGGAGCCTAGTCAAGCCTGAGAATTACAGGAGACTGGACATC 
R.Norvegicas      CGGTGCCTTCAGGTTGTACGGAGCCTGGTCAAGCCTGAGAACTACAGGAGGCTGGACATC 
M.Musculus        CGGTGCCTTCAGGTTGTGCGGAGCCTGGTCAAGCCTGAGAACTACAGGAGACTGGACATC 
                  ** ***** ******** ******** ************** ******** ********* 
 
H.Sapiens         GTCAGGTCGCTCTACGAAGATCTGGAAGACCACCCAAATGTGCAGAAAGACCTGGAGCGG 
R.Norvegicas      GTCAGGTCGCTCTATGAAGACTTGGAAGACCACCCAAATGTGCGGAAAGACATACAGCGG 
M.Musculus        GTCAGGTCACTCTATGAGGATTTGGAGGACTACCCAAGTGTGCGGAAGGACATACAGCGA 
                  ******** ***** ** **  **** *** ****** ***** *** *** *  ****  
 
H.Sapiens         CTGACACAGGAGCGCATTGCACATCAACGGATGGGAGA------T------------TGA 
R.Norvegicas      CTGACCCAAGAGCACCTCGAGAATCAGGCCCTGGGAGAGGAGCCTGAAGGAGTCCACTGA 
M.Musculus        CTGAGCCAAGAGCACCTTGAGAGTCAGCACCTGGAAGAGGAGCCT------------TGA 
                  ****  ** **** * * *    ***     *** ***      *            *** 
 
Figure 30. Nucleotide sequence alignment of predicted VHL open reading frames in human (H.Sapiens), rat 
(R.Norvegicus) and mouse (M.Musculus).  Evolutionary analysis would suggest that the N-terminal repetitive 
sequence in pVHL30 (red) is of less functional importance than those regions present in both pVHL30 and pVHL19 due 
to lack of conservation. Identity with human: Mouse: 81.8%; Rat: 80.7%. 
 
 As already discussed, the N-terminal sequence of pVHL30 contains eight copies of 
a GxEEx acidic repeat motif in human and higher primates, but only three copies were 
present in the marmoset, and only one copy was present in rodent VHL genes [116, 
119]. Due to lack of conservation, evolutionary analysis would suggest that the N-
terminal repetitive sequence in pVHL30 is of less functional importance than those 
regions present in both pVHL30 and pVHL19. Importantly however, there is good 
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correlation between the pVHL domains that demonstrate most evolutionary conservation 
and those that were most frequently mutated in tumours.  
 
Comparative analysis like that illustrated in Figure 30 has demonstrated 
conservation of the VHL gene product across many millions of years during evolution.  
Studies undertaken by Woodward et al. have highlighted not only this conservation 
throughout primates, but also as far back as to C.Elegans, demonstrating a much older 
evolutionary lineage dating from the beginnings of metazoan evolution [119]. The 
identification of a C.Elegans homologue is important for several reasons. First, 
conservation of amino acid sequence across such an evolutionary distance suggests the 
presence of a protein of significant functional importance. Second, C.Elegans provides 
an excellent experimental model organism in which to study the basic processes that are 
altered in human disease, and as we will see in chapter 4, the system from which the 
proline hydroxylases, proteins essential for HIFα regulation by pVHL, were isolated. 
 
 
H.Sapiens           MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPR 
M.Musculus          MPRKAAS-----------------PEEAAGE--------P---GPE------EEMAGPRR 
R.Norvegicus        MPRKAAS-----------------PEEAERM--------P---GSE------EIEAGRPR 
D.Melanogaster      --------------------------MALQI----------------------AQNNRDG 
C.Elegans           --------------------------MSDGS---------------------MDDDGRLF 
                                                                          : .*   
 
H.Sapiens           PVLRSVNSRE-PSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLF 
M.Musculus          PVLRSVNSRE-PSQVIFCNRSPRVVLPLWLNFDGEPQPYPILPPGTGRRIHSYRGHLWLF 
R.Norvegicus        PVLRSVNSRE-PSQVIFCNRSPRVVLPLWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLF 
D.Melanogaster      QQLVGADQGKVEVYVLFANTTYRTLDLYWVCERERENMYLTLKPFEEVRVNTFTTHSWLF 
C.Elegans           PDLGSSTHDNREIRVRFLNRCAYPVDVFWLNPSKQPTKYGTLAQKKYLDIKTFKDHPWVA 
                      * .    :    * * *     :   *:    .   *  *       ::::  * *:  
 
H.Sapiens           RDAGTHDGLLVNQTELFVPS--------LNVDGQPIFAN---ITLPVYTLKERCLQVVRS 
M.Musculus          RDAGTHDGLLVNQTELFVPS--------LNVDGQPIFAN---ITLPVYTLKERCLQVVRS 
R.Norvegicus        RDAGTHDGLLVNQTELFVPS--------LNVDGQPIFAN---ITLPVYTLKERCLQVVRS 
D.Melanogaster      RDYYTGERMHVRSQRIFQPIRVRVPKSQQSPDQLVDVRSEVLIHFPMRSLRENCLWLVAR 
C.Elegans           RRSFDGCKVLVNEKEVFWPE--------PAPRMNLIVRNHCVITMKVQSLREIAGRSFLR 
                    *       : *.. .:* *                 . .   * : : :*:* .   .   
 
H.Sapiens           -LVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD------ 
M.Musculus          -LVKPENYRRLDIVRSLYEDLEDYPSVRKDIQRLSQEHLESQHLEEEP---- 
R.Norvegicus        -LVKPENYRRLDIVRSLYEDLEDHPNVRKDIQRLTQEHLENQALGEEPEGVH 
D.Melanogaster      WLIRTSNAPRRIIHGYHIPSTLKQQLLSLLTCIESYSRVAGTRRRR------ 
C.Elegans           -HNPTEVPNKIKGLPRELQFEVKHFLDRKQEYSEIVCRSIPPPGPQRPQQ-- 
                        ..   :            .              :               
 
 
 
 
Figure 31. Amino acid sequence alignment of pVHL in human (H.Sapiens), mouse (M.Musculus), rat 
(R.Norvegicus), fly (D.Melanogaster) and worm (C.Elegans).  Alignment according to ClastalW 
ch.EMBnet.org. Underlined are GXEEX acidic repeats. 
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As already mentioned, doubt has been cast on the importance of a second 
translational start site due to the lack of mutations found between the first and second 
methionine codons of the VHL gene in both sporadic and VHL-associated tumours. This 
observation suggests that mutation in this region might not lead to VHL inactivation if 
translation could be initiated at the second methionine codon, producing a functional VHL 
protein. Furthermore, both rat and mouse contain only 19 of the 53 amino acids present 
in this region of the human VHL ORF. 
 
 
Interestingly, the acidic motif Gly-X-Glu-Glu-X, which is repeated eight times in the 
N-terminal 53-amino acid region of the human sequence (fig.31), is repeated only once in 
the rodents and not at all in the fly or worm [119]. However, according to Woodward et 
el., all primates with available sequences contained eight acidic repeats, with the 
exception of the marmoset, which only had three. The marmoset reflects evolutionarily, 
the oldest of the primates in this study. Therefore it is likely that this motif arose in 
progressively higher species by a series of duplications. Ironically, when the VHL gene 
was identified, the only significant homology between the predicted VHL gene product 
and other known proteins was the G-X-E-E-X repeat, showing similarity to a pro-cyclic 
surface membrane protein of Trypanasoma brucei.  However, as already mentioned, 
subsequent investigations have cast doubt on the significance of this acidic repeat 
domain. Nonetheless, one study reports a significant pathogenic VHL mutation in the first 
53 amino acids [5]. Here, 102 Swedish renal cell carcinomas were analysed for VHL 
mutations.  In 47 patients, 70 new mutations were found, and most of them represented 
novel variations of the VHL gene.  
 
Fig 33. Distributions of the detected VHL mutations according to Ma et al. [5]. The X-axis indicates the 
number of the residue affected by mutations. The Y-axis indicates the number of renal cell carcinomas carrying 
mutations at designated residues. In red is the novel hotspot region located between residues 1-53. 
1st Met 2nd Met
1 54
Figure 32. Amino acids 1-54 of human VHL. Eight acidic pentameric repeat sequences are present (GxEEx). 
Only one repeat is present in rat and mouse, while all are conserved in primates. 
 GxEEx GxEEx GxEEx GxEEx GxEEx GxEEx GxEEx GxEEx                      
 M   PRRAENWDEAEV GAEEA GVEEY  GPEED  GGEES  GAEES  GPEES GPEEL GAEEE M  
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Three novel hotspots were detected in the study, among them, an interesting 
mutation located in the N-terminal sequence of VHL. Five clear cell renal cell carcinomas 
and one chromophilic renal cell carcinoma harboured a 15-nucleotide in-frame deletion 
(codons 41-45) at a duplex tandem repeat sequence site. In 5 out of 6 patients the wild-
type allele was lost in the tumour samples, suggesting a causal role for the mutations in 
renal cell carcinoma. However, five patients with this deletion reside in the same hospital 
district. Unfortunately, the authors were unable to determine if the deletion was an 
inherited polymorphism or a sporadic mutation, because no other normal tissue was 
available from these patients or their biological relatives. 
 
This study indicates a potentially significant role for the N-terminal region. 
Furthermore, the fact that several groups have shown that both translational initiation 
sites are utilised in vivo, and that two protein products, despite the acidic repeat 
discrepancies, are conserved from rodents through to humans, and that pVHL19 exhibits 
functional activity as well as an alternative cellular localisation pattern suggests distinct 
functions for both protein products, pVHL30 and pVHL19 [102, 107, 120]. It could also be 
suggested that mutations within the pVHL30 N-terminal region may not be tolerated, 
thereby reflecting a critical role for this region in VHL biology in higher species. 
 
 
Concluding Remarks 
 
The comparative analysis of genomes is an important strategy in the molecular study of 
gene function. Such studies enable the reconstruction and understanding of functions 
that have been acquired, those that have been lost, and those that have a common 
heritage. The identification of specific mutations associated with human disease 
phenotypes complements the definition of regions of conserved homology across 
different animal species, and together these approaches provide a powerful molecular 
genetic tool toward the understanding of structure-function relationships in genes and 
proteins. Before looking at the functional implications of the VHL protein product, it is 
important to understand the fundamentals of VHL gene alterations, a topic which strikes 
at the core of VHL disease and the subject of consideration in the following chapter. 
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CHAPTER 3 
Mutational analysis of the VHL gene 
 
 
3.1 Introduction 
 
Von Hippel-Lindau disease is caused by germline mutation of the VHL tumour 
suppressor gene followed by somatic inactivation of the remaining wild-type allele. 
Somatic biallelic VHL inactivation can also give rise to tumours, and requires inactivation 
of both VHL alleles after birth. In the following section, an introduction to the concept of 
tumour suppressor gene inactivation is discussed, followed by an outline of the types of 
mutations that occur in the VHL gene. While mutational analysis in VHL disease is 
somewhat complicated, an attempt to simply this has been based on the following 
general criteria: 
 
A. Genotype-phenotype correlations 
B. Germline mutations 
C. Somatic mutations 
- Allelic deletions 
- Intragenic mutations 
- Methylation 
D. Somatic mutations in sporadic tumours 
 
There have been conflicting reports as to whether the spectrum of VHL mutations 
observed in VHL disease differs with respect to the mutations observed in sporadic 
tumors [121, 122]. It is possible that some sporadic VHL mutations would not be 
tolerated in the germ line (e.g., if associated with certain "gain-of-function" effects) and 
that some sporadic VHL mutations are non-random because of exposure to specific 
environmental carcinogens. This chapter is aimed at summarising the available 
information regarding germ-line and sporadic mutations found in the VHL gene. The 
mutations identified are and will be useful in pre-symptomatic diagnosis. Such analyses 
that identify mutations associated with phenotypes contribute to the understanding of 
fundamental genetic mechanisms of VHL disease. 
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Molecular analyses reveal a broad spectrum of somatic 
VHL defects. Almost any nucleotide of the coding sequence 
may be affected by substitutions, deletions, or insertions (table 
10) [122-126], and other changes may involve methylation 
[95]. Although most of these alterations seem distributed at 
random, some occur more frequently. For example, somatic 
mutations in RCCs cluster within VHL exon 2 [123]. Although 
many reports have added a lot of knowledge about VHL, it 
must be recognised that many patients with VHL disease still 
experience insufficient counselling [127]. Databases like that 
established by Beroud et al where to date some 823 VHL 
mutations are documented, help greatly 
to clinically characterise mutations in 
VHL [2]. However, for most mutations 
the number of known carriers is very 
low. To get a rough idea of a mutation-
based VHL type, more than 10 carriers 
(though preferably 30-50) should be 
analysed. Table 11 outlines mutations 
in which 10 or more carriers have been 
analysed. It is also important to 
characterise for each lesion the 
percentage of symptomatic and 
asymptomatic carriers, sex distribution, 
age of onset of symptoms or detection 
as an asymptomatic lesion. For many 
mutations, this information is 
unavailable, but efforts, like those by 
Beroud et al. are helping to centralise 
this information and process the 
overwhelming abundance of 
information generated by such 
mutational studies. Figure 34 illustrates 
the mutational profile across the VHL 
poly-peptide. These studies have 
highlighted mutational hotspots in 
pVHL, which in turn have helped in the 
identification of protein interface regions 
important in pVHL tumour suppression, 
namely Elongin C and Hifα. 
Table 10. Spectrum of 
mutations in the VHL gene
Mutation     VHL 
 Total 795 
 Frameshifts  297 (36,08%)
 Deletions  235 (28,55%)
 Insertions  62 (7,53%) 
 Point mutations  496 (63,68%)
 Missense  399 (48,48%) 
 Nonsense  97 (15,2%) 
Table 11. Top 20 mutated 
residues in pVHL 
Position Number of Frequency
 records 
 1. 167  54  6,56 % 
 2. 161 33  4,01 % 
 3. 155  24  2,92 % 
 4. 98  23  2,79 % 
 5. 114  20  2,43 % 
 6. 76  20  2,43 % 
 7. 86  19  2,31 % 
 8. 81  19  2,31 % 
 9. 158  18  2,19 % 
10. 162  17  2,07 % 
11. 78  15  1,82 % 
12. 178  13  1,58 % 
13. 65  13  1,58 % 
14. 68  12  1,46 % 
15. 117  12  1,46 % 
16. 88  12  1,46 % 
17. 136  11  1,34 % 
18. 89  11  1,34 % 
19. 175  10  1,22 % 
20. 96  10  1,22 % 
Figure 34. Distribution 
of VHL-mutations are 
concentrated in the 
HIFα and Elongin C 
binding domains. Red 
bars highlight the ten 
most frequent mutations 
as outlined in box 2. 
Below the histogram is 
the VHL protein. 
Noteworthy, residues 88-
111 constitute the pVHL- 
Hyp564 interacting 
interface which harbours 
the frequently mutated 
residue Y98, the ‘black 
forest’ founder  mutation.
Some 823 germ-line and 
somatic mutations have 
been collected so far 
(www.umd.be) - Beroud 
et al. 1998; Maddock et 
al. 1996; Maher et al. 
1999. 
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3.2 Structural analysis of pVHL highlights mutational hot-spots 
 
The tumour-derived mis-sense mutations map 
evenly to the α- and β-domains, each of the 
domains containing three of the six most 
frequently mutated residues [2]. In the α-domain, 
the H1 helix (fig.24, chapter 2) is the primary 
target of tumourigenic mutations. It contains the 
most frequently mutated residue, Arg167, which 
has a structural role stabilising the H1 helix and 
the α-β domain interface, and an additional 
mutational hotspot, Cys162, which contacts 
Elongin C (Fig.25). The third hotspot in the α-
domain is Leu178, and it has dual roles interacting with Elongin C and also stabilising the 
H2-H3 packing of the α-domain. The remaining α -domain mutations map to residues 
involved in the packing of the helices (such as Val170, Ile180, Leu184, and Leu188), or in 
stabilising the α-β inter-domain interface (Arg161 and Gln164). Several of these residues 
also make important contacts to Elongin C (Arg161, Ile180, and Leu184). This pattern of 
mutations in the α-domain solidifies the role Elongin C binding has in the tumour 
suppressor activity of VHL. 
 
As already mentioned in 
chapter 2, the pVHL residues that 
interact with Hyp564 residue of HIF-
1α are highly conserved in the 
human, mouse, frog, fly, and worm 
pVHL orthologues (Fig.28.B, 
chapter 2) and mutations of Tyr98, 
Ser111, and Trp117 of pVHL have 
been shown to abolish HIF1α 
binding [115]. The importance of a 
pVHL-HIFα interaction is supported 
by the distribution of VHL tumour-
derived missense mutations, which 
tend to cluster at the Hyp564 binding 
site of pVHL (Fig.35) [2]. All of the 
five pVHL residues that contact 
Hyp564 are mutated at high frequencies. In fact, Tyr98, whose side chain is not important 
for the structural integrity of the β sandwich but which contacts both the pyrrolidine ring 
Figure 35. The VHL ribbon diagram is coloured by mutational 
frequency. Grey indicates an absence of tumour-derived 
mutations, red less than 1.5% of the total mutations, orange 1.5 to 
3% of total mutations, and yellow 3 to 17% [2]. The latter 
correspond to the six most frequently mutated residues, which are 
labelled. Elongin C is shown in blue. The mutational cluster of 
surface residues on the β domain is indicated.  
Adapted from Stebbins et al.1999 
Box 12. 10 Most frequently 
mutated residues 
Residue Records Function 
R167 54 Packing of α-helices
R161 33 Elongin C binding 
V155 24 Elongin C binding 
Y98 23 Hyp564 binding 
G114 20 HIF binding? 
F76 20 HIF binding? 
P86 19 HIF binding? 
P81 19 HIF binding? 
L158 18 Elongin C binding 
C162 17 Elongin C binding 
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and backbone carbonyl group of Hyp564, is the second most frequently mutated amino 
acid of pVHL (the first one, Arg167, maps to the α-β inter-domain interface) [111, 128]. 
 
Understanding how mutations in pVHL contribute to tumourigenesis is crucial in 
trying to delineate molecular mechanisms underlying the pathological phenotype. A 
theory proposed by a renowned cancer researcher has helped our understanding of 
tumourigenesis, a theory to which VHL conforms, and the subject of the next section. 
  
3.3 Knudson’s two-hit hypothesis for tumourigenesis 
 
Much of what scientists know about the origins of cancer and the role of tumour 
suppressors can be traced back 33 years to the elegant theory of cancer researcher 
Alfred G. Knudson. Widely thought to be one of the most significant theories in modern 
biology, the "two-hit" theory explains the relationship between the hereditary and 
nonhereditary, or sporadic, forms of retinoblastoma, a rare cancer affecting one in 
20,000 children. Years prior to 
the age of gene cloning, 
Knudson's 1971 paper 
proposed that individuals will 
develop cancer of the retina if 
they either inherit one mutated 
retinoblastoma (Rb) gene and 
incur a second mutation 
(possibly environmentally 
induced) after conception, or if 
they incur two mutations or 
hits after conception [129]. If 
only one Rb gene functions 
normally, the cancer is 
suppressed. Knudson coined 
these preventive genes anti-
oncogenes; other scientists 
renamed them tumour 
suppressors. 
 
Knudson’s two-hit theory of tumour development may not apply to all cancers, but 
the basic concept was validated with the cloning of the Rb tumour suppressor gene. It 
was demonstrated that in retinoblastomas, both copies of Rb genes are inactivated, thus 
the ‘hits’ necessary to transform a cell toward malignancy can be both inherited and 
acquired. In agreement with this hypothesis, previous analyses of VHL disease-
Figure 36. Knudson’s two-hit hypothesis for tumourigenesis.  (A) Somatic 
inactivation of both alleles of a tumour suppressor gene (TSG) is necessary for 
tumour formation. (B) As one inactivated allele has already been inherited, only 
inactivation of the corresponding TSG allele is necessary for tumour 
progression. 
Adapted from Richards et al. 2002 
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associated neoplasms have consistently demonstrated both VHL gene mutations and 
deletions in tumours that are associated with the syndrome [79]. That is, people with the 
disease are born with one mutated copy of the VHL gene. Tumours develop when the 
other, normal, copy is inactivated (by mutation or hyper-methylation) in a susceptible cell. 
People with two normal copies of the VHL gene may also develop sporadic cancers if 
both copies are inactivated. In this case, the VHL gene is inactivated some time after 
birth. 
 
3.4 Genotype-Phenotype Correlations in VHL Disease 
 
Complex genotype-phenotype associations are a notable feature of VHL disease. As 
already mentioned in section 1.1, although retinal angiomas and CNS 
haemangioblastomas are hallmarks of the disease, some families display a high risk of 
concurrent phaeochromocytoma (type 2 VHL) but others do not (type 1 VHL) [35]. Type 
2 VHL families can be further subdivided into type 2A (low risk of renal cell carcinoma), 
type 2B (high risk of renal cell carcinoma) and type 2C (exclusively phaeochromocytoma 
without other characteristics of VHL disease). This is outlined in table 3 and includes 
some mutations most commonly associated with the phenotype.  
 
In general, type 2 disease is associated with subtle VHL mutations, such as 
missense mutations, that would be predicted to give rise to conformationally intact pVHL 
mutants [35, 127, 130-133]. In contrast, type 1 disease is often associated with mutations 
that should grossly alter the structure of pVHL or lead to complete absence of pVHL. This 
latter set of observations has led to speculation that type 2 mutants acquire a ‘gain of 
function’ that is linked to the induction of phaeochromocytoma [43, 111]. Alternatively, it 
Table 13. VHL disease types and different germ-line VHL mutations 
VHL disease type Tumour types observed in families 
Germline VHL mutation types most 
commonly associated with phenotype 
 HB RCC Phaeo  
Type 1 + + - Deletions and truncations1 
Type 2A + - + Missense Tyr98His2 and Tyr112His 
Type 2B + + + Missense 
Type 2C - - + Missense Leu188Val, Val84Leu, Ser80Leu 
1 Truncations include both frameshift and nonsense mutations. 
2 The ‘Black Forest’ founder mutation. 
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is possible that complete loss of pVHL function is incompatible with phaeochromocytoma 
development. 
 
In addition to regulation of HIF, pVHL has been implicated in the control of 
extracellular matrix formation and the cell-cycle (functional analysis of pVHL is discussed 
in more detail in chapter 4) [134-138]. Hoffman et al. showed that type 2C pVHL mutants 
retained the ability to interact with HIFα and to down-regulate HIFα target genes when 
reintroduced into pVHL-defective tumour cells. This provides a biologically plausible 
mechanism to account for the low risk of haemangioblastoma associated with these 
mutants. Furthermore, they demonstrated that pVHL mutant L188V can suppress renal 
carcinoma growth in vivo, suggesting that deregulation of HIF contributes to pVHL-
defective renal tumourigenesis. In contrast however, L188V, like classical null pVHL 
mutants, is defective in promoting extracellular fibronectin matrix assembly. This might 
suggest that abnormal extracellular matrix formation following pVHL inactivation 
contributes to the development of phaeochromocytoma in the setting of VHL disease, 
thereby, at least in part, explaining the clinical sub-divisions in VHL disease. These 
studies strengthen the notion that HIF deregulation plays a causal role in 
haemangioblastoma and renal carcinoma, and raises the possibility that abnormal 
fibronectin matrix assembly contributes to phaeochromocytoma pathogenesis in the 
setting of VHL disease. 
 
 
3.5 Germline Mutations 
 
Germ cells are the 
reproductive cells of the 
body, i.e. the sperm and egg 
cells. Germ-line mutations 
are those present in a parent 
that can be passed on to 
offspring through the egg or 
sperm cell. Because the 
mutation is present at 
conception in the original 
fertilised egg, when that cell 
replicates its genetic material 
and divides, the mutation is 
copied in all future cells. Thus, an inherited mutation is present in every cell of the body. 
A person who inherits a mutation in a specific cancer susceptibility gene, like the VHL 
gene, can develop cancer more easily, have bilateral or multiple cancers, and at a 
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younger age than a person born without such a mutation. The reason being that every 
cell already carries an inherited mutation. Therefore, every cell is already one step closer 
to malignant transformation. 
 
Germline mutations are found in up to almost 100% of the families fulfilling the 
clinical VHL criteria [31, 34, 43]. Missense, nonsense, splice site mutations, and micro-
deletions and –insertions, are detected in approximately two-thirds of patients [34, 35, 
133]. In one-third of the VHL families, large deletions (4-380 kb) are found. Such 
deletions are demonstrated by southern blot analysis [34], pulsed field gel 
electrophoresis [139], or fluorescent in situ hybridisation (FISH) . 
 
The scope of this thesis does not allow 
addressing each mutation individually, instead a 
summary of the more frequent germ-line mutations 
will be discussed as outlined in table 14.  Codon 167 
missense mutations are particularly associated with 
Type 2B VHL disease, with a high incidence of 
phaeochromocytoma within the families. Two 
specific missense mutations are associated with 
Type 2A VHL (presenting with phaeochromocytoma 
and haemangioblastoma, but no RCC); these are 
Tyr98His (the Black Forest mutation) and Tyr112His, 
otherwise referred to as Y98H and Y112H 
respectively [35, 140, 141]. Interestingly, a different 
missense mutation at codon 112 (Tyr112Asn) in one 
family has given rise to VHL disease that has so far resulted in RCC, retinal and 
cerebellar haemangioblastoma and one case of phaeochromocytoma (Type 2B) [142]. 
Specific missense mutations have also been observed in families with 
phaeochromocytoma but none of the other features of VHL (Type 2C VHL disease, or 
familial phaeochromocytoma); these are Leu188Val [62, 63], Val84Leu [65] and 
Ser80Leu [143]. Individuals with these mutations are unlikely to develop 
haemangioblastomas or RCC. However, some patients with apparently isolated 
phaeochromocytoma have mutations in Type 2B VHL disease (e.g. Arg167Trp); these 
individuals are at risk of developing the other tumour types [65]. 
 
The lack of protein-truncating mutations in Type 2 VHL disease suggests a bias 
against complete loss-of-function mutations for susceptibility to phaeochromocytoma; 
this has been confirmed by mapping of the mutations onto the structure of pVHL [111].  
Table 14. Examples of germ-
line VHL-mutations and 
disease class correlations 
Mutation Cases Class 
Y98H 21 Type 2A 
Y112H 4 Type 2A 
Y112N 1 Type 2B 
F119L 5 Type 2B 
R167W 21 Type 2B 
F119S 1 Type 2C 
L188V 5 Type 2C 
V84L 1 Type 2C 
- Type 1 disease is associated 
generally with deletions and 
truncations which include both 
frameshift and nonsense mutations 
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3.6 somatic mutations 
 
In contrast to germline mutations, somatic mutations are confined to somatic cells of an 
individual (i.e. any cell type except germ cells), and are therefore not heritable. Somatic 
mutations that occur in tumour suppressor genes in relevant tissues might initiate cancer 
development. Tumours from VHL patients generally show deletion, mutation or 
methylation of the wild-type allele such that there is loss of the normal function of VHL in 
tumours. This is characteristic of a tumour suppressor gene. There have been conflicting 
reports as to whether the spectrum of VHL mutations observed in VHL disease differs 
with respect to the mutations observed in sporadic tumours [121, 122], and as already 
mentioned, it is possible that some sporadic VHL mutations would not be tolerated in the 
germ line (e.g., if associated with certain "gain-of-function" effects) and that some 
sporadic VHL mutations are non-random because of exposure to specific environmental 
carcinogens. 
 
In an interesting study by Prowse et al., the mechanism of tumourigenesis in VHL 
disease tumours was investigated to determine whether there were differences between 
tumour types or classes of germ-line mutations [144]. Fifty-three tumours (30 RCCs, 15 
haemangioblastomas, 5 phaeochromocytomas, and 3 pancreatic tumours) from 33 
patients (27 kindreds) with VHL disease were analysed. Overall, 51% of 45 informative 
tumours showed loss of heterozygosity (LOH) at the VHL locus. In 11 cases it was 
possible to distinguish between loss of the wild-type and mutant alleles, and in each 
case the wild-type allele was lost. LOH was detected in all tumour types and occurred in 
the presence of both germ-line missense mutations and other types of germline mutation 
associated with a low risk of phaeochromocytoma. Intragenic somatic mutations were 
detected in three tumours (all haemangioblastomas) and in two of these it was shown to 
occur in the wild-type allele. This provided the first example of homozygous inactivation 
of VHL by small intragenic mutations in this type of tumour. Hypermethylation of the VHL 
gene was detected in 33% (6/18) of tumours without LOH, including 2 RCCs and 4 
haemangioblastomas. Although hypermethylation of the VHL gene has been reported 
previously in non-familial RCC and although methylation of tumour-suppressor genes 
has been implicated in the pathogenesis of other sporadic cancers, this was the first 
report of somatic methylation in a familial cancer syndrome. 
 
3.6.1 Allelic deletions 
 
In many patients with VHL disease, germ-line mutations of the coding region of the VHL 
gene are absent. Instead, most of these patients exhibit deletion of one entire copy or at 
least a substantial part of the VHL gene [145]. The criteria for establishing VHL disease 
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are based on clinical diagnosis and identification of VHL gene mutations. Although 
substantial progress has been made in defining the precise mutations causing the 
disease, approximately 20% of patients with clinically established VHL disease do not 
show mutations with exhaustive VHL gene sequencing analysis [122, 130, 133]. 
Previous studies have shown that some of these VHL patients carried constitutional 
deletions of the VHL gene [146, 147]. However, there is no simple and reliable technique 
to detect gene deletions in the germ-line screening of VHL. 
 
In the past, pulse field gel electrophoresis has been used to detect VHL germ-line 
deletions [59, 146, 147]. Presently, quantitative normalised Southern blot analysis is 
used for deletion screening [34]. However, these techniques are laborious and rely on 
quantitative comparison of band intensities. Therefore, results can be difficult to interpret 
and may require confirmation by other methods. In addition, extended deletions can be 
missed by this technique because of the small size of the genomic probes typically used. 
In an article published in Cancer Research in 1999, Pack et al. demonstrated that 
fluorescent in situ hybridization  (FISH) can be used to detect deletions in the VHL locus. 
FISH has already been successfully used in gene mapping studies as well as in the 
identification of gene alterations, including deletions and translocations, in a variety of 
human diseases, and was the premise for this study [148]. FISH had until then not been 
applied to the detection of constitutional VHL gene alterations. The advantages of using 
this technique are manifold, and include: the ability to assess individual cells; detection of 
variable deletion sizes; technical simplicity; and the ability to identify deletion mosaicism. 
In the study, Pack et al. used FISH and genomic probes that cover the VHL locus and its 
flanking regions to analyse constitutional deletions in patients clinically diagnosed with 
VHL disease who did not possess VHL gene point mutations.  They re-examined a group 
of VHL patients shown previously by single-strand conformation and sequencing analysis 
not to harbour point mutations in the VHL locus. Constitutional deletions were found in 
29 of 30 VHL patients in this group using probes that cover the VHL locus. Six 
phenotypically normal offspring from four of these VHL families were then tested: two 
were found to carry the deletion and the other four were deletion-free. In addition, germ-
line mosaicism of the VHL gene was identified in one family. In summary, FISH was 
found to be a simple and reliable method to detect VHL germ-line deletions and 
practically useful in cases where other methods of screening had failed to detect a VHL 
gene abnormality. 
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3.6.2 Intragenic mutations 
 
Figure 37 below is adapted from Richards et al. and develops the distribution of VHL 
mutations illustrated in Figure 34 by comparing Germline VHL mutations that have been 
documented in a panel of 120 VHL families from the UK, and Somatic VHL mutations 
detected in 152 RCCs [35, 132]. Mapping the mutational distributions onto the VHL 
protein highlights mutational hotspot areas. In both cases, mutations cluster within the α 
and ß domains of VHL disrupting the Elongin C and HIFα interface surfaces. Mutational 
documentation and generation of data like that illustrated in figure 37 is crucial in trying 
to identify areas of functional interest within a poly-peptide.  In the case of pVHL, it has 
highlighted the importance of Elongin C and HIFα binding to pVHL. 
Figure 37. The distribution of intragenic VHL mutations. 
Truncating mutations (frameshift and nonsense) are shown with light-green lines; missense mutations 
are indicated with dark-green lines. (A) Germline VHL mutations in a panel of 120 VHL families from 
the UK (Crossey et al. 1994; Zbar et al. 1996). Note that not all of the mutation ‘hotspots’ were 
detected in this panel of families. (B) Somatic VHL mutations detected in 152 renal cell carcinomas 
(RCCs), from the VHL mutation database created by C. Beroud et al.1998. (c) The protein domains 
encoded by the VHL gene aligned to illustrate that most mutations are in the α- and ß-domains. 
Adapted from Richards et al. 2002 
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3.6.3 Methylation 
 
Cancer cells are associated with focal hypermethylation of specific gene promoters. 
Hypermethylation of gene promoters results in the inactivation of the corresponding 
genes. This methylation-associated gene silencing has been demonstrated in various 
genes including tumour suppressor genes – p15, p16, p73 and VHL [149]. Therefore, 
gene promoter hypermethylation collaborates with other mechanisms of gene 
inactivation such as deletion and intragenic mutations to fulfil Knudson’s hypothesis. 
 
DNA methylation, catalysed by 
DNA methyltransferase, involves the 
addition of a methyl group to the carbon 
5 position of the cytosine ring in the 
CpG dinucleotide and results in the 
generation of methyl-cytosine. 
Methylation of cytosine to methyl-
cytosine in DNA is a heritable genetic 
alteration which occurs during cell 
replication in the absence of any change 
in the genetic sequence. In the normal 
mammalian genome, the CpG di-
nucleotides have been progressively 
depleted from the eukaryotic genome 
during evolution, and thus are 
underrepresented in the mammalian 
genome. However, CpG rich regions, 
CpG islands, exist and these are often 
found within the promoter of genes. 
 
The DNA methylation pattern of a 
cell is accurately reproduced after DNA 
synthesis and is stably transmitted to 
the daughter cells. The covalent 
addition of methyl groups to CpG sites 
in the newly synthesized DNA strand is 
mediated by an enzyme known as DNA 
methyltransferase 1 (DNMT1) (Fig.38). 
This enzyme is targeted to the 
replication fork where it efficiently 
methylates DNA containing hemi-
Fig. 38. Schematic overview of DNA 
Methylation. (A) The human genome is decorated with methyl 
groups, which occur nearly exclusively at cytosine residues within 
the symmetric CpG dinucleotide. (B) The postreplicative addition 
of a methyl group to cytosine is catalyzed by DNA 
methyltransferase (DNMT), using S-adenosyl-L-methionine 
(SAM) as a substrate.  
Adapted from Worm et al.2002 
Figure 39. Unmethylated cytosines are found at high densities 
in CpG islands, which usually map to the promoter and first 
exon regions of housekeeping genes. (A) The fully 
unmethylated state of a promoter CpG island (open circles) is 
associated with transcriptional activity, whereas (B) dense 
methylation (closed circles) causes transcriptional silencing. 
Adapted from Worm et al.2002 
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methylated CpGs (postreplicative maintenance methylation). Two additional active DNA 
methyltransferases have been cloned, DNMT3A and DNMT3B, both of which catalyse 
the transfer of methyl groups to 'naked' DNA (de novo methylation) [150]. The 
methylation state of promoter CpG islands confers information about the transcriptional 
activity at these loci. It has been known for many years that, in general terms, there is an 
inverse relationship between the density of promoter methylation and the transcriptional 
activity of a gene (Fig.39). However, the actual mechanisms by which DNA methylation 
modulates gene expression have remained elusive. 
 
Hypermethylation and silencing of tumour suppressor gene expression are 
emerging as an important mechanism in tumourigenesis. Herman et al. reported 
methylation of a normally unmethylated CpG island in the 5’ end of the VHL gene in 19% 
(5/26) of clear cell renal cell carcinoma cell lines [95]. In these lines, VHL 
hypermethylation was associated with silencing of the VHL gene transcript, whereas 
their subsequent chemical demethylation resulted in its re-expression. In addition, 
Prowse et al. demonstrated de novo methylation of the wild-type VHL allele in primary 
tumours from VHL patients concluding that VHL methylation is a specific and important 
event in the pathogenesis of VHL disease [144].  As already mentioned, they showed 
hypermethylation detected in 33% of VHL tumours that do not demonstrate LOH, 
including RCC and haemangioblastoma. 
 
There are now numerous examples of tumour suppressor genes inactivated by 
aberrant CpG island promoter methylation in human cancers [151, 152]. De novo 
methylation of these genes may occur early in tumour progression and lead to abnormal 
function of important cellular pathways, including those controlling cell cycle, apoptosis 
and cell-to-cell growth signalling. 
 
3.7 Somatic mutations in sporadic tumours 
 
Knudson’s tumour suppressor gene hypothesis states that familial cancers arise due to 
the inheritance of a mutated tumour suppressor gene and that a second mutational event 
involving the wild type allele of that gene leads to malignancy. The model predicts that 
the more common, sporadic tumours would arise in the same cell-type after somatic 
inactivation of both copies of the gene responsible for the hereditary cancer [129]. In 
keeping with its role as a tumour suppressor gene, loss of normal VHL function has been 
observed in sporadic tumours of the same types as occur in VHL disease. For this 
reason, identifying and documenting mutations in the VHL gene locus with respect to 
frequency and consequence is very important. Moreover, by comparing specific VHL 
inactivating mutations in both germ-line and sporadic tumours, we can define mutational 
hotspots that help us to functionally investigate VHL function based on structural and 
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biochemical analysis. This ultimately allows us to propose concepts of VHL involvement 
in the more common, sporadic tumours that may arise in tissues similar to those that 
arise in VHL disease. The following sections will detail VHL involvement in sporadic 
RCC, haemangioblastoma and phaeochromocytoma. Unfortunately, due to data 
limitation, other sporadic tumours that form in tissue similar to that of tumours in VHL 
disease could not be discussed. This does not therefore exclude the possibility of VHL 
involvement in other sporadic tumours of the same type as associated with VHL disease.  
 
3.7.1 Mutations in sporadic renal cell carcinoma 
 
Like cancers of the breast, colon and prostate, kidney cancer occurs in both a hereditary 
and a sporadic (non-hereditary) form. The year 2003 marked the 10th anniversary of the 
discovery of the VHL tumour suppressor gene, the first gene identified for hereditary 
RCC that is now known to be involved in approximately 80% of sporadic RCCs, 
accounting for some 2% of all adult neoplasma [153].  In many VHL families, the 
diagnosis of VHL can now be made at birth by detection of VHL gene mutations in blood 
cells. The finding of frequent VHL gene mutations in tumour tissue from patients with 
sporadic kidney cancer provides the opportunity for scientists to significantly improve 
methods for diagnosis of kidney cancer by detecting such mutations, either in tissue 
removed at surgery or by biopsy or, potentially, by searching for VHL gene mutations in 
the urine or circulating cells of patients with this disease. 
 
In a study published in 1994, to elucidate the aetiological role of the VHL gene in 
human kidney tumourigenesis, Gnarra et al. analysed localised and advanced tumours 
from 110 patients with sporadic renal carcinoma for VHL mutations and loss of 
heterozygosity (LOH) [123]. VHL mutations were identified in 57% of clear cell renal 
carcinomas analysed and LOH was observed in 98% of those samples. The 
identification of VHL mutations in a majority of localised and advanced sporadic renal 
carcinomas indicates that the VHL gene plays a critical part in the origin of this 
malignancy [123]. 
 
In another study carried out by Brauch et al. in 2000 to investigate the role of 
somatic alterations for renal cancer aetiology and prognosis, 227 sporadic renal epithelial 
tumours were analysed for mutations and hypermethylations in the VHL gene. Somatic 
VHL mutations were identified by PCR, single-strand conformation polymorphism 
analysis, and sequencing, and hypermethylations were identified by restriction enzyme 
digestion and Southern blotting. Frequencies of VHL alterations were established, and an 
association with tumour type or tumour type and tumour stage was evaluated. VHL 
mutations and hypermethylations were identified in 45% of clear cell renal cell 
carcinomas (CCRCCs). RCCs carrying VHL alterations showed, in nine cases (12%), 
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mutations at a hot spot involving a thymine repeat (ATT.TTT) in exon 2. Tumour staging 
was critical to the VHL mutation/hypermethylation detection rate in CCRCCs shown by 
separate evaluation of patients from medical centers in Münich, Heidelberg, and Mainz. 
The spectrum of pT119, pT2, and pT3 CCRCCs and the VHL mutation/hypermethylation 
detection rate varied among these three groups. Altogether, VHL alterations were 
significantly associated with pT3 CCRCCs. This was the first evidence of frequent 
somatic VHL mutations at a particular site within exon 2 and an association of VHL 
mutations/hypermethylations with a standard prognostic factor. 
 
The spectrum of VHL mutations is enormous.  As already discussed, almost any 
nucleotide of the coding sequence may be affected by substitutions, deletions or 
insertions and other changes may involve methylation. Although most of these 
alterations seem distributed at random, some occur more frequently. For example, 
somatic mutations in RCCs cluster within VHL exon 2 [123]. Also, RCCs of patients with 
defined occupational exposure to a human carcinogen, i.e., the organic solvent 
trichloroethylene, show frequent cytosine to thymine (C→T) transitions and/or a VHL hot 
spot mutation in exon 1 [154]. With the exception of patients with known environmental 
exposure for which non-random VHL mutations may be linked to a specific carcinogen, 
the origin of frequent mutations at other sites remains elusive.  The idea that non-random 
distribution of somatic VHL mutations not only originating endogenously but also from 
exposure to exogenous carcinogens, is supported by the observation of regional 
variations in RCC incidence. For example, for yet unknown reasons, the Bas Rhin region 
of France has one of the highest incidences of RCC in the world [155]. Furthermore, on 
the molecular level, the findings of a wide spectrum of somatic VHL mutation frequencies 
in patients from Europe, the United States, and Japan are unexplained. Therefore, 
comprehensive molecular and histo-pathological data analyses of patients from 
potentially high-risk areas may provide further clues to the aetiology of RCCs and the 
meaning of somatic VHL alterations.  
 
In summary, the contribution of VHL mutation to onset of human RCC has been 
observed in hereditary and is now accepted to be involved in the most cases of sporadic 
RCCs. Current data shows that VHL mutations mainly occurred in clear cell renal cell 
carcinoma. Tumour-type specificity of VHL mutation suggests that different 
carcinogeneic mechanisms underlie different tumour types of RCC, and might determine 
different biological behaviours of tumours, e.g. invasiveness and metastasis. Finally, 
evidence exists, which suggests that the VHL mutation rate might be associated with 
advanced tumour stage of CCRCC. 
                                                 
19 "T" describes the primary tumour within the organ. A small "p" (p stands for pathology) before the T describes how the cancer cells 
look under a microscope. pT1: The primary tumour is localised to tissue of origin. pT2: The tumour is found in tissue of origin, and 
has begun to invade the blood vessels or lymphatic vessels next to the tumour. pT3: The tumour has invaded further blood vessels. 
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3.7.2 Sporadic mutations in CNS haemangioblastoma 
 
Hemangioblastoma is one of the benign tumours in the central nervous system and is a 
hallmark of VHL disease. CNS hemangioblastoma is one of the most frequent 
manifestations of VHL disease, but also may manifest as a sporadic tumour. The 
molecular basis for the development of sporadic haemangioblastomas is however not 
known. Previous reports on mutation analysis of the VHL gene in VHL disease related 
and sporadic CNS haemangioblastomas have yielded a wide range of differing results 
[132, 144, 156-161]. Reported frequencies of loss-of-heterozygosity (LOH) on 
chromosome 3p in disease related haemangioblastomas are 14% (1/7) [132], 27% (3/11) 
[144], 66% (2/3) [158], 100% (4/4) [159] and 62% (13/21) [161] with an average of 40%. 
This indicates that a classic two hit inactivation of the VHL gene is a common 
mechanism in disease-associated haemangioblastomas, i.e germ-line carriers. In a study 
by Gläsker et al., of the 13 sporadic tumours analysed, 23% showed a single somatic 
mutation of the VHL gene that was not present in the germ-line. 3p LOH was identified in 
50% of informative sporadic tumours. No promoter hypermethylation was demonstrated 
in either disease-related or sporadic tumour investigated in this study, which is in 
agreement with Tse et al. [158] but contradicts investigations by Prowse et al. who 
showed that four out of eight CNS haemangioblastoma analysed, demonstrated 
hypermethylation, albeit VHL disease-related tumours, not sporadic tumours. Due to the 
fact that investigations of hypermethylation of the VHL gene in CNS 
haemangioblastomas are based on a small series, it is difficult to draw conclusions, it is 
nonetheless tempting to suggest that the absence of hypermethylation in sporadic cases 
of CNS haemangioblastoma reflect an activity associated uniquely with VHL disease-
related haemangioblastomas.  
 
Cerebellar haemangioblastoma is a benign central nervous system neoplasm with 
characteristic proliferation of vascular and stromal cells. There is increasing evidence 
that the stromal cell population may represent the neoplastic component of 
haemangioblastoma, whereas the vascular component may be composed of reactive, 
non-neoplastic cells. Therefore, successful genetic testing for loss of heterozygosity 
requires selective analysis of target cell populations. In a study by Lee et al. [160], tissue 
micro-dissection was used to selectively analyse the stromal cell component of 20 
sporadic cerebellar haemangioblastomas for loss of heterozygosity at the VHL gene and 
somatic VHL gene mutations. Allelic deletions at the VHL gene locus were detected in 
the stromal cell in 10 of 19 (52.6%) informative cases. In all cases, heterozygosity at the 
VHL gene locus was retained in the vascular component. In two cases, aberrant bands 
in exon 2 of the VHL gene were demonstrated in the stromal cells by PCR-based single-
strand conformation polymorphism analysis, and somatic mis-sense mutations were 
successfully characterised in two of the sporadic haemangioblastomas by direct 
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sequencing. The results support the notion that allelic losses and mutations of the VHL 
tumour suppressor gene play a role in sporadic cerebellar haemangioblastoma 
tumorigenesis. Furthermore, because the genetic changes were detected in selectively 
procured stromal cell areas, the data provide strong evidence that the stromal cell 
represents a neoplastic component of haemangioblastoma. This may explain why VHL-
involvement in sporadic cancer may be under-appreciated, as isolation of the target cell 
population like those studies perfomed by Lee et al., might be necessary in order to 
reveal the true implication of VHL in sporadic tumourigenesis. 
 
However, to reiterate Gläsker et al., they found only three (23%) somatic VHL 
gene mutations in sporadic haemangioblastomas. Only one of these tumours showed 
biallelic VHL gene inactivation due to an additional LOH of the VHL gene region at 3p. 
Their findings of relatively low frequencies of somatic VHL gene mutations in sporadic 
haemangioblastomas and biallelic VHL gene inactivation agree with previous reports, in 
which somatic mutations have been reported with an average of 18% [156-158, 160]. In 
previous studies, no sporadic tumour were shown to have biallelic VHL gene inactivation, 
as these studies did not investigate all inactivating mechanisms, or the tumours retained 
heterozygosity. By contrast, Gläsker et al. investigated all known VHL gene inactivating 
mechanisms and their results are highly suggestive that biallelic VHL gene inactivation is 
not a common mechanism in the tumourigenesis of sporadic CNS haemangioblastoma. 
 
In conclusion, it would seem therefore that the data to date, despite the above-
mentioned findings by Lee et al., would suggest that the genetic pathways involved in 
pathogenesis in VHL disease haemangioblasroma versus sporadic haemangioblastoma 
are distinct. Further investigations on chromosome 3p in CNS haemangioblastomas are 
warranted to clarify this hypothesis further. 
 
3.7.3 Sporadic mutations in phaeochromocytoma 
 
Phaeochromocytomas arise sporadically and as an associated tumour of the inherited 
cancer syndromes VHL, multiple endocrine neoplasia type 2 (MEN 2), and type 1 
neurofibromatosis. Germ-line mutations of the VHL tumour suppressor gene are 
responsible for VHL disease, and germ-line RET proto-oncogene mutations are 
associated with MEN 2. Bender et al. conducted an investigation to examine a large 
series of 36 VHL-related phaeochromocytomas for somatic VHL and RET gene 
alterations and loss of heterozygosity (LOH) of markers on chromosome arm 3p, 
hypermethylation of the upstream VHL-CpG island, and LOH of markers at chromosomal 
arms with putative relevance for MEN 2 and sporadic phaeochromocytomas, namely 1p 
and 22q [162-165]. For comparison, the same analyses were performed in 17 sporadic 
phaeochromocytomas. They found no somatic intragenic mutations within VHL and RET 
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in any VHL or sporadic phaeochromocytoma, and no phaeochromocytoma demonstrated 
upstream VHL gene hypermethylation. Interestingly, they found significantly different 
LOH frequencies between sporadic and VHL tumours; the more than 91% LOH of 
markers on 3p and the relatively low frequencies of LOH at 1p and 22q (15% and 21%, 
respectively) in VHL phaeochromocytomas argue for the importance of VHL gene 
deregulation and dysfunction in the pathogenesis of almost all VHL 
phaeochromocytomas. In contrast, the relatively low frequency of 3p LOH (24%) and the 
lack of intragenic VHL alterations compared with the high frequency of 1p LOH (71%) 
and the moderate frequency of 22q LOH (53%) in sporadic phaeochromocytomas argue 
for genes other than VHL, especially on 1p, that are significant for sporadic 
tumourigenesis and suggest that the genetic pathways involved in sporadic versus VHL 
phaeochromocytoma tumourigenesis are distinct. 
 
Originally VHL disease-associated phaeochromocytomas were believed to abide 
by the Knudson two-hit mechanism of tumourigenesis. This was based on 4 studies 
encompassing a total of only 12 VHL pheochromocytomas and a broad range of 3p LOH 
frequencies with an average of 50% [144, 162, 166, 167]. The study by Bender et al. is 
based on 36 VHL-associated pheochromocytomas, and demonstrated for the first time 
that indeed a complete and biallelic 2-hit VHL inactivation is a necessary pathogenetic 
mechanism for these tumours. In more than 91% of such tumours, the second hit is 
somatic deletion of the 3p region encompassing the remaining wild-type VHL allele. In 
contrast to VHL tumours, sporadic phaeochromocytomas have a relatively low frequency 
of 3p LOH, which supports 4 other reports that demonstrated LOH at 3p in 35% of a total 
of 52 sporadic tumours [162, 164, 165, 167]. These studies together with the observation 
of a lack of somatic intragenic VHL mutations in sporadic tumours indicate that VHL-
related and sporadic phaeochromocytomas do not share common pathogenic pathways. 
Bender et al. demonstrate convincingly that although the VHL gene plays a principal role 
in the tumourigenesis of VHL phaeochromocytoma, alterations in VHL appear in sporadic 
phaeochromocytomas to a significantly lesser extent. Instead, an as yet unidentified 
factor(s) residing perhaps on 1p plays a major role in sporadic tumourigenesis. Tumour 
suppressor genes on 22q may also contribute to sporadic phaeochromocytoma.  
 
 
Concluding Remarks 
 
These observations of genetic alterations in VHL-related and sporadic 
pheochromocytoma (and indeed CNS haemangioblastomas) are in contrast to 
observations that have been made among inherited cancer syndromes with involvement 
of tumour suppressor genes to date. Sporadic counterparts of associated tumours in 
several inherited cancer syndromes share a common genetic aetiology and pathogenic 
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pathway. The classic example is retinoblastoma, on which the Knudson two-hit 
hypothesis is based. In heritable retinoblastoma, the first hit is germ-line mutation of the 
RB gene, and the second hit is a somatic mutation or deletion of RB [168, 169]. In 
sporadic retinoblastoma, two somatic mutations affecting RB are the genetic basis of 
tumourigenesis [169]. This is also true of p53 mutations in Li-Fraumeni syndrome and its 
sporadic counterpart tumours osteosarcoma, soft tissue sarcomas, and glioblastomas 
[170, 171], and APC mutations in familial adenomatous polyposis and a subset of 
sporadic colon cancer [172, 173]. With respect to the VHL gene, its biallelic inactivation is 
a well-known feature in VHL-related as well as sporadic renal clear cell carcinomas 
where inactivation is observed in up to 80% of sporadic cases. However, there are other 
examples in the literature where the genetic pathway in a hereditary cancer is different 
from the sporadic counterpart. For example, although germ-line BRCA1 and BRCA2 
mutations are associated with the hereditary breast-ovarian cancer syndrome, less than 
1% of sporadic breast cancers or ovarian cancers harbour somatic BRCA1 or BRCA2 
mutations [174, 175]. Further, breast carcinomas from BRCA1 mutation carriers have 
been described to harbour different genetic alterations compared with their sporadic 
counterparts [176-178]. Thus, the different frequencies of VHL inactivation, and LOH at 
1p, 3p, and 22q between VHL disease-associated and sporadic phaeochromocytoma 
suggest that in contrast to renal clear cell carcinoma, different genetic pathways might be 
involved in hereditary versus sporadic disease, a situation more akin to the BRCA loci 
and breast cancer.  
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CHAPTER 4 
Functional analysis of the VHL tumour suppressor 
 
 
4.1 Introduction 
 
This chapter outlines the role of pVHL as a substrate recognition component of an E3 
ligase complex that specifically targets hypoxia inducible factor α (HIFα) for degradation. 
It details HIF regulatory mechanisms and hypoxia-induced gene expression and 
discusses the consequences of this ubiquitin-mediated proteolytic event. Finally, 
additional substrates, which have been identified for the pVHL E3 ligase complex, and 
other protein interactions that are either ligase independent or facilitate pVHL’s function 
as an E3 ligase, are discussed. 
 
4.2 pVHL and ubiquitin-mediated proteolysis 
 
The discovery of the complex cascade of the ubiquitin pathway revolutionised the field of 
protein degradation. It is now clear that degradation of cellular proteins is a highly 
complex, temporally controlled, and tightly regulated process that plays major roles in a 
variety of basic pathways during cell life and death, and in health and disease. With the 
multitude of substrates targeted, and the myriad of processes involved, it is not 
surprising that aberrations in the pathway are implicated in the pathogenesis of many 
diseases, as is the case in VHL disease. The discovery of the ubiquitin/proteasome 
pathway emerged from efforts to understand why intracellular proteolysis, measured as 
the release of amino acids from intact cells, requires metabolic energy [179]. Key 
elements of the answer became clear in the early 1980's as a result of the pioneering 
biochemical studies of Hershko and coworkers. These investigators found that energy, in 
the form of ATP, is needed to modify proteolytic substrates with ubiquitin, a highly 
conserved 76 amino acid polypeptide that is joined to a substrate lysine side chain 
through an isopeptide bond to ubiquitin's C terminus [180, 181]. Ubiquitination occurs 
through sequential steps catalysed by activating (E1), conjugating (E2), and ligase (E3) 
enzymes (Fig.40) [182]. The presence of multiple substrate-linked ubiquitins recruits the 
26S proteasome, a 2.5 MDa complex that uses energy derived from ATP hydrolysis to 
unfold the substrate polypeptide chain and translocate it into an interior chamber [183]. 
Having arrived at this site, the substrate is hydrolysed by a nucleophilic mechanism to 
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produce small peptides. Ubiquitin is spared from degradation through its release from the 
substrate (or a substrate fragment) by deubiquitinating enzymes [181]. Thus, there are 
two independent reasons why ATP is required for intracellular proteolysis: to activate 
ubiquitin's C-terminus in preparation for conjugation, and to support the proteasome's 
substrate unfolding and translocation activities. 
 
As figure 40 illustrates, ubiquitin 
(Ub) is conjugated to other 
proteins through an amide bond, 
called the isopeptide bond, 
between the C-terminal (glycine 
76) residue of Ub and the ε-amino 
group of a lysine residue in an 
acceptor protein. Ub is activated 
for conjugation to other proteins 
by a Ub-activating enzyme (E1), 
which couples ATP hydrolysis to 
the formation of a high-energy 
thioester bond between Gly76 of 
Ub and a specific cysteine residue 
of E1. The E1-linked Ub moiety is moved, in a trans-esterification reaction, from E1 to a 
Cys residue of a Ub-conjugating enzyme (E2), and from there to a lysine residue of an 
ultimate acceptor protein, yielding a Ub-protein conjugate. This last step requires the 
participation of another component, called the E3, which acts as the substrate 
recognition complex recruiting specifically substrates to be ubiquitinated and 
subsequently degraded. It has been shown by our laboratory and others that pVHL 
constitutes an E3 ligase complex, and acts as the substrate recognition component of 
this complex [184, 185].  
 
4.3 pVHL is a component of an E3 ubiquitin ligase complex 
 
Because protein degradation must be highly selective in order for the cell not to destroy 
itself, the substrate recognition step mediated by enzymes called E3 ubiquitin ligases is 
crucial. Not surprisingly, given the multitude of substrates, E3 ligases are a highly 
diverse group. One way in which the cell achieves such diversity is by engaging 
numerous substrate-specific adapter proteins that recruit protein substrates to core 
ubiquitin complexes. A superfamily of E3 ubiquitin ligase complexes have emerged – the 
SCF (Skp1-Cdc53/Cul1-F-box protein) family, the APC (Anaphase Promoting Complex) 
family, and the more recently discovered VCB-Cul2 (VHL-Elongin C/Elongin B-cullin 2) 
Figure 40. Components and Mechanisms in the Ubiquitin-
Proteasome Pathway. Overview of  ubiquitin-mediated proteolysis 
showing how ATP is used in its conjugative and degradative 
phases. E1, E2, and E3 are ubiquitin activating, conjugating, and 
ligase enzymes, respectively.  
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complex (Fig.41). The SCF family is the exemplar for combinatorial control of E3 ligase 
specificity. SCF complexes contain adapter subunits called F-box proteins that recognise 
different substrates through specific protein-protein interaction domains [186]. F-box 
proteins link up to a core catalytic complex – composed of Skp1, Cdc53 (cullin 1 in 
metazoans), and the E2 ubiquitin-conjugating enzyme, Cdc34 – through the F-box motif, 
which is a binding site for Skp1. There are hundreds of F-box proteins, and known 
targets of SCF complexes range from cell cycle regulatory proteins such as cyclins and 
CDK inhibitors and transcriptional regulators such as IκB and β–catenin, among many 
others [187, 188]. For example, our laboratory demonstrated that the F-box protein SKP2 
promotes p27Kip1 degradation and induces S phase in quiescent cells [189]. 
 
 
The APC is a second E3 ligase that uses different adapters to target different 
substrates, which include mitotic cyclins and other proteins that regulate mitosis [190]. 
Interestingly, the APC2 subunit of the APC complex turned out to be a homologue of 
Cdc53, fuelling the idea that the SCF and APC complexes had a possible distant 
relationship. The third complex, composed of pVHL and its associated subunits Elongin 
B, Elongin C, and cullin 2 was presumed to comprise an E3 ligase complex based on 
sequence and structural similarity between complex components.   
 
It had been well established that pVHL stably associates with the two regulatory 
subunits B and C of the trimeric transcription elongation factor, elongin [191-193]. Initial 
investigation demonstrated that pVHL bound tightly and specifically to elongin B and C 
subunits and it was proposed that, by virtue of its ability to compete for elongin A, this 
binding inhibited the activity of the transcriptional elongation complex, SIII, which is a 
complex consisting of Elongin A, B and C [191]. However this evidence was only shown 
in vitro, and has since never been confirmed. Furthermore the authors acknowledge in a 
Figure 41. Comparison of 
the structural homology 
between SCF, APC and 
VCB-Cul2 ubiquitin ligase 
complexes. Each complex 
interacts with a set of adapter 
molecules that recruit different 
binding partners through 
specific protein-protein 
interaction domains such as 
WD40 repeats and leucine-
rich repeats (LRR). 
Representative examples are 
shown below each complex. 
Rbx1 and its homologue 
Apc11 may play a role in 
tethering components to each 
other and in activating the E2 
enzyme. Question marks 
indicate speculative 
components of interactions. 
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follow up paper in 1997 that they were unable to prove this in vivo and that since pVHL is 
found in a stable complex with elongin B and C, it is unlikely that pVHL actively 
competes with elongin A thereby affecting transcriptional elongation. This finding led 
them to rethink their model and propose an alternative cellular function for the VCB 
complex. In addition the pVHL-elongin C binding interface represents a 12 amino acid 
stretch shown to be a mutational hotspot region which further underlines the functional 
significance of this complex [192].  This region is referred to as the BC-box motif and is 
contained within the SOCS box domain as explained in chapter 2 [111].  
 
Pause et al. further demonstrated that the VCB complex bound a member of the 
cullin family of proteins, cullin 2, which had been previously shown to be involved in cell-
cycle control in yeast, and in cell growth in C.Elegans. Cullin 2 interaction was shown to 
be dependent on the integrity of trimeric VCB complex, and that naturally occurring 
mutations that interfere with binding of elongin’s also eliminate binding to cullin 2.  
 
The emergence of Rbx1 (Ring-box) proved equally important in helping to define 
the first known function of pVHL. Kamura et al. defined Rbx1 as a stoichiometric 
component of the mammalian VCB-Cul2 complex and, prompted by the finding that 
Rbx1 interacts directly with the Cdc53 homologue cullin 2, determined that Rbx1 was 
also an integral component of the human and yeast SCF complexes [194]. Rbx1 is a 
close homologue of the APC subunit Apc11, which together with Rbx1 defines a distinct 
subclass of RING finger proteins. The RING finger is a small, metal-binding domain often 
found in sub-units of multi-protein complexes [111].  In the SCF complex, Rbx1 interacts 
with Cdc53/Cul1, Cdc34 (E2 enzyme), and with several different F-box proteins, but 
does not interact with Skp1 [194]. Kamura et al. also demonstrated that Rbx1 co-
precipitates independently with pVHL and elongin B/C complexes. One pivotal role of 
Rbx1 is to recruit Cdc34 into the SCF complex by bridging or stabilising the Cdc34-
Cdc53 interaction. Furthermore, it has been shown that Rbx1-SCF complexes greatly 
stimulate the catalytic activity of Cdc34. In addition, Rbx1 has been shown to be required 
for catalysing Skp2 auto-ubiquitination in the presence of E1, E2 and ubiquitin during the 
G0/G1 phases of the cell cycle [195]. Similarly, the role of Rbx1 within the VCB-Cul2 
ligase might therefore be in recruiting an as yet unidentified E2(s) to the complex thereby 
facilitating more efficient ligase activity. 
 
The first proof that this newly defined VCB-Cul2 complex possessed ligase activity 
came in 1999 when two independent studies, one of which coming from our own 
laboratory, demonstrated biochemical evidence that the complex is involved in the 
process of ubiquitination [184, 185]. Moreover, selected, naturally occurring mutants of 
pVHL failed to exhibit this activity in ubiquitination assays further highlighting the 
functional importance of this complex. With the VCB-Cul2 complex established as an E3 
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ubiquitin ligase with pVHL as the probable substrate recognition component, the search 
had begun for a substrate(s) for this ligase. 
   
4.4 pVHL targets HIF-α for degradation 
 
By studying the involvement of pVHL in oxygen-regulated gene expression of two VHL-
deficient renal carcinoma lines, RCC4 and 786-O, Maxwell et al. could demonstrate that 
the up-regulation of hypoxia-inducible mRNAs in VHL-defective cells extended to a broad 
range of oxygen-regulated genes and involved a constitutive 'hypoxia pattern' for both 
positively and negatively regulated genes [114]. VHL disease predisposes sufferers to 
highly angiogenic tumours [10]. Enhanced glucose metabolism and angiogenesis are 
classical features of cancer, involving up-regulation of genes that are normally induced 
by hypoxia [196]. In addition to stimulation by the hypoxic microenvironment, genetic 
alterations contribute to these effects [196, 197]. Constitutive up-regulation of hypoxically 
inducible messenger RNAs encoding vascular endothelial growth factor (VEGF) and 
glucose transporter 1 (GLUT-1) in these tumour cells is correctable by re-expression of 
pVHL. Furthermore, Maxwell et al. investigated the role of pVHL in HIF-1 regulation and 
tested for interactions between HIF α-subunits and pVHL using a combination of hypoxia 
and/or proteasomal blockade to induce HIF-α subunits. Anti-pVHL immunoprecipitates of 
extracts from proteasomally blocked RCC4/VHL20 cells, but not RCC4 cells, contained 
both HIF-1α and HIF-2α. Similar results were obtained with hypoxia in the absence of 
proteasomal blockade. As HIF-1 activation by hypoxia is mimicked by cobaltous ions and 
iron chelation, Maxwell et al. could also show that the pVHL/HIF-1α complex could not 
form in cells exposed to these stimuli, and proposed an iron-dependent model of 
interaction [198, 199]. 
 
While direct evidence of a VCB-Cul2 ligase dependent Hif-α ubiquitination event 
was at this time not shown, it was presumed, based on the given data, that this was 
indeed the case. These experiments defined a function for pVHL in the regulation of 
HIFα. Given the importance of HIF in tumour angiogenesis [200] [201], constitutive HIFα 
activation is clearly consistent with the angiogenic phenotype of VHL disease. Whether it 
is a sufficient explanation for oncogenesis is less clear. HIF mediates gene activation not 
only by hypoxia, but also by growth factors such as insulin and insulin-like growth factor-
1 [202]. HIF targets such as molecules involved in enhanced glucose metabolism and 
angiogenesis [196] [203] are classically up-regulated (by different mechanisms) in many 
forms of cancer, supporting an important role in tumour progression, although their role 
in the initiation of oncogenesis is less clear. It is now firmly established that pVHL plays a 
                                                 
20 RCC4/VHL refer to renal cell carcinoma cell where VHL has been reintroduced 
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central role in regulating this key transcription factor. Figure 42. illustrates a simplified 
diagrammatic representation of HIF-α control by pVHL. 
Figure 42. Diagrammatic representation of HIF-α control by the VCB-Cul2 ubiquitin-ligase complex.
Under normoxia, HIFα undergoes an hydroxylation event facilitating interaction with pVHL which recruits 
components of the VCB-Cul2 E3 ubiquitin ligase complex. This complex targets HIFα to the 26S 
proteosome for degradation. Under hypoxia, HIFα is stabilised, translocates to the nucleus where it 
dimerises with HIFß, and binds to promoter regions containing a Hypoxia-Responsive-Element (HRE) and 
thereby initiates transcription of these genes. 
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4.5 The HIF system 
 
The two subunits, HIFα and HIFβ, 
aryl hydrocarbon receptor nuclear 
translocator (ARNT), belong to the 
basic helix-loop-helix (bHLH)-PAS 
(Per/Amt/Sim) family (Figure 43). 
HIFα dimerises with HIFβ and 
functions as a transcription factor. 
The constitutively expressed HIFβ 
resides in the nucleus and acts as a 
common subunit of multiple bHLH-
PAS transcription factors. HIFα constantly varies in its protein level, according to 
changes in the microenvironmental oxygen concentration. Therefore, the HIFα 
transcriptional activity is determined by the hypoxic induction and modifications of the 
HIFα protein level [204]; [205]. 
 
Beginning at the N-terminus, HIF-1α contains the bHLH domain, PAS domain, ID 
(inhibitory) domain containing the ODD (oxygen-dependent domain), and finally the N- 
and C-TAD (transactivational domains). These domains are involved in the regulatory 
machinery of HIF-1 biological activation. The bHLH and PAS domains are required for 
dimerisation with HIF-1β and DNA binding [114, 206-208]. The transcriptional activity of 
HIF-1 is regulated through N-TAD, C-TAD and ID [209]. Under normoxia, the 
hydroxylation of Pro-402 and Pro-564 in ID or N-TAD of HIF-1α, respectively, by specific 
proline hydroxylases is required for the binding of pVHL, which recruits the VCB-Cul2 E3 
ubiquitin-protein ligase that targets HIF-1α for degradation. In the absence of oxygen, 
the prolyl hydroxylases are not active, consequently the unhydroxylated prolyl-HIF-1α 
cannot interact with pVHL [7, 13, 210]. For this reason, these domains are also called 
oxygen-dependent degradation (ODD) domains. VHL also recruits histone deacetylases 
(HDAC) that interfere with the transactivation domain function. An asparaginyl 
hydroxylase, FIH-1 (factor inhibiting HIF-1), which binds to both pVHL and HIF-1α, also 
inhibits the transcriptional activity of HIF-1 [19, 211].  
 
 The protein level of HIF-1α is regulated at the level of synthesis and stability. 
Activation of tyrosine kinases, such as SRC, HERneu, and the IGF and EGF receptors, 
stimulate the PI3 kinase–PKB–FRAP and ERK/MAPK signal transduction pathways, 
which lead to the increased translation of HIF-1α mRNA into protein [212, 213]. 
Figure 43. Structural domains and key regulatory residues 
of HIF-1α. Domains, residues and abbreviations are explained 
in the text . OH and Ac represent hydroxylation and acetylation 
modifications respectively. 
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Both the HIF-α and HIF-β subunits 
exist as a series of isoforms encoded by 
distinct genetic loci. HIF-β subunits are 
constitutive nuclear proteins, whereas HIF-α 
subunits are inducible by hypoxia. Among 
three HIF-α isoforms, HIF-1α and HIF-2α 
appear closely related and are each able to 
interact with hypoxia response elements 
(HREs) to induce transcriptional activity 
[214]. In contrast, HIF-3α appears to be 
involved in negative regulation of the 
response through an alternately spliced 
transcript termed inhibitory PAS domain 
protein [215].  Table 15. gives an overview of 
some HIF-regulated genes (adapted from 
Semenza et al. [216]). 
 
 Aside from pVHL-mediated 
degradation, reports have shown that p53 
can promote Mdm-2 mediated ubiquitination 
and proteasomal degradation of HIF-1α 
through direct interaction with HIF-1α in 
hypoxia [217]. The inhibitory PAS domain 
(IPAS) protein is also reported to target HIF-1 
and plays a role as a negative regulator of 
the hypoxia induced gene expression. The 
expression of IPAS in hepatoma cells impairs 
the induction of genes under hypoxic 
conditions, notably the VEGF gene, and 
results in retarded tumour growth and tumour 
vascular density in vivo [215].  Under hypoxic conditions, HIF-α is stabilised and exerts 
its transcriptional activity by binding to the p300/CBP, SRC-1 (steroid receptor co-
activator-1) family co-activators, nuclear redox regulator Ref-1, and molecular chaperone 
heat shock protein 90 (HSP90) [218-220]. The HIF-1α-mediated transcriptional 
regulation is synergistically enhanced by p300/CBP, SRC-1 and Ref-1. The control of 
HIF-1α stability by post-translational modification or protein-protein interaction appears to 
be essential for the transcriptional activity of HIF-α (Fig.45). 
 
Table 15. Examples of Genes 
regulated by HIF-1 
Genes 
Growth factor related 
Endocrine gland-derived VEGF 
Erythropoietin 
IGF-II 
IGF-binding protein I/II/III 
TGFβ1 
VEGF 
Receptors 
FLT-1 
α1B-adrenergic receptor 
CxCR4 
Glucose metabolism 
Aldolase A (ALDA) 
Aldolase C (ALDC) 
Enolase I 
Glucose transporter 1 
Glucose transporter 3 
Glyceraldehyde-3-P-dehydrogenase 
Hexokinase 1 
Hexokinase 2 
Phosphoglycerate kinase 1 
Lactate dehydrogenase A (LDHA) 
Pyruvate kinase M (PKM) 
Others related in vascular growth and metabolism 
Adenylate kinase 3 
Adrenomedulin 
Ceruloplasmin 
Collagen type V, α1 
Endothelin-1 
ETS-1 
Haeme oxygenase-1 
LDL receptor-related protein 1 
Nitric oxide synthase 2 
p21 
p35srj 
plasminogen activator inibitor 1 (PAI-1) 
Prolyl-4-hydroxylase αI 
Transferrin 
Transglutaminase II 
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In addition to the 
abovementioned interactions, HIFα 
has also been shown to bind Jab-1, a 
protein originally described as a 
transcriptional co-activator of c-Jun 
and Jun D [28]. Jab-1 plays a role in 
a variety of signalling pathways. 
These include integrin signalling, cell 
cycle control, and steroid hormone 
signalling [221-223]. This protein is 
also known as a subunit, CSN5, of 
the mammalian COP9 signalosome 
(CSN) complex, a highly conserved 
protein complex implicated in diverse 
biological functions that involve 
ubiquitin-mediated proteolysis. This subunit has been shown to phosphorylate 
transcriptional regulators such as c-Jun, IκB, p105 and p53 [224-226]. Bae et al. 
demonstrated that Jab-1 interacts with the ODD domain of HIF-1α and in this way may 
control HIF-1α stability and activity by competition with p53. The interaction of Jab-1 with 
HIF-1α contributes to the up-regulation of the HIF-1α protein level under hypoxic 
conditions. However, under normoxia, Jab-1 has no effect on the up-regulation of the 
HIF-1α protein level. This is due to the strong affinity of pVHL for HIF-1α, which leads to 
the rapid degradation of HIF-1α. p53 directly interacts with the ODD domain of HIF-1α 
and down-regulates the hypoxia-induced expression of HIF-1α by promoting the 
ubiquitination of HIF-1α under hypoxic conditions but not under normal oxygen 
conditions [114, 217]. The Jab-1 mediated stabilisation of HIF-1α might therefore, by 
directly interfering with the HIF1α-p53 interaction, play a central role in HIF regulation 
under hypoxic conditions.  
 
Another protein that has been shown to interact with HIF-1α is ARD1, an 
acetyltransferase [23]. While there is only one report regarding ARD1 regulation of Hifα, 
the evidence reported by Jeong et al. in Cell convincingly describes acetylation of HIF-1α 
by ARD1, and that this modification is important in HIFα regulation. Acetylation is found 
in various proteins, including histones, ERF1, MyoD, GATA-1 and p53 [227-230]. The 
authors showed that ARD1 binds HIF-1α more strongly under normoxic conditions than 
under hypoxic conditions. The over-expression of ARD1 significantly decreases HIF-1α 
protein stability, whereas the down-regulation of the ARD1 level with anti-sense ARD1 
transfection increases the stability of HIF-1α. This suggests that ARD1 functions as a 
negative regulator of HIF-1α. ARD1 acetylates lysine 532 in the ODD domain of HIF-1α. 
Figure 45. Post-translational control of HIF1α. Modifications 
and protein interactions are explained in the text. 
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Interestingly, it has been previously reported that lysine 532 is critical for the degradation 
of HIF-1α under normoxia [27]. Although it is unclear how the ARD1-mediated 
acetylation of HIF-1α leads to its decreased stability, it is proposed that a conformational 
change of HIF-1α by the acetylation may effectively facilitate its interaction with pVHL 
and enhance the subsequent proteosomal ubiquitination of HIF-1α. 
 
4.5.1 HIF and regulation by protein hydroxylation 
 
As already mentioned, recent analysis of post-
translational modifications that mediate processes 
involving HIF stability has revealed a direct 
interface with the availability of oxygen through a 
series of non-haeme, iron-dependent oxygenases 
that hydroxylate specific HIF-α residues in an 
oxygen-dependent manner [11-13, 17, 210, 211, 
231]. Hydroxylation at two proline residues 
(Pro402 and Pro564 in human HIF-1α) mediates 
interactions with pVHL and the subsequent E3 
ubiquitin ligase complex that targets HIF-α for 
proteasomal destruction (Fig.46). Each site can 
interact independently with pVHL, potentially 
contributing to the extremely rapid proteolysis of 
HIF-α that is observed in oxygenated cells [7]. 
These sites contain a conserved LxxLAP motif 
and are targeted by a newly defined prolyl hydroxylase activity that in mammalian cells is 
provided by three isoforms termed PHD (prolyl hydroxylase domain) 1–3. Determining 
the relative importance of different PHD isoforms in the regulation of HIF-α and other 
potential hydroxylation targets is the subject of active research. In a second 
hydroxylation-dependent control, β-hydroxylation of an asparaginyl residue in the C-
terminal activation domain of HIF-α (Asn803 in human HIF-1α) is regulated by a HIF 
asparaginyl hydroxylase termed FIH (factor inhibiting HIF) [17, 19]. Hydroxylation at this 
site blocks interaction of the HIF-α C-terminal activation domain with the transcriptional 
co-activator p300. 
 
 In oxygenated cells, these hydroxylation reactions provide a dual mechanism of 
HIF inactivation that involves proteolytic destruction and inhibition of transcriptional 
activity. The HIF hydroxylases are all Fe(II)- and 2-oxoglutarate-dependent 
dioxygenases that have an absolute requirement for molecular oxygen, allowing HIF to 
escape inactivation in hypoxia. The enzymatic process splits di-oxygen, with one oxygen 
Figure 46. Dual regulation of HIF-α subunits 
by prolyl and asparaginyl hydroxylation. 
Hydroxylation sites are indicated for the human 
HIF1α polypeptide. 
Adapted from Pugh et al.2003 
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atom creating the hydroxylated amino acid, and the other oxidising 2-oxoglutarate to 
succinate with the release of CO2 [232]. Fe(II) at the catalytic centre is loosely bound by 
a 2-histidine-1-carboxylate coordination motif, and may be displaced or substituted by 
other metals, such as cobaltous ions, with loss of catalytic activity. Given the role of HIF 
in the regulation of genes involved in the process of angiogenesis, these findings 
therefore couple angiogenic regulation to metabolic demand through minimal pathways 
linking molecular oxygen availability, HIF hydroxylase activity, HIF-dependent 
transcription and angiogenic growth factor expression. They also account for the up-
regulation of angiogenic growth factors by cobaltous ions and iron chelators and indicate 
a route to therapeutic manipulation of angiogenesis. 
 
Characterisation of the HIF pathway has therefore provided a clear focus for the 
investigation of the role of hypoxia in angiogenesis associated with development, 
ischemic and hypoxic disease, and neoplasia. Nevertheless, hypoxia influences many 
other transcriptional pathways, such as those mediated by fos and jun, NF-kB and p53. 
How these pathways interface with HIF, and whether they involve different targets for 
currently defined and other predicted protein hydroxylases, is the subject of active 
investigation. Recent data implicating prolyl hydroxylation in the VHL-dependent 
ubiquitylation of subunit 1 of RNA polymerase II indicates that regulatory prolyl 
hydroxylation extends beyond the HIF system and is discussed in the following section. 
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4.6 Additional ubiquitination targets of pVHL 
 
Reports are available which demonstrate evidence that, in addition to HIFα, pVHL 
targets other proteins for ubiquitin-mediated proteolysis. While strong genetic evidence is 
required to establish these substrates as physiologically relevant, they may represent 
novel aspects of VHL functioning. To date these targets include RNA polymerase II 
subunits, a subfamily of deubiquitinating enzymes, and activated atypical protein kinase 
C (table 16). 
 
 
 
 
 
 
 
 
 
 
4.6.1 Hyperphosphorylated-RNA polymerase II large subunit, hsRPB1 
 
The finding originates from one group that had previously published work relating to the 
regulation of tyrosine hydoxylase (TH) by pVHL in rat phaeochromocytoma (PC12) cells 
[233] [234]. Phaeochromocytomas express high levels of tyrosine hydroxylase (TH), the 
rate-limiting enzyme in catecholamine21 biosynthesis. The initial observations involved 
stably transfecting PC12 cells with either wild type or mutated pVHL. It was shown that 
while wild type pVHL represses levels of TH mRNA and protein, a truncated pVHL 
mutant, pVHL(1-115), induces accumulation of TH mRNA and protein. The author’s 
present evidence, which suggests that repression results from inhibition of RNA 
elongation at a downstream region of the TH gene. Hypoxia, a physiological stimulus for 
TH gene expression, alleviates the elongation block. A truncated pVHL mutant, pVHL(1-
115), stimulates TH gene expression by increasing the efficiency of TH transcript 
elongation. This was the first report showing pVHL-dependent regulation of specific 
transcript elongation in vivo, as well as dominant negative activity of pVHL mutants in 
phaeochromocytoma cells. Furthermore, in a separate report, the group published data 
demonstrating the first evidence that endogenous pVHL is a physiological regulator of 
                                                 
21 Catecholamines include adrenaline, noradrenaline and dopamine. Levels can be measured in blood and urine and elevations may 
be seen in phaeochromocytoma 
Table.16 Ubiquitination targets of the VCB-Cul2 E3 ligase 
Function   Target    References 
Transcription factor  Hypoxia inducible factor α >100 
RNA polymerase II subunit  Hyperphosphorylated RPB1 1 
RNA polymerase II subunit  RPB7    1 
Deubiquitinating enzymes VDU-1 and -2   3 
Kinase    Atypical protein Kinase C 2
* VDU – VHL-interacting deubiquitinating enzyme
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the catecholaminergic phenotype, thereby suggesting that loss of pVHL function may be 
causative in phaeochromocytoma-associated hyper-catecholaminemia and arterial 
hypertension [234, 235].  
 
The transition from transcription initiation to elongation involves phosphorylation of 
the large subunit (Rpb1) of RNA polymerase II on the repetitive carboxyl-terminal 
domain. The elongating hyper-phosphorylated Rpb1 is subject to ubiquitination, 
particularly in response to UV radiation and DNA-damaging agents. Regions of Rpb1 
and the adjacent subunit 6 of RNA polymerase II (Rpb6) that share sequence and 
structural similarity with the domain of HIF-1α that binds pVHL were identified. In 
agreement with the computational model, Kuznetsova et al. showed biochemical 
evidence that pVHL specifically binds the hyper-phosphorylated Rpb1 in a proline-
hydroxylation-dependent manner, thereby targeting it for ubiquitination. The exact role 
that ubiquitination of hyperphosphorylated Rpb1 by pVHL plays in the function of the 
RNA polymerase complex remains to be determined. Because ubiquitination of Rbp1 
occurs in a transcription-dependent manner, and because the abovementioned 
observations indicate that pVHL levels effect in vivo elongation of TH transcripts, the 
authors anticipate that ubiquitination of Rbp1 by pVHL complex is likely to regulate 
efficient transcript elongation through elongation-pause and –arrest sites of specific 
genes. In particular, given the above, it may be involved in the regulation of TH transcript 
elongation. This finding is interesting in light of already mentioned data regarding in vitro 
inhibition of the SIII transcriptional elongation complex, where it was suggested that 
pVHL actively competes for Elongin’s B and C from this complex composed of Elongin’s 
A, B and C. 
 
Finally, the authors speculate as to a more universal role of the pVHL-Rpb1 
interaction, and that gene regulation may not be limited to the TH gene alone. The 
authors present data that exhibit regulation of this interaction by UV-stress. Thus pVHL 
could play a role in the regulation of transcription complexes under conditions of DNA-
damage, such as UV irradiation. Reports already exist regarding increased apoptotitc 
susceptibility in pVHL-negative cells following UV treatment when compared to their 
pVHL wild-type expressing counterparts [236]. 
 
4.6.2 RNA polymerase II subunit hsRPB7 
 
Using yeast two-hybrid technology, Na et al. showed that pVHL can directly bind to 
another RNA polymerase II subunit, human Rpb7, through its β-domain [237]. 
Furthermore, they demonstrated that naturally occurring mutations in this domain could 
decrease binding. Introducing wild-type pVHL into human kidney tumour cell lines 
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carrying endogenous mutant non-functional pVHL facilitates ubiquitination and 
proteasomal degradation of Rpb7, and decreases its nuclear accumulation. pVHL can 
also suppress Rpb7-induced VEGF promoter transactivation, mRNA expression and 
VEGF protein secretion.  
 
Three dimensional structural studies of yeast Pol II have revealed that the Rpb4-
Rpb7 sub-complex is located between the two major domains that form the DNA-binding 
cleft of the Pol II complex and suggested that Rpb7 might be involved in inducing tighter 
closure of the DNA-binding cleft and thus stabilising the Pol II complex [238]. This may 
help explain why Rpb7 is important in the initiating transcription for a subset of genes 
during the stress response.  How Rpb7 is regulated during the stress response could be 
crucial for understanding how Pol II functions in the regulation of gene expression.  
 
Together with the finding that pVHL can target another RNA pol II subunit, Rpb1, 
for proteasomal degradation, indicates that pVHL could regulate gene expression 
through RNA Pol II subunits [239]. It would be important to identify other genes that 
could be specifically regulated by Rpb7 other than VEGF, as well as determining their 
roles in tumourigenesis. 
 
4.6.3 VHL-interacting deubiquitinating enzymes 
 
Following a yeast two-hybrid aimed at identifying pVHL interacting proteins, a novel 
protein named VHL-interacting deubiquitinating enzyme 1 (VDU1) was identified as 
being able to directly interact with pVHL in vitro and in vivo [240]. In a follow-up report, 
the same group showed that another uncharacterised deubiquitinating enzyme, VDU2, is 
also bound to pVHL [241]. Based on human and mouse cDNA sequences, VDU1 and 
VDU2 are identical in approximately 59% of the amino acids with strong homology in the 
N-terminus and C-terminus and a weaker similarity in the middle region. Both 
deubiquitinating enzymes contain the signature motifs of the ubiquitin-specific processing 
protease family and possess deubiquitinating activity. They interact with pVHL β-domain 
and naturally occurring mutations in this region effect binding. It was also demonstrated 
that these two proteins can compete with each other to bind to pVHL. Finally, they 
showed that VDU1 and VDU2 can both be ubiquitinated and degraded in a pVHL-
dependent manner. Based on their amino acid sequence homology and functional 
interaction with pVHL, VDU1 and VDU2 define a subfamily of ubiquitin specific 
processing proteases. Since deubiquitination, by reversing ubiquitination, has been 
recognised as an important regulatory step in ubiquitination-related processes, VDU1 
and VDU2 could be important substrates of pVHL E3 ligase complex. 
 
Chapter 4 – Functional analysis of the VHL tumour suppressor 
 79
Furthermore, Curcio-Morelli et al. demonstrated deubiquitination of type 2 
iodothyronine deiodinase by enzymes VDU1 and VDU2, and they provide evidence to 
show that this interaction could help regulate thyroid hormone activation [242]. The type 
2 iodothyronine deiodinase (D2) is an integral membrane ER-resident selenoenzyme 
that activates the pro-hormone thyroxine (T4) and supplies most of the 3,5,3'-
triiodothyronine (T3) that is essential for brain development. D2 is inactivated by 
selective conjugation to ubiquitin, a process accelerated by T4 catalysis and essential for 
the maintenance of T3 homeostasis. D2 interaction with VDU1 and VDU2 was confirmed 
in mammalian cells. Both VDU proteins co-localise with D2 in the ER, and their co-
expression prolongs D2 half-life and activity by D2 deubiquitination. VDU1, but not 
VDU2, is markedly increased in brown adipocytes by noradrenaline or cold exposure, 
further amplifying the increase in D2 activity that results from catecholamine-stimulated 
de novo synthesis. Thus, deubiquitination regulates the supply of active thyroid hormone 
to brown adipocytes and other D2-expressing cells. The present studies identify D2 as 
the only known specific substrate of VDU1 and VDU2, which in turn are the first 
ubiquitin-specific processing proteases known to specifically deubiquitinate an ER–
Associated Degradation (ERAD) substrate. Although no functional significance is implied 
with respect to presence or absence of pVHL, it is interesting to note that pVHL has been 
shown to partially localise to the ER which might suggest a functional relevance. It is 
tempting to speculate that pVHL could be involved in down-regulating the 
deubiquitinating pathways controlled by VDU1 and VDU2. The authors also raise the 
interesting possibility of these deubiquitinating enzymes being able to deubiquitinate 
already ubiquitinated substrates of the VCB-Cul2 E3 ligase, i.e. Hif-α, thereby modifying 
the ubiquitinating capacity of the ligase depending on certain stimuli. While no evidence 
exists, it has been suggested that pVHL itself undergoes ubiquitin-medited proteasomal 
degradation. An interesting question to address is whether regulation of VDU’s can 
facilitate re-employment of ubiquitinated pVHL in cases where it is necessary, and what, 
if any, would be the pathological outcomes of aberrations in this system. 
 
4.6.4 Atypical protein kinase C 
 
Pal et al. were the first group to propose a model of pVHL and PKC functional interaction 
[243]. They suggested that the well-vascularised tumours associated with VHL disease 
could, in part, be explained by the fact that under normal conditions, pVHL inhibited 
protein kinase C (PKC) activity.  They demonstrated that when over-expressed, PKC 
isoforms ζ and δ formed cytoplasmic complexes with pVHL preventing recruitment of 
these isoforms to the cell membrane where they would otherwise engage in a signal 
transduction mechanism leading to VEGF up-regulation. Aberrations in this regulatory 
pathway could therefore result in up-regulation of VEGF, as seen in VHL-associated 
tumours [243]. In a follow up paper the same group described experiments 
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demonstrating that the transcription factor Sp1, when bound to a PKC ζ, promotes the 
transcription of VEGF through phosphorylation of the zinc finger of Sp1 [244]. 
Interestingly, in the presence of wild-type pVHL, this interaction was shown to be 
inhibited, and VEGF transcription subsequently repressed. However, these experiments 
all entailed over-expression studies, and no endogenous interaction of PKC isoforms and 
pVHL had been shown. 
 
 An independent study has confirmed a pVHL-PKC interaction [245]. In their study, 
Okuda et al. demonstrated that pVHL could directly interact with atypical PKC isoforms 
(aPKC) ζ and λ. They demonstrated that interaction with these two isoforms was 
mediated through the β-domain of pVHL. It wasn’t until a follow up paper from the same 
group emerged however, that evidence was reported demonstrating that these aPKC 
isoforms could represent ubiquitination targets of pVHL. They showed that PKCλ is 
ubiquitinated by the VCB-Cul2 E3 ligase complex, demonstrating ubiquitination of PKCλ 
in vivo and in vitro, and that pVHL mediates the ubiquitination of the recombinant 
activated form of PKCλ through an interaction with the regulatory domain of PKCλ. 
These results strengthen their previous finding. Together, these results strongly suggest 
that the VCB-Cul2 complex is responsible for the down-regulation of activated aPKC via 
the ubiquitin-proteolytic pathway, which terminates aPKC-mediated cellular signalling. 
 
Ubiquitination and degradation of proteins often depend on post-translational 
modifications. Target proteins for the SCF complex-type ubiquitin ligases, such as β-
catenin, p27kip, and IκB, are recognised by F-box proteins only when phosphorylated at 
defined amino acid residues [188]; [246]. This molecular mechanism allows quick, 
phosphorylation-dependent degradation of proteins, which plays crucial roles in the 
regulation of the cell cycle, growth, and differentiation. As already mentioned, 
degradation of HIF-α, a target of VCB-Cul2 ubiquitin ligase, is dependent upon a 
molecular oxygen-mediated hydroxylation event at specific HIF-α residues, which is 
prevented under hypoxic conditions. Based on this, we are forced to ask how then does 
pVHL recognise active aPKC? To date, this question remains unanswered. 
 
Contribution of aPKC in the formation of tight junction and actin filament 
organisation has been reported [247]; [248]. It is interesting to note that pVHL has also 
been shown to be involved in such cellular events. Ectopic expression of pVHL in VHL-
deficient renal cell carcinoma cells induces the formation of focal adhesions and stress 
fibers, as well as β1-fibrillar adhesions [249]; [250]. pVHL is also involved in the 
establishment and maintenance of contact inhibition of cell growth [251]. Taken together, 
these observations support the idea that some of pVHL's functions as a tumour 
suppressor are attained at least in part by the control of aPKC activity. Given the 
Chapter 4 – Functional analysis of the VHL tumour suppressor 
 81
preferential pVHL interaction and ubiquitination/degradation of the active form aPKC, one 
might predict that the loss of pVHL function leads to the endurance of activated aPKC, 
which may cause disorders in cytoskeletal organisation and cell-substrate and cell-cell 
interaction as are commonly observed in tumorigenic cells. This topic is further discussed 
in the following chapter. 
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4.7 Alternative pVHL interactions 
 
4.7.1 pVHL interacts and stabilises microtubules 
 
A novel function of pVHL emerged from our laboratory, and as a co-author of this paper 
published in Nature Cell Biology in 2003, contributory results pertaining to this study are 
outlined in the results section of this thesis. pVHL was shown to specifically bind 
microtubules through a region in pVHL defined as residues 95-123. This region 
constitutes part of the α-domain through which Elongin C binds to pVHL. Interestingly a 
microtubule-pelleting assay in which both endogenous pVHL30 and pVHL19 co-
sedimented with polymerised microtubules, showed no other E3 ligase complex 
components. This suggests that this function of pVHL is independent from its ligase 
activity. Endogenous immunoprecipitation of pVHL30 showed co-precipitation of α-tubulin 
in HCT116 cells. Furthermore, integrity of the microtubule network proved to be 
important with respect to pVHL localisation. Microtubule stabilising and destabilising 
drugs were used to show that when microtubules are stabilised, pVHL remains 
cytoplasmic and microtubule-bound. However using vincristine or some other 
microtubule destabilising drug renders a strong pVHL signal in the nucleus, with 
concomitant reduction in cytoplasmic signal. It is still not clear whether these differences 
in localisation patterns reflect an active migration of pVHL into the nucleus upon 
microtubule destabilising conditions, or whether an active degradation of cytoplasmic 
pVHL under destabilising conditions occurs. Given the evidence available regarding the 
ability of pVHL to shuttle in and out of the nucleus in a ran-mediated, exon 2-dependent 
fashion, it would not be surprising if pVHL could actively move to the nucleus upon 
microtubule destabilising conditions. This idea will be further explored in chapter 7, part 
II. 
 
To address the functional significance of pVHL binding to microtubules, and given 
the fact that stability of the microtubule network is important for pVHL localisation, an 
assay was established which investigated the potential of ectopically expressed 
GFPVHL30 to protect microtubules under what would normally be destabilising 
conditions. The results showed that GFPVHL30 does indeed protect microtubules, but 
that binding alone was not sufficient to induce this effect as certain VHL point mutants 
bound, but did not stabilise. Importantly, upon analysis, the point mutants which did not 
stabilise, could be all classed clinically as those mutants related to type 2A VHL disease, 
i.e. Y98H and Y112H (with the exception of one type 2C; F119S). A single, but specific 
amino acid mutation is sufficient. Even Y98N and Y112N retained their stabilising 
capabilities. Type 2A patients exhibit predisposition to phaeochromocytoma and 
haemangioblastoma but a reduced risk to renal cell carcinoma. The correspondence 
between type 2A mutants and microtubule stabilisation might suggest a contributory 
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causal role on behalf of the microtubule network regarding development of malignancies 
associated with this sub-class of VHL disease, or that the mutational effect somehow 
mitigates against the RCC predisposition? Trying to explain how this can correlate with 
the high risk of RCC associated with completely inactivating VHL mutations is difficult. It 
has been however suggested that as type 2A mutants bind microtubules, perhaps they 
act as dominant-negative versions of their normally tumour suppressing wild-type 
counterparts. In this regard, and as postulated in the paper, they could be viewed as 
oncoproteins. 
 
Due to the difference in localisation of pVHL30 and pVHL19, it might also be 
suggested that the different translation products, while both capable of binding 
microtubules and in recruiting HIFα to the VCB-Cul2 complex, differ in their functions due 
to their sub-cellular locations. As pVHL19 predominantly localises to the nucleus, perhaps 
it represents the main HIF targeting pVHL species while pVHL30, which demonstrates 
predominant cytoplasmic localisation, may represent the microtubule binding species. 
Evidence for pVHL19 acting as a nuclear E3 ligase has already been confirmed [208].  If 
this is indeed the case, then a functional difference between pVHL19 and pVHL30 has for 
the first time been described. 
 
 
4.7.2 TAT-binding protein-1 (TBP1); An ATPase involved in HIF-α degradation 
Recently a study emerged by Corn et al. demonstrating a novel interaction between the 
β-domain of pVHL and TAT-binding protein-1 [252]. TBP-1 is a core component of the 
19S regulatory particle of the 26S proteasome. The 19S particle contains six ATPases, 
including TBP-1, that belong to the ATPases-associated-with-different-cellular-activities 
(AAA) family [252]. The precise role of these ATPases in proteasome function is 
unknown, but they are thought to mediate the hydrolysis of ATP that is required for 
proteasome-mediated degradation of intracellular proteins [253]; [254]. In addition, the 
19S regulatory particle seems to recognise poly-ubiquitinated substrates and is involved 
in both the unfolding of target proteins and their subsequent translocation into the 20S 
proteolytic core [253]; [254]. Three principal observations from their data help to 
characterise the functional consequences of the pVHL-TBP-1 interaction. First, the ability 
of TBP-1 to promote Hif-1α degradation requires an intact ATPase domain, suggesting 
that this is an energy-dependent process. Second, TBP-1 enhancement of Hif-1α 
degradation depends on wild-type pVHL function. Third, TBP-1 does not seem to affect 
the regulation of ubiquitinated proteins generally, but rather regulates the pVHL E3 
ubiquitin ligase pathway in a relatively specific manner. These data support a model in 
which the 19S regulatory particle acts as a chaperone that promotes substrate unfolding 
and translocation of target proteins into the 20S proteolytic core [253]; [255]. In 
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summary, these data suggest a model for the role of TBP-1 in the pVHL-mediated 
degradation of Hif-1α. After hypoxic stress in normoxia, wild-type pVHL exists in a 
complex with Hif-1α, TBP-1, elongin C and Cul-2 that ubiquitinates Hif-1α and targets it 
to the proteasome for degradation. In contrast, complexes containing a pVHL mutant that 
does not bind TBP-1 (for example, pVHL-P154L) no longer effectively chaperone Hif-1α 
to the proteasome, resulting in impaired degradation of Hif-1α. These results thus 
provide a novel mechanism for Hif-1α stabilisation in some pVHL-deficient tumours. 
Interestingly, a proteomics approach has identified another member of the AAA-family of 
ATPases which interacts with pVHL, namely p97. This will be discussed in detail in 
chapter 7. 
4.7.3 Tric/CCT; a protein chaperonin involved in VCB assembly 
 
Feldmann et al. demonstrated in 1999 that the folding and assembly of VHL into a 
complex with its partner proteins, elongin B and elongin C, is directly mediated by the 
chaperonin TRiC, also called CCT [256]. The authors provide evidence which shows that 
the association of pVHL with TRiC is required for formation of the VHL-elongin B-elongin 
C complex. They demonstrate that a 55-amino acid domain of pVHL (amino acids 100 to 
155) is both necessary and sufficient for binding to TRiC. Hansen et al. investigated this 
interaction further and demonstrated that blocking the interaction of pVHL with elongin 
B/C resulted in accumulation of pVHL within the TriC complex [257]. pVHL present in 
purified VHL-TRiC complexes, when added to rabbit reticulocyte lysate, proceeded to 
form VCB and VCB-Cul2. The authors conclude that, TRiC thus likely functions, at least 
in part, by retaining VHL chains pending the availability of elongin B/C for final folding 
and/or assembly.  
 
In 2003, Melville et al. used the yeast Saccharomyces cerevisiae as a model 
system to examine in vivo the chaperone requirements for assembly of the VBC 
complex. Human pVHL and elongin B/C expressed in yeast assembled into a correctly 
folded VBC complex that resembles the complex from mammalian cells. Unassembled 
VHL did not fold and remained associated with the cytosolic chaperones Hsp70 and 
TRiC/CCT, in agreement with results from mammalian cells [258]. Analysis of the folding 
reaction in yeast strains carrying conditional chaperone mutants indicates that 
incorporation of VHL into VBC requires both functional TRiC and Hsp70. VBC assembly 
was defective in cells carrying either a temperature-sensitive ssa1 gene as their sole 
source of cytosolic Hsp70/SSA function or a temperature-sensitive mutation in CCT4, a 
subunit of the TRiC/CCT complex. Finally, Friedman et al. followed up their initial finding 
by showing that TRiC is specified by two short hydrophobic beta strands in VHL that, 
upon folding, become buried within the native structure [259]. These TRiC binding 
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determinants are disrupted by tumour-causing point mutations that interfere with 
chaperonin association and lead to mis-folding. The results reveal a class of disease-
causing mutations that owing to their ability to disrupt chaperone-mediated folding in 
vivo, ultimately inactivate the protein function of pVHL. 
 
4.7.4 von Hippel-Lindau binding protein – VBP1 
 
Following a yeast 2-hybrid, Tsuchiya et al. found four clones; elongin C, the HIV tat-
binding protein, the actin-binding protein Filamin (ABP280), and the HIBBJ46 protein 
they named VBP-1 [260]. They demonstrated that VBP-1 required the C-terminal end of 
pVHL for binding. It was also established that epitope-tagged pVHL strongly forms 
complexes with VBP-1 in vivo. VBP-1 was widely expressed in various cell lines tested, 
in which VHL mRNA can also be detected. When the VBP-1 protein was solely 
expressed, it located to the cytoplasm and did not localise to the nucleus. However, 
when co-expressed with pVHL, it could translocate to the nucleus. These results 
indicated that VBP-1 can form a complex with VHL protein in vivo and hence pVHL might 
affect the intracellular localisation of VBP-1 protein.  
 
A recent study demonstrated functional analysis of VBP-1 in the nematode, C. 
elegans [119]. The C. elegans VBP-1 gene was expressed in adults only in the gonads 
and was also expressed in early stage embryos. Double-stranded RNA interference 
against VBP-1 resulted in an arrest of embryogenesis at morula stages. The authors 
suggest that the VBP-1 protein product is necessary for morphogenesis. However, since 
its identification, the significance of a pVHL-VBP1 interaction, if any, remains elusive. 
 
 
Concluding Remarks 
 
The identification of pVHL as a constituent of an E3 ubiquitin ligase represents a 
hallmark in VHL biology and served to pave the way for the identification of what is to 
date the most important aspect of pVHL functioning, proteolytic regulation of hypoxia 
inducible factor α. The implication of this interaction in the context of tumour growth and 
progression is the topic of discussion in the final chapter of this introduction. While other 
potential substrates outlined in this chapter may represent interesting novel aspects to 
the function of pVHL, the lack of physiological investigation renders these observations 
momentarily undeveloped. Finally, protein interactions, notably with microtubules, TBP-1 
and PKC isoforms are beginning to highlight functions of pVHL separate from its role as 
a substrate recognition component of an E3 ligase, and may represent novel aspects of 
pVHL function. 
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CHAPTER 5 
VHL and Tumourigenesis 
 
 
5.1 Introduction 
 
This chapter summarises current data regarding the role of VHL in tumourigenesis. By 
analysing animal models where VHL has been specifically targeted, it questions the 
concept of mutations in pVHL as a causal event in tumour formation and analyses the 
role of VHL in tumour progression. While HIF-dependency represents the principal 
mechanism of action underlying known VHL-mediated cellular events to date, efforts are 
made to highlight HIF-independent functions of VHL. The VHL tumour suppressor is 
emerging as an integral protein in key cellular events leading to cell proliferation, survival, 
angiogenesis, polarity, invasion and metastasis. This chapter aims at trying to summarise 
information available regarding these cellular phenomena.  
 
 
5.2 VHL knockout and functional inactivation studies 
 
To analyse the role of VHL in normal cell growth and differentiation, knockout studies 
aimed at specific inactivation of the VHL gene have been undertaken. The following 
section will focus on the complete knockout of the VHL locus and four subsequent 
studies that have emerged as a result of the need to develop an in vivo system for 
studying the functional requirement of the VHL gene. 
 
5.2.1 Complete Knockout: VHL-/- 
 
Gnarra et al. developed a mouse line lacking VHL [261]. While heterozygous VHL+/− 
mice appeared phenotypically normal and surviving 15 months without evidence of 
spontaneous disease, VHL-/- mice died in utero at 10.5 to 12.5 days of gestation (E10.5 
to E12.5). Homozygous VHL-/- embryos appeared to develop normally until E9.5 to 
E10.5, when placental dysgenesis developed. Embryonic vasculogenesis of the placenta 
failed to occur in VHL-/- mice, and haemorrhagic lesions developed in the placenta. 
Subsequent haemorrhage in VHL-/- embryos caused necrosis and death (Fig.47). These 
results indicate that VHL expression is critical for normal extra-embryonic vascular 
development. 
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Among the earliest differentiation events 
in the mammalian embryo are those that direct 
cells to develop into the extra-embryonic 
tissues, the placenta, the yolk sac, and the 
amnion (Fig.48). The placenta is derived from 
trophoblast cells and mesodermal cells from 
the inner cell mass, and these cell types 
appear histologically normal in VHL-deficient 
mice. However, loss of normal VHL expression 
in the trophoblasts and mesodermal cells 
appears to account for the lack of 
vasculognesis in the placenta, leading to 
placental failure, the major cause of embryonic 
lethality in VHL-deficient mice. 
 
Negative regulation of VEGF expression 
by VHL is well established and has been 
demonstrated with respect to pVHL’s ability to 
target HIF for ubiquitin-mediated degradation 
[114, 200]. HIF is a transcription factor capable 
of transcribing the VEGF gene. However, in 
this study, Gnarra et al. found VEGF 
expression to be decreased in VHL-deficient 
placental trophoblasts. This contradicts our 
understanding of HIF regulation by VHL and 
subsequent VEGF suppression. Consistent 
with constitutively active HIF, depletion of VHL 
should result in an up-regulation of VEGF as 
seen in VHL null tumours [262-264]. In the 
lethal phenotype observed upon VHL depletion 
in mice, this is however not the case. VEGF is 
down-regulated in VHL-/- placental derived 
trophloblast cells, and embryos die due to a 
lack of vascularisation of the placenta. 
However, it has yet to be fully determined 
whether this decrease is directly related to VHL 
inactivation which would indicate an alternative form of regulation in placental 
trophoblasts than seen in vascular tumours related to VHL disease, or a secondary effect 
and an early indicator of placental failure. 
 
It is interesting to note that mice deficient for VEGF or it’s receptors, VEGF-R1 
and VEGF-R2, have been developed and show embryonic lethality by E9.5 to E11.5, 
Figure 48. Early mammalian embryonic development. 
The trophoblast and mesoderm cells are important 
because they will connect the uterine wall to the embryo, 
develop into the chorion, and enable the mother to nourish 
the embryo by forming the placenta. 
Adapted from: www.med.unc.edu/embryo 
Figure 47. E12.5 embryos from an inter-cross 
of VHL +/- mice. (A) Three abnormal embryos of 
12-litter (marked with asterixes). VHL-/- embryos 
are necrotic, and one is shown with haemorrhagic 
placenta. (B) Another E12.5 litter demonstrating 
one abnormal embryo and another where the 
embryo appears normal but is attached to a 
haemorrhaging placenta. 
Adapted from Gnarra et al 1997 
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similar to the VHL-deficient embryos described above [265-268]. Lethality in VEGF and 
VEGF receptor mice appears to involve defects in vasculogenesis as well as 
haematopoiesis. Interestingly, VEGF heterozygous mice also show embryonic lethality 
by E10.5 to E11.5, indicating that gene dosage is important for VEGF [265, 268]. These 
results imply that the decreased VEGF levels seen in VHL homozygous embryos may 
play a contributory role in embryonic lethality, but mechanistically, how this is linked to 
loss of VHL remains unclear. 
 
5.2.2 Heterozygotic predisposition to tumourigenesis: VHL+/- 
 
Chapter 3 explains that genotyping has shown that most, if not all, VHL tumours tested 
show inactivation of the inherited wild-type VHL allele and retention of the inherited 
inactivated allele, as predicted by Knudson. In trying to develop a model that would 
mimic the germ-line situation, Gnarra et al. in the aforementioned study observed that 
heterozygous VHL null mice in a C57BL/6 background lived beyond 15 months without 
evidence of significant disease. Further analysis of VHL mice beyond 15 months was 
necessary to provide a better understanding of the role of VHL in development and 
tumourigenesis, and has since emerged. The first evidence provided by Haase et al. who 
contradicted the previous findings, demonstrated that clinical features of VHL disease 
can indeed be reproduced by targeted mutagenesis of VHL in mice [269]. They 
generated a conditional VHL null allele (2-lox allele) and null allele (1-lox allele) by Cre-
mediated recombination in embryonic stem cells. They demonstrated that heterozygote 
mice for the 1-lox allele develop cavernous haemangiomas of the liver.  
 
Their findings demonstrated that mice heterozygous for a VHL null mutation are 
susceptible to the development of spontaneous vascular tumours, reminiscent of those 
found in VHL patients. However, the authors are keen to admit that the discrepancy 
between their observation and the previously reported findings in heterozygous VHL 
knockout mice may result from differences in genetic background. It is well established 
that differences in genetic background can account for variable phenotypic penetrance of 
targeted null mutations [270]. The conditional inactivation of the VHL gene was carried 
out in the livers of BALB/c mice. Nonetheless, in contrast to the variety of tumours that 
arise in the human disease, the tumour spectrum and location in mice were restricted to 
cavernous haemangiomas of the liver. The authors speculate that in VHL+/- mice, 
hepatocytes are particularly susceptible to loss or inactivation of their wild-type VHL 
allele. The nature of this inactivation was not ascertained. Furthermore, it remains 
unclear why vascular tumours in mice occurred in the liver only and why, in contrast to 
humans, other VHL-associated tumours such as RCC could not be found. It is possible 
that the development of RCCs in VHL+/- heterozygotes may require additional mutations 
in other tumour suppressor or modifier genes [271]. Nonetheless, the study shows that 
inactivation of VHL leads to the up-regulation of VEGF, Glut-1, and Epo mRNAs, as well 
as stabilisation of HIF-2α in hepatocytes. This finding suggests that pVHL acts as a 
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global regulator of HIF-α stability, and not only a regulator in VHL disease effected 
tissues. This points to a more general role of pVHL in the regulation of HIF-α. 
 
Interestingly, two recent reports supporting the above study have been published. 
Ma et al. have undertaken attempts to generate a mouse model that closely mimics the 
human VHL disease and avoids embryonic lethality by using similar Cre/lox site-specific 
recombination technology. Under the control of the ß-actin promoter, which drives 
expression in many organs, mice have been shown to develop multiple, hepatic 
haemangiomas that lead to premature death, as well as angiectasis22 and angiogenesis 
in multiple organs, including pancreas, kidney, spleen and heart. Furthermore, testes 
were shown to be unusually small and very low in sperm count resulting in infertility, 
which represents a potentially novel function of VHL in the process of spermatogenesis. 
Importantly the authors note that the differences in phenotypic consequence of the 
heterozygous VHL deleted allele, which were observed among three different mouse 
strains, suggest that strain-specific modifier genes may provide protection against the 
formation of hepatic haemangiomas as observed in C57BL/6 mice, or may enhance the 
development of the vascular phenotype as seen in BALB/c or A/J mice. 
 
The most recent study involving the investigation of whether VHL heterozygote 
mice (VHL+/-) exhibit increased susceptibility to tumourigenesis, was published by 
Kleymenova et al [272]. They tested whether VHL+/- mice would demonstrate increased 
susceptibility to renal carcinogenesis when treated with the well-characterised renal 
carcinogen, streptozotocin. Neither Wild-type nor VHL+/- mice exhibited an increase in 
renal lesions in response to 50-200 mg/kg streptozotocin, however VHL+/- mice did 
develop vascular proliferative lesions of the liver, uterus, ovary, spleen, and heart. 
Lesions included angiectasis and haemangiosarcoma23, and were most prominent in the 
liver. These data along with the previous two studies indicate that heterozygosity at the 
VHL locus predisposes mice to a vascular phenotype, which is consistent with the ability 
of VHL to control key proteins that participate in angiogenesis. 
 
The absence of a kidney phenotype in VHL heterozygotes contrasts sharply with 
mice heterozygous for the TSC-224 tumour suppressor gene. TSC-2+/- mice develop 
spontaneous renal cell tumours with an incidence of 100% by 10 months of age [273, 
274]. It is not clear why mice are refractory to VHL-related kidney tumours and 
susceptible to TSC-2-related renal cell tumours. This predisposition to renal tumours in 
TSC-2 heterozygous mice is especially interesting in light of recent data showing that 
similar to loss of VHL function, loss of TSC-2 gene function also results in stabilisation of 
HIFα and increased expression of VEGF [275, 276]. Consistent with stabilisation of HIF-
2α in TSC-2-null tumours, TSC-2 knockout mice also develop hepatic haemangiomas 
                                                 
22 Angiectasis – dilation of lymphatic or blood vessel 
23 haemangiosarcoma  - rare malignant neoplasm characterised by rapidly proliferating, extensively infiltrating, anaplastic cells derived 
from blood vessels and lining irregular blood-filled spaces 
24 Tuberous sclerosis complex (TSC) is a human syndrome characterised by a widespread development of benign tumours. This 
disease is caused by mutations in the TSC1 or TSC2 tumour suppressor genes (reviewed in [18]) 
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similar to those that occur in VHL heterozygotes [273]. Interestingly, rats carrying the 
Eker25 mutation in the TSC-2 gene (TSC-2Ek/+) that develop renal cell tumours also 
develop vascular lesions. Haemangiomas occur in a variety of organs, although these 
tumours arise predominately in the spleen [277], but unlike the situation in TSC-2 
knockout mice, vascular proliferative lesions have not been noted in the hepatic 
parenchyma of TSC-2Ek/+ rats.  
 
In conclusion, due to the high degree of cellular heterogeneity in these tumours, 
neither Kleymenova, Kobayashi nor Haase were able to determine if loss of the wild-type 
VHL allele occurred in the vascular lesions that develop in VHL (or TSC-2) knockout 
mice. Although these efforts are continuing, the question of whether the vascular lesions 
that develop in VHL knockout mice are themselves clonal in origin and follow Knudson's 
‘two-hit’ hypothesis remains an open question. Nonetheless, VHL+/- mice should prove to 
be a useful model for increasing our understanding of the factors that contribute to 
vascular tumorigenesis as they provide an in vivo system with which to dissect and study 
the sequence of events leading from pre-neoplastic changes to tumour initiation and 
progression. 
 
While biochemical and genetic evidence clearly demonstrate that pVHL regulates 
HIFα degradation to mediate normal cellular responses to changing oxygen 
concentration, it remains unclear whether deregulation of HIFα has a causal role for 
tumour formation when VHL is mutated. Studies investigating the tumour growth of RCC 
cell lines in nude mouse models support the idea of HIF-dependent tumour suppressor 
activities of pVHL. Inhibition of HIF-2α expression by siRNA inhibits growth of VHL 
negative tumours [278], while re-introduction of a degradation-resistant mutant of HIF-2α 
abolishes the ability of VHL to suppress growth of these cell lines [279]. While these 
studies display the importance of HIF-2α in the growth of established tumour cell lines in 
vivo, they do not demonstrate that deregulation of HIF degradation is sufficient to induce 
de novo tumour formation. Importantly, VHL ablation in mouse embryonic stem cells 
results in smaller tumour formation than controls, in spite of displaying maximal HIF 
activity [280]. This observation suggests that loss of VHL may actually cause a growth 
disadvantage in an otherwise normal genetic background and implies that malignancies 
associated with inactivation of the VHL tumour suppressor may manifest only in the 
background of other genetic alterations, and are perhaps not solely attributable to loss of 
VHL. Therefore, in this setting, HIF activity alone is not capable of driving tumour 
progression. Furthermore, as already mentioned, while re-introduction of VHL into RCC 
cells eliminated tumour growth, these cells are known to harbour alternative genetic 
abnormalities [121, 263, 281] . Defining molecular mechanisms with respect to VHL 
                                                 
25 Hereditary RCC occurs in Eker rats that are heterozygous for an insertion mutation in the TSC2 tumour suppressor gene, the Eker 
mutation. The germ-line mutation renders heterozygous mutants highly susceptible to renal carcinogens. The utility of this model in 
studying potential renal carcinogens is due to an ordered progression of proliferative renal lesions that can be identified and counted 
microscopically. The quantitative nature of the model allows for the production of statistically powerful data to understand the relative 
degree and potency of chemical effects and allow analysis of genetic alterations that may be chemical specific (reviewed in [22]). 
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alone in an already effected background is therefore difficult and requires caution. 
Moreover, several lines of evidence suggest that VHL has HIF-independent tumour 
suppressor functions, namely, a subclass of VHL mutations that retain the ability to 
induce HIFα degradation still predispose to phaeochromocytoma-only (type 2C) VHL 
disease. These findings raise interesting questions as to whether VHL-related tumours 
are a consequence of aberrant VHL control of HIFα or rather a means of promoting 
growth advantage within a given genetic background. 
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5.3 VHL involvement in tumour growth 
 
Development of malignancy requires that tumour cells undergo biological changes 
allowing them to proliferate, escape apoptosis, form new blood supplies, invade 
surrounding tissue and metastasise to distant sites. Recent evidence now suggest that 
VHL loss-of-function results in the deregulation of a number of signalling pathways that 
play key roles in one or more of these biological processes. The following sections 
outline VHL involvement in these events and the pathological consequence of its 
functional inactivation. 
 
5.3.1 Angiogenesis  
 
Figure 49 demonstrates how an 
angiogenic stimulus ‘activates’ 
endothelial cells lining an 
existing micro-vessel to 
dissolve their underlying 
basement membrane (BM), 
forming capillary sprouts in the 
perivascular connective tissue 
[282-284]. Key molecules in the 
angiogenic process are 
integrins, which might 
contribute to endothelial cell 
migration and survival, and 
proteases such as matrix 
metalloproteinases (MMPs), 
which degrade the BM and 
components of the perivascular 
extracellular matrix (ECM) which facilitate liberation of angiogenic factors such as VEGF. 
VEGF increases vascular permeability, resulting in spillage of plasma proteins such as 
fibrinogen into the perivascular environment, which contributes to a provisional matrix for 
further vascular remodelling. Vascular sprouts elongate in the direction of the angiogenic 
stimulus as a result of the migration and proliferation of the endothelial cells proximal to 
the migrating front, and gradually form a lumen. Eventually they anastomose26 with each 
other, forming capillary loops, thus allowing blood flow to begin. Angiogenesis is 
considered a key step in tumour progression implying a fundamental role for HIF in the 
later stages of tumour progression. However, the link between VHL loss, HIF activation, 
and how this relates to loss of growth control remains a key unanswered question. 
                                                 
26 Anastomose - cause to join or open into each other by anastomosis, as of blood vessels 
Figure 49. Initial stages of angiogenesis. See text for explanation.
Adapted from Lafleur et al.2003 
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Targeted inactivation of either HIF-1α or HIF-1β in the mouse results in abnormal 
vascular development and embryonic lethality [285-288]. Despite marked reduction in 
VEGF expression by HIF-1α-/- embryonic stem cells in hypoxic tissue culture, analysis of 
the developing HIF-1α-/- embryos detected a surprising increase in VEGF mRNA 
expression. This suggests that compensatory stimuli may operate to induce VEGF, and 
that reduced vascular development may be mediated by other pathways. 
 
Targeted inactivation of HIF-2α results in quite different and variable phenotypes. 
Though one study showed a defect in vascular remodelling, differing phenotypes have 
been observed in three other studies [289-292]. The reason for variability is unclear, 
although it appears more likely to reflect differences in genetic background rather than 
incompletely inactivated Hif-2α alleles. Overall, reports to date suggest that despite 
similar activity on HRE-linked reporter genes, HIF-1α and HIF-2α have important non-
overlapping, non-redundant functions in the regulation of endogenous gene expression in 
development. The unexpected and variable phenotypes presumably reflect the 
complexity of these responses. 
 
Experiments on cells bearing 
inactivating mutations in the HIF pathway 
have emphasised the importance of HIF 
(particularly HIF-1α) on the regulation of 
genes involved in angiogenesis [200, 285, 
286, 293, 294]. For a substantial number 
of these genes, promoter analysis has 
also clearly identified HREs that interact 
directly with HIF. The expression of other 
genes may be affected indirectly by 
secondary cascades of gene regulation. 
Even with respect to a single molecule, 
there may be many interfaces with 
hypoxia and hypoxia pathways. This is 
well-illustrated for VEGF (Fig.50). In 
hypoxia, VEGF transcription is up-
regulated by HIF, mRNA stability is increased by binding of proteins to specific 
sequences in the 3' UTR, and an internal ribosomal entry site allows preserved 
translation in the face of normal cellular hypoxic shutdown [294-297]. The biological 
activity of secreted VEGF is further influenced by hypoxia-inducible expression of the 
VEGF-R1 receptor, post-transcriptional regulation of the VEGF-R2 receptor and VEGF-
induced effects on soluble VEGF-R1, which inhibits VEGF action [298-300]. 
 
Microenvironmental activation of HIF in cancer occurs at the simplest level by 
physiological activation of the oxygen-sensitive pathways by hypoxia within the growing 
Figure 50. Multiple interfaces of hypoxia pathways 
with the angiogenic growth factor VEGF. IRES, internal 
ribosomal entry site. Flt-1 and Kdr are VEGF-R1 and –R2 
respectively. 
Adapted from Pugh et al. 2003 
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mass of cells. Findings suggest that reduction of cellular iron availability, as well as 
hypoxia, may limit proline hydroxylase activity in cancer cells and contribute to the 
general activation of HIF in tumours. 
 
5.3.2 Growth factors and enhanced cell proliferation 
 
It has been shown that pVHL can suppress certain genes that are over-expressed in 
renal carcinomas. Some of these genes are proangiogenic genes, and help in our 
understanding of why VHL derived tumours are highly vascular, and also help us to 
understand mechanisms of VHL tumour invasion and metastasis. Overproduction of 
angiogenic factors, like VEGF, might explain why VHL negative tumours are so highly 
vascularised, but whether this overproduction is sufficient for oncogenesis still remains 
unknown. Some of these factors that have been implicated in VHL disease are described 
below. 
 
A number of polypeptide growth factors that stimulate proliferation of normal cells 
have pathological consequences in tumourigenesis when deregulated.  RCC cells 
lacking functional pVHL over-express various growth factors including PDGFß, VEGF 
and transforming growth factor (TGF)-α. The latter is a bona fide renal cell mitogen that 
activates the Ras-Raf-MAP kinase signalling cascade through its cognate EGF cell-
surface receptor [301]. Overproduction of TGF-α in RCC cells, at least in part, is HIF-
dependent and a major contributory event that confers growth advantage to these cells 
[302, 303]. Indeed, transgenic expression of TGF-α in mice leads to the formation of 
multiple renal cysts reminiscent of pre-neoplastic lesions of the human kidney [33, 304, 
305]. These findings highlight a direct link between pVHL loss-of-function, activation of 
HIF and the ensuing deregulated production of a potent growth factor of renal epithelial 
cells. 
 
5.3.3 Cell survival and apoptotic evasion 
 
Several studies have associated loss of VHL function to decreased susceptibility of cells 
to undergo apoptosis and promote cell survival [200, 236, 306, 307]. Interestingly, while 
the molecular pathway(s) is unclear, tumour necrosis factor (TNF)-α, a 17 kDa pro-
inflammatory cytokine, has been shown to promote HIF-1α accumulation and this may 
involve a VHL-dependent step [308-311]. TNF-α is an endogenous mediator of 
inflammation and apoptotic cell death [312]. Jung et al. recently investigated TNF-α-
induced HIF-1α accumulation and demonstrated that an NFκB-mediated event normally 
associated with inflammation and cell survival, caused protein accumulation in normoxic 
cells [313]. While the report fails to identify the mechanism of HIF-1α accumulation, it is 
suggested that this might interfere with the pVHL-mediated HIF-1α degradation process. 
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Further studies support the 
concept of a pVHL-dependent 
cytotoxicity in RCC cells to 
TNF-α [314, 315]. In particular it 
has been reported that RCC 
cells can be sensitised to TNF-
α induced cytotoxicity by re-
introducing wild-type VHL [315]. 
Interestingly, the authors 
highlight the fact that TNF-
receptor engagement by TNF-α 
triggers the activation of 
atypical PKC (aPKC), which, 
through phosphorylation of 
IKKβ phosphorylation, liberates 
NFκB thereby initiating 
transcription of genes involved 
in apoptosis. pVHL has been 
shown to directly bind various 
aPKC isoforms and to target 
aPKCλ for ubiquitin-mediated 
degradation [245, 316]. 
Deregulation of this process 
may therefore have significant 
impact on NFκB transcriptional activity, and ultimately represents a means of promoting a 
selective pressure for populations of cells lacking functional pVHL to survive under 
adverse environmental conditions. 
 
5.3.4 VHL and the extracellular matrix 
 
Fibronectin is a multifunctional component of the extra-cellular matrix (ECM) that elicits 
intracellular signals that regulates cell adhesion, proliferation, differentiation, and 
tumourigenesis [317]. It is an extracellular glycoprotein that binds and signals through 
heterodimeric cell surface receptors known as integrins27 [318]. Loss of fibronectin matrix 
organisation has been recognised for many years as a very important event in cellular 
transformation and is a common feature in most cancer cells. Fibronectin has the ability 
to decrease the metastatic behaviour of malignant cells by increasing the interaction 
                                                 
27 Integrins are receptor proteins. They are the main way that cells both bind to and respond to the extracellular matrix. They are part 
of a large family of cell adhesion receptors that are involved in cell-extracellular matrix and cell-cell interactions. Functional integrins 
consist of two transmembrane glycoprotein subunits, called α and β, that are non-covalently bound. The α subunits all share some 
homology to each other, as do the β subunits. The receptors always contain one α chain and one β chain and are thus called 
heterodimeric. Until now 16 α and 8 β subunits have been identified. From these subunits some 22 integrins are formed in nature, 
which implies that not all possible combinations exist. 
Fig. 51. Model of pVHL involvement in TNF-α-mediated signaling. TNF-
α elicits apoptotic and antiapoptotic signals. In the apoptotic pathway, 
TNFR engagement of TNF-α triggers the activation of caspase-protease 
cascade leading to programmed cell death. In the anti-apoptotic pathway, 
TNFR engagement of TNF-α triggers the activation of aPKC, which is in a 
complex with TRAF2, RIP, and P62/ZIP. Activated aPKC phosphorylates 
IKKß, which phosphorylates IκB, triggering its ubiquitination and 
subsequent degradation. This releases NFκB from its inhibitor IκB, allowing 
the translocation of NFκB to the nucleus where it activates the transcription 
of numerous anti-apoptotic genes, including c-FLIP, Survivin, c-IAP-1, and 
c-IAP-2, which are inhibitors of caspases 8 and 3. Thus, completing the 
anti-apoptotic pathway. One possibility is that pVHL directly targets aPKC 
for ubiquitin-mediated destruction or pVHL affects the nuclear localisation 
and activation of NFκB independent of pVHL-mediated degradation of 
aPKC. 
Adpated from Jung et al. 2003 
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between tumour cells and their micro-environment via the integrin receptor family [319]. 
Several lines of evidence have demonstrated that pVHL interacts with fibronectin and is 
also responsible for the lack of extra-cellular fibronectin arrays in RCC cells lacking 
functional pVHL and in VHL negative mouse fibroblasts [134, 250, 320]. Although most 
disease-causing pVHL mutations hinder the regulation of the HIF pathway, every 
disease-causing pVHL mutant tested to date has failed to promote the assembly of the 
fibronectin matrix, underscoring its potential importance in VHL disease. Nevertheless, 
the exact nature of such an association and the mechanism by which VHL regulates the 
assembly of this ECM are poorly understood. It had been postulated that abnormally 
processed or misfolded fibronectin might accumulate inside cells in the absence of 
correctly functioning VHL, and that these aberrant fibronectin species, if secreted, could 
at least potentially interfere with the assembly of normal fibronectin. However, in a study 
by Esteban-Barragán et al., failure to detect any accumulation of endogenous fibronectin 
in VHL negative cells, as assessed by Western blot of total and intracellular fibronectin, 
cast doubt on this hypothesis [250]. In addition, neither the use of exogenous normal 
fibronectin nor culture on fibronectin-coated coverslips improved the ability of VHL 
negative cells to organise extra-cellular fibronectin. From these findings, they suggest that 
the abnormal ECM organisation in VHL null RCC cells might require a different 
explanation. Moreover, they showed that α3, β1, αv, and to a lesser extent, α2 and α5 
integrins are up-regulated in VHL negative cells demonstrating that the altered assembly 
of the fibronectin matrix is not attributable to decreased integrin expression. These results 
are also consistent with the highly migratory phenotype that has been reported previously 
in VHL null RCC cells [136, 321].  
 
Esteban-Barragán et al. demonstrated that the restored ability of VHL positive 
transfectants to assemble extracellular fibronectin is mediated by β1 integrins because it 
is completely abrogated by β1-blocking antibodies. They propose that an abnormal 
organisation of β1-fibrillar adhesions28 could help to explain the deficient fibronectin 
assembly of VHL negative cells. Nevertheless, they cannot formally rule out the possibility 
that an undetectable amount of abnormal fibronectin is accumulated and secreted in VHL 
negative cells, interfering with normal fibronectin assembly. Furthermore, the question still 
remains how VHL regulates the formation of β1-fibrillar adhesions and subsequent 
fibronectin organisation? VHL could regulate the expression or function of any of the 
intracellular constituents of the fibrillar adhesion. Given VHL’s current role in cytoskeleton 
stabilisation, it could be modulating proteins, such as the small GTP-binding proteins 
Rho, Rac, and cdc42, which play an important role in the control of cytoskeleton and 
regulate the formation of cell-matrix adhesions? 
 
                                                 
28 There are two major cell-matrix adhesions; focal and fibrillar adhesions. They not only differ in their morphology but also in their 
constituents. Classic focal adhesions are arrowhead shaped, contain αv or β1 integrins, and are rich in talin and vinculin proteins. 
Conversely, fibrillar adhesions are elongated, contain exclusively β1-integrins, and possess low levels of vinculin and talin. 
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An interesting twist to this story has recently emerged in a report that a ubiquitin-
like molecule called NEDD8 covalently modifies pVHL, and that a non-neddylateable 
pVHL mutant, while retaining its ability to ubiquitinate HIF, cannot bind to and promote 
the assembly of the fibronectin matrix. Furthermore, expression of the neddylation-
defective pVHL in RCC cells, while restoring the regulation of HIF, was insufficient to 
suppress the formation of tumours in nude mice models. These results suggest that 
NEDD8 modification of pVHL plays an important role in fibronectin matrix assembly and 
that in the absence of such regulation, an intact HIF pathway is insufficient to prevent 
VHL-associated tumourigenesis. 
 
5.3.5 VHL and cell polarity 
 
Emerging evidence indicates an 
inhibitory role for pVHL in the 
regulation of components that 
have been implicated in 
establishing/maintaining cell 
polarity and directed cell 
migration, in particular protein 
kinase C (PKC) isoforms. 
Regulation of insulin growth 
factor (IGF)-I-mediated cell 
invasion of RCC cells appears to 
be dependent upon PKCδ inhibition by pVHL. This inhibition is mediated through protein-
protein interaction involving a domain of pVHL which shows similarity to protein kinase 
inhibitor (PKI), a natural inhibitor of cAMP-dependent protein kinase (PKA) (table 17) 
[322]. In contrast to protein-binding inhibition, evidence has shown that pVHL binds both 
atypical PKC isoforms λ and ζ through it’s β-domain, and in the case of activated aPKCλ, 
mediates it’s turnover as part of pVHL’s function as an E3 ligase [245, 316]. While the 
functional significance of this inhibition remains elusive, given the central role for atypical 
PKC’s, namely aPKCζ, in establishing cell polarity in conjunction with PAR6 and the 
GTPase CDC42 [323], one could envisage a scenario whereby loss of pVHL leads to 
altered cell polarity, and by extension, aberrant cell migration. 
 
Consistent with this above-noted view, pVHL30 has been shown to co-localise with 
the microtubule network in vivo and to promote microtubule stabilisation [107]. Since 
microtubule dynamics have been intimately linked to the process of directed cell 
migration [323], this functional association may be an additional element of pVHL’s 
tumour suppressing activity. Indeed, the microtubule stabilising function of pVHL is 
specifically disrupted by type 2A disease mutants that predispose to a defined tumour 
spectrum of haemangioblastoma and phaeochromocytoma with a low predisposition to 
develop RCC. It is certainly tempting to draw parallels between the tumour suppressor 
Table 17. Comparison of VHL with protein 
kinase inhibitor regions 
Inhibitors   Amino Acid Sequence 
PHK substrate  RQM-SFRL 
VHL   97PYPTLP--PGTGRRIHSYRGH115
PKI    TYADFIASGRTGRRNAI--HD 
PKCδ    MNRRGAI—KQ 
PHK substrate means subtrate recognition sequence for phosphorylase 
kinase. PKI is the inhibitor sequence for cAMP-dependent protein kinase. 
Adapted from Datta et al. 2000 
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pathways regulated by 
pVHL and that by the 
adenomatosis polyposis 
tumour suppressor (APC) 
gene product, whose 
inactivation is the most 
frequently observed in 
hereditary and sporadic 
colon cancers [324]. 
Analogous to VHL, APC 
also binds to microtubules 
[323], and it has been 
shown that for APC this 
association culminates in 
cytoskeletal 
rearrangements and 
changes in cell polarity 
upon activation of the 
CDC42-PAR6-aPKCζ 
pathway (summarised in figure 52). Studies aimed at pVHL’s role with respect to cell 
polarity and directed cell migration are therefore clearly warranted. 
 
5.3.6 Branching morphogenesis and vasculogenesis 
 
VHL has been implicated in the process of branching morphogenesis in the fly, 
Drosophila Melanogaster.  Here Adryan et al. addressed the discrepancy between the 
fact that mutations in VHL predispose individuals to highly vascularised tumours, while 
VHL-deficient mice die in utero due to a lack of placental vascularisation. To help resolve 
the contradiction, Adryan et al. cloned the Drosophila VHL homologue (d-VHL) and 
studied its function [117]. The Drosophila VHL homolgue has since been shown to bind 
complex components Cul2, Elongin’s B and C, and Rbx1, and that this complex exhibits 
ligase activity towards the HIF-1α homologue in flies [118]. Adryan et al. showed that 
during embryogenesis, d-VHL is expressed in the developing tracheal regions where 
tube outgrowth no longer occurs. Reduced d-VHL activity caused breakage of the main 
vasculature accompanied by excessive looping of smaller branches, whereas over-
expression caused a general lack of vasculature. Importantly, human VHL can induce the 
same gain-of-function phenotypes. The authors suggest that VHL could be involved in 
halting cell migration at the end of vascular tube outgrowth. Loss of VHL activity could 
therefore lead to disruption of major vasculature, which requires precise cell movement 
and tube fusion, thus helping to explain the lack of placental vascularisation in VHL-
deficient mice. Once the primary vascular structure is laid out, a lack of VHL activity, and 
hence excessive cell migration and branching, could possibly lead to over-
Figure 20. Downstream activating pathways of the Rho-GTPase family of 
proteins, which include Rho, Rac, and Cdc42, and their participation in cell 
polarity. Atypical PKCζ forms a complex including Par6 and Cdc42. Etienne-
Manneville et al. demonstrated, through the use of primary rat astrocytes in a cell 
migration assay, that Par6-PKCζ interacts directly with and regulates glycogen 
synthase kinase-3β (GSK-3β) to promote polarisation of the centrosome and to control 
the direction of cell protrusion. Cdc42-dependent phosphorylation of GSK-3β occurs 
specifically at the leading edge of migrating cells, and induces the interaction of the 
APC tumour suppressor protein with the plus ends of microtubules. 
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vascularisation, as observed in the secondary branches of drosophila and in human 
tumours. 
 
Nonetheless, the question remains what is the true in vivo action of VHL in the 
vasculogenesis pathway? While in vitro its contributory role seems apparent, no 
evidence to date indicates a possible mechanism. Further analysis is necessary to 
explain these observations. 
 
5.3.7 VHL and tumour cell invasion 
 
Recently, important mediators of cell invasion were shown to be regulated by the pVHL 
tumour suppressor and these include hepatocyte growth factor (HGF) acting through the 
Met tyrosine kinase receptor [136, 321, 325-329]. Koochekpour et al. examined the HGF 
responsiveness of VHL-negative RCC cells and found that certain VHL-negative RCC 
cells were highly invasive and exhibited an extensive branching morphogenesis 
phenotype in response to HGF when compared to their wt-VHL expressing isogenic 
counterparts [136]. This same study demonstrated that VHL loss-of-function negatively 
regulates tissue inhibitor of metalloproteinase 2 (TIMP-2), resulting in the up-regulation of 
matrix metalloproteinases 2 and 9 (MMP2/9), thereby implicating pVHL in the control of 
these molecules. Matrix metalloproteinases (MMPs) are responsible for the degradation 
of ECM and have been associated with cellular invasiveness [330]. Importantly, it has 
been recently shown that hypoxia promotes tumour cell invasion by inducing the 
expression of the Met receptor [331]. This establishes a mechanism whereby 
transformed cells can be spurred to exit a hypoxic microenvironment and invade 
surrounding tissues, which provide more favourable growth conditions. Given the fact 
that HIF-1α has been shown to be involved in Met gene expression, constitutive HIF-1α 
activation as a consequence of pVHL deregulation provides a mechanism explaining the 
observation that expression of HGF and Met receptor is associated with genetic 
alterations of VHL in primary RCC. Hypoxic cell-sensitisation to HGF has therefore been 
proposed as an ‘invasive switch’ which facilitates cell movement away from an area of 
low oxygen availability, and is dependent on pVHL’s ability to degrade HIFα. 
 
5.3.8 VHL and tumour metastasis 
 
Tumour cell migration and metastasis share many similarities with leukocyte trafficking, 
which is critically regulated by chemokines and their receptors. In a report by Müller et 
al., the chemokine receptors CXCR4 and CXCR7 were shown to be highly expressed in 
human breast cancer cells, malignant breast tumours and metastases (Fig.51) [6] [332]. 
Breast cancer is characterised by a distinct metastatic pattern involving the regional 
lymph nodes, bone marrow, lung and liver. CXCR4 and CXCR7 respective ligands 
CXCL12/SDF-1α and CCL21/6Ckine exhibited peak levels of expression in organs 
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representing the first destinations of breast cancer 
metastasis. In breast cancer cells, signalling 
through CXCR4 or CXCR7 has been shown to 
mediate actin polymerisation and pseudopodia 
formation, and subsequently induces chemotactic 
and invasive responses. In vivo, neutralising the 
interactions of SDF-1α/CXCR4 significantly impairs 
metastasis of breast cancer cells to regional lymph 
nodes and lung. Malignant melanoma, which has a 
similar metastatic pattern as breast cancer but also 
a high incidence of skin metastases, shows high 
expression levels of CXCR10 in addition to CXCR4 
and CXCR7. Their findings indicated that 
chemokines and their receptors have a critical role 
in determining the metastatic destination of tumour 
cells, thereby fulfilling the chemoattraction theory of 
tumour metastasis. Interestingly, mice knockout 
studies of the CXCR4 gene exhibit defects in 
branching and/or remodelling of certain blood 
vessels [333]. Furthermore, VEGF has been shown 
to induce expression of CXCR4 supporting the 
notion that this chemokine receptor is important in 
remodelling the vasculature under hypoxia [334]. 
 
The gene encoding the chemokine receptor 
CXCR4 has been discovered as a novel HIF target 
based on microarray comparison of genetic profiles 
derived from VHL null RCC cells and their isogenic 
wild type VHL-expressing counterparts [321]. The 
fact that CXCR4 is a hypoxia-inducible gene 
provided a potential mechanistic explanation for 
CXCR4 up-regulation during tumour cell evolution. 
CXCR4-induced surface expression due to VHL 
loss-of-function confers enhanced migratory 
potential to RCC cells in response to its cognate 
ligand stromal-derived factor 1  (SDF1). In addition, CXCR4 might be needed to promote 
the survival of tumour cells in a hypoxic environment. Thus, the ability of a cell to 
generate genetic programmes capable of evading unfavourable growth conditions is 
reflected at least in part by the up-regulation of CXCR4 in response to a hypoxic 
microenvironment. However, unlike the Met receptor, and perhaps other hypoxic 
responsive factors that promote cell motility and invasion, CXCR4, due to its chemotactic 
responsiveness to SDF1, might confer not only a migratory potential but also the 
Figure 53. Targeted metastasis of primary 
breast cancer cells, according to the results 
of Müller et al. Compared with normal breast 
epithelial cells (top), their malignant 
counterparts are enriched for the surface 
expression of the chemokine receptor CXCR4. 
The chemokines (such as SDF-1α) that 
recognise these receptors are released in high 
quantities only by certain organs, such as bone 
marrow, liver, and lung. Other organs, such as 
kidney, skin and brain, contain low amounts of 
these chemokines. Malignant primary breast 
cancer cells invade their underlying 
extracellular matrix and circulate in the blood 
and lymphatic systems. Breast cancer cells 
passing through those organs with large 
amounts of the chemokines will be attracted to 
leave the circulation and enter the organs. So 
the final distribution of metastases reflects the 
relative abundance of chemokines in the 
different organs, and represents the 
chemoattractive theory of metastasis. 
Adapted from Liotta et al. 2001 
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possibility of targeting migrating cells to specific secondary sites.  Interestingly, strong 
CXCR4 expression can be correlated to poor tumour-specific survival in clear cell RCC, 
reflecting the metastatic potential of these tumours. This further implies that CXCR4 
expression levels may influence the metastatic behaviour of these cells. The question 
remains however, whether CXCR4 up-regulation is a result of a cell’s ability to 
metastasise, or whether this up-regulation itself primes the cell to metastasise. What ever 
this may represent, a cell’s ability to migrate to specific target sites may therefore be 
determined, in part, by loss of VHL, suggesting that these cells may be primed from an 
early stage to spread to other sites in the body. CXCR4 could represent a novel target 
site for therapeutic intervention in the prevention of cancer metastasis, the major cause 
of death in RCC patients and of many other solid tumours. 
 
 
Concluding Remarks 
 
 
Research to date shows that pVHL functions in the correct orchestration of cell 
proliferation, survival and angiogenesis through the control of the HIF pathway. However, 
VHL has also been linked to the regulation of cell polarity and directed cell migration in 
part through its association with aPKC and the microtubule network. Finally, intimate 
mechanistic linkages have been established between loss-of-function of pVHL and the 
processes of invasion and metastasis. Thus, a deeper appreciation of the many aspects 
of VHL biology and their deregulation within a pathological setting will help us to 
understand the molecular details pertaining to these pathways and key processes of the 
cancer phenotype. 
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CHAPTER 6 
Materials and Methods 
 
 
6.1 Materials 
 
 
6.1.1 General Chemicals 
Reagent Supplier 
Acetic acid BDH 
Activated CH sepharose 4B Pharmacia
Acrylamide Bio-Rad 
Agar Gibco BRL 
Agarose Progen 
Ammonium acetate BDH 
Aprotinin Boehringer 
Bovine serum albumin (BSA) Sigma 
Bio-Rad Protein Assay Bio-Rad 
Bromophenol blue Ajax 
Caesium chloride BDH 
Centricon Millipore 
Chloroform BDH 
Creatine phosphate Calbiochem 
Deoxynucleotide mix Stratagene 
Dextran sulphate Sigma 
D-(-)-Luciferin Boehringer 
DAPI (4’6’-Diamidine-2’-Phenylindole Dihydrochloride) Boehringer
Diethyl pyrocarbonate (DEPC) Sigma 
Dimethylsulfoxide (DMSO) Sigma 
Sodium hydrogen phosphate (Na2HPO4) BDH 
Dithiothreitol (DTT) Promega 
Distilled water GibcoBRL 
DNA Ladder:  
1kb Promega 
- Marker II – ( 0,12-23.1) Roche 
- Marker III – (0.12-21.2kbp) Roche 
- Marker V – (26-501bp) Roche 
- Marker VI – ( Roche 
DNA polymerase:    
- cloned Pfu Stratagene 
- Pwo  Roche 
- Taq Stratagene 
EN3HANCE NENTM 
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Reagent Supplier 
Enhanced chemi-luminescence Amersham 
Ethanol BDH 
Ethidium bromide  Sigma 
Ethylenediamine tetra-acetic acid (EDTA) Boehringer 
Ethyleneglycol-bis-(aminoethyl ether)-N,N,N',N'-tetraacetic acid 
(EGTA) 
 
Sigma 
Ficoll Pharmacia 
Formaldehyde BDH 
Glutathione sepharose 4B Pharmacia 
Glycerol BDH 
Hemocyanin, keyhole limpet (KLH), Megathura Crenulata Calbiochem 
Hydrochloric acid BDH 
Hydrogen peroxide BDH 
Isopropanol BDH 
Isopropylthio-β-D-galactoside (IPTG) BRL 
Klenow enzyme Boehringer 
Lambda protein phosphatase New Eng Bio. 
Leupeptin Auspep 
Magnesium chloride BDH 
Magnesium sulfate BDH 
Methanol BDH 
3-(N-Morpholino)propane-sulfonic acid (MOPS) Sigma 
N,N,N’,N’-Tetramethylethylenediamine (TEMED) Bio-Rad 
N,N’-methylene bisacrylamide ICN 
Mowiol Calbiochem 
N-2-Hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) Boehringer  
Nickel chloride BDH 
Nitrocellulose membrane Schlei. & Schuell
NP-40 Sigma 
Oligo-dT cellulose Pharmacia 
Paraformaldehyde BDH 
PCR nucleotide mix Boehringer 
Pepstatin A Boehringer  
Phenol GibcoBRL 
Phenyl-methyl-sulphonyl-fluoride (PMSF) Boehringer 
Polydeoxyinosinic-deoxycytidylic acid (poly [dI:dC]) Sigma 
Polyvinyl pyrrolidone Sigma 
Potassium acetate Amresco 
Potassium chloride Amresco 
Potassium ferricyanide BDH 
Potassium ferrocyanide BDH 
Protein A / G sepharose Pharmacia 
Proteinkinase K GibcoBRL 
Propidium iodide (PI) Sigma 
RNase H reverse transcriptase GibcoBRL 
RNase inhibitor Boehringer 
Protease Inhibitor cocktail tablets (compete) Boehringer 
Sodium acetate BDH 
Sodium chloride BDH 
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Reagent Supplier 
Sodium dihydrogen orthophosphate (NaH2PO4) BDH 
Sodium Dodecyl Sulfate (SDS) ICN 
Sodium Hydroxide BDH 
Spermidine New Eng bio. 
T4 DNA ligase Sigma 
Thrombin (bovine) Calbiochem 
TNT-Coupled reticulocyte lysate system Promega 
Tris(hydroxymethyl)aminomethane (Tris base) BDH 
Tri-Sodium citrate BDH 
Triton X-100 BDH 
Tween-20 BDH 
Ubiquitin aldehyde Affiniti 
Ubiquitin Calbiochem 
Ubiquitin (K84R) Bio-Rad 
Wheat germ extract Promega 
5-bromo-4-chloro-3-indolyl-B-D-galactopyranoside (X-Gal) Promega 
Xylene cyanol Ajax 
Zeocin Invitrogen 
 
 
 
6.1.2 Drugs and tissue culture reagents 
Reagent  Supplier 
Actinomycin D Sigma 
Ampicillin Fisons  
β-mercaptoethanol Sigma 
5-Bromo-2'-deoxyuridine (BrdU) Sigma 
Chloramphenicol Sigma 
Cell proliferation kit I (MTT) Roche 
Concanavalin A Sigma 
CSF-1 (recombinant human) Chiron Corp 
Colcemid Sigma 
Cycloheximide Sigma 
Doxorubicin DBL 
Dulbecco’s Modified Eagle Medium (DMEM) GibcoBRL 
Etoposide Sigma 
Foetal Bovine calf Serum (FCS) HycClone 
Folic acid Sigma 
G418 (geneticin) GibcoBRL 
Grace’s insect medium Sigma 
Hygromycin B Boehringer
Ionomycin Sigma 
Kanamycin Sigma 
L-asparagine Sigma 
Leptomycin B Sigma 
Lipofectamine GibcoBRL 
Lipofectamin 2000 GibcoBRL 
L-Glutamine Trace 
LPS (E.coli 0111:B4) Sigma 
MEK inhibitor Promega 
MEM non-essential amino acids GibcoBRL 
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Reagent Supplier 
Methyl -D-mannopyranoside Sigma 
Nocodazole Sigma 
Oligofectamine Invitrogen 
Optimem GibcoBRL 
Penicillin  Trace 
Phorbol 12-myristate 13-acetate (PMA) Sigma 
Phosphate Buffered Saline (PBS) Trace 
Poly-L-Lysine solution Sigma 
Puromycin GibcoBRL 
Renal proximal tubular epithelial cells (RPTEC) BioWhittake Inc. 
RPMI GibcoBRL 
Staurosporine Dr.B.Hemmings 
Streptomycin Trace 
Taxol (Paclitaxel) Sigma 
Trichostatin A BIOMOL 
Trypsin EDTA GibcoBRL 
Trypsin versene  CSL 
Vincristine Sigma 
 
 
6.1.3 Antibodies 
Antigen Conjugation Clone / Cat#  Supplier 
Acetylated-tubulin  6-11B-1 Sigma 
Akt 
ARNT 1 (C-19) 
 9272 
Sc-8076 
Cell signaling 
Santa Cruz 
BrdU FITC 347583 Becton Dickinson 
Caesin kinase Iα  Sc-6478 Santa Cruz 
Caesin kinase Iε  610446 BD Pharmingen 
β-catenin  14 / C19220 BD Trans. labs 
Cyclin A 
cyclin B1 
Cyclin B1 
Cyclin D1 
Cyclin E 
Cyclin F 
Cyclin G 
Cyclin H 
CDK2 
CDK3 
CDK4 
CDK7 
CXCR4 
 C-22 / sc-160 
H-433 / sc-752 
GNS1 / sc-245 
72-13G / sc-450 
HE12 / sc-247 
C-20 / sc-952 
FL-249 / sc-851 
FL-323 / sc-855 
Sc-163-G 
Sc-826 
Sc-260 
Sc-856 
12G5 / MAB170 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Santa Cruz 
R&D Systems Inc. 
Drebrin 
Dynein (intermed. chain) 
E2F-1 
EB1 
 M2F6 / D029-3 
70.1 / D5167 
05-379 
5 / e46420 
LabForce 
Sigma 
Upstate biotech. 
BD Trans. labs 
Elongation factor 1a  05-235 Upstate Biotech. 
EPAS-1 (C-16) 
Fibronectin 
Sc-8712 
P1H11/MAB1926
Santa Cruz 
Chemicon Int. 
FLAG 
 
M5 or M2 Kodak 
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Antigen Conjugation Clone / Cat#  Supplier 
GAL4  5398-1 Clontech 
GAL4 (DBD)  RK5C1 / sc-510 Santa Cruz 
GFP  7.1 and 13.1 Boehringer 
Glut1  GT12-S JURO 
α-Goat IgG HRP  Amersham 
GSK-3 
GST 
 7 / 610202 
GST-2 / G1160 
BD Trans. labs 
Sigma 
HA.11  MMS-101R BAbCO 
HDAC6  Sc-5255 Santa Cruz 
HDAC6  184 Gift: Tso-Pang Yao 
HDAC6 
HIF-1alpha 
HIF-1alpha 
HIF-2alpha 
 2162 
54 / H72320 
NB 100-123 
NB 100-122 
Cell signalling 
BD Trans. labs 
Novus-Biologicals 
Novus-Biologicals 
HSP60  MA3-012 Affinity Bioreagents 
Lamin A/C (346) 
NFκB p50 
NFκB p65 
α-Mouse IgG 
α-Mouse IgG 
α-Mouse IgG 
 
 
 
Cy5 
FITC 
Texas Red 
Sc-7293 
Sc-7178 
Sc-109 
715-175-150 
715-095-150 
715-075-150 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Dianova 
Dianova 
Dianova 
α-Mouse IgG HRP NA 931 Amersham 
α-Mouse IgG Alexa 488 A-11029 Molecular Probes 
α-Mouse IgG Texas red 595 T-862 Molecular Probes 
Mouse IgG1κ 
Myc (supernatant) 
Myc (c-Myc) 
Myosin II (nonmuscle) 
Myosin II (nonmuscle) 
P-Akt (Thr308) 
P-Akt (ser473) 
P-histone 
P-IκB-α (ser32) 
 M7894 
9E10 
sc-789 
PRB-440P 
CMII23 
9275 
9271 
06-570 
9241 
Sigma 
Cell culture 
Santa Cruz 
BabCO 
Dev.Stud.Hyb.Bank 
Cell signaling 
Cell signaling 
Upstate 
Cell signaling 
p-cofilin   Cell signaling 
P-p44/42 MAP kinase 
P-p70 S6 kinase(Thr 389) 
Prolyl hydroxylase 2 
 
 
9101 
9205 
100-137 
Cell signalling 
Cell signaling 
Novus Biologicals 
p21  Sc-397 Santa Cruz 
p27 
p27 
p53 
p53 
p53 
PARP 
PKC-ζ 
PKC-µ 
PTEN 
 
 
57 / K25020 
sc-527 
Ab-7 
Sc-100 
G59-12 / 14211A 
C2-10 / 556362 
sc-7262 
sc-936 
sc-6818 
BD Trans. labs 
Santa Cruz 
Oncogene 
Santa Cruz 
BD Pharmingen 
BD Pharmingen 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Rabbit IgG (purified)  02-6102 Zymed 
α-Rabbit IgG Cy5 711-175-152 Dianova 
α-Rabbit Texas Red 711-075-152 Dianova 
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Antigen Conjugation Clone / Cat#  Supplier 
Rabbit IgG (purified) 
α-Rabbit IgG 
α-Rabbit 
α-Rabbit IgG 
 
Cy5 
Texas Red 
Nanogold 
02-6102 
711-175-152 
711-075-152 
Zymed 
Dianova 
Dianova 
Nanpprobes 
α-Rabbit IgG HRP NA 934 Amersham 
α-Rabbit IgG 
α-Rabbit IgG 
Alexa 488 
Texas Red 595 
A-11008 
T-2767 
α-Rat IgG HRP - 
RNA pol II 
Skp2 
Skp2 
T7 
β-TRCP 
α-Tubulin 
β-Tubulin 
γ-Tubulin 
Ubiquitin 
 
 
 
 
 
 
MMS-134R 
monoclonal 
Sc-1566 
69522-3 
Sc-8863 
MAS 077 / YL1/2 
Tub 2.1 / T4026 
GTU-88 / T6557 
MMS-258R 
Molecular Probes 
Molecular Probes 
Dako 
BAbCO 
Krek Lab 
Santa Cruz 
Novagen 
Santa Cruz 
Harlan Sera-lab 
Sigma 
Sigma 
BAbCO 
Ufd1 
VCP 
VCP (G-20) 
VEGF (147) 
VHL-mouse 
VHL (M-20) 
VHL (R-20) 
Vimentin 
Vimentin 
 611643 
612183 
sc-9783 
sc-507 
Ig32 / 65031A 
Sc-1534 
Sc-1535 
V2258 
64-740-1 
BD Trans. Labs 
BD Trans. Labs 
Santa Cruz 
Santa Cruz 
BD Pharmingen 
Santa Cruz 
Santa Cruz 
Sigma 
ICN Biochemicals 
 
6.1.4 Radiochamicals 
PRO-MIX L-[35S] in vitro cell labelling mix (Amersham) with a specific activity of 
>37TBq/mM (>1000Ci/mM) and radioactive concentration of 530 MBq/ml (14.3mCi/ml) 
was used for metabolic labelling. [γ-32P]dATP (~3000 Ci/mmol) were obtained from 
Amersham as 10mCi/mL solutions. 
 
6.1.5 Restriction Enzymes 
Restriction enzymes were purchased from Boehringer, New England Biolaboratories or 
Promega and used with supplied buffers according to recommended protocols.  
 
6.1.6 Bacterial strains and media 
Plasmid DNA was grown in the bacterial strain DH5α (Life Technologies). Luria modified 
medium, Luria broth and Terrific broth for growth of bacteria were generated by FMI 
Media Kitchen staff. 
Chapter 6 – materials and methods 
 108
6.1.7 Oligonucleotides 
Sequencing oligonucleotides 
T7 TAATACGACTCACTATAGGG 
T3 ATTAACCCTCACTAAAG 
SP6  GATTTAGGTGACACTATAG 
M13-5’ GTAAAACGACGGCCAGT 
M13-3’ AGCGGATAACAATTTCACACAGGA 
pBabe-P-5’ CCCTAAGCCTCCGCCTCCTCTTCC 
pBabe-P-3’ CATGCTTTGCATACTTCTGCCTGC 
p97-int-5’ GCCAATGAGACTCATGGTCAT 
p97-int-3’ TGAACATAGGGCTGCCAAATC 
hHDAC61144-5’ CTGGAGGGTGGCTACAACCTCCGCGCC 
hHDAC61227-3’ CATGGGGCAAGGGTCTCCCAGAAGGGT 
hHDAC62401-5’ GACCCACCACCCCTGCTGACCCTGCCA 
hHDAC624933’ CCAGTATCTGCGATGGACTTGGATGGT 
 
Oligonucleotides for protein tags 
HA TACCCATACGACGTGCCAGACTACGCT 
FLAG GATTATAAAGATGATGATGATAAA 
T7 AGCTTCTCCCTCCTGCTGAAAGAGCTACTCTTG 
Myc CTACAGGTCCTCCTCGGAGATCAGCTTCTGCTCC 
NLS CCAAAGAAGAAGCGCAAGGTC 
NES CTCCCTCCTGCTGAAAGAGCTACTCTT 
 
Oligonucleotides for generation of pcDNA3 / pBABE(puro) -HA/GST/GFP/untagged -VHL 
constructs 
GST-5’ CTCCACGGCAAGCTTACCATGTCCCCTATACTAGGTTATTGG 
GST-3’ CTCCACGGCTCTAGATCAGTCACGATGAATTCCCGGGGA 
GFP-5’ CGCTACGTAACCATGGTGAGCAAGGGCGAG 
GFP-5’ CTCCACGGCGAATTCACCATGGTGAGCAAGGGCGAGGAG 
GFP-3’ CTCCACGGCCTCGAGTTACTTGTACAGCTCCTCGTCCAAATGAAC 
VHL30-5’ CTCCACGGCGAATTCACCATGCCCCGGAGGGCGGAGAACTGG 
VHL-3’ GCGAATCTCAATCTCCCATCCGTTGATGTGCAAT 
VHL19-5’ CTCCACGGCGAATTCACCATGGAGGCCGGGCGGCCGCGGCCC 
VHL1-157-3’ CTCCACGGCGGATCCAGTATACACTGGCAG 
VHL-STOP CTCCACGGCGAATTCTCAATCTCCCATCCGTTGATGTGCAATGCG 
VHL1-53-3’ CTCCACGGCGGATCCCTCCTCCTCGGCGCCCAGTTCCTC 
HAVHL30-5’ GCGGATCCACCTACCCATACGACGTGCCAGACTACGCTATGCCCC 
HAVHL19-5’ GCGGATCCACCTACCCATACGACGTGCCAGACTACGCTATGGAGG 
NLSVHL30-5’ GCGAATTCCCAAAGAAGAAGCGCAAGGTCATGCCCCGGAGGGCG 
NLSVHL19-3’ GCGAATTCCCAAAGAAGAAGCGCAAGGTCATGGAGGCCGGGCGG 
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Oligonucleotides for PROTEOMICS 
15301015-5’ CTCCACGGCGGATCCACCATGAGCTTCGTGGCATACGAGGAGCTG 
MYC153..-5’ GCGAATTCCTACAGGTCCTCCTCGGAGATCAGCTTCTGCTCCATGC 
p97MM-5’ GCGGATCCACCATGGCCTCTGGAGCCGAT 
p97MM-3’ GCGATATCTTAGCCATAGAGGTCATCGTC 
MYCp97-5’ GCGGATCCACCATGGAGCAGAAGCTTGATCTCCGAGGAGGACCTG 
15301015-3’ CTCCACGGCGAATTCTAGCCTGGGGTCTTGGTGGCGAAGGTCAGG 
HA153..-5’ GCGGATCCACCTACCCATACGACGTGCCAGACTACGCTATGAGCT 
153STOP-3’ GCGAATTCCTAGCCTGGGGTCTTGGTGGCGAAGGT 
Dj967n21-5’ CGTAAGCAGCGGGAAATCCCCCCCCCTCCC 
Dj967n21-3’ CTCCACGGCTCTAGATCAAAGCAGACAAGGAGAAAGAGAATGCCA 
HAXP_04-5’ GCGGATCCACCTACCCATACGACGTGCCAGACTACGCTATGGAGG 
XP_04-3’ CTCCACGGCGAATTCTTAAGAGTCAGACTCTGGGCATTTTCG 
 
Oligonucleotides for construct clonings or sequencing 
HAODDHif1α5’ GCGGATCCACCTACCCATACGACGTGCCAGACTACGCTAGCCGAGGAAGA 
ODDHif1α-3’ GCGAATTCTCAGGTCATAGGTGGTTTCTTATACCCACA 
NHE-1-5’ CTCCACGGCAAGCTTACCATGGTTCTGCGGTCTGGCATCTGTGGC 
NHE-1-3’ CTCCACGGCGGATCCCTGCCCCTTGGGGAAGAACGGTTCTCCCTC 
NHE-1-5’ CTCCACGGCGGTACCCTGCCCCTTGGGGAAGAACGGTTCTCCCTC 
HANpl4-5’ GCAAGCTTACCTACCCATACGACGTGCCAGACTACGCTATGGCCGAGAGC 
Npl4-3’ GCGAATTCCTAGGTCCTGGGGAGGCTGCA 
Npl4rat-5’ GCAAGCTTACCATGGCCGAGAGCATCATAATCCGT 
HANpl4rat-5’ GCAAGCTTACCTACCCATACGACGTGCCAGACTACGCTATGGCCGAGAGC 
HAufd1-5’ GCAAGCTTACCTACCCATACGACGTGCCAGACTACGCTATGTTCTCTTTCA 
Ufd1-3’ GCGGATCCTTAGGGCTTTCTTCCCTTTTT 
Ufd1mm-5’ GCGGATCCACCATGTTTTCTTTCAACATGTTTGACCACCCG 
HAufd1mm-3’ GCGGATCCACCTACCCATACGACGTGCCAGACTACGCTATGTTTTCTTTCA 
Ufd1MM-3’ GCTCTAGATTAGGGCTTTCTTCCCTTCTTACG 
HDAC6HS-5’ GCAAGCTTACCATGACCTCAACCGGCCAGGAT 
HDAC6HS-5’ GCGAGCTCACCATGACCTCAACCGGCCAGGAT 
HDAC6HS-3’ GCTCTAGATTAGTGTGGGTGGGGCATATCCTC 
HDAC6HS-3’ GCAGATCTTTAGTGTGGGTGGGGCATATCCTC 
HD6 FLAG -3’ GCTCTAGATTATTTATCATCATCATCTTTATAATCGTGTGGGTGGGGCATAT
CCTCCCCAAA 
HDAC6MM-5’ GCGAATTCACCATGACCTCCACCGGCCAAGATTCT 
HDAC6MM-3’ GCCTCGAGTTAGTGTGAGTGGGGCATGTCCTC 
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PHD2-5’ GCGGATCCACCATGGCCAATGACAGCGGCGGG 
PHD2-3’ GCGAATTCCTAGAAGACGTCTTTACCGACCGA 
 
Oligonucleotides to be annealed and inserted into vectors for general usage 
NES-5’ AGCTTCTCCCTCCTCTCGAAAGACTTACTCTTG 
NES-3’ GATCCAAGAGTAAGTCTTTCGAGAGGAGGGAGA 
NESM-5’ AGCTTCTCCCTCCTGCTGAAAGAGCTACTCTTG 
NESM-3’ GATCCAAGAGTAGCTCTTTCAGCAGGAGGGAGA 
FLAG-5’ AGCTTTCTAGAGATTATAAAGATGATGATGATAAAA 
FLAG-3’ AAGATCTCTAATATTTCTACTACTACTATTTTTCGA 
 
Oligonucleotides for antisense VHL approach  (pSuper) 
VHL21mer-5’ GATCCCCGTCATCTTCTGCAATCGCAGTTTCAAGAGAACTGCGATTGCAGA
AGATGACTTTTTGGAAA 
VHL21mer-3’ AGCTTTTCCAAAAAGTCATCTTCTGCAATCGCAGTTCTCTTGAAACTGCGAT
TGCAGAAGATGACGGG 
VHL19mer-5’ 
 
GATCCCCGTCATCTTCTGCAATCGCATTCAAGAGATGCGATTGCAGAAGAT
GACTTTTTGGAAA 
VHL19mer-3’ AGCTTTTCCAAAAAGTCATCTTCTGCAATCGCATCTCTTGAATGCGATTGCA
GAAGATGACGGG 
 
Oligonucleotides for siRNA – target sequences 
VHL #1 AAGAGTACGGCCCTGAAGAAGAC 
VHL #2 GTCATCTTCTGCAATCGCAGT 
VHL #3 CTCAATGTTGACGGACAGCCT 
VHL #4 ACACAGGAGCGCATTGCACAT 
p97 AACAGGTAGCCAATGAGACTC 
PHD2 CTTCAGATTCGGTCGGTAAAG 
MDM2 AACAAGAGACCCUGGUUAGAC 
CKI-α GGCCAGGCATCCCCAGTTGT 
Cullin 2 AAGAAGTCAGCGAAAGGGATG 
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6.2 DNA and RNA manipulation 
 
6.2.1 Isolation of plasmid DNA 
 
Nucleobond from Machery-Nagel was used to isolatate plasmid DNA. Cultures were 
inoculated by mini-culture or directly from glycerol stock and left incubate over-night (10-
12 hrs) in 100-500ml LB media supplemented with appropriate antibiotic if necessary. 
The following day, bacteria were pelleted by centrifuging at 5000g for 5mins and the 
pellet was re-suspended in appropriate volume of S1 buffer supplemented with RNase A 
(50mM Tris/HCl, 10mM EDTA, 100µg RNase A/ml, pH8.0, stored at 4oC). Samples were 
lysed in S2 buffer for 5mins at room temperature (200mM NaOH, 1% SDS), followed by 
addition of S3 buffer (2.80M KAc, pH5.1) and left incubate for a further 5mins on ice. 
Filter paper was prepared in glass funnels by dampening them with ddH20 prior to 
filtration of the lysate. The filtrate was collected and added to DNA binding columns that 
had already been calibrated with buffer N2 (100mM Tris, 15% ethanol, 900mM KCl 
adjusted with H3PO4 to pH6.3, 0.15% Triton X-100). The filtrate was passed through the 
column (for low copy plasmids, this was repeated) to allow the plasmid DNA to bind to 
the column. Contaminants were washed from column using buffer N3 (100mM Tris, 15% 
ethanol, 1150mM KCl adjusted H3PO4 with to pH6.3). Buffer N5 was used to elute the 
plasmid DNA (warmed to 50oC for low copy plasmids) and DNA was precipitated by 
addition of approximately 0.8 volumes of isopropanol. Samples were centrifuged at 
>15,000g for 30mins at 4oC, and the pellets were washed with 70% ethanol and further 
centrifuged at 15,000g for 10mins at 4oC. Pellet was dried and re-suspended in 
appropriate amount of ddH20 or TE buffer. Concentration was calculated by measuring 
OD260. 
(NB: Plasmid isolation kits were also used from Qiagen, and followed manufacturer’s 
instructions. Miniprep plasmid isolation was performed using Wizard Plus SV Miniprep 
kit). 
 
Alternatively – Cesium Chloride preparation 
200-400ml culture was grown up over-night, pelleted at 5000rpm for 5mins and re-
suspended in 20ml of Solution 1 (50mM Glucose, 25mM Tris/HCl pH8.0, 10mM EDTA 
pH8.0) containing 3mg/ml lysozyme. After incubation on ice for 10mins, 40ml of solution 
2 (0.2M NaOH, 1% SDS – mix fresh) was added, and left incubate for a further 30mins. 
Samples were centifuged at 8000rpm for 10mins, and the supernatant collected and 
passed through gauze into new tubes. 0.6 volumes isopropanol was added, and samples 
centrifuged at 12000rpm for 10mins. The supernatant discarded and the pellet re-
suspended in 8.5ml ddH2O. 8g of CsCl2 was prepared in a 15ml polyprene falcon and 
8ml of DNA solution was added. CsCl2 had to entirely dissolved before continuing. 
Carefully 640µl of a 10mg/ml stock of ethidium bromide was added and mixed gently. 
Samples were centrifuged at 3000rpm for 5mins, supernatant removed and centrifuged 
further at 45,000rpm for 22 hours at 15oC. Following the ultra-centifugation, there should 
be a band corresponding to the plasmid DNA. This band was collected and extracted 
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with the same volume of isobutanol (3-4 times). ddH2O was added to the extraction 
solution to make up a final volume of 6ml supplemented with 0.6ml of 3M NaOAc 
(pH5.2). A further 12ml of 100% ethanol was added and DNA precipitated at –20oC for 
60mins. Samples were centrifuged at 13000rpm for 15mins, supernatant discarded and 
pellet re-suspended in 2-4ml of ddH2O. Phenol/chloroform extracted and ethanol 
precipitated as usual. Pellets were re-suspended in an appropriate volume of ddH2O or 
TE buffer. 
 
6.2.2 Isolation of DNA from agarose gels 
DNA fragments were excised from agarose gels in a minimum volume using a scalpel, 
and purified using QIAquick Gel Extraction kit from Qiagen. 
 
6.2.3 Isolation of total RNA 
Snap-frozen tissue samples were homogenised in F15 Falcon tubes in TRIzol reagent 
(GibcoBRL). Tissue culture cells were lysed directly in TRIzol reagent. Samples were 
incubated for 15 minutes at room temperature, 0.2 volumes of chloroform was added, 
and shaken vigorously for 15 seconds, followed by a further incubation for 5 minutes at 
room temperature. The mix was then spun at 12000g and 4˚C for 15 minutes, separating 
it into three phases. The upper, clear aqueous phase, containing the RNA, was removed 
into a fresh eppendorf tube and 0.5 volumes (calculated from the initial volume of TRIzol 
used) isopropanol added. Following 10 minutes at room temperature, the sample was 
centrifuged at 12000g and 4˚C for 10 minutes to pellet the RNA. The supernatant was 
discarded, and the pellet washed with 1mL 70% ethanol. After air-drying, the RNA pellet 
was re-suspended in TE and incubated for 15 minutes at 55oC. Concentration was 
determined at OD280.  
 
6.2.4 Northern Blot Analysis 
Gel apparatus was soaked in 0.2M NaOH (20mins) to inactivate any RNase activity and 
rinsed thoroughly with ddH20. Appropriate agarose gel and running buffer 
(MOPS/EDTA:0.2M MOPS, 50mM Na-acetate, 10mM EDTA, pH7.0, supplemented with 
2.2M formaldehyde) was prepared. Samples were equalised with loading buffer and left 
at 65oC for 10 minutes. 1µl of ethidium bromide was added to each sample before 
loading onto gel. Following migration, the gel was incubated in 10x SSC for 30 minutes, 
as was the nylon membrane for 10 minutes. Capillary transfer of RNA from the agarose 
gel onto membrane was employed. Following transfer, the membrane was washed in 5x 
SSC for 15 minutes and subjected to UV-cross-linking using a Stratlink. 
-Probe preparation as per MEGA-prime DNA Labelling Systems: 25ng/µl of template was 
used to yield a 50µl reaction volume, which included template, primers and ddH20. DNA 
was denatured at 95oC for 5 minutes, and the following was added - 4µl unlabelled 
dNTP, 5µl 10x reaction buffer, 5µl radio-labelled dNTP, 2µl enzyme. Reaction mixture 
was incubated for 10 minutes at 37oC, and stopped upon the addition of 0.2M EDTA. The 
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mixture was heated for a further 5 minutes at 95oC. Specific activity was calculated for 
probe, which was then subject to a Nick-spin sepharose G-50 column (Pharmacia-
Biotech) to eliminate unincorporated nucleotides and further measured for specific 
activity which should not drop below 106cpm. Probe was stored at –20oC until ready for 
use. 
- Pre-hybridisation: Membrane was incubated for 15 minutes in 65oC pre-warmed Church 
& Gilbert Hybridisation buffer (0.25M Na2HPO4 pH7.3, 1% BSA, 1mM EDTA pH8.0, 7% 
SDS – all sterile filtered). 
- Hybridisation: 100µl of salmon sperm DNA (10mg/ml) and probe were denatured by 
heating to 95oC for 5 minutes, and then added to each other. This DNA mixture was then 
added to 10ml of C&G buffer and incubated with the membrane at 65oC overnight. The 
membrane was washed 4x30 minutes with washing buffer (20mM Na2HPO4 pH7.3, 1mM 
EDTA pH8.0, 1% SDS). Following the final wash, the membrane was dried between 
whatmann paper, and exposed to film. 
 
6.2.5 Construction of plasmids 
VHL sub-cloning was derived from pcDNA3-VHL30 following BamHI/EcoRI digestion, 
unless otherwise stated. pcDNA3-HA-VHL30 (R82P), (P86H), (N90I), (Q96P), (Y112H) 
were a gift from P. Ratcliffe. All other point mutants of pVHL were generated by a two-
step PCR-based mutagenesis procedure using pcDNA3-HA-VHL30 as template. 
Individual PCR products were subsequently digested with BamHI and EcoRI and cloned 
into pcDNA3-derivative containing an HA epitope. pcDNA3-GST was generated by a one 
step PCR reaction involving pGEX-2TK  and insertion of GST into pcDNA3 HindIII/xbaI. 
To generate pcDNA3-GST-VHL30/VHL19/VHL1-115, pcDNA3-GST was cut BamHI/EcoRI. 
PcDNA3-GST-VHL1-157 was sub-cloned from pCMV-HAVHL1-157 BamHI/XbaI.  
 
Retroviral expression of GFP-fusion VHL constructs was obtained by sub-cloning 
VHL into pBABE(puro). Olionucleotides were designed to remove the stop codon from 
VHL by PCR, and the product was sub-cloned BamHI/EcoRI. The GFP sequence was 
amplified following a one step PCR reaction from the commercially available vector 
pEGFP-N1 (Clontech) and sub-cloned 3’ to the respective VHL construct BamHI/XhoI. 
To obtain pGST-VHL30 mutants, the corresponding fragments were sub-cloned into 
pGEX-4T-1 (bacterial expression) or pAc-GST (for expression in Sf9 cells) using BamHI 
and EcoRI. To obtain pcDNA3-HIF1α and pcDNA3-HIF2α, both cDNAs were amplified 
by PCR, subsequently digested with BamHI and XbaI, before ligating into pcDNA3. 
Baculvoviral constructs included pvL1393-VHL30 was cloned BamHI/EcoRI from pAC-
GST-VHL30; pAC-GST-Elongin C from pvL1393-GST-Elongin C by BamHI/EcoRI; PAC-
GHLT(B)-VHL30 from pvL1393-VHL30 by pstI/NcoI. PAC-GHLT(B)-Elongin C was cloned 
from pvL1393-Elongin C by pstI/NotI. cDNA clones of HNMHC IIA and IIB were gifts from 
R.Aldestein. pCS2-HDAC6-flag and pCS2-MT-HDAC6-flag were gifts from Dr.S.Hook. 
p97, pET26-Ufd1 and pET30-Npl4 were gifts from Dr.H.Meyer. p97 was sub-cloned 
BamHI/EcoRV following PCR amplification of cDNA. Subsequent tags (HA/Myc) were 
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included within oligonucleotides. pVL1393-p97 was cloned BamHI/NotI. Clones 
15301015, dj967n21.3 and XP_045589 were obtained from the IMAGE consortium and 
amplified via one-step PCR reactions and sub-cloned into appropriate vectors. pcDNA3-
15301015 sub-cloning involved a BamHI/EcoRI digestion. For HA or Myc tagged 
constructs, the tag was included in the oligonucleotide, generating for example pcDNA3-
HA-153101015.  
 
All PCR-derived constructs were confirmed by sequence analysis. The primers 
used for constructing and sequencing the above-described plasmids have been listed 
within the materials section of this chapter. 
 
6.2.6 Standard recombinant DNA reactions 
Standard DNA manipulation techniques such as restriction enzyme digestion, blunting of 
3' and 5' overhangs, λ-phosphatase treatment, oligonucleotide annealing/sub-cloning 
and ligation of DNA fragments were performed by standard methods using enzymes in 
buffers supplied by the manufacturers. 
  
6.2.7 Polymerase chain reaction 
PCR was carried out according to the manufacturers protocol regarding the polymerase 
employed. Standard usage involved Pfu polymerase. However, the Expand Long 
Template proofreading PCR system (Boehringer Mannheim) was used for generation of 
larger DNA fragments used to construct. Taq polymerase was also used. 
 
6.2.8 Reverse transcriptase-PCR 
RT-PCR was performed as per manufacturers instructions - GibcoBRL Superscript first-
strand synthesis system (cat.#11904-018). 
 
6.2.9 DNA sequencing 
Samples were dried down in a speed-vac at approximately 1µg per sample, and 
processed by the automated DNA sequencing facility at the FMI which employs the use 
of an ABI PRISM 377 DNA sequencer. This sequencer performs slab gel electrophoresis 
with fluorescence detection of individual nucleotides. Alternatively, samples were sent 
externally to Microsynth, a commercially available source for sequencing. 
 
6.3 Cell culture 
 
6.3.1 Culture of immortalised cell lines 
All cells, unless otherwise stated, were maintained in Dulbecco’s Modification of Eagles 
Medium (DMEM) supplemented with 10% foetal calf serum. NIH-3T3 cells were cultured 
in DMEM containing 5% bovine calf serum. Renal proximal tubule epithelial cells 
(RPTECs) were cultured as described by the manufacturer. Stable cell lines expressing 
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construct of interest routinely invlolved transfection of construct within a mammalian 
expression vector, namely pcDNA3. Following transfection, cells were subjected to 
selective media containing 0.5mg/ml G418 (for neomycin resistance). Cultures were sub-
cloned and/or stable pools established under selective media. Cells were counted using 
a haemocytometer. 
 
6.3.2 Transfection of cells 
Transfection of cells was performed using various tansfection protocols. For 293 and 
Hela cells, a calcium phosphate protocol was employed. For more difficult transfections, 
or for those that required a higher transfection efficiency, lipid-based transfection media 
were employed, e.g. fugene and lipofectamine 2000.  
 
6.3.3 siRNA transfection of cells 
Unless otherwise stated, logarhythmically growing cells were transfected to yield a final 
concentration of 130nM siRNA oligonucleotide mixture (Qiagen). For a 6 well plate, 10µl 
of the oligonucleotide mixture was added to 175µl Opimem. In a separate eppendorf, 3µl 
of oligofectamine was added to 15µl of Optimem and left to stand for 5 minutes before 
being added to the oligonucleotide mixture, which was then incubated for a further 20 
minutes. Target cells were washed once with medium lacking serum, and 800µl of serum 
free medium was added to the cells. The transfection complex was overlayed and cells 
were incubated at 37oC for 4 hours. The medium was then supplemented with 500µl of 
medium containing 30% serum and left incubate for appropriate time, normally 24-48 
hours. (NB. While most cell lines tested showed significant knockdown of target protein, 
all attempted experiments demonstrated Hela cells as being the cell line in which most 
efficient knockdown could be achieved). 
 
6.3.4 Retroviral transduction of cells 
In order to generate retroviral pools, the packaging cell line PT-67 (Clontech) was 
fugene-transfected with pCMV(neo-retro) or with pBABE(puro) constructs. Tissue culture 
supernatant was harvested 24 hours later, passed through a 0.45µm filter and added to 
target cells in the presence of 0.8µg/ml polyprene (detergent). Infected cells were 
selected by growth in the presence of 1 mg/ml G418 or puromycin. Clones were sub-
cultured and/or stable pools (uncloned mass culture) cells were maintained in DMEM 
supplemented with 10% FCS and 0.5 mg/ml G418 or puromycin. 
 
6.4 Cell cycle analysis 
 
6.4.1 Fluorescent activated cell sorting (FACS) 
Cells were trypsinised, washed, pelleted and re-suspended in 300µl cold PBS. While 
vortexing, 1ml of cold (-20oC) 100% ethanol was added drop-wise. Samples were 
incubated at –20oC overnight (up to one month), pelleted, washed once in PBS, and re-
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suspended in 500µl of FACS solution (38mM sodium citrate pH7.5; 69µm propidium 
iodide) supplemented freshly with 10µg RNase. Cells were left at 37oC for 30mins and 
read at 488nm using a Becton Dickinson FACS Calibur flow cytometer incorporating a 
class 3B laser. Cellquest, version 3.13 from Immunocytometry, was used to analyse 
data. 
 
6.4.2 Arresting cells 
Cells were arrested in late G1/S-phase by a double thymidine (2mM) block or 
thymidine/aphidicolin block (14hrs thymidine - 14hrs DMEM - 14hrs thymidine or 
aphidicolin - release).  Alternatively, hydroxyurea and mimosine were employed, albeit to 
a lesser extent. Nocodazole (500ng/ml) was used to block cells at G2/M. Serum 
starvation (overnight) and contact inhibition (6 days post confluency with daily medium 
changes) arrested cells in G0. 
 
6.5 Protein manipulation 
 
6.5.1 Immunoprecipitation and Western blotting 
Immunnoprecipitations were performed from cells lysed at 4oC in either TNN buffer 
(50mM Tris-HCl pH7.5; 120mM NaCl; 5mM EDTA; 0.5% NP-40; 50mM NaF; 0.2mM 
Na3VO4; 1µM DTT, 1µM PMSF, 1mg/ml aproteinin) or alternatively from whole cell 
extract, WCE, buffer (20mM Hepes pH7.6; 0.4M NaCl; 25% glycerol, 1mM EDTA; 5mM 
NaF; 0.1% NP-40; 0.5mM Na3VO4; 1mM DTT; 1µM PMSF; 1mg/ml aproteinin). Proteins 
were equalised using Bradford method (Biorad). Lysates were cleared using 
centifugation, and pre-cleared using protein A sepharose beads. The 
immunoprecipitating antibody was added for a period of one hour to overnight. 
Concentrations varied among antibody, but generally, an average concentration of 2µg 
per 1-2ml of lysate was used. Following IP, protein A sepharose was added for one hour 
(NB. Protein G sepharose was used in the case of monoclonal antibodies). Beads were 
washed at least three times in lysis buffer, boiled in laemmli buffer and loaded on an 
SDS-PAGE gel (NB: where necessary, gradient gels were used as per Hoefer). 
 
Immunoblotting was performed onto Nitrocellulose membrane (Schleicher & 
Schuell) at 400mA for 1-2 hours for min-gels (10x6cm approx.), and 450-500 mA 
overnight for large gels (13x15cm approx). Membranes were blocked in 5% milk (unless 
otherwise stated) and incubated with primary antibody in 5% milk from one hour to 
overnight. Membranes were washed 3x10mins TBST, and further incubated with a 
relevant HRP-conjugated secondary antibody in 5% milk for one hour. Western blots 
were processed using enhanced chemi-luminescence according to the manufacturer’s 
instructions. 
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6.5.2 Cell fractionation  
Basic cytoplasmic/nuclear fraction preparation 
Cells were harvested from a 10cm plate by scraping in 1ml of ice cold PBS. Cells were 
pelleted at 5000rpm for 5mins at 4oC. Supernatant was discarded, and the cells 
resuspended in 400µl of hypotonic buffer (10mM MOPS pH7.5, 10mM KCl, 2mM MgCl2, 
0.1mM EDTA and 5mM DTT). The resuspension was transferred to a chilled dounce 
homogeniser and lysed with approximately 10 strokes on ice. Lysate was pelleted at 
5000rpm for 2-3mins. The supernatant corresponded to the cytosolic extract. Pellet was 
washed four times in hypotonic buffer containing 0.1% NP40 and spun down again at 
5000rpm at 4oC. Pellet was then lysed in extraction buffer (S6K extraction buffer 
containing 1% NP40) and centrifuged at 14,000rpm for 10mins at 4oC. Supernatant 
corresponds to nuclear extract. 
 
Optimised for preparation of nuclei 
Medium was aspirated from cells from a 10cm well plate and washed twice in PBS. 5ml 
of  DMEM containing cytochalasin B was added nad the cells were let incubate for 
40mins at 37oC. Cells were washed again twice in PBS, and scraped into a 15ml falcon. 
Cells were collected by centrifuging at 800g for 5mins.Cells were washed in 2ml of 
solution 1 (10mM KCl, 1.5mM MgCl2, 1mM DTT, 0.1mM PMSF, 1µg/ml pepstatin, 1µg/ml 
leupeptin, and 1µg/ml trypsin inhibitor). Cell pellet was placed on ice and re-suspended in 
1ml of solution 1 supplemented with 10µM cytochalasin B. Cells were incubated on ice 
for 20mins and then transferred to a chilled Weaton glass homogeniser. The plasma 
membranes were disrupted by approximately 20 gentle strokes (the efficiency of cell 
breakage could be monitored by phase-contrast microscopy). The homogenate was 
transferred to a 1ml eppendorf tube.The homogenate was under-layed with 200µl of 
solution 1 supplemented with 40% sucrose and centrifuged at 800g for 15mins. Aspire of 
the supernatant (membrane and cytoplasmic fraction) and the sucrose cushion and re-
suspend the pellet accordingly in PBS.   
 
Isolation of mitochondria from tissue culture cells 
For a cell pellet of 1-2ml - the cell pellet was re-suspended in 11ml of ice-cold RSB 
(hypotonic buffer: 10mM NaCl, 1.5mM MgCl2, 10mM Tris-HCl pH7.5) and transferred to a 
dounce homogeniser. Cells were allowed to swell for 5-10mins. Add 8ml of 2.5x MS 
buffer (525mM mannitol, 175mM sucrose, 12.5mM Tris-HCl pH7.5, 2.5mM EDTA pH7.5) 
to give a final concentration of 1x MS (210mM mannitol, 7.mM sucrose, 5mM Tris-HCl 
pH7.5, 1mM EDTA pH7.5 – an iso-osmotic buffer to maintain the tonicity of the 
organelles and prevent agglutination). The homogeniser was covered with parafilm and 
the homogenate mixed by careful inversion. Homogenate was transferred to a tube for 
differential centrifugation (total volume 30ml) and centrifuged at 1300g for 5mins to 
remove nuclei, unbroken cells and large membrane fragments. The supernatant was 
removed to a new tube and the nuclear spin-step repeated twice. Supernatant was again 
transferred to a new tube and the mitochondria pelleted at 17000g for 15mins. The 
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supernatant was discarded and the pellet washed by re-suspending it 1x MS and 
repeating the 17000g sedimentation. Again the supernatant is discarded and the pellet 
re-suspended in a suitable volume in appropriate buffer for subsequent work. 
 
6.5.3 Glycerol gradient 
A 10-40% glycerol gradient was used in 20mM Hepes pH7.5, 50mM NaCl, 0.1% NP-40 
and 0.5mM DTT. A Standard two chamber pump was used to pour gradients into 12.5ml 
ultra-centrifuge tubes on which was over-layed the protein preparation of interest and a 
control (catalase 232kDa, aldolase 158 kDa, BSA 67 kDa, ovalalbumin 43kDa). Tubes 
were placed inside a SW41 rotor and centrifuged at 40,000rpm for 24hrs. Fractions were 
carefully collected using an automatic collection carousel. From a total of 12.5ml, 
approximately 60 fractions were collected, from which every 5th sample of the control was 
ran on a gel and stained with coomassie in order to estimate the size distribution across 
the various fractions.  
 
6.5.4 Far Western 
Protein transfer was performed in methanol-free transfer buffer (192mM Glycine; 25mM 
Tris; 0.01% SDS). Proteins were de-natured and re-natured on the membrane: At 4oC 
gently agitate membrane in the following decreasing concentrations of Guanine-HCl in 
Hyb75 (20mM Hepes pH7.7; 75mM KCl; 0.1mM EDTA; 2.5mM MgCl2; 0.05% NP-40; 
1mM DTT) - 2x5mins 6M; 4x10mins 3M; 4x10mins 1.5M; 4x10mins 0.75M; 4x10mins 
0.375M. Block membrane – 2x30mins Hyb75; 1x30mins Hyb75 + 5% milk; 1x30mins 
Hyb75 + 1% milk. Overlay with probe (made up in Hyb75 and supplemented with 
proteinases and NaN3) and incubate overnight at 4oC. Wash 3x15mins with Hyb75. 
Incubate with antibodies of interest against probe components and develop as normal 
western blot. 
 
- Probe Preparation: Complex components Skp1/Skp2 or pVHL30/ElonginC/ElonginB 
were co-expressed in Sf9 cells and purified via GST-pulldown. Complexes are verified by 
western blot analysis and eluted from beads using 15mM Glutathione elution buffer and 
buffered for glycerol gradient conditions and store at –80oC. Load probe onto glycerol 
gradient of 10-40% (20mM Hepes pH7.5; 50mM NaCl; 0.1% NP-40; 0.5mM DTT). 
Comparative standards included catalase 232kDa, aldolase 158kDa, BSA 67 kDa, 
Ovalbumin kDa. Samples were spun at 40,000rpm for 24 hours in an SW41 rotor. 
Following fractionation, western blot analysis was performed for every fifth fraction from 
standards to estimate range of interest. Following this, every second fraction was taken 
from sample corresponding to this range, and prepared for western blot. Fractions 
containing complex were pooled. Protein concentration was estimated against BSA 
standards on a coomassie-stained gel, and concentration of probe used per Far western 
ranged between 2-3µg. 
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6.5.5 Metabolic labelling of cells 
Logarhythmically growing cells are washed twice and incubated for 30mins in 
methionine-free DMEM without serum (or dialysed). Radioisotopic labelling was 
performed by incubating cells in methionine-free DMEM supplemented with [35S]-
methionine (100µCi/ml) (PROMIX) and 10% dialysed FCS for 4 hours at 37oC in a 
humidified 10% CO2 incubator. Following SDS-PAGE protein resolution, signals can be 
enhanced by incubating gel for 1 hour in destain (acetic acid; methanol, water), 1 hour in 
EN3HANCE solution, and finally 30mins in water. 
 
6.5.6 In vitro transcription/translation reactions 
In vitro transcription/translation reactions were made using TNT reticulocyte translation 
system with the addition of [35S]-L-methionine according to the manufacturer’s protocol 
(2x TNT rabbit reticulocyte lysate; 25x TNT reaction buffer; 50x amino acid mix minus 
methionine; 1 unit Rnase inhibitor; 1.5µg DNA; 50x TNT T7 RNA polymerase; 40µCi 
[35S]-methionine; ddH2O to 50µl).  
 
6.5.7 Generation and affinity-purification of antibodies 
Generation and purification of anti-pVHL30 antibody has been described previously [184]. 
Polyclonal rabbit serum to full-length mouse was raised against the corresponding GST-
fusion protein purified from bacteria. Anti-pVHLCT peptide antibody was raised against 
the synthetic peptide LERLTQERIAHQRMGD, corresponding to the carboxy-terminus of 
human pVHL. Before injection into rabbits, the peptide was coupled to keyhole limpet 
hemocyanin (Pierce) by glutaraldehyde coupling. Polyclonal rabbit serum to mouse pVHL 
was affinity purified by incubation with first a GST affinity column, followed by a GST-
pVHL25 fusion protein affinity column, previously prepared by covalently cross-linking the 
respective proteins to glutathione-Sepharose with dimethylpimelimidate. Anti-peptide 
antibody was affinity purified by coupling 10mg of synthetic peptide to 1g of CH-
Sepharose 4B (Pharmacia) according to manufacturer’s protocol. To obtain anti-pVHLNT 
antibody, polyclonal rabbit serum to human pVHL was affinity purified by incubation with 
first a GST affinity column, followed by a GST-pVHL1-53 fusion protein affinity column. 
Incubation and elution of antibodies was carried out as described [335]. All commercially 
available antibodies used, or those given as gifts are listed in the Materials section of this 
chapter. 
 
6.5.8 Bacterial expression and purification of GST-fusion proteins 
E. Coli DH5α containing expression plasmids for GST-fusion proteins were inoculated 
overnight and the next morning diluted 1/10 in LB containing 0.2mM IPTG. After 4.5 
hours of incubation at 37°C, bacteria were harvested by centrifugation at 5,000 rpm for 5 
minutes. After resuspending cells in TNN buffer (50mM Tris, 250mM sodium chloride, 
5mM EDTA, 0.5 % NP-40, 50mM sodium fluoride, 0.2mM ortho-vanadate, 1mM 
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dithiothreit, 10mM PMSF and 1µg/ml aprotinin at pH 7.5), bacteria were sonicated. Cell 
debris was collected by centrifugation at 5,000 rpm for 5 minutes, and the supernatant 
transferred to a fresh tube. Meanwhile, Glutathione-sepharose 4B beads were pre-
incubated in 5 % milk for 10-15 minutes and washed 2-3 times with TNN buffer, before 
adding the beads to the bacterial lysate. After 1-2 hours of incubation at 4°C, the beads 
were collected by centrifugation and washed 3-4 times with TNN buffer. Depending on 
the experimental setting beads were subsequently washed with other buffers (e. g. 
kinase buffers), incubated with other proteins (e. g. in vitro translated molecules) or 
processed directly for SDS-PAGE. 
 
6.5.9 Covalent coupling of antibody  to protein A sepharose 
For general purpose procedures, approximately 2mg of antibody per millilitre of wet 
beads were bound. The antibodies and protein A sepharose were incubated at rooom 
temperature for 1hr with gentle rocking. Beads were washed twice with 10 volumes 0.2 
sodium borate (pH9.0) by centrifugation for 5mins or 10,000g for 30 seconds. They were 
then re-suspended in 10 volumes of 0.2M sodium borate (pH9.0) and the equivalent of 
10µl of beads was removed (for subsequent testing). Enough dimethylpimelimidate was 
added to bring the final concentration to 20mM and incubated for 30mins at room 
temperature on a shaker. Again remove an equivalent of 10µl of beads. Reaction was 
stopped by washing the beads once in 0.2M ethanolamine (pH8.0) and incubated for 
2hrs at room temperature in 0.2M ethanolamine with gentle mixing. The beads were 
washed again three times in PBS and stored as a 50% slurry in PBS supplemented with 
0.05% sodium azide. 
 
6.5.10 Baculoviral expression of proteins 
The Baculovirus Expression Vector System (BEVS) from PharMingen was used as a 
eukaryotic expression system. The baculovirus DNA used is the Autographa californica 
nuclear polyhedrosis virus (AcNPV). Heterlogous genes are cloned into transfer vectors 
and co-transfection of transfer vector and AcNPV infection of Spodoptera frugiperda 
(Sf9) cells allows recombination between homologous sites, transferring the 
heterologous gene from the vector to the AcNPV DNA. AcNPV infection of sf cells results 
in the shut-off of host gene expression allowing for a high rate of recombinant mRNA and 
protein production.  
- Transfection of sf9 cells: 2x106 sf9 per 6cm plate are seeded. 0.5µg BaculoGold DNA 
(modified AcNPV) is added to 4µg of DNA (cloned into appropriate vector) and left stand 
5mins before adding 1ml transfection buffer B (25mM Hepes, pH7.1, 125mM CaCl2, 
140mM NaCl). Cells are aspirated and 1ml of transfection buffer A (Grace’s medium 
containing 10% FCS) is gently added. Transfection mixture is then added to cells, which 
are then incubated at 27oC for 4 hours. Cells are washed once with 3ml medium, and left 
at 27oC for 5 days in a further 3ml medium. Supernatant containing virus is collected, 
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passed through a 0.45µm filter, and used to infect sf9 cells for further amplification of 
virus or for protein expression. 
- Infection of sf9 cells: 5x106 sf9 cells per 10cm plate are seeded. Infect by overlaying 
1ml of virus containing supernatant (>108 virus particles). Harvest cells 48 hours post 
infection.  
- Amplification of virus: 5x106 sf9 cells per 10cm plate are seeded. Infect by overlaying 
400µl of virus containing supernatant (∼0.4x108 virus particles). Collect supernatant 72 
hours post infection. Pass supernatant through a 0.45µm filter and store and 4oC in dark. 
 
6.6 Cellular and biochemical assays 
 
6.6.1 Cell Proliferation Assay 
For adherent cell lines, cells were seeded down at 0.5x104/100µl in a 96-well plate and 
after 24 hours the medium was replaced. Celle were hence manipulated according to 
application. The cells were then gently washed in 100µl PBS, and 50µl of 0.5mg/ml of the 
tetrazolium salt solution (MTT) was added to each well and left incubate at 37oC for one 
hour (NB. reaction is light sensitive). Following incubation, 200µl DMSO was added as a 
solubilising agent. The absorbance of each sample is measured spectrophotometrically 
at λ570. The mean absorbance of each quadruplicate was calculated subtracting the 
ethanol control. Standard statistical analysis was perfomed to evaluate any significant 
findings. 
 
6.6.2 Reporter gene assay 
1x105 cells per 6 well were seeded down in triplicate. 24 hours later cells are transfected 
using FUGENE or Lipofectamine 2000 with 100ng/well of the β-galactosidase plasmid for 
normalisation and 100ng/well reporter plasmid. Cells are washed and lysed in 250µl 
extraction buffer (0.1M KPO4 pH 7.8, 0.1% Tritonx100, 1mM DTT). Lysates are 
centrifuged at 14,000rpm, and 100µl transferred to 96-well plate. Lysates were combined 
with luciferin reagent (0.3mM luciferin, 22mM MgSO4, 37mM glycyl-glycine, 5mM ATP) 
or with galactose reagent (Galacto reaction kit) for normalisation. Plate was read using a 
Microlumat plus LB 96V plate reader (Berthold Technologies). 
 
6.6.3 In vitro ubiquitination assay 
Reaction volume is 20-30µl and is performed at 30oC for 30mins. Reaction mixture: 2µl of 
I.V.T substrate; S100 extract supplemented with 8µg/µl ubiquitin; 100ng/µl ubiquitin 
aldehyde; energy regenerating system (20mM Tris pH7.4, 2mM ATP, 5mM MgCl2, 40mM 
creatine phosphate, 0.5µg/µl creatine kinase). I.V.T. is subsequently immunoprecipitated 
and prepared for western blot. 
 
- S100 extract preparation: Cells are lysed for 15-30mins in Hypotonic buffer (20mM Tris 
pH7.4, 5mM MgCl2, 8mM KCl, 1mM dithiothreitol, 0.5mM PMSF, 10µg/ml leupeptin, 
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1µg/ml pepstatin, 0.1mM PABA, 10µg/ml aproteinin). Lysates are centrifuged at 
14,000rpm to remove cell debris. Supernatants are transferred and are further ultra-
centrifuged at 100,000g for 4 hours. 
 
6.6.4 Microtubule co-sedimentation assay 
Cells were washed with ice-cold PBS, scraped into 1 ml of PBS and collected by 
centrifugation. The cells were solubilised in PTN buffer (100 mM PIPES, 30 mM Tris, 50 
mM NaCl, 1 mM EGTA, 1.25 mM EDTA, 1 mM DTT, 1% Triton X-100, pH 6.9) containing 
protease inhibitors. Supernatants were cleared by centrifugation for 30 minutes at 
100,000×g at 25°C. Tubulin (Sigma; 5mg/ml in buffer A: 100 mM MES, 1 mM EGTA, 0.1 
mM EDTA, 0.5 mM MgCl2, 100 µg/ml sucrose, 1 mM DTT, 0.1 mM GTP, 1 µg/ml 
leupeptin, 1 µg/ml aprotinin, pH 6.8) was polymerised with 50 µM taxol in the presence of 
2.5 mM GTP for 30 minutes at 37°C. 50µg of re-polymerised microtubules per assay 
were pelleted by centrifugation for 30 minutes at 100,000×g at 25°C. The microtubules 
were resuspended in 60 µl of pre-cleared cell supernatant containing 50µM taxol and 
incubated for 30 minutes at 37°C. Samples were then centrifuged for 30 minutes at 
100,000xg at 25°C, and supernatants and pellets were analysed by SDS-PAGE and 
immunoblotting. Plasmid DNA was in vitro translated using the TNT Quick Coupled 
Transcription/Translation Systems (Promega). 10 µl of cold in vitro translated HA-tagged 
pVHL was incubated with polymerised microtubules in a total volume of 60µl and 
processed as described above. 
 
6.6.5 Microtubule stability assay 
MT stabilisation assays were performed as described previously (Krylova et al., 2000). 
Briefly, exponentially growing COS-7 were plated on coverslips and transfected the next 
day with indicated constructs using Fugene as described by the manufacturer. 44-48 
hours post-transfection cells were- treated with 10µM nocodazole for the indicated time 
points before processing cells for immunofluorescence using anti-acetyl-tubulin and anti-
HA (Y11) antibodies. Untagged pVHL was detected using anti-pVHL30 antibody. DNA 
was stained with DAPI. At least 300 cells per experiment were analysed for an intact MT 
network. Only cells with intact nuclei and a clearly detectable cytoplasmic signal of HA-
pVHL (or pVHL-GFP) were included in the evaluation. Experiments were repeated as 
blind assays. 
 
The following adjustments were made for experiments described in Part B: 
exponentially growing COS-7 cells were plated on coverslips and transfected the next 
day with indicated constructs using Fugene as described by the manufacturer. 18-24 
hours post-transfection cells were- treated with 10µM nocodazole for 20 minutes before 
processing cells for immunofluorescence using anti-α-tubulin (YL1/2), anti-HA (Y11), 
where in this case the HA-tagged protein represents an additional protein of interest, 
e.g.p97. Untagged pVHL was detected using anti-pVHL30 antibody. At least 300 cells per 
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experiment were analysed for an intact microtubule network. Only cells with intact nuclei 
and a clearly detectable cytoplasmic signal of pVHL and HA-tagged protein of interest 
were included in the evaluation. In this way, effects of other factors that may alter VHL’s 
ability to stabilise microtubules can be investigated. 
 
6.6.6 In vitro phosphorylation of pVHL 
GST-fusion constructs were expressed in E. coli or sf9 cells and purified using 
glutathione-Sepharose affinity resin. Purified protein was incubated with kinase of 
interest in appropriate buffer (e.g. 20-50mM Tris, 10mM MgCl2, 5mM DTT at pH 7.5) 
supplemented with 10µCi of [γ-P32]-ATP (2,000 Ci/mmol). Kinase reactions were 
performed for 30 minutes at 30°C. Phosphorylated proteins were separated by SDS-
PAGE, the gels were dried and visualised by auto-radiographic exposure. 
 
6.7 Imaging 
 
6.7.1 Immunofluorescence microscopy 
Exponentially growing cells were plated on coverslips and processed for indirect 
immunofluorescence microscopy. Cells were washed with wash buffer (PBS/0.05% 
Tween/EGTA), fixed in 3% paraformaldehyde / 2% sucrose in PBS (pH 7.4) for 10-15 
minutes at 37°C and permeabilised using 0.2% Triton X-100 in PBS for 2 minutes at 
room temperature, or in acetone (-20°C) for 30 seconds. Alternatively, cells were fixed for 
5 minutes in methanol/acetone (-20°C) or in freshly prepared 4 % formaldehyde in PBS 
for 10 minutes at room temperature and permeablised using acetone (-20°C) for 30 
seconds. All subsequent steps were carried out at room temperature. Coverslips were 
rinsed with wash buffer and incubated for one hour with indicated primary antibody 
diluted in 1% BSA/1% goat serum in PBS. After three washes with wash buffer for 5 min 
each, coverslips were incubated with the appropriate secondary antibody. Secondary 
antibodies included donkey anti-rabbit aminomethylcoumarin (AMCA), donkey anti-
mouse fluorescein isothiocyanate (FITC), anti-rat Texas-Red, donkey anti-rabbit FITC 
and anti-mouse Texas-Red. DNA was counterstained with 1µg/ml 1,4,6-diamidino-2-
phenylindole (DAPI) or 10 µg/ml propidium iodide. F-actin was stained with Texas Red-
conjugated phalloidin. Coverslips were then inverted into 5 µl Vecta-shield mounting 
medium. For labelling of mitochondria, cells were incubated with MitoTracker (M-7512) 
for 30 minutes at a final concentration of 100nM prior to fixation. Images were obtained 
with an Eclipse E800 microscope using a CoolPix950 digital camera (Nikon) or with a 
Fluoview FV500 confocal laser-scanning microscope (Olympus). Photographic images 
were processed using Adobe Photoshop, version 6.0. 
 
6.7.2 Time-lapse video microscopy 
For live microscopy, cells were mounted in purpose-built observation chambers (Type 1, 
Life Imaging Services, Olten, Switzerland) and imaged at 37°C on a Leica DM-IRBE 
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inverted microscope using high numerical aperture oil-immersion lenses and a GFP-
optimised filter set (Chroma Technology, Brattleboro, Vermont). Images were captured 
using a MicroMax cooled CCD camera (Princeton Instuments, Trenton, NJ) and 
MetaMorph Imaging Software (Universal Imaging Corporation, West Chester, PA). 
Images were taken every 15 s with a 2 s exposure using neutral density filters to prevent 
photo damage.  
- Image Analysis: Still images from individual frames of original video recordings were 
prepared using Metamorph 2.75 (Universal Imaging, West Chester, PA), and pictures 
were assembled with Adobe Photoshop. 
 
6.8 Proteomics 
 
6.8.1 2D-gel electrophoresis 
- Protein precipitation: 4x volume methanol was added to protein sample and vortexed. 
1x volume chloroform is added to the mixture, vortexed and spun. 3x volumes of ddH2O 
was added, vortexed and spun again. Aqueous (upper) phase was discarded. A further 
3x volume of methanol was added, vortexed and spun. Supernatant was removed, pellet 
was dried in speed-vac and stored at –80oC. 
- 2D-gel electrophoresis: Protein pellet was re-suspended in re-hydration buffer (7M 
urea, 2M thiourea, 4% CHAPS, 1% DTT and 2% Pharmalyte 3-10). Samples were 
loaded onto onto pH3-10 (minigel) or pH4-7 (large gel) linear IPG strip (Pharmacia) by 
re-swelling the strips in buffer. Iso-electric focusing for approximately 6.5kV (minigel) or 
100kV (large gel) at 20oC was followed by equilibration with 2% DTT followed by 5% 
iodoacetamide. For second dimension migration, IPG strips were applied to SDS-PAGE 
gels (12.5% acrylamide, unless otherwise stated) and run at 30mA (minigel) or 200mA 
(large gel).  
- Gel processing: Gels were subsequently prepared for western blotting or stained with 
Colloidal Coomassie Blue G-250. Stained gels were digitalised using Personal 
Densiometer SI (Molecular Dynamics) and statistically evaluated for differences in spot 
intensity. Stained protein spots were isolated, washed twice with 50% acetonitrile in 0.1M 
ammonium bicarbonate and evaporated. Gel pieces were reduced with DTT and 
alkylated with iodo acetamide, washed, dried and swollen in digestion buffer (50mM 
ammonium bicarbonate, 5mM CaCl2) containing 12.5µg/mg trypsin for 45 minutes on ice. 
Samples were centrifuge for 5 minutes at 10,000g following  incubation in digestion 
buffer for 16 hours at 37oC without enzyme. Peptides were identified as outlined below. 
 
6.8.2 Peptide Identification 
 
- MALDI-TOF: Protein Identification involved protein digestion using trypsin, and the 
masses of the generated peptides measured by MALDI-TOF (Tofspec 2E, 
Micromass) peptide mass fingerprinting. The programme, 
ProteinLynxGlobalServer (PLGS), was used for protein identification. 
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- LC-MSMS: Failing protein identification by peptide mass fingerprinting, protein 
Identification using LC-MSMS was employed. Proteins are digested with trypsin 
and the peptides are separated by capillary LC online connected to an IonTrap 
MS (Finnigan Deca XP). In the MS, the peptides are fragmented and the masses 
of the fragments provide sequence information. The programme TurboSequest 
was used to identify the corresponding proteins. Since proteins are identified with 
sequence information of single peptides this method can also be used to identify 
proteins in complex mixtures and to search genomic and EST libraries. 
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CHAPTER 7 
RESULTS – PART I: 
 
Identification of novel VHL interacting proteins 
 
 
 
7.1 Introduction 
 
As discussed in chapter 3, genotype-phenotype relations in patients with VHL disease 
suggest that VHL has multiple functions, and that some of these functions may be tissue 
specific. Indeed, mutations that give rise to type 2C disease, those corresponding to 
predisposition to phaeochromocytoma but to no other VHL-associated tumours, retain 
their ability to degrade HIFα. This strongly suggests, that in these individuals, lesions of 
the adrenal glands arise independent of HIF inactivation, supporting the notion that non-
HIF related functions of pVHL exist. 
 
In an attempt to elucidate novel functions of pVHL, or to help further explain 
already existing knowledge, efforts were made to identify new pVHL-protein interactions. 
Previous undertakings by various groups had revealed crucial insights into normal VHL 
functioning within the cell. When beginning this project, VHL-protein interactions were 
limited to the VCB-Cul2 ligase components [192-194] and the extra-cellular matrix protein 
fibronectin [134]. Since then many other protein interactions have been identified which 
have helped our understanding of VHL biology (see chapter 4), and in particular the 
finding that pVHL interacts with the basic helix-loop-helix transcription factor HIFα and 
targets it for ubiquitin-mediated proteasomal degradation [114]. This interaction represent 
a milestone in VHL biology and has helped us to appreciate how VHL is involved in the 
process of oxygen sensing and the pathological consequences that arise as a result of its 
deregulation. 
 
Identification and confirmation of pVHL-protein interactions has involved various 
protein-protein interaction approaches ranging from basic immuno-precipitation reactions 
to yeast tetra-hybrid systems. It was felt that a new approach of searching for pVHL-
protein interactions might facilitate the identification of novel candidates. Some of these 
methods are outlined below. While initial attempts may not have proved successful, they 
helped pave the way for a more successful large-scale endogenous proteomics 
approach and are therefore briefly discussed. 
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7.2 Towards defining an experimental approach 
 
Initial attempts involved trying to purify the VBC complex (pVHL-Elongin B-Elongin C), 
which would then be used to screen for novel substrates of the VBC-Cul2 ligase. Far 
western technology, a method involving the renaturation of proteins on a membrane in 
the presence of decreasing concentrations of guanidine-HCl, was used to define the 
specificity of the purified complex. This technique had already been employed by others 
to show pVHL interactions with fibronectin and HIF2α [134]. Identification of where the 
probe binds the membrane would indicate the specificity of the probe and its potential as 
a tool to screen two λgt11 expression libraries, human cerebellum and human foetal 
kidney, in a fashion similar to Harlow et al. in the identification of NPAT, a novel substrate 
for the cyclin E/CDK2 complex shown to promote S-phase entry [336]. In light of the fact 
that cyclins are involved in substrate specificity of cyclin dependent kinases (CDKs), it 
seemed important to consider that ligase components could influence the binding of 
pVHL to other proteins. Therefore it was 
deemed more suitable to use the ligase 
complex to probe for new physiological 
substrates than pVHL alone. Before beginning 
with purification of the trimeric VBC complex, 
the experimental parameters were tested 
using a simpler system – the ability of the 
dimeric complex, pSkp1-pSkp2, to bind its 
substrate, the cyclin dependent kinase 
inhibitor p27. As this was an established 
interaction, and the complex easier to purify, it 
was used to define experimental conditions. 
The approach involved co-expressing GST-
Skp1 and untagged pSkp2 in sf9 cells, 
followed by a GST-pulldown which would co-
precipitate pSkp2. After thrombin cleavage 
from the GSH sepharose, the protein 
precipitate was separated on a glycerol 
gradient so as to separate complexed from 
uncomplexed pSkp1 and pSkp2. Following 
the glycerol gradient, the fractions were 
pooled that corresponded to complexed 
pSkp1-pSkp2 and this was used in far 
western as a probe to screen constructs 
previously expressed in bacteria including 
GST, p21, pVHL, wild-type p27 and a mutated 
p27 construct (termed p27KANA/NADA which 
prevents CDK2/Cyclin A binding). Figure 54 
Figure 54. A novel means of mapping the SCFSkp2
complex-p27 interaction. A) Following co-expression 
in sf9 cells, complexed pSkp1 and pSkp2 were 
isolated over a glycerol gradient. B) The complex 
pSkp1/pSkp2 was assayed for it’s binging to renatured 
GST, p21, pVHL, wild-type and mutant p27. While for 
pSkp2 a signal is present for both wild-type p27 and 
p21, the pSkp1 signal which overlays with that of the 
pSkp2 signal demonstrates that pSkp1 determines 
specificity of the pSkp1/pSkp2 complex, albeit in this 
assay. The western blot demonstrates expression of 
all components. 
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demonstrates that under these conditions, the pSkp1-pSkp2 complex, and only when 
complexed, binds wild-type p27 but not mutated p27 thereby representing a novel means 
of mapping the pSkp2-p27 interaction. Interestingly, a pSkp2 signal was also observed 
for renatured p21, yet when probed with α-Skp1, the only overlapping signal between 
pSkp2 and pSkp1 was that of wild-type p27, suggesting that pSkp1 determines, at least 
in part, substrate specificity of the SCFSkp2 complex for p27. 
 
However, while this technique was successful with respect to pSkp1-pSkp2 
recognition of wild type p27, trying to purify a VBC trimeric complex of sufficient purity 
was difficult. All three protein components, pVHL, Elongin B and Elongin C, were co-
expressed in sf9 cells and GST-VHL30 successfully precipitated elongins B and C. 
However problems were encountered when cleaving the protein complex from the 
glutathione sepharose beads with the ser/thr protease, thrombin. Interestingly, thrombin 
cleavage resulted not only in cleaving of GST from recombinant pVHL30, but also in 
specifically cleaving pVHL30 itself. This was completely unexpected. Sequence analysis 
revealed no particular consensus site, though such sites for thrombin remain poorly 
defined. Intriguingly, the VHL crystal structure was performed on a VBC complex purified 
from bacteria, where GST was fused to VHL19 and thrombin-cleaved prior to crystal 
structure analysis. There is no mention of pVHL cleavage by thrombin. As a result of this 
cleavage, it was opted to elute the complex using free glutathione, a disadvantage of 
which was that the complex retained the rather large and bulky GST tag.  
 
Additional challenges arose when purifying the VBC complex over a glycerol 
gradient. Unlike the gradient shown for pSkp1 and pSkp2, this resulted in smearing of the 
VBC complex components across many fractions and disruption of the protein complex. 
Using glycerol gradients to isolate a complex suitably pure to be used as a screening 
probe was therefore abandoned in favour of large scale sf9 expression using spinner 
flasks and concentration of the complex using Centricon devices (YM100, 000) of 
appropriate molecular weight size that retained the complex, but allowed proteins of 
lower molecular weight to be discarded. Nonetheless, when this complex was used as a 
probe on far western to probe whole cell extracts derived from 786-0 cells to visualise 
HIF2α, the non-specific binding of the probe rendered the approach inappropriate (data 
not shown). For this reason, the approach was abandoned and an alternative in vivo one 
sought.  
 
The first in vivo approach involved establishing stably expressing GST-fusion 
proteins of pVHL30, pVHL19 and pVHL1-157, a naturally occurring truncated mutation. 
Expressing a GST-fused version of pVHL within a mammalian cell line would facilitate 
large-scale isolation of pVHL and could increase the probability of co-precipitation of 
protein interactions. Moreover an in vivo approach would allow for the identification of 
physiological substrates, as any binding partners necessary for specific recognition, like 
elongin C and B, would already be present. Cell lines were established in HEK (293) 
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cells, a human foetal kidney cell 
line with high transfection 
efficiency. Metabolic labelling of 
these cells using S35-
incorporation and subsequent 
GST-pulldown facilitated an 
overview of proteins 
precipitated with the GST 
fused-proteins of interest, and 
furthermore allowed 
comparisons between the 
selected pVHL forms and GST 
control. Figure 55 illustrates the 
results obtained from one such 
in vivo labelling experiment. 
The conclusion from this 
experiment was that differences 
occurred among samples, and 
that reproducible and specific 
bands could be seen 
precipitated with GST-VHL 
forms that do not precipitate 
with the GST control. This 
experiment was the first 
indication that an in vivo 
approach of this kind could be 
used to identify pVHL 
interacting proteins, some of 
which would hopefully prove to 
be physiologically relevant. 
 
 In order to identify the 
proteins, GST-pulldown 
experiments were ran out on 
large (15cm) SDS-PAGE gels 
and the bands of interest cut 
out and processed for peptide 
mass fingerprinting or LC-
MSMS as outlined in material 
and methods, chapter 6. As the 
vast majority of bands of 
interest lay within a 40-200 kDa 
Table 18. Results from in vivo GST-pulldown 
 
Protein species kDa Function 
Myosin (MHCIIA) 225  Actin binding motor protein 
Cullin 2  80 VBC-Cul2 E3 ligase 
Drebrin  70 Actin binding protein 
Heat Shock Protein 60  60 Mitochondrial import chaperone
Vimentin  53 A class III intermediate filament
Figure 55. GST-VHL precipitates 
a variety of specific bands. A) 
293 cells were stably transfected 
with GSTVHL30, GSTVHL19, 
GSTVHL1-157, and GST. Cells were 
metabolically labelled and ran on 
an 8% gel following GST pull-down. 
Red arrows indicate some of the 
differences specific to the VHL pull-
down, and blue arrows indicate 
GSTVHL30 and GSTVHL19. Two 
independent clones and a mixed 
pool of GST-VHL30 demonstrate the 
reproducibility of the results. B) 
Expression control confirming 
expression of all cell lines. 
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range, 8% gels were ran for greater 
resolution. The results of the protein 
identification are summarised in table 18. 
While other proteins were identified, they 
mainly represented background, e.g., 
Keratin, and are not shown. The 
identification of Cullin 2 demonstrated that 
the approach not only could identify 
specific and direct pVHL interactions, but 
also indirect interactions as cullin 2 does 
not bind pVHL directly, but rather via 
elongin C. These proteins were 
investigated individually, but unfortunately 
rendered no promising results. No 
endogenous interaction could be shown 
for Drebrin, nor HSP60, and in 
immunofluorescence, vimentin did not co-localise with pVHL (despite the fact that data 
exists which has shown that another tumour suppressor, p53, physically associates with 
vimentin [337]). Initially, the actin motor protein myosin heavy chain nonmuscle type II A 
(MHCIIA) seemed interesting. Figure 54 outlines an experiment showing that ectopically 
expressed GST-VHL30 can precipitate endogenous MHCIIA, whereas other GST-fused 
protein products failed to do so. Given the fact that at this time p53 had been shown to 
bind the microtubule cyctoskeleton, an interaction which facilitated its shuttling in and out 
of the nucleus, and that evidence supported a similar cellular shuttling for pVHL, it 
seemed logical to suggest that pVHL may be binding to a component of the cytoskeleton 
which too may have facilitated its shuttling in and out of the nucleus. For p53, Dynein had 
been shown as the component capable of bridging p53 to the microtubules. Dynein is a 
minus-end directed microtubule motor protein. Intriguingly, myosin is also a motor 
protein, albeit an actin binding motor protein, and at this time it seemed plausible, given 
the p53 finding, that pVHL could also bind a motor protein that may participate in its 
intracellular shuttling behaviour. However, despite the result in figure 56, many attempts 
were made to demonstrate a functional significance for a pVHL-MHCIIA interaction, but 
to no avail. It has since emerged that MHCIIA frequently occurs in such pull-down 
experiments, and should be considered with caution. For these reasons, an alternative, 
more robust assay was developed. 
 
7.3 Endogenous pVHL IP and analysis by mass spectrometry 
 
Previous approaches had failed due to their inability to reproduce an endogenous 
interaction between pVHL and the identified protein. For this reason, an alternative 
approach was devised that would circumvent this problem from the outset. A proteomics 
approach was developed which entailed immuno-precipitating endogenous pVHL and its 
Figure 56. Repetition of GST-pulldown to verify that 
ectopically expressed GST-VHL30 binds endogenous 
MHCIIA in vivo. Two independent clones of GSTVHL30 
demonstrate MHCIIA precipitation, whilst other pVHL 
constructs do not. 
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subsequent bound protein partners. In this way, endogenous interactions were 
established from the beginning, which would facilitate ease of experimental manipulation 
when confirming the interaction later. 
 
The major obstacle in this approach was in attaining protein amounts sufficient for 
sequence analysis. Three antibodies capable of immuno-precipitating pVHL were 
analysed for their efficiency to target pVHL. VHLIg32 is a commercially available 
monoclonal mouse-α-human antibody recognising both pVHL30 and pVHL19. VHLNT is an 
antibody raised against full-length pVHL30 but purified to recognise only pVHL30 and not 
pVHL19. Finally, VHLCT is a polyclonal rabbit-α-human antibody raised against the last 20 
amino acids of pVHL and recognises both pVHL30 and pVHL19, thereby reflecting the true 
abundance of these two proteins with respect to each other. Figure 57 demonstrates an 
experiment where cells have been metabolically labelled with S35 prior to IP. The result 
reveals interesting differences between IP reactions, and that the pattern of co-
precipitating proteins differs among the different antibodies used. Figure 57(B) further 
demonstrates recognition of both VHL forms in western blotting following IP with VHLCT 
Figure 57. Antibody and cell line characterisation for endogenous proteomics approach. A) 293 cells were 
metabolically labelled with 35S and prepared for immuno-precipitation by three pVHL specific antibodies, VHLIg32, 
VHLCT and VHLNT. B) Comparison of pVHL30 and pVHL19 immuno-precipitation by VHLNT versus VHLCT. C) Cullin 2 
precipitation by VHLIg32 and VHLCT. D) Comparison of pVHL levels in five transformed cell lines: HCT116 - human 
colon carcinoma; Hela – human cervix carcinoma; U2OS – human osteosarcoma; 293 – human foetal kidney; Caki –
human renal cell carcinoma. 
Chapter 7: Results – Part I 
 132
compared to VHLNT, and figure 57(C) shows the ability of VHLCT and VHLIg32 to co-
precipitate indirect pVHL interacting proteins, namely cullin 2. Due to the efficiency of 
pVHL recognition in IP reactions, the ability to recognise both pVHL forms, and an 
unlimited source of antibody, the VHLCT antibody was chosen as the antibody to be 
employed for the proteomics approach. 
 
The next experimental parameter to 
be defined was the cell line. Figure 55(D) 
demonstrates that pVHL levels fluctuate 
considerably among a panel of different 
transformed cell lines, especially with 
respect to their comparative levels of 
pVHL30. HCT116 cell are immortalised 
cells derived from a human colon 
carcinoma. They demonstrated high 
expression of both pVHL30 and pVHL19, 
and for this reason were chosen as the 
cell line to be used. 
 
Initial experiments aimed at 
attaining enough material for sequencing 
were hampered by problems of antibody 
contamination. For this reason, VHLCT, 
and its corresponding IgGrabbit control, 
were covalently cross-linked to protein A 
sepharose beads. This reduced 
dramatically the extent of antibody 
contamination and facilitated better 
visualisation of co-precipitating bands. 
Furthermore it permitted the use of more 
antibody, as it was cross-linked to beads 
at a high concentration, 2mg of antibody 
per millilitre of beads, thereby facilitating 
the maximum immuno-precipitation of 
pVHL. Figure 58 shows the ability of 
coupled-VHLCT to efficiently immuno-
precipitate both pVHL forms, pVHL30 and 
pVHL19, in HCT116 cells. 
 
For greater resolution of proteins 
following large-scale immuno-precipitation 
of pVHL, 2D gel-electrophoresis analysis 
Figure 59.  Overlay of trial VHL and control IgG 
IP to investigate differences specific to pVHL. 
Samples were separated on 10cm IPTG strips of 
pH 3 to 10, and ran on 10% SDS-PAGE gels. Gels 
were stained using colloidal coomassie blue, 
scanned, and overlayed in Adobe photoshop, 
version 6.0 
Figure 58. VHLCT coupled to potein A 
sepharose immuno-precipitates both pVHL30 
and pVHL19. Antibody was bound at a 
concentration of 2mg of antibody per ml of beads.
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was used to separate proteins in two dimensions based on isoelectric focusing and 
standard SDS-PAGE electrophoresis. While the obvious advantage of enhanced 
resolution of this approach over its standard one-dimensional counterpart justified its use, 
one disadvantage was that greater protein amounts were necessary for subsequent 
protein detection by MALDI-TOF peptide mass fingerprinting or LC-MSMS nano-spray 
approaches. Figure 59 illustrates a trial experiment to estimate how much material would 
be required. The gels were stained with colloidal coomassie blue, scanned and overlayed 
in Adobe photoshop. The aim was to compare protein samples between the pVHL IP 
reaction and that of its corresponding control in an effort to identify proteins unique to the 
pVHL IP reaction. Based on this experiment, it was apparent that differences could be 
seen using this endogenous IP method, but that in order to gain sequence information 
pertaining to the identity of these candidate pVHL protein partners, the input needed to 
be further increased. 
  
The final approach involved an experiment consisting of a pVHL IP from 
approximately 2.25x109 HCT116 cells using 1.25ml of coupled VHLCT beads, 
corresponding to a concentration of 2.5mg of antibody (see material and methods for 
sample preparation). Cells were grown, lysed and pVHL immuno-precipitated in separate 
batches so as not to compromise the quality of sample preparation. Following protein 
precipitation after each IP reaction, the precipitated protein pellet was stored at –80oC 
until all samples were ready for loading onto the 2D gel. The pellets were pooled together 
and re-solubilised in the appropriate amount of rehydration buffer overnight.  Figure 60 
illustrates the results from one such experiment. 
Figure 60. 2D-gel analysis of VHL and control IP from HCT116 cells. Samples were loaded onto a 10cm 
IPTG strip of pH range 3-10, and further migrated on a 10% SDS-PAGE. Gels were stained using colloidal 
coomassie to detect proteins. The red arrows indicate some of the differences specific to the VHL IP. 
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Protein spots that were found in both gels were considered as background, and 
only those spots unique to the pVHL IP reaction were excised and prepared for analysis. 
Proteins were first prepared for analysis by MALDI-TOF peptide mass fingerprinting. If 
detection was unsuccessful, the protein sample was further analysed by LC-MSMS, 
which employs technology capable of protein identification in a much lower range. 
Following the attainment of sequence information pertaining to the peptides isolated, 
protein identification was achieved using two databases; swpnr39.2 and Prowl in NCBInr 
060901. Table 19 outlines the results from this experiment. While 27 spots were excised, 
many of these spots represent different fragmented versions of the same protein species 
and therefore appear more than once. 
 
Table 19. Results of protein identification following large-scale pVHL IP. 
Sample MALDI LC-MSMS Comments 
01E102 Q15369 - RNA pol 
peptides no hit 02E102 
03E102 Q15370 
Q15370 
- 
Elongin B 
Elongin B 
04E102 peptides no hit P55072, tera_hum p97; VCP 
05E102 peptides no hit peptides no hit - 
06E102 peptides no hit - - 
07E102 Keratin I & II Keratin I, II & IX - 
08E102 weak spectra - - 
09E102 weak spectra - - 
10E102 Q9ULR7, dj967n21.3 - Homologue to 
11E102 peptides no hit Q9ULR7, dj967n21.3 yeast-trans. in. 
12E102 dj967n21.3 - factor 3-gamma 
13E102 dj967n21.3 -  
14E102 Q9ULR7, dj967n21.3 -  
15E102 peptides no hit peptides no hit  
16E102 gi/15301015 - R-RNA-A   
17E102 gi/15301015 - dimethylases 
18E102 gi/15301015/AAH10167 -  
19E102 gi/15301015 -  
20E102 VHL VHL_human VHL 
21E102 peptides no hit Q9UJA5, dj967n21.3 - 
22E102 Q9UJA5, dj967n21.3 - - 
23E102 peptides no hit - - 
24E102 peptides no hit peptides no hit - 
25E102 peptides no hit peptides no hit - 
26E102 peptides no hit peptides no hit - 
27E102 peptides no hit peptides no hit - 
 
NB: Colours denote proteins of the same species 
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7.4 pVHL interacts with the AAA-ATPase family member, p97 
 
 
7.4.1 Introduction 
 
The proteomics approach of section 7.3 revealed that p97, a member of the family of 
AAA-ATPase’s, co-precipitated with pVHL following immuno-precipitation of pVHL by 
VHLCT. The protein was identified by LC-MSMS identifying 10 peptides all directly 
corresponding to p97. 
 
The ubiquitous ATPase p97 
(also called vasolin-containing 
protein (VCP) in animals; Cdc48 
in yeast; VAT in archaebacteria; 
AtCDC48 in Arabidopsis; TER94 
in Drosophila and p97 in 
Xenopus) is abundant in all 
cells, comprising ∼1% of all the 
cell cytosol [338], and 
participates in several cellular 
functions. p97 has been shown 
to be essential for viability in 
yeast [339] and flies [340]. It has 
been implicated in post-mitotic 
homotypic membrane fusion of 
the endoplasmic reticulum and 
the golgi apparatus [341, 342], 
assembly and growth of the 
nucleus [343], apoptosis [343, 
344] and DNA replication [345, 
346]. In addition, it has been 
shown to play a role in the 
extraction of misfolded lumenal 
and membrane proteins from 
the endoplasmic reticulum for 
cytosolic degradation [347-350]. 
Most interestingly with respect 
to pVHL biology however, is the 
fact that p97 has been shown to 
be involved in the ubiquitin-
proteasome-dependent 
degradation pathway [351-355].  
 
Figure 61. Schematic representation of the different domains 
of the full-length p97 monomer. p97 contains an N-terminal 
domain followed by two AAA domains, D1 and D2, which contain 
the first and second ATPase modules respectively. Gel filtration 
and light-scattering experiments have shown that p97 forms 
hexameric complexes. 
Box 1. The AAA family of proteins 
 
The AAA proteins, members of the larger AAA+ superfamily, are a
family of enzymatic machines involved in diverse cellular functions
ranging from DNA repair and replication to organelle biogenesis,
membrane trafficking, transcriptional regulation, and protein quality
control. The characteristic feature of this family is the presence of one
or two conserved ATPase domains, referred to as AAA cassettes,
which contain Walker A and Walker B motifs that mediate ATP
binding and hydrolysis, respectively. AAA proteins were defined as
ATPases associated with various cellular activities, but this definition
disguises the breadth and importance of their functions and the
common structures and mechanisms of action that underlie their
activities. 
 
AAA proteins do a lot of heavy work in the cell: erecting or
disassembling complexes, unfolding or unwinding macromolecules,
and transporting cellular cargo. This mechanical work requires a
chemo-mechanical converter, the AAA module, which derives its
energy from ATP hydrolysis. AAA modules are composed of 200–250
amino acids (Neuwald et al. 1999). The motor module is attached to
other domains that act as tool heads, the latter interacting with
substrates either directly or through 'adaptor' molecules. The
connectors between the motor and the tool heads thus act as
coupling devices, converting movements of the motor into the
specialized motion required for a particular activity. 
 
AAA proteins have either one (D1) or two non-identical (D1 and D2)
AAA modules, each of which consists of a core with an α−β−α
nucleotide binding fold and a C-terminal domain with at least three α-
helices. AAA modules tend to oligomerise into hexameric rings, with
all subunits oriented in the same direction. 
Chapter 7: Results – Part I 
 136
 Interestingly, almost all p97’s activities are directly or indirectly related by the 
ubiquitin-proteasome system. The ubiquitin-proteasome-mediated degradation pathway 
consists of two sequential steps. The destined substrate is first conjugated with poly-
ubiquitin chains, which tag it for proteolysis. The poly-ubiquitinated substrate is then 
moved, possibly guided by molecular chaperones, to the 26S proteasome for final 
degradation. The involvement of both p97 and the ubiquitin-proteasome systems in 
similar cell activities suggests that p97 may act as a chaperone in the ubiquitin-
proteasome pathway, thus regulating the various cellular functions through the ubiquitin-
proteasome pathway. Both genetic and biochemical studies indicate that this is indeed 
the case. Mutations in the CDC48 gene result in cell cycle arrest and the accumulation of 
poly-ubiquitinated proteins in yeast [339, 355]. Depletion of p97 from cell extracts 
abolishes the ubiquitin-proteasome-mediated degradation of cyclin E, leading to the 
accumulation of poly-ubiquitinated proteins in mammalian cells [355]. The involvement of 
p97 in the ubiquitin-proteasome degradation pathway was further supported by the 
findings that p97 directly binds poly-ubiquitinated proteins, as well as other ubiquitin-
proteasome pathway components, such as Ufd1, Ufd2 and Ufd3 (proteins involved in the 
ubiquitin fusion degradation pathway), and the 26S proteasome [351-353, 356-358].   
 
The ATPase p97 appears to 
perform different cellular functions 
depending on its association with 
cofactors [353]. Mammalian p97 can 
interact in a mutually exclusive manner 
with either p47 or a dimer consisting of 
Ufd1 and Npl4. In mammals, the 
complex of p97–p47 appears to play a 
role in the homotypic fusion of ER and 
Golgi membranes [341, 359, 360]. The 
p97–p47 complex binds ubiquitinated 
proteins via a UBA (ubiquitin 
association) domain in p47, and this 
domain is essential for its activity in Golgi membrane fusion [361]. In Saccharomyces 
cerevisiae, the complex of Cdc48–Ufd1–Npl4 has been implicated in the release of 
polypeptides from the ER membrane [362]. This release step is essential for both 
retrotranslocation of misfolded proteins from the ER into the cytosol, and for the activation 
of the transcription factor Spt23 from its ER-anchored precursor [363, 364]. SPT23 is a 
relative of mammalian NF-κB and controls unsaturated fatty acid levels [348]. It is 
synthesised as a latent ER/nuclear membrane-localised precursor, and is activated by 
limited ubiquitin-proteasome degradation, similar to that seen with NF-κB p105 
processing. Mammalian p97 has also been shown to function in retrotranslocation [347], 
but a requirement for the cofactor Ufd1–Npl4 has not yet been demonstrated.  
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Exactly how p97 and its cofactor Ufd1–Npl4 extract polypeptides from the ER 
membrane during retrotranslocation is unclear. It is not known how the ATPase binds to 
the ER membrane, nor how the two ATPase domains collaborate to "pull" polypeptides 
out of the membrane. The mechanism of substrate recognition has been particularly 
difficult to address because its elucidation requires complex systems in which p97/Cdc48 
acts on physiological substrates emerging from the ER membrane. Two possibilities of 
substrate recognition have been proposed. In one model, p97 would interact directly with 
an unfolded polypeptide segment as it emerges from the ER membrane. Alternatively, 
the recognition signal could be a poly-ubiquitin chain attached to a substrate. This model 
is based on the fact that all polypeptides emerging from the ER undergo poly-
ubiquitination, and that this modification is required for the release of substrates from the 
ER membrane into the cytosol (reviewed in [362]).  
 
The second model is based on the fact that mammalian Ufd1–Npl4 has been 
shown to bind poly-ubiquitin and has therefore been proposed to mediate substrate 
binding by p97 [361]. A zinc-binding motif in Npl4, the Npl4 zinc finger (NZF) domain, has 
been identified as the major binding site for ubiquitin [361, 365]. The relevance of the 
reported ubiquitin interactions for retrotranslocation is unclear, particularly because the 
ubiquitin binding to p97 is weak and the yeast homologue of Npl4 lacks an NZF domain. 
Ye et al. have proposed a dual recognition mechanism in which a non-ubiquitinated 
segment of a substrate is initially recognised by p97 itself, and subsequently, the 
polyubiquitin chain is bound by both p97 and the cofactor Ufd1–Npl4 [366].  
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7.4.2 pVHL interacts with p97 
 
Figure 62 is a representation of the proteomics approach undertaken to identify novel 
pVHL interacting proteins (section 7.3). In the VHL IP a spot corresponding to 
approximately 100 kDa is present, but absent in the control. 
 
As outlined below, the identity of p97 was apparent from 10 separate peptides 
located throughout the p97 open reading frame corresponding to a protein coverage of 
15% amino acid count, and 14.5% by mass. The file name tera_human p55072 homo 
sapiens represents the file name as per swpnr39.2, and refers to human p97. 
 
>tera_human P55072 homo sapiens (human) – protein coverage: 15% amino acid count; 14.5% by mass 
MASGADSKGD DLSTAILKQK NRPNRLIVDE AINEDNSVVS LSQPKMDELQ LFRGDTVLLK GKKRREAVCI VLSDDTCSDE 
KIRMNRVVRN NLRVRLGDVI SIQPCPDVKY GKRIHVLPID DTVEGITGNL FEVYLKPYFL EAYRPIRKGD IFLVRGGMRA 
VEFKVVETDP SPYCIVAPDT VIHCEGEPIK REDEEESLNE VGYDDIGGCR KQLAQIKEMV ELPLRHPALF KAIGVKPPRG 
ILLYGPPGTG KTLIARAVAN ETGAFFFLIN GPEIMSKLAG ESESNLRKAF EEAEKNAPAI IFIDELDAIA PKREKTHGEV 
ERRIVSQLLT LMDGLKQRAH VIVMAATNRP NSIDPALRRF GRFDREVDIG IPDATGRLEI LQIHTKNMKL ADDVDLEQVA 
NETHGHVGAD LAALCSEAAL QAIRKKMDLI DLEDETIDAE VMNSLAVTMD DFRWALSQSN PSALRETVVE VPQVTWEDIG 
GLEDVKRELQ ELVQYPVEHP DKFLKFGMTP SKGVLFYGPP GCGKTLLAKA IANECQANFI SIKGPELLTM WFGESEANVR 
EIFDKARQAA PCVLFFDELD SIAKARGGNI GDGGGAADRV INQILTEMDG MSTKKNVFII GATNRPDIID PAILRPGRLD 
QLIYIPLPDE KSRVAILKAN LRKSPVAKDV DLEFLAKMTN GFSGADLTEI CQRACKLAIR ESIESEIRRE RERQTNPSAM 
EVEEDDPVPE IRRDHFEEAM RFARRSVSDN DIRKYEMFAQ TLQQSRGFGS FRFPSGNQGA GPSQGSGGGT GGSVYTEDND 
DDLYG 
Figure 62. 2D SDS-PAGE of α-VHL IP from HCT116 cells. Isoelectric focusing was performed on 7cm 
IPTG strips with a pH range of 3-10. Samples were then ran on a standard SDS-PAGE gel and stained 
with colloidal blue as per material and methods. Spots of interest were excised, and prepared for analysis 
by MALDI-TOF peptide mass fingerprinting, and if necessary LC-MSMS. The sample here illustrates the 
identification of p97 as a candidate protein specific to the VHL IP. 
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7.4.3 Verification of a pVHL – p97 interaction 
 
Following the identification of p97 by LC-MSMS, it was necessary to investigate the 
reproducibility of this finding. Figure 63(A) illustrates an identical experiment to that 
performed for the original LC-MSMS analysis with the exception that the amounts used 
were far less, and the resultant 2D-gels were processed for western blot analysis instead 
of being prepared for sequence analysis. A commercially available antibody against p97 
was used to probe the membranes. A signal corresponding to p97 is clearly apparent in 
the VHL IP but completely absent in the IgGrabbit control. The ‘zoom in’ panel to the right 
of these blots highlights to a greater magnification the specificity of p97 for the VHL IP, 
and indeed that the VHL IP itself was successful in immuno-precipitating pVHL. This 
Figure 63. Verification of pVHL-p97 interaction. A) Conformation of an endogenous pVHL-
p97 interaction. B) Over-expressed GST fused p97 in sf9 cells specifically precipitates co-
expressed untagged VHL30. C) S35-metabollically labelled p97 is specifically precipitated by 
recombinant GST-VHL30. 
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experiment was repeated successfully using two independent VHL antibodies, VHLCT as 
with the original proteomics approach, and VHLNT19, an antibody raised against the N-
terminus of pVHL19.  
 
Figure 63(B) shows that when GST-fused p97 is co-expressed with untagged 
pVHL30 in sf9 cells, then a subsequent GST-pulldown efficiently precipitates pVHL30, 
whereas GST alone does not. This result further confirms the ability of p97 to interact 
with pVHL30 in vivo. Finally, figure 63(C) demonstrates that in vitro translates of p97 
when radiolabelled with S35 and then incubated with either recombinant GST-VHL30 or 
GST, are precipitated uniquely by GST-VHL30 but not GST. This result again strengthens 
the possibility that p97 and pVHL interact physiologically. 
 
7.4.4 Towards a functional significance for a p97-VHL interaction 
 
7.4.4.1 Sequence analysis 
 
Sequence analysis of p97 has indicated a lack of sequence homology between structural 
regions in HIFα and also the binding interface region of elongin C known to interact with 
pVHL. Unlike HIFα, no obvious LxxLAP motif can be observed which might suggest a 
potential hydroxylation event that could facilitate pVHL binding, and perhaps proteasomal 
targeting of p97 by pVHL. Nor in the case of Elongin C are residues present in p97 that 
show significant homology with those residues known to interact with pVHL. The 
sequences below demonstrate the regions in HIF1α and Elongin C that were used to 
search for sequence homology in p97. Sequence analysis could therefore neither identify 
p97 as a potential substrate nor as a binding partner that may bind in a similar manner to 
Elongin C. 
  
• HIF1α binding interface 
1st Destruction sequence containing Hyp564: DLDLEMLAPYIPMDDDFQLR 
 
 
2nd Destruction sequence containing Hyp402: PDALTLLAPAAGDTIISLDFGSN 
NB. Red indicates conserved residues. 
 
• Elongin C binding interface 
MDGEEKTYGG CEGPDAMYVK LISSDGHEFI VKREHALTSG TIKAMLSGPG QFAENETNEV 
NFREIPSHVL SKVCMYFTYK VRYTNSSTEI PEFPIAPEIA LELLMAANFL DC 
                            
NB. Red indicates residues that bind pVHL. In blue are residues conserved among human, drosophila and 
yeast elongin C. 
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7.4.4.2 VHL RNAi does not effect p97 levels 
 
To biochemically consider the possibility that p97 is a target for pVHL-mediated 
proteasomal degradation, p97 levels were measured in a series of renal cancer cell lines 
expressing or lacking wild-type pVHL (786-0/A498). By western blot analysis, levels of 
p97 were comparable between cell lines expressing wild-type pVHL and their non-
expressing isogenic counterparts (data not shown). In contrast levels of HIFα, an 
established pVHL target, were markedly lower in cell lines expressing wild-type pVHL.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 An alternative approach to investigate whether p97 is a target of pVHL-mediated 
proteasomal degradation employed the use of depleting endogenous pVHL by siRNA. 
Figure 64 demonstrates that when Hela cells are treated with siRNA oligonucleotides 
against VHL (see results part III), no fluctuations in p97 protein levels were observed. If 
p97 were a pVHL-targeted substrate for the VBC-Cul2 E3 ligase, then fluctuations in 
protein amounts should be observed upon depletion of pVHL. Alternatively the lack of 
signal change may reflect the fact that p97 is a very abundant protein and that merely 
down-regulating pVHL, as in the case of siRNA treatment, may not be sufficient to render 
a response that can be visualised by western blotting. Furthermore, as part III of this 
results section will outline in more detail, VHL RNAi fails to up-regulate HIF in all 
assays attempted. Perhaps a more radical eradication approach is therefore necessary, 
for example targeting of VHL via cre-lox recombinase technology, an approach now 
being established in the laboratory (Frew and Krek). Nonetheless given the previous data 
that p97 levels do not fluctuate in renal cell carcinoma cells lacking functional pVHL when 
Figure 64. p97 levels in VHL RNAi treated cells. No fluctuations 
in p97 protein levels are observed when expression of 
endogenous pVHL is reduced. 
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compared to their pVHL-expressing isogenic counterparts and that the analysis of the 
primary sequence has failed to identify any known putative target sequence in p97 by 
pVHL, it is unlikely that p97 is a target of pVHL-mediated degradation. 
 
7.4.4.3 p97 involvement in proteolytic control of HIFα 
 
As already discussed in the introduction, 
p97 is involved in a plethora of distinct 
cellular functions among which includes 
the process of ubiquitin-mediated 
proteolytic degradation. p97 forms a 
homohexamer that binds to several 
different adapter proteins, and  it has 
been shown that p97 complexes bind 
poly-ubiquitin chains, exhibiting a 
chaperone activity that facilitates its 
‘segregase’ function – the ability to 
separate ubiquitinated proteins from their 
binding partners. Initial evidence 
pertaining to this idea was published by 
Dai et al [352]. Here the authors 
demonstrated that p97 physically and 
functionally targets the ubiquitinated 
nuclear factor κB inhibitor, IκBα, to the 
proteasome for degradation. Figure 65 
illustrates a model proposed by the 
authors regarding proteasome 
presentation of IκBα by p97 and 
subsequent liberation of NF-κB. Since 
then, p97 has emerged as being an 
important link in protein degradation and 
perhaps represents a common 
mechanism that underlies many of the 
functions of p97.    
 
Interestingly the notion that pVHL ubiquitin-mediated degradation of HIFα might 
involve ATPase activity emerged recently. A member of the AAA family, TBP-1 (TAT 
binding protein 1), was shown to bind to pVHL and was involved in the degradation of 
HIF1α. It was shown that this event was energy-dependent, highlighting the requirement 
for an intact ATPase domain [252]. They demonstrated that pVHL, TBP-1 and HIF1α 
subunits form a complex in vivo which certain tumour-derived pVHL mutants can disrupt. 
Interestingly, some pVHL mutations that retain their ability to bind HIFα, did not bind 
Figure 65. A model proposed by Dai et al. regarding 
the involvement of p97 (VCP) in the proteolytic 
degradation of IκBα. In response to stimulation, IκBα is 
phosphorylated and poly-ubiquitinated and only then can 
p97 physically associate with it, thereby liberating NFκB, 
which subsequently translocates to the nucleus.  
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TBP-1, shedding perhaps useful light on a molecular mechanism underlying type 2C 
disease. These data demonstrate the importance of an ATPase-mediated event in the 
ubiquitination of HIFα, and therefore support the idea that pVHL may physiologically 
interact with p97 thereby affecting pVHL-mediated protein degradation of HIFα in a 
manner similar to TBP-1. 
 
Given the above, it seems reasonable to suggest that p97 may influence the 
proteolytic degradation of HIFα via a pVHL dependent interaction. To first test this 
hypothesis, RNAi against p97 was performed to see if any fluctuations in HIFα levels 
could be observed when p97 protein levels were reduced. As figure 66 illustrates, no 
fluctuations in HIFα levels were observed. However, given the fact that HIFα levels are 
not affected by VHL RNAi (see part III), it seemed unlikely that any fluctuations in HIFα 
under these experimental conditions would be observed. 
 
A second attempt to investigate the effect of depleting cells of endogenous p97 on 
HIFα degradation was undertaken. This involved studying the kinetics of HIFα 
degradation in the presence of p97 RNAi compared to a control RNAi oligonucleotide. No 
effect on HIF1α degradation kinetics was observed. However, as figure 87 shows in part 
III of this chapter, even RNAi against pVHL does not show any changes in the kinetics of 
HIF degradation. If p97 does affect HIFα degradation, there are two possible 
explanations why an effect is not observed using siRNA against p97. First, despite the 
efficacy of the p97 siRNA, only a partial knockdown of p97 expression could be 
consistently achieved. It is therefore possible that residual p97 is sufficient for HIFα 
degradation. The presence of even low levels of endogenous wild-type p97 might also 
Figure 66. p97 RNAi in different transformed cell lines renders no changes 
in HIF1α or pVHL protein levels. Cells were transfected with the siRNA and 
harvested for western blot after 48 hours. 
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explain why introduction of p97QQ, an ATPase mutant p97, also showed no fluctuation in 
HIF1α levels. Therefore, a cell line with a complete knockout of p97 (as with a somatic 
knockout or embryonic stem cell knockout) might exhibit up-regulated HIFα, which goes 
unobserved when using siRNA. Secondly, other proteins besides p97 might regulate the 
pVHL-mediated degradation of HIFα. Based on the above-mentioned regarding TBP-1, 
we now know this is the case. Clearly, the presence or absence of pVHL is the most 
important factor in HIFα degradation, as p97 (or TBP-1), does not promote HIFα 
degradation in pVHL deficient cells. The possibility of alternative proteins that could 
substitute p97 and promote HIFα degradation suggests that pVHL can still degrade 
HIFα, albeit less efficiently. 
  
Efforts to identify a p97-HIFα interaction 
have also been investigated. This approach 
involved the generation of an ubiquitinated HIFα 
species, and assaying for the ability of p97 to 
bind the poly-ubiquitinated protein species. In 
vitro ubiquitination of HIFα had been 
demonstrated by Ohh et al in 2000, where they 
showed that ubiquitinated Gal4-fused HIFα-ODD 
was bound by the ß-domain of pVHL. Figure 67 
shows an ubiquitination assay of HA/Gal4-HIFα-
ODD which was incubated in similar reaction 
conditions as those described by Ohh et al and 
demonstrates a characteristic pattern of bands 
representing poly-ubiquitinated HIFα-ODD. 
Preliminary data suggest that GST-p97 bound to 
beads can precipitate this ubiquitinated 
HA/Gal4-HIF1α-ODD, but further confirmation is 
necessary before any statement is made (data 
not shown). In light of the developing literature 
demonstrating increasingly that p97 relies on 
adapter proteins to execute its functions, it is now apparent that this experiment should 
be repeated in the presence of an appropriate protein adapter(s) to see if binding can be 
optimised, i.e. Ufd1 and/or Npl4. These experiments are underway. 
 
Figure 67. In vitro ubiquitination assay 
using HA/Gal4-HIFα-ODD as substrate. 
High molecular weight bands represent poly-
ubiquitinated substrate. 
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7.4.4.4 Role of p97 in microtubule stability 
 
Other aspects of p97 involvement in pVHL biology have also been investigated, namely 
the functional significance of a p97-pVHL link in context of pVHL’s ability to stabilise 
microtubules. pVHL has been shown to bind microtubules and to promote their stability in 
an assay which tested the ability of pVHL to stabilise microtubules under depolymerising 
conditions (work related to this finding is outlined in part II of this chapter). Interestingly, 
M. Tagaya and colleagues identified SVIP (small VCP interacting protein) as a novel 
adaptor protein for p97 [367]. Although SVIP function is as yet unknown, its over-
expression in cells caused extensive vacuolation and deformation of ER and also of 
microtubules. 
  
An established assay to test the ability of a candidate protein to affect microtubule 
stability involves treating cells, which have been previously transfected with a protein of 
interest, with nocadozole, or some other depolymerising agent, and score for intact 
Figure 68. A). Investigating the role of p97 in microtuble (MT) stability. COS-1 cells were 
transfected with indicated constructs and treated 24 hours later with 5µM nocadazole for 4 hours. 
Cells were prepared for IF, and scored for intact microtubule array. B). Expression control of indicated 
constructs in pVHL and HA-p97 co-transfections. C). Results from a microtubule-pelleting assay 
indicating precipitation of over-expressed HA-VHL30 with polymerized microtubules, but not 
endogenous p97. 
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microtubule array’s after a given period which would normally induce breakdown of the 
microtubule network in untransfected cells.  This assay has shown that for pVHL, 
microtubule stabilisation is promoted to 50% following transfection of both pVHL30 and 
pVHL19. Co-transfection of HA-p97 along with pVHL30 in context of this assay was 
undertaken to investigate whether p97 might affect pVHL’s ability to promote microtubule 
stability. Multiple analyses revealed that in the presence of ectopically expressed p97, 
microtubule stability was promoted to approximately 85%, thus far exceeding that of 
pVHL alone. To assess whether the ability of p97 to promote stability was dependent on 
ectopically expressed pVHL, the effect of transfecting p97 alone was analysed. As figure 
68(A) illustrates, the results demonstrated that p97 alone can stabilise microtubules in 
this assay up to 85%, suggesting that the effect may be independent of over-expressed 
pVHL. To address the question of whether this stabilisation by p97 relied upon its 
ATPase activity, p97QQ, a dominant-negative mutant that lacks ATPase activity, was 
transfected and tested. P97QQ rendered confusing results that fluctuated at times below 
20% and reached stability of up to >70%. As results using p97QQ were neither 
reproducible nor accurate, no conclusion can be made regarding the requirement of an 
intact ATPase domain in microtubule stability. The ability of p97 to bind microtubules in 
vitro was also investigated. Figure 68(C) shows that, unlike pVHL, p97 does not bind 
polymerised microtubules in vitro. Immuno-fluorescence of p97 supports the pelleting 
assay in that no co-localisation is observed between p97 and microtubules. Partial 
localisation is seen associated with the ER, but the predominant signal is a diffuse 
cytoplasmic signal. Whatever the function of over-expressed p97 is on microtubule 
stability, it seems that it does not elicit a direct effect through binding, but rather might be 
involved in functionally regulating other components involved in microtubule stability, like 
pVHL. 
 
 In an effort to investigate 
cross-talk between pVHL and 
p97 with respect to microtubule 
stability, cells were transfected 
with siRNA oligos against p97, 
and assayed for the ability of 
transfected pVHL30 to stabilise 
miocrotubules. While a 
reduction in stability was 
observed ranging from 35-45% 
compared to 50%, the 
reduction is not dramatic. It 
would seem that if there is cross-talk between p97 and pVHL regarding microtubule 
stability, then residual p97 remaining following p97 RNAi is sufficient to maintain 
microtubule integrity to almost the maximum as seen by transfecting pVHL alone. A 
complete knockout situation could highlight more significant effects. 
Figure 69. The effect of depleting endogenous p97 by siRNA on 
pVHL’s ability to stabilise microtubules in COS-1 cells. Cells 
were transfected with siRNA oligos against p97, then transfected 
with pVHL30 and assayed for microtubule stability. 
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7.4.4.5 pVHL interacts with HDAC6 
 
Seigneurin-Berny et al demonstrated that immuno-purification of endogenous murine 
histone deacetylase 6 (mHDAC6), a member of the class II HDACs, allowed the 
identification of two associated proteins [368]. Both were mammalian homologues of 
yeast proteins known to interact with each other and involved in the ubiquitin signalling 
pathway: phospholipase A2-activating protein, a homologue of yeast UFD3 (ubiquitin 
fusion degradation protein 3) and the ATPase p97. Furthermore, using an ubiquitin pull-
down approach, several major ubiquitin-binding proteins were identified and mHDAC6 
was found to be one of them. All of these findings strongly suggest that mHDAC6 could 
be involved in the control of protein ubiquitination, thereby establishing a link between 
protein acetylation and protein ubiquitination and a link that, at least in part, could be 
mediated by p97. 
 
Histone deacetylases (HDACs) 
are a family of enzymes whose 
functions have been overwhelmingly 
associated with gene expression and 
chromatin dynamics (reviewed in [369, 
370]). However, recent evidence 
indicates that not all functions of HDACs 
are dedicated to regulating gene transcription and chromatin remodelling (reviewed in 
[371]). The prominent example of such a non-canonical function is illustrated by the 
cytoplasmic deacetylase HDAC6. Hook et al. showed that the C terminus of HDAC6 is 
both necessary and sufficient for specific association with poly-ubiquitin [372]. In addition, 
Hubbert et al. reported in Nature 2002 that HDAC6 functions as a tubulin deacetylase 
[373]. They demonstrated that HDAC6 was localised exclusively in the cytoplasm, where 
it associates with microtubules. Furthermore, they provide evidence that over-expression 
of HDAC6 promotes chemotactic cell movement, supporting the idea that HDAC6-
mediated deacetylation regulates microtubule-dependent cell motility. They thereby 
suggest that decreasing tubulin acetylation reduces microtubule stability. However, 
following a brief communication by Gunderson et al. in Nature 2003, it is now clear that 
microtubule stabilisation is in fact not promoted by tubulin acetylation, but rather a 
modification of already stabilised microtubules. Therefore the cell motility observed by 
Hubbert et al. in cells over-expressing HDAC6 seems to result not from changes in the 
formation of stable microtubules, but in the degree of tubulin acetylation.  
 
Given the fact that HDAC6 had be shown to bind p97 and other proteins involved 
in the process of ubiquitination, and that it co-localised with microtubules, it was tested 
whether HDAC6 could interact with pVHL. Figure 71 demonstrates in vitro binding of 
HDAC6 to pVHL. HDAC6 bound very strongly to pVHL19, but failed to bind the naturally 
occurring mutant pVHL∆exon2. Fine mapping revealed that the binding interface of HDAC6 
Figure 70. In the C-terminal region of HDAC6, a conserved 
zinc finger-containing domain mediates the specific 
binding of ubiquitin by HDAC6. 
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and pVHL lay between residues 93-122 of pVHL. Interestingly, this region corresponds to 
pVHL’s microtubule-binding domain.  
 
The significance of this finding remains unclear. Evidence exists that HDAC6 is 
ubiquitinated in vitro and in vivo [372], but no evidence has been shown that this is 
pVHL-dependent. On the contrary, attempts to see whether over-expressing pVHL or 
depleting cells of endogenous pVHL with siRNA can affect tubulin acetylation, have to 
date shown no changes in acetylation status. This casts doubt on the idea that pVHL 
might target HDAC6 for degradation (Fig.72) suggesting that either a pVHL-HDAC6 
interaction does not interfere with HDAC6’s tubulin deacetylation function, or that under 
these conditions, depletion of pVHL is not sufficient to effect HDAC6 function. 
 
Figure 72. Acetylation
status of tubulin
following endogenous
depletion of pVHL by
RNAi. No differences are
observed in acetylation
levels of tubulin  
Figure 71. HDAC6 in vitro interaction with pVHL. A) Sf9 expressed GST-HDAC6 binds S35-labelled 
VHL19/1-157 but not VHL∆EXON2. B) Expression of GST-HDAC6 in sf9 cells. C) Mapping of pVHL-HDAC6 
identifies residues 95-123 of pVHL as the binding interface. 
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Further mapping of a HDAC6-pVHL interaction involved investigation of the 
binding of pVHL mutants within the binding domain ∆95-123 (Fig.71). Experiments to 
date suggest that HDAC6 can bind these mutants in vitro. If this were indeed the case, 
then it would seem that mutants that have inactivation of VHL at these sites retain their 
ability to bind HDAC6. As a functional significance of this interaction has yet to be 
elucidated it is impossible to draw any conclusions, but it would be tempting to suggest 
that perhaps mutation at these sites instead of preventing interaction, prevent 
dissociation, thereby acting to cause pVHL to function inappropriately. 
 
In the December 12th issue of Cell, 2003, a report was published that HDAC6 
functions as an adaptor that links cargos of aggregated protein to the minus end-directed 
motor, cytoplasmic dynein. Molecular motors are the long-haul carriers of eukaryotic 
cells, moving cargos bi-directionally along microtubule tracks [374]. Misfolded protein 
aggregates are transported and removed from the cytoplasm by dynein motors via the 
microtubule network to a novel organelle termed the aggresome where they are 
processed [375]. The efficient clearance of cytotoxic misfolded protein aggregates is 
critical for cell survival. However, the means by which dynein motors recognise misfolded 
protein cargo, and the cellular factors that regulate aggresome formation, remain 
unknown. Kawaguchi et al. discovered that HDAC6, a microtubule-associated 
deacetylase, is a component of the aggresome. They demonstrated that HDAC6 has the 
capacity to bind both poly-ubiquitinated misfolded proteins and dynein motors, thereby 
acting to recruit misfolded protein cargo to dynein motors for transport to aggresomes. 
Indeed, cells deficient in HDAC6 fail to clear misfolded protein aggregates from the 
cytoplasm, cannot form aggresomes properly, and are hypersensitive to the 
accumulation of misfolded proteins. These findings identify HDAC6 as a crucial player in 
the cellular management of misfolded protein-induced stress. In light of p97’s role in 
retrotranslocation, and the fact that cells lacking functional VHL exhibit deposition of an 
incorrectly folded fibronectin array might suggest a general role for all three protein 
components in the malfolded protein response, and that this role may, in part, be 
mediated by direct or indirect interaction with the microtubule network. The potential 
significance of a p97-pVHL interaction is further discussed in chapter 8. 
 
Figure 73. Mutational 
hotspots within the pVHL 
microtubule binding 
domain ∆95-123. All 
mutants bind HDAC6 in vitro
suggesting that mutational 
inactivation does not hinder 
an HDAC6-pVHL interaction. 
Asterixes denote mutants 
tested. 
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7.5 pVHL precipitates human homologues of Gcd10p/Gcd14p  
 
 
7.5.1 Introduction 
 
From the proteomics approach outlined in section 7.3 four additional poly-peptides, of 
unknown function, were isolated. Figure 74 illustrates their location on a 2D-SDS 
polyacrylamide gel. Interestingly, poly-peptides C and D, when assembled together, 
constituted the poly-peptide A. Therefore, it is assumed that C and D correspond to 
fragmented versions of the same poly-peptide, and from here on reference will only be 
made to poly-peptides A and B.  
 
The sequences overleaf represent the protein coverage of these two novel polypeptides, 
A and B. Both were identified by peptide mass fingerprinting with peptides totalling to 
>40% coverage in both cases. Both were uncharacterised protein species. However, 
NCBI database searches identified homologues for both of these polypeptides in the 
budding yeast, Saccharomyces Cerevisiae. 
 
 
 
Figure 74. A proteomics approach identified four novel, uncharacterised poly-peptides. The assembled 
open reading frame of polypeptides C and D were shown to constitute the poly-peptide encoded by A, and 
therefore represent fragments of the same species. 
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Protein A was identified as 
having strong sequence 
homology with a protein found in 
Saccharomyces Cerevisiae, 
termed Gcd10p. Protein B was 
also found to have a yeast 
homologue termed Gcd14p. 
Gcd10p is found in a nuclear 
complex with Gcd14p, which 
contains conserved motifs for 
binding S-adenosylmethionine 
(AdoMet) [376, 377]. Evidence 
exists which suggests that this 
complex is involved in a crucial 
methylation event at position 58 
on the T-arm (TΨC loop) of 
initiator methionine transfer RNA 
(tRNAiMet). The modified 
nucleoside 1-methyladenosine 
(m1A) is found at position 58 in 
the TΨC loop of many eukaryotic tRNAs. The absence of m1A from all tRNAs in 
Saccharomyces Cerevisiae mutants lacking Gcd10p elicits severe defects in processing 
and stability of tRNAiMet. These facts, plus the demonstration that gcd14∆ cells lacked 
m1A, strongly suggested that Gcd10p/Gcd14p complex is the yeast 
tRNA(m1A)methyltransferase [(m1A)MTase]. 
 
The maturation of tRNA occurs through a series of posttranscriptional processing 
steps, including splicing, end-trimming, and base or ribose modifications. Modified 
nucleosides have been identified in all cellular RNAs, but the tRNAs by far contain the 
greatest number and variety of modifications. Of these, the most widely distributed and 
Protein A: PuBMed - XP_045589; 43% Protein coverage 
 
MEGSGEQPGP QPQHPGDHRI RDGDFVVLKR EDVFKAVQVQ RRKKVTFEKQ WFYLDNVIGH SYGTAFEVTS
GGSLQPKKKR EEPTAETKEA GTDNRNIVDD GKSQKLTQDD IKALKDKGIK GEEIVQQLIE NSTTFRDKTE 
FAQDKYIKKK KKKYEAIITV VKPSTRILSI MYYAREPGKI NHMRYDTLAQ MLTLGNIRAG NKMIVMETCA
GLVLGAMMER MGGFGSIIQL YPGGGPVRAA TACFGFPKSF LSGLYEFPLN KVDSLLHGTF SAKMLSSEPK 
DSALVEESNG TLEEKQASEQ ENEDSMAEAP ESNHPEDQET METISQDPEH KGPKERGSKK DYIQEKQRRQ 
EEQRKRHLEA AALLSERNAD GLIVASRFHP TPLLLSLLDF VAPSRPFVVY CQYKEPLLEC YTKLRERGGV 
INLRLSETWL RNYQVLPDRS HPKLLMSGGG GYLLSGFTVA MDNLKADTSL KSNASTLESH ETEEPAAKKR 
KCPESDS 
Protein B: PuBMed – gi:15301015; 45% Protein coverage 
 
MSFVAYEELI KEGDTAILSL GHGAMVAVRV QRGAQTQTRH GVLRHSVDLI GRPFGSKVTC GRGGWVYVLH
PTPELWTLNL PHRTQILYST DIALITMMLE LRPGSVVCES GTGSGSVSHA IIRTIAPTGH LHTVEFHQQR
AEKAREEFQE HRVGRWVTVR TQDVCRSGFG VSHVADAVFL DIPSPWEAVG HAWDALKVEG GRFCSFSPCI
EQVQRTCQAL AARGFSELST LEVLPQVYNV RTVSLPPPDL GTGTDGPAGS DTSPFRSGTP MKEAVG 
HTGYLTFATK TPG 
Figure 75. In S.Cerevisiae, the Gcd10p/Gcd14p complex functions 
as a methyltransferase transferring a methyl group from the methyl-
donor S-adenosylmethionine onto adenine 58 positioned on the T-
arm (TΨC loop) of tRNAiMet. Sequence homology would suggest that 
Proteins A and B found in a pVHL pulldown are the mammalian 
counterparts of this complex.  
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prevalent tRNA modification is base or ribose methylation. Several tRNA modification 
enzymes have been cloned and characterised from eubacteria and eukaryotes. 
Remarkably, only one tRNA modification, the subject of this report, has been found to be 
essential for cell growth under normal conditions. In other instances, the modifications 
are required for efficient decoding during protein synthesis [378]. A 2'-O-phosphoribosyl 
modification of A64 in tRNAiMet prevents inappropriate interaction of the initiator with 
translation elongation factor 1α [379]. 
 
The occurrence of 1-methyladenosine (m1A) at position 58 of the TΨC loop has 
been reported in tRNAs from all three kingdoms [378], suggesting an evolutionarily 
conserved role in tRNA structure or function. In the yeast Saccharomyces Cerevisiae, 
m1A58 is widespread but not universal, occurring in 21 of 32 sequenced tRNAs [380]. 
This modification seems to be crucial only for tRNAiMet because a null mutation in GCD10 
that eliminates m1A in all yeast tRNAs leads specifically to reduced processing and 
stability of the initiator. This defect is lethal unless tRNAiMet is overproduced in the 
gcd10∆ mutant to compensate for reduced accumulation of mature initiator [376]. It was 
proposed that m1A58 is singularly required for tRNAiMet production because it contributes 
to a unique substructure involving tertiary interactions between the TΨC and D loops 
[381].  
 
Temperature-sensitive gcd14 mutations lead to accumulation of precursors and 
reductions in mature tRNAiMet, and exacerbate the effects of a temperature-sensitive 
gcd10 mutation on cell growth and tRNAiMet production. Furthermore, the lethal 
phenotype of a gcd14∆ allele has been shown to be suppressed by over-expressing 
tRNAiMet [377]. It was predicted that the defect in tRNAiMet processing observed in gcd14 
mutants also derives from the absence of m1A in tRNA.  
 
Most of the known tRNA methyltransferases (MTases) use S-adenosylmethionine  
(AdoMet) as the methyl donor, and most contain a domain comprised of four conserved 
motifs (I, post-I, II, and III) [382]. The three-dimensional structures of several MTases 
reveal that motifs I and post-I directly contact AdoMet, and mutation of motif I impairs 
AdoMet binding. The presence of motifs I, post-I, and II in Gcd14p suggested that it can 
bind AdoMet and function directly as the yeast tRNA(m1A)MTase [376]. Because all well-
characterised tRNA MTases are single-subunit enzymes, the role of Gcd10p was more 
difficult to predict. The Gcd10p/Gcd14p complex could be a two-subunit 
tRNA(m1A)MTase, requiring Gcd10p for intrinsic enzymatic activity. Alternatively, Gcd10p 
might function in nuclear localisation of the complex, or as a tRNA chaperone, and be 
required for m1A formation only in vivo.  
 
In a report by Anderson et al, they report that the purified Gcd10p/Gcd14p 
complex demonstrated tRNA(m1A)MTase activity and that a mutation in motif I of the 
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putative AdoMet binding domain in Gcd14p eliminated this (m1A)MTase activity in vitro 
thereby abolishing m1A formation in vivo. These results prove that Gcd10p and Gcd14p 
function directly in m1A formation in yeast tRNAs. Purified Gcd14p alone was shown to 
have no enzymatic activity and was defective for tRNA binding compared with the 
Gcd14p/Gcd10p complex. These findings, combined with the previous demonstration 
that Gcd10p alone has RNA binding activity [383], leads to the supposition that Gcd10p 
is required for tight binding of the tRNA substrate. Thus, the AdoMet and tRNA binding 
functions required for m1A formation seem to depend on distinct subunits of a two-
component tRNA methyltransferase as depicted in figure 73.  
 
7.5.2 Towards defining a function for a pVHL-protein A/B interaction 
 
Protein B (Gcd14p homologue) was cloned from 
the image consortium (see chapter 6, materials 
and methods). Protein A (Gcd10p homologue) 
posed problems when cloning due to a lack of 
construct availability. Nonetheless, it has since 
been cloned in collaboration with another doctoral 
student, P.Ballschmietter. In vitro binding assays 
involving radio-labelling of protein B with S35 and 
incubation with pVHL expressed as GST-fused 
poly-peptides in sf9 cells, demonstrated that 
protein B can bind GST-VHL30 and GST-VHL19 in 
vitro (figure 76). Antibodies have since been raised 
against Protein B, and preliminary evidence exists 
showing that ectopically expressed protein B can 
precipitate endogenous pVHL thereby confirming the in vitro result in figure 76 
(Ballschmieter, Barry and Krek, data not shown). Furthermore, ectopically and 
endogenously expressed protein A has recently been shown to co-precipitate over-
expressed and endogenous pVHL, and importantly that ectopically expressed protein A 
and protein B co-precipitate (Ballschmieter, Barry and Krek, data not shown). These 
results confirm that complex formation occurs in vivo, and that this complex is capable of 
interacting with pVHL. 
 
Nonetheless, despite the fact that these proteins complex in vivo, and that this 
complex precipitates endogenous pVHL, no physiological relevance is available to assign 
any potential significance to this interaction. Firstly, evidence that this complex is the 
mammalian orthologue is necessary, that is, that complexed proteins A and B can 
demonstrate methylation activity. Secondly the role, if any, pVHL plays in context of 
protein methylation must be investigated. These studies are underway. 
 
Figure 76. GST-VHL30 and GST-VHL19 bind 
radiolabelled protein B, the assumed 
Gcd14p mammalian homologue based on 
sequence similarity. 
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Concluding remarks 
 
This section has outlined the development of a novel experimental approach for 
identifying new pVHL protein interactions. In a field that has been exhaustively examined 
for novel pVHL partners, this approach was successful in isolating two candidates that 
may help to shed light on the role of pVHL in tumourigenesis. The first, p97, represents 
an ATPase, and binding assays have confirmed this interaction both in vivo and in vitro. 
Current literature would support a model where p97 may facilitate pVHL-mediated Hifα 
degradation, a hypothesis under investigation. Preliminary data would also support a role 
of p97 in the stabilisation of microtubules, thereby linking its function to that of pVHL’s in 
microtubule regulation. Finally, pVHL has been shown to bind the microtubule binding 
histone deacetylase HDAC6 in vitro, and that this binding is mediated through it’s 
microtubule binding domain. Given the fact that p97 also binds HDAC6 and that all three 
proteins are involved in the malfolded protein response, suggests a putative functional 
interaction of all three in this process that may, at least in part, be mediated by the 
microtubule cytoskeleton.  
 
In addition, pVHL has been shown to interact with two uncharacterised proteins, 
which show homology to a conserved complex in yeast, namely the tRNA(m1A) 
methyltransferase. Preliminary data have confirmed the interaction, but further 
experimentation is needed to confirm whether this complex is the true mammalian 
orthologue of its yeast countereparts, and what the effect VHL may have in the process 
of methylation. The significance and potential impact these interactions might have on 
VHL biology is further discussed in chapter 8. 
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RESULTS – PART II: 
 
Investigating pVHL intracellular dynamics 
 
 
7.6 Introduction 
 
This section outlines the contribution made to an article published in Nature Cell Biology 
in December 2002 regarding the association of pVHL with microtubules and the effect 
that disruption of the microtubule cytoskeleton has on pVHL intracellular localisation 
[107]. 
 
Tumour suppressor proteins control the proliferation and survival of normal cells; 
consequently, their inactivation by gene mutations can initiate or drive cancer 
progression. Most tumour suppressors have been identified by genetic screening, and in 
many cases their function and regulation are poorly understood. Many such proteins 
have recently been shown to contain nuclear transport signals that facilitate their 
"shuttling" between the nucleus and cytoplasm [384]. This type of dynamic intracellular 
movement not only regulates protein localisation, but also often impacts on function. 
Tumour suppressors including APC [385], p53 [386], BRCA1 [387], and also VHL [99] 
cross the nuclear envelope and the impact of regulated nuclear import/export on protein 
function is only beginning to be appreciated. 
 
When beginning this project, work, pioneered in particular by Stephen Lee, had 
shown that nuclear/cytoplasmic localisation of over-expressed pVHL was a cell density 
dictated event, and that in densely grown cells, pVHL was predominantly cytoplasmic, 
whereas in sparse cultures, most of the protein was detected in the nucleus [99]. Lee et 
al. also identified a putative nuclear localisation signal (table 20). They developed their 
findings further, and provided evidence suggesting that VHL-GFP shuttles between the 
nucleus and cytoplasm in an transcription-dependent, Ran-mediated manner and that 
deletion mutants of pVHL lacking exon 2 failed to do so [388],[389]. The fact that exon 2 
mutants over-expressed in 786-0 cells failed to suppress HIF2α as demonstrated by up-
regulation of the HIF regulated gene GLUT1 (glucose transporter) suggested that 
shuttling may be important for pVHL tumour suppressor activity. 
Table 20. Putative VHL nuclear import/export signals 
VHL Nuclear localisation sequence and import pathway: 
Import Elements Sequence Receptor/pathway References 
Bipartite NLS 1PRR(X)53RPRPV60 Importin-α/β Lee et al 1996 
 
VHL nuclear export sequence and export pathway: 
Export Elements Sequence Receptor/pathway References 
Exon 2 a.a. 114-154 CRM1-independent Lee et al 1999 
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Figure 77. Localisation of GFP-VHL30 and GFP-VHL19 following 
retroviral transduction in NIH3T3 mouse fibroblasts. A) GFP 
expression following retroviral transduction. B) GFP-VHL19 
expression demonstrates that GFP-VHL19 localises predominantly to 
the nucleus. C) GFP-VHL30 localises predominantly to the cytoplasm. 
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7.6.1 Intracellular localisation of ectopically 
expressed pVHL19 and pVHL30 
 
While it was clear that pVHL, at least when over-
expressed, could localise in both the nucleus and 
cytoplasm, and that an active transport between 
both cellular compartments was likely, no 
understanding of why this might be the case was 
available, and no consideration to different pVHL 
forms, namely pVHL30 and pVHL19, had be given. 
For this reason, it was interesting to investigate 
participation of both protein species in this cellular 
event. Figure 77 demonstrates that GFP-VHL30 and 
GFP-VHL19 localise differently. Like GFP alone, 
GFP-VHL19 localises predominantly to the nucleus 
showing some cytoplasmic signal. In contrast, 
GFP-VHL30 localises predominantly to the 
cytoplasm, showing some nuclear localisation. The 
findings were in accordance with previous reports.  
 
7.6.2 Intracellular localisation of endogenous 
pVHL30 
 
Endogenous visualisation of pVHL30 by 
indirect immuno-fluoresence confirmed the 
previous exogenous approaches in that pVHL30 
was predominantly cytoplasmic, but could also 
localise to the nucleus. The results showed 
however much clearer than before, that pVHL30 
could at times be localised uniquely to the nucleus, 
uniquely to the cytoplasm, or present in both 
simultaneously (Fig.78). In light of an article that 
emerged at the time regarding p53’s ability to 
associate with cellular microtubules [390], which 
facilitated its transport to the nucleus in a dynein-
dependent fashion, it seemed reasonable to 
suggest that pVHL may, like some other tumour 
suppressor proteins (p53 and APC), be capable of 
participating in nuclear/cytoplasmic trafficking in a 
cytoskeletal-dependent manner. As the first part of 
this chapter outlines, initial attempts were aimed at 
defining an interaction between pVHL and the actin 
Figure 78. Endogenous pVHL30 patterns 
stained with VHLNT in Hela cells. A) pVHL30 
localises uniquely in the nucleus, uniquely in the 
cytoplasm, or a mixture of the two. B) IP 
demonstrating the specificity of VHLNT for pVHL30.
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cytoskeleton based on the observation that GST-VHL30 co-precipitated the actin-binding 
motor protein myosin heavy chain type IIA (MHCIIA). However, when experiments cast 
doubt on a true in vivo interaction between pVHL and MHCIIA, attention was again 
reverted towards the microtubule cytoskeleton. Subsequent immuno-fluorescence 
demonstrated that endogenous pVHL30 did indeed co-localise with assembled 
microtubules (Fig.77). While in vitro assays have demonstrated that pVHL19 can also 
bind assembled microtubules [107], the endogenous distribution of both pVHL forms 
suggests that only pVHL30 participates in an in vivo microtubule association. 
 
7.6.3 The importance of microtubule stability in pVHL30 intracellular localisation 
 
While cytoplasmic pVHL30 had been shown to associate with microtubules, 
endogenous pVHL30 could nonetheless at times still be observed either partially or totally 
in the nucleus. Approaches were undertaken to examine the endogenous dynamics of 
pVHL30 and involved reinvestigating already documented observations – cell density and 
transcriptional-dependent shuttling - as well as observing pVHL30 localisation throughout 
the cell cycle.  While differences in localisation patterns were observed, conclusions were 
difficult to make based on the inconsistent observations. Contact inhibition did indeed 
seem to affect pVHL30 localisation, but in contrast to Lee et al, confluent cultures showed 
a predominantly nuclear signal, whereas sparse cultures showed a predominantly 
cytoplasmic localisation. No obvious changes in localisation or expression were observed 
throughout the cell cycle, with the exception that during mitosis, pVHL30 can bind the 
spindle apparatus (Hergovich and Krek, unpublished). However, when investigating 
Figure 79. Endogenous pVHL30 co-localises with microtubules. A) Hela cells were double-labelled with 
VHLNT and anti-tubulin (Tub27b) and slides processed by confocal microscopy. B) An enlargement of the 
highlighted area in (A) demonstrating the association of pVHL30 with microtubules at a higher magnification.
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transcription-dependent trafficking of 
pVHL30, the results were striking. In 
cells treated with Actinomycin D, an 
RNA polymerase II inhibitor, or 
leptomycin B, an inhibitor of CRM-1 
dependent protein nuclear export, 
pVHL30 was observed to be uniquely 
nuclear (Fig.80.A). This was 
unexpected, given the fact that Lee et 
al. had recently published that while 
VHL-GFP is sensitive to ongoing RNA 
polymerase II activity, it is not affected 
by treatment with leptomycin B [389]. 
 
Interestingly, co-staining for 
microtubules highlighted an important 
observation, namely that in cells that 
exhibited a nuclear pVHL30 signal, no 
intact microtubules were observed. 
This does not mean that the drug 
treatment by leptomycin B or 
Actinomycin D directly depolymerises 
microtubules, nor that pVHL30 shuttles 
in a CRM1-dependent fashion, but 
rather that this treatment might mimic 
a stress response resulting in the 
breakdown of the microtubule network 
and subsequent re-localisation of 
pVHL30.  
 
7.6.4 The effect of microtubule 
stabilising/destabilising 
drugs on pVHL30 intracellular 
localisation 
 
To further analyse this 
observation, cells were treated with 
drugs that were known to destabilise 
microtubules. Treatment with 
vincristine, nocodazole or colcemide 
all disrupted microtubules, and all 
resulted in a uniquely nuclear signal of 
pVHL30, whereas untreated cells 
Figure 80. pVHL30 nuclear accumulation corresponds to a 
disruption of the microtubule network. A) Leptomycin B treatment 
resulted in a nuclear accumulation of pVHL30, but also a breakdown 
in microtubule array. B) Hela cells treated with known depolymerising 
agents render the same pVHL30 nuclear accumulation as with 
leptomycin B, whereas untreated cells that maintain an intact 
microtubule array show a cytoplasmic pVHL30 signal. 
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retained a cytoplasmic, 
microtubule-associated 
pVHL30 localisation pattern 
(Figs 78(B), 79(A)). 
Furthermore, when cells 
were treated with a 
microtubule stabilising drug 
like Taxol, a strong pVHL30 
signal was retained in the 
cytoplasm (Fig.81.B). 
Nonetheless, taxol treated 
cells also exhibited some 
nuclear staining. While Taxol 
stabilises microtubules, it 
renders them inactive, and 
thereby creates a non-
physiological environment for 
the cell, which may in part be 
interpreted as stress. 
Perhaps for this reason, 
despite the stabilised 
microtubule network, more 
nuclear staining is observed 
than would be expected for 
untreated. Regardless, 
maintaining microtubule 
integrity resulted in pVHL cytoplasm retention. At this point it became apparent that the 
microtubule architecture was implicated in pVHL30 intracellular localisation and that 
disrupting microtubules resulted in pVHL30 re-localising to the nucleus. Disruption could 
be induced by drug induced depolymerisation, or seemingly by other treatments that are 
registered as stress by the cell, like global inhibition of transcription by Actinomycin D, or 
drug treament by leptomycin B. Unfortunately, various attempts to visualise pVHL30 
migration to the nucleus by time-lapse video microscopy following treatment of cells with 
a microtubule depolymerising agent were unsuccessful in demonstrating this live. 
Moreover, while immuno-fluorescence data is convincing, biochemical data is missing to 
show that cellular fractionation in the presence or absence of a microtubule destabilising 
drug can show fluctuations in nuclear and cytoplasmic pools of pVHL30. This has been 
attempted, but for technical reasons has been unsuccessful. It is thought that due to its 
small size, pVHL30 simply diffuses through the nuclear pores upon mechanical disruption 
of the cells. Perhaps cross-linking cells with glyceraldehyde prior to lysing may prevent 
passive diffusion of proteins which are below the nuclear pore exclusion size and could 
represent a solution to this problem. 
Figure 81. Microtubule stability affects pVHL30 
nucelar/cytoplasmic localisation. A) Treatment of Hela cells with 
vincristine, a microtubule depolymerising agent, caused pVHL30 to 
localise predominantly in the nucleus. B) Treatment of Hela cells with 
Taxol, a microtubule stabilising agent gives rise to a greater pVHL30 
cytoplasmic retention. 
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7.6.5 Recombinant VHL30 and VHL19 can exhibit both nuclear and cytoplasmic  
ubiquitination activity 
 
Given the fact that 
pVHL19 predominantly localises 
to the nucleus and pVHL30 to 
the cytoplasm, it was interesting 
to investigate their respective 
ubiquitination activity with 
respect to nuclear and 
cytoplasmic intracellular 
compartments. More 
specifically, the question asked 
was whether pVHL19 could 
exhibit ubiquitination activity in 
the cytoplasm, and whether 
pVHL30 could exhibit 
ubiquitination activity in the 
nucleus. If this were not the 
case, then their intracellular 
separation might be based on 
their ubiquitination activity 
capacity. A crude assay was 
used to test this which involved 
reconstituting an in vitro 
ubiquitination assay with either 
GST-VHL30 or GST-VHL19 as 
the source of ligase. The 
reaction mixture involved the 
addition of an E1 enzyme, 
cdc34 - as E2, ATP as a source 
of energy, ubiquitin aldehyde 
and finally a concentrated lysate 
input which would provide 
additional components 
necessary for pVHL activity. This lysate input was divided into whole cell extracts, 
nuclear lysate preparations, and cytoplasmic preparations with the intention of 
investigating whether specific components were located in either compartment that might 
be necessary for the ubiquitination activity of either pVHL30 or pVHL19. Finally these 
reactions were performed in the presence or absence of ubiquitin. As figure 82 illustrates, 
both GST-VHL19 and GST-VHL30 were capable of generating ubiquitination activity in 
both cytoplasmic and nuclear fractions, albeit to a lesser extent than the whole cell 
extract. This activity is reflected by a black smear in the high molecular weight range. 
Figure 82. Comparison of the ubiquitination activity of pVHL30 and 
pVHL19 with respect to sub-cellular localisation. A) GST-VHL forms 
were purified from sf9 cells and incubated with appropriate ubiquitination 
assay components (see  text) supplemented with lysate derived from 
WCE (whole cell extract), nuclear extract, or cytoplasmic extract in the 
presence or absence of ubiquitin. Activity is reflected by high molecular 
weight black smear. B) The fractionation of Hela cells prior to 
ubiquitination assay. Tubulin is used as a cytoplasmic marker, and cyclin 
A for the nuclear fraction.
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While it was shown that pVHL30 did not bind other VBC-Cul2 E3 ligase components 
when microtubule-bound, its nuclear localisation would be devoid of any microtubule 
association. It was therefore presumed that, when in the nucleus, pVHL30 could 
reconstitute an E3 ligase complex. If this was indeed the case, then a scenario was 
beginning to emerge that VBC-Cul2 activity could also be a nuclear event, and not 
merely a cytoplasmic event as previously thought. Evidence supporting this idea was 
published by Berra et al in 2001, which showed that HIF1α could indeed be degraded in 
both cellular compartments and with the same kinetics [208]. This is in contrast to the 
mechanism that controls p53 degradation by MDM2 which requires ubiquitinated p53 
expulsion from the nucleus before being degraded [386]. Experiments at the time were 
thus aimed at trying to show that pVHL30 might be entering the nucleus following hypoxic 
insult in order to degrade HIFα in the nucleus following re-oxygenation, thereby mounting 
an efficient response that would rapidly down-regulate HIFα (NB. HIFα half-life is 5-8 
minutes). Such studies were published during the course of this work by Groulx et al. 
who showed that ubiquitinated forms of HIFα, as well as VHL-ubiquitinated-HIFα 
complexes, are found solely in the nuclear compartment of normoxic or re-oxygenated 
VHL-competent cells [391]. However, in contrast to Berra et al. who suggested that HIFα 
could be degraded within the nucleus by nuclear proteasomes, Groulx et al. demonstrate 
that HIFα localises exclusively in the nucleus of hypoxic cells but is exported to the 
cytoplasm upon re-oxygenation following nuclear ubiquitination. Nonetheless, regardless 
of where HIFα is degraded, both groups demonstrated that HIFα could be ubiquitinated 
in the nucleus, thus highlighting the need for a pVHL presence in this compartment 
capable of mounting an efficient response following hypoxia. While pVHL19 presumably 
operates to prevent any unwarranted HIF activity in normoxic cells, one could envisage a 
scenario whereby cells, following hypoxia, accumulate pVHL30 in the nucleus in order to 
assist the already present pVHL19 to ubiquitinate HIFα as quickly and efficiently as 
possible. It is tempting to suggest that this transport to the nucleus, analogous to p53, 
may be along microtubules, whose subsequent disruption upon stress signalling, as with 
hypoxia, facilitates pVHL30’s nuclear accumulation.  
 
Interestingly a paper emerged last year in Cancer Cell, which described a novel 
anti-tumour and anti-angiogenic agent currently in clinical trials, 2-methoxyestradiol 
(2ME2). Administration of 2ME2 resulted in a down-regulation of HIFα, and that this 
down-regulation was dependent upon disruption of interphase microtubules [392]. The 
authors suggest that their data establishes this drug as an inhibitor of HIFα and provides 
a mechanistic link between the disruption of the microtubule cytoskeleton and inhibition 
of angiogenesis. By extension, perhaps one aspect of pVHL tumour suppressor activity 
in vivo is to re-locate to the nucleus following a hypoxic cue, which not only facilitates 
down-regulation of HIFα, but by uncoupling itself from its microtubule-association, 
pVHL30 re-location also destabilises the microtubule cytoskeleton. The question however 
remains whether microtubule disruption is the causal event in pVHL30 re-location to the 
nucleus, or whether pVHL30 re-location is the causal event in microtubule disruption. 
Chapter 7: Results – Part II 
 163
Which ever this represents, the findings documented here may represent a possible 
molecular mechanism that can, in part, explain the down-regulation of Hifα following 
2ME2 treatment, and by extension, can therefore be implied in normal physiological 
cellular control. Interestingly, cytoplasmic retention of 53 has been shown to be 
dependent on vimentin, an intermediate filament protein scaffold [337]. Disruption of 
intermediate filaments causes p53 to accumulate in the nucleus. Whether disruption of 
the cytoskeleton is a general phenomenon of tumour suppressor nuclear re-localisation 
remains unstudied. 
 
 
Concluding Remarks 
 
This section has demonstrated the initial findings that pVHL is functionally linked to 
the cytoskeleton. It demonstrates that in normal logarhythmically growing cells, 
GFPVHL30 and GFPVHL19 exhibit different localisation patterns. Endogenous pVHL30 
resides predominantly in the cytoplasm where it co-localises with the microtubule 
network. Disruption of the microtubule cytoskeleton renders nuclear re-localisation of 
pVHL30. The reason for this is unclear, but postulated to be involved in mounting an 
efficient response in conjunction with pVHL19 to target Hifα for proteolytic degradation 
following its accumulation due to hypoxic stress, or some alternative means of rendering 
a HIF response. This work contributed to an article in Nature Cell Biology, where it was 
further shown that pVHL can protect microtubules from depolymerisation, and that 
certain tumour derived mutations in VHL, while capable of binding microtubules, could 
not stabilise them. These mutants could be all classed clinically as those mutants related 
to type 2A VHL disease where patients exhibit predisposition to phaeochromocytoma 
and haemangioblastoma but a reduced risk to renal cell carcinoma. The correspondence 
between type 2A mutants and microtubule stabilisation might suggest a contributory 
causal role on behalf of the microtubule network regarding development of malignancies 
associated with this sub-class of VHL disease, or that the mutational effect somehow 
mitigates against the RCC predisposition. 
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RESULTS – PART III: 
 
Investigating VHL RNA Interference 
 
 
 
7.1 Introduction 
 
pVHL functional inactivation studies at the time of commencing this project had relied 
predominantly on the comparison of tumour derived cell lines lacking functional pVHL 
and comparing findings to an isogenic counterpart into which pVHL had been 
reintroduced. These cells, which include 786-0, A498, RCC4, are RCC derived cell lines, 
whose pVHL status is not entirely clear. It could be argued that, they are non-functional 
with respect to known pVHL functions, but whether all pVHL functioning is effected is 
unclear. Furthermore as RCC cells are known to harbour a myriad of genetic alterations 
aside from those associated with pVHL, drawing conclusions about observations solely 
attributable to pVHL based on reintroduction of pVHL into these cell lines is difficult.  
 
For this reason, an alternative approach was sought. Attempts at targeting pVHL 
by anti-sense oligonucleotide approaches had failed. However, at the time, small 
interfering RNA (siRNA) oligonucleotides were beginning to emerge as a potential tool 
that could be used to effectively, and specifically knockdown target proteins in 
mammalian cell culture. The laboratory had not established this technology, and the aim 
of the project was to establish siRNA as a standard reagent to be used, and in particular 
to analyse the effect of depleting cells of endogenous pVHL.  
 
Post-transcriptional gene silencing (PTGS), which was originally thought to be a 
phenomenon limited to petunias and other plant species, represents one of the most 
highlighted areas of molecular biology [393]. It is now understood that PTGS occurs in 
both plants and animals and has roles in viral defence and transposon silencing. From an 
experimental point of view, the most exciting development stemming from PTGS is RNA 
interference (RNAi) – PTGS initiated by the introduction of double stranded RNA 
(dsRNA) – as a tool to knock down expression of specific genes [393, 394]. Cells can be 
transfected with dsRNA oligonucleotides, and within hours of transfection, results can 
already be observed for many proteins targeted in this way. Compared to the time spent 
generating knock out models in organism like mice or flies, this approach is fast 
becoming the molecular biologists prerequisite before attempting any timely knockout 
strategies. Due to its ability to manipulate gene expression experimentally, RNAi is 
currently being applied to probe gene function on a whole-genome scale. However, one 
disadvantage using RNAi is that targeting results in knockdown in protein expression, not 
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knockout, and if residual amounts of a candidate protein are sufficient to fulfil its function, 
then unfortunately RNAi is unlikely to render significant results. 
 
 
7.2 VHL RNA interference 
 
RNA oligonucleotides corresponding to a 19 base pair stretch of the VHL coding region 
were ordered and prepared as per materials and methods.  Hela cells were chosen as a 
cell line to define an optimal working concentration. Cells were treated with differing 
concentrations of oligos for 48 hours and samples prepared for western blotting. Figure 
83(A) demonstrates a dose dependent down-regulation of pVHL30. A final concentration 
of 128nM of dsRNA was used for all future experiments unless otherwise stated. Figure 
83(B) illustrates the results obtained from transfecting four different human tumour 
derived cell lines with siRNA oligos against VHL. The results demonstrate that maximal 
pVHL19 knockdown is achieved in Hela cells. All subsequent experiments were hence 
carried out in Hela cells unless otherwise stated. Figure 81 demonstrates VHL RNAi time 
dependency. Samples were first transfected over a 24-96 hour period. Figure 83.C(i) 
shows that maximal knockdown is reached after only 24 hours, and that this level of 
 
Box 2. The Biochemical Mechanism of RNAi 
It is generally accepted that RNAi includes both an initiation and effector step. In the initiation step,
input dsRNA is digested into 21-23 nucleotide small interfering RNAs (siRNAs). Evidence indicates
that siRNAs are produced when the enzyme Dicer, a member of the RNase III family of dsRNA-
specific ribonucleases, processively cleaves dsRNA (introduced directly or via a transgene or virus)
in an ATP-dependent, processive manner. Successive cleavage events degrade the RNA to 19-21
bp duplexes (siRNAs), each with 2-nucleotide 3' overhangs (Hannon et al 2002; Bernstein et al
2001).  
 
In the effector step, the siRNA duplexes 
bind to a nuclease complex to form what is known 
as the RNA-induced silencing complex, or RISC. An 
ATP-depending unwinding of the siRNA duplex is 
required for activation of the RISC. The active RISC 
then targets the homologous transcript by base 
pairing interactions and cleaves the mRNA ~12 
nucleotides from the 3' terminus of the siRNA 
(Hammond et al 2001; Sharp et al 2001; Hutvagner 
et al 2002). Although the mechanism of cleavage is 
to date unclear, research indicates that each RISC 
contains a single siRNA and an RNase that appears 
to be distinct from Dicer (Hannon et al 2002). 
  
Because of the remarkable potency of RNAi 
in some organisms, an amplification step within the 
RNAi pathway has also been proposed. 
Amplification could occur by copying of the input 
dsRNAs, which would generate more siRNAs, or by 
replication of the siRNAs themselves. Alternatively 
or in addition, amplification could be effected by 
multiple turnover events of the RISC. 
Adapted from Hannon et al 2002 
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knockdown is maintained up to 96 hours, and presumably beyond. Figure 83.C(ii) 
highlights more dramatically the efficacy of pVHL knockdown. VHL RNAi can elicit an 
effect 3-4 hours post-transfection, reaching a near maximum after a mere 5 hours.  
 
Finally, cells were analysed for adverse affects, which might be either VHL RNAi 
specific, or technique related. Figure 84 overleaf demonstrates that cells proliferated 
normally and that cell viability of both VHL and control RNAi was comparable to 
untreated control. Furthermore, FACs analysis demonstrated that cell growth profiles 
were unaffected (data not shown). These results indicated that VHL RNAi does not result 
in a defect in cell proliferation or viability. Furthermore, it demonstrates that the 
experimental conditions used were not toxic. 
 
Figure 83. Defining VHL RNAi conditions. A) pVHL depletion by siRNA oligos is concentration 
dependent. A final concentration of 128nM was defined as an optimal concentration for future 
experiments. B) Four different tumour derived cell lines were analysed for the efficiency of VHL RNAi. C) 
Time dependent knockdown of pVHL by RNAi. i) Hela cells were transfected with oligos and harvested 
24-96 hours post-transfection. Maximal knockdown was observed after 24 hours. ii) Cells were 
transfected with oligos and harvested 0-5 hours post-transfection. Knockdown is observed after 4 hours.
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7.3 VHL RNAi does not up-regulate HIF-α protein levels nor HIF transcriptional 
activity 
 
As discussed in chapter 5, negative regulation of VEGF expression by VHL is well 
established and has been demonstrated with respect to pVHL’s ability to target HIF for 
ubiquitin-mediated degradation [114, 200]. However, Gnarra et al. found VEGF 
expression to be decreased in VHL-deficient placental trophoblasts. This contradicts our 
understanding of HIF regulation by VHL and subsequent VEGF suppression. Consistent 
with constitutively active HIF, depletion of VHL should result in an up-regulation of VEGF 
as seen in VHL null tumours [262-264]. In the lethal phenotype observed upon VHL 
depletion in mice, this is however not the case. VEGF is down-regulated in VHL-/- 
placental derived trophloblast cells, and embryos die due to a lack of vascularisation of 
the placenta. However, it has yet to be fully determined whether this decrease is directly 
related to VHL inactivation which would indicate an alternative form of regulation in 
placental trophoblasts than seen in vascular tumours related to VHL disease, or a 
secondary effect and an early indicator of placental failure. Nonetheless, in this scenario, 
an inability to up-regulate HIF in the absence of pVHL has lethal consequence for the 
developing embryo. 
 
Haase et al. demonstrated that knockout of the VHL gene in mice can lead to a 
stabilisation of HIF [269]. The conditional inactivation of the VHL gene in the livers of 
BALB/c mice shows that inactivation of VHL leads to the up-regulation of VEGF, Glut-1, 
and Epo mRNAs, as well as stabilisation of HIF-2α in hepatocytes. This finding suggests 
that pVHL acts as a global regulator of HIF-α stability, and not only a regulator in VHL 
disease effected tissues, which points to a more general role of pVHL in the regulation of 
HIFα. Additionally, a very recent report from our laboratory suggests that specific VHL 
Figure 84. VHL RNAi does not affect cell proliferation. A) Counting adherent and non-adherent, a measure of 
cell death, show no proliferation defects. B) A cell viability assay using tetrazolium (MTT) salt incorporation. No 
significant difference in viability is observed with VHL RNAi treated cells. 
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inactivation in neuronal precursor cells in the brain results in increased vasculogenesis in 
brain tissue, reflective of up-regulated Hifα in the absence of pVHL (Ballschmieter and 
Krek). While additional studies are needed, this finding may for the first time demonstrate 
that inactivating pVHL in the brain is sufficient to cause brain manifestations like those 
observed in CNS haemangioblastoma, and thereby supporting the idea that inactivating 
mutations in the VHL gene are a causal role in these tumour formations. These and other 
studies have clearly demonstrated the role of pVHL in HIF degradation, but given the fact 
that VHL-/- mice die in utero due to lack of placental vasculogenesis owing at least in part 
to a reduction in Hifα activity, the discrepancy between this and the highly vascularised 
tumours associated with VHL disease reflecting up-regulated Hifα activity, remains 
unexplained. 
 
The first question to address therefore was whether endogenous depletion of 
pVHL in cell culture was sufficient to render a HIF response. Figure 85.A is a 
representation of multiple attempts to visualise Hif1α on western blot following VHL 
RNAi. While the positive control, CoCl2 treated Hela cells, showed positive for Hif1α, no 
signal is seen when depleting cells of endogenous pVHL. To ensure that the result seen 
by western blot was not simply a reflection of the fact that any fluctuations in Hif-1α went 
unobserved due to the lack of detection sensitivity, a reporter assay using the VEGF-
reporter gene was analysed to investigate any HIF-induced transactivation that might be 
increased by depletion of endogenous pVHL by RNAi. Figure 85(B) demonstrates that 
the positive control, Hif1α ∆proline, elicits strong transactivation of the VEGF-reporter, 
whereas VHL and control siRNA oligo-treated samples were indistinguishable. The result 
therefore demonstrates that VHL RNAi does not cause any detectable up-regulation in 
HIF activity. 
Figure 85. Depleting Hela cells of endogenous pVHL, does not increase HIFα protein levels, or HIF 
transcriptional activity. A) Hela cells were treated with VHL siRNA over a 24-72 hour period and prepared for 
western blot analysis to see if protein levels of HIFα had changed. B) Cells treated with VHL siRNA and appropriate 
controls were prepared for VEGF-reporter gene transactivation analysis. HIF-1α∆Pro refers to a HIF1α mutant 
which has both proline residues, P564 and P402, mutated to facilitate constitutive HIFα activation. 
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 The next parameter to investigate was whether the kinetics of Hif-1α degradation 
could be affected in the presence of VHL RNAi. Hela cells were treated with CoCl2 for 4 
hours to induce a hypoxic response, and re-oxygenation was mimicked by changing the 
medium to that of medium lacking CoCl2. The cells were harvested at various time 
points, and the speed of Hif-1α degradation examined. Figure 86 demonstrates an 
example of one such experiment. The result shows no obvious changes in Hif-1α 
degradation kinetics in the presence of VHL RNAi. This result is surprising, in light of the 
fact that pVHL is considered the principle ligase for HIF. Two conclusions can be drawn 
from this experiment. Either residual amounts of pVHL that remain following down-
regulation of pVHL by RNAi are sufficient to suppress HIF, even after a hypoxic insult or 
that an alternative HIF ligase can replace pVHL under these conditions. Given the fact 
that HIF continues to be negatively regulated in placental derived trophloblast cells of the 
VHL-/- mice, it seems plausible that other mechanism of HIF proteolytic control are 
physiologically more relevant than perhaps thought. Reports already exist demonstrating 
that p53 promotes Mdm2-mediated ubiquitination and proteasomal degradation of HIF-
1α [217]. Perhaps under these circumstances, Mdm2 compensates for the loss of pVHL 
in Hif-1α degradation. 
 
  
Interestingly, a report emerged from Berra et al. demonstrating that specific 
silencing of proline hyrdroxylase 2 (PHD2) using siRNA is sufficient to stabilise and 
activate Hif-1α in normoxia in all human cells investigated. They demonstrated a dose 
dependent Hif-1α response to PHD2 siRNA under normoxia, an increase in Hif-1α 
immunofluorescence signal following RNAi, and reporter assays demonstrated Hif-1α 
activity under normoxia following PHD2 knockdown. Intriguingly, they state that the same 
is observed for VHL, but no data is shown. In fact, VHL RNAi has to date never been 
published, and international correspondence with peers has confirmed the inability to 
show a consistent and reproducible HIF up-regulation in response to VHL depletion by 
Figure 86. Kinetics of Hif1α degradation following hypoxia mimetic, CoCl2, 
are not affected by VHL RNAi. Hela cells were transfected with VHL and control 
siRNA oligos 48hrs prior to CoCl2 treatment for 4 hrs. They were then released 
into fresh medium and harvested at the noted time points. 
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RNAi. The question therefore 
was whether the finding that 
PHD2 knockdown really was 
sufficient to mount a HIF 
response, and if so, why the 
same could not be observed 
for VHL RNAi. Figure 87 
represents a reporter assay 
whereby, Hela cells were 
investigated for their 
transactivation capacity of a 
VEGF-reporter gene following 
siRNA treatment. RNAi for 
pVHL, Mdm2, a potential 
alternative Hif-1α ligase, and 
PHD2 were performed. The 
same oligonucleotides as 
published by Berra et al. were 
used to target PHD2. As the 
figure demonstrates, with the 
exception of the positive 
control, a non-degradable Hif-1α mutant, no significant transactivation activity was 
observed amongst the various siRNA treated cells. Even when siRNA oligos for VHL and 
Mdm2 were combined, no fluctuations in activity were observed. These results contradict 
those published by Berra et al., and cast serious doubt on whether depletion of one 
proline hydroxylase isoform is sufficient to up-regulate Hif-1α. Nonetheless, the question 
remains why no HIF response is seen in the absence of pVHL. Cre-lox specific targeting 
of VHL in mouse embryonic fibroblasts is being established in the laboratory (Frew and 
Krek). Interestingly, no HIF response has to date been observed in these cells, despite 
efficient targeting of the VHL gene. This observation supports those observed for VHL 
RNAi. For this reason, it merits further investigation, which ultimately may help explain 
the phenomenon of down-regulated HIF target genes in the developing placenta of VHL-/- 
mice. 
 
7.4 VHL RNAi confirms pVHL regulation of phosphorylated cofilin 
 
Collaborative work between Joanna Listzwan, a former doctoral student in the laboratory, 
and the proteomics centre at Novartis, Basel, had demonstrated that following a 
proteomics approach aimed at identifying novel proteins differentially expressed in 786-0 
VHL-/- cells and their isogenic counterparts stably expressing HA-pVHL30, several 
candidate proteins shown to be involved in cell shape changes were identified. In 
particular, levels of phosphorylated cofilin were approximately 2.5 fold higher in 786-0 
Figure 87. No transactivation activity of a VEGF-reporter gene is 
observed in Hela cells treated with siRNA for pVHL, Mdm2 or PHD2. 
Cells were transfected singularly or in combination 48hrs prior to preparation 
for reporter assay.  
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vector control cell line when compared to their 
isogenic counterpart expressing re-introduced 
HA-VHL30. This finding was later confirmed by 
2D gel western blotting, comparing phospho-
cofilin levels between 786-0 cells expressing or 
lacking pVHL (Lisztwan and Krek; 
unpublished). However, evidence lacked 
regarding whether endogenous depletion of 
pVHL from cells that normally express wild-
type pVHL, would show increases in phospho-
cofilin levels, or whether this observation was a 
phenomenon of 786-0 cells. Collaborative work 
investigating the affect of VHL RNAi on 
phospho-cofilin levels demonstrated for the first 
time that depleting cells of endogenous pVHL 
increased the level of phospho-cofilin. Figure 
88 illustrates these findings, thereby confirming 
independently the original proteomics result. 
Up-regulation of phospho-cofilin represents the 
first consistent and reproducible readout from 
VHL RNAi treatment. 
 
Cofilin is an actin depolymerising factor, 
whose phosphorylation is mediated by LIM-
kinase (LIMK) [395]. LIMK was initially 
identified in a screen for a novel member of the 
c-Met/HGF receptor tyrosine kinase family 
[396], and to date is known to consist of two 
members, LIMK1 and LIMK2. Recently, it has 
been shown that both LIMK1 and LIMK2 
regulate actin cytoskeletal reorganisation 
downstream of the Rho family GTPases, and 
LIMK-induced actin cytoskeletal rearrangement 
is mediated by the phosphorylation of cofilin 
[397, 398]. Therefore, LIMK may be a key 
component of a fundamental signal 
transduction system that connects extracellular 
stimuli to intracellular actin cytoskeletal 
rearrangements in a distinct biological context. 
pVHL was shown not to interact with 
cofilin, but rather its upstream kinase, LIMK 
(Lisztwan and Krek, unpublished). This 
Figure 88. VHL siRNA in Hela cells results in up-
regulation of phospho-cofilin. Hela cells were transfected 
48hrs prior to preparation for western blot analysis. While no 
fluctuations in HIFα are observed, a known target of the 
VCB-Cul2 ligase, phospho-cofilin is up-regulated in the 
absence of pVHL. 
Figure 89. Signal transduction of LIMKs and cofilin 
mediated by the Rho family GTPases in actin 
cytoskeletal dynamics. Activated LIMK catalyses 
phosphorylation of cofilin. Phosphorylated cofilin cannot 
bind actin and is impaired in its activity to depolymerise 
actin filaments, thus leading to actin filament stabilisation. 
Activation of Cdc42, Rac, and Rho specifically induces 
formation of actin reorganisation-based cellular structures of 
filopodia, lamellipodia or membrane ruffling, and stress-
fibers, respectively. In cellular signalling, LIMK1 is 
specifically activated by Rac via activation of a well-known 
Rac effector, Pak. In contrast, LIMK2 activity is enhanced 
by Rho and Cdc42, which are mediated by their specific 
effectors, ROCK and MRCKα, respectively. 
Adapted from Takahashi et al. 2003 
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interaction has been shown to inhibit phosphorylation of cofilin by LIMK1, thereby helping 
to explain the results from the initial proteomics approach and subsequent RNAi data. 
However the biological significance of this inhibitory interaction remains unclear. 
Previous work has suggested that reintroduction of pVHL into RCC cells lacking pVHL 
promotes the assembly of stress fibres, focal adhesion formation and cell spreading - all 
reflective of changes in the actin cytoskeleton. Whether pVHL’s effects on the actin 
cytoskeleton are direct remains to be determined, but it is interesting to note that 
although LIMK is activated by all three Rho GTPase family members, each GTPase 
promotes very different morphological changes (Fig.89) [399].  Rearrangements in the 
actin cytoskeleton are conducive to cell shape changes and motility, and aberrations in 
their control may be reflected in the highly invasive or migratory phenotype of certain 
tumour cells, as seen with cells derived from RCC. Reintroduction of pVHL into RCC 
cells lacking functional pVHL has been shown to decrease the migratory and invasive 
behaviour of these cells [136]. Furthermore, contact inhibition, a feature often lost in 
transformed cells, has been shown to be restored in RCC upon pVHL reintroduction 
[249, 251]. Interestingly, recent evidence from our laboratory suggests that phospho-
cofilin accumulates upon cell contact (Sayi and Krek, unpublished). Given the fact that 
pVHL has been shown to relocalise upon cell confluency, that depletion of pVHL 
augments phospho-cofilin levels and that pVHL itself has already been shown to affect 
the actin cytoskeleton [249], it must be assumed that pVHL is functionally involved in 
actin cytoskeletal rearrangements. Interestingly, as already mentioned in chapter 5, VHL-
/- MEFs are no longer capable of assembling an extracellular fibronectin matrix. Taken 
together with the fact that pVHL binds microtubules, is involved in integrin receptor 
expression and that RCC cells lacking pVHL exhibit a highly migratory phenotype, the 
involvement of pVHL in cell shape changes which culminate in the migratory phenotype 
observed for VHL-/- RCC cells may in part therefore be explained by pVHL’s affect on 
phospho-cofilin. Further studies are clearly warranted. 
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Concluding Remarks 
 
 
The recent studies on RNAi have taken the research world by storm. The ability to 
quickly and easily create loss-of-function phenotypes has researchers rushing to learn as 
much as they can about RNAi and the characteristics of effective siRNAs. In the future, 
RNAi may even hold promise for development of gene-specific therapeutics. This section 
has outlined the investigation of endogenous depletion of pVHL from cultured tumour 
cells using RNA interference, and the physiological impact this may have. pVHL was 
observed to be maximally knocked down after 5 hours, and that this was sustained for up 
to 96+ hours.  HIF activation was not up-regulated following pVHL knockdown. This 
could represent the inefficiency of pVHL RNAi, or the fact that residual amounts of pVHL 
are sufficient to target Hifα for degradation. As no VHL RNAi has to date been published, 
one could speculate however, that this scenario may be more complicated. Perhaps 
alternative mechanisms are initiated upon pVHL depletion that control HIF and 
identification of this mechanism(s) could prove important in explaining the discrepancy 
between the highly vascularised tumours associated with VHL disease, and the lack of 
placental vasculogenesis that result in embryonic lethality in VHL-/- mice. Finally, as a 
collaborative undertaking, VHL RNAi confirmed the observation that down-regulation of 
pVHL results in a concomitant up-regulation in phosphorylated cofilin. Given the role of 
cofilin in cell shape changes and movement, deciphering the mechanism of this 
interaction may prove important in understanding the highly invasive and metastatic 
properties of RCC cells where VHL is found inactivated. 
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CHAPTER 8 
 
Discussion and Future Perspectives 
 
 
 
 
This chapter is divided into two sections. The first section outlines a peer review currently 
in press in Trends in Molecular Medicine, entitled; The von Hippel Lindau Tumour 
Suppressor; a multi-faceted inhibitor of tumourigenesis. This review was based on the 
work detailed in chapters 1-5 and serves as a critical synopsis of these chapters. It 
attempts to review our current understanding of VHL in tumour growth and progression. 
 
 
 The second part of this chapter aims at briefly summarising the work outlined in 
chapter 7 submitted as partial fulfilment of this doctoral thesis. Emphasis is given to how 
this work will be continued and the potential impact it might have on VHL biology. 
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Abstract 
 
Proteolytic degradation of hypoxia inducible factor (HIF)α by the von Hippel-Lindau (VHL) 
tumour suppressor protein, pVHL, has emerged as a key cellular mechanism in the control of 
adaptive gene expression programmes in response to changes in oxygen levels.  Inactivation of 
this mechanism is phenotypically depicted by the vascular nature of VHL-associated tumours and 
has also recently been associated with the processes of invasion and metastasis. However, the 
complex genotype-phenotype correlations, which are a hallmark of VHL disease, demonstrate that 
the function of pVHL is likely to extend beyond its critical role in oxygen signal transduction and 
may include roles of pVHL in the regulation of microtubule dynamics, cell polarity and directed 
cell migration. Studies aimed at defining the normal function of VHL in these processes will help 
identify molecular mechanisms underlying pVHL-associated tumourigenesis. 
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VHL disease 
The identification of genes that cause rare 
familial cancer syndromes has yielded 
fundamental insights into the 
mechanisms of tumourigenesis that 
underlie sporadic cancers. This concept 
applies very well to VHL disease, an 
autosomal dominantly inherited familial 
cancer syndrome that affects between 1 
in 36,000-45,500 live births [10, 400]. In 
accordance with Knudson’s two-hit 
tumour suppressor model, tumours from 
VHL patients with a germ-line VHL 
mutation display somatic inactivation of 
the remaining wild-type allele [129].  
VHL disease is characterised by a 
diverse, but defined, array of tumours 
(summarised in Table 1 and Figure 1). 
Patients are classed into two general 
types depending on the risk of developing 
phaeochromocytoma. Type 1 patients do 
not develop phaeochromocytoma 
whereas type 2 patients do. Type 2 is 
further sub-divided based on the 
development or absence of 
haemangioblastoma and renal cell 
Table 1. Tumour frequency and age of onset 
Frequency  Age of onset
Central Nervous System  (Average) (range) 
Craniospinal haemangioblastoma  69% 29 (9-78) 
Endolymphatic sac tumours  10% 22 (12-50) 
Retinal angioma 47% 25 (1-67) 
Visceral organs 
Pheochromocytoma  13%  30 (5-58) 
Pancreatic islet cell tumours  42%  36 (5-70) 
Renal cell carcinoma  30%  39 (16-67) 
Epididymal cystadenoma  42%  Unknown 
Broad ligament cystadenoma  Unknown  Unknown 
Adapted from references Lonser et al 2003; Maddock et al 1993; Maher et al 1990; Ricjards 1998 
Table 2. Clinical sub-divisions in VHL disease
Class  Tumour types observed in families 
Haem. RCC Phaeochr. 
Type 1 + + − 
Type 2A + − + 
Type 2B + + + 
Type 2C − − + 
Haem. – Haemangioblastoma; RCC – Renal cell carcinoma; Phaeochr. - 
Phaeochromocytoma 
Figure 1. Tumours associated with von Hippel-Lindau disease. 
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carcinoma (RCC) (Table 2).  
 
Germ-line mutations are found in up 
to 100% of families fulfilling the 
clinical VHL criteria [31, 34, 43]. 
Mis-sense, non-sense, splice site 
mutations, and micro-deletions and 
insertions, are detected in 
approximately two-thirds of patients 
[34, 35, 133] while in the remaining 
one-third of VHL families, large 
deletions (4-380 kb) are found. Box 
1 outlines the ten most frequently 
occurring VHL mutations and 
highlights the functional significance 
of these residues. Box 1 outlines the 
ten most frequently occurring VHL 
mutations and highlights the 
functional significance of these 
residues. Interestingly, the pattern of 
mutations present in familial VHL 
disease correlates with clinical sub-
classification in terms of 
predisposition to tumour type. In 
general, mis-sense mutations are 
associated with the development of 
Box 1. 10 Most frequently 
mutated residues 
Residue Records Function 
R167  54 Packing of α-helices 
R161  33 Elongin C binding 
V155  24 Elongin C binding 
Y98  23 Hyp564 binding 
G114 20 HIF binding? 
F76 20 HIF binding? 
P86 19 HIF binding? 
P81 19 HIF binding? 
L158 18 Elongin C binding 
C162 17 Elongin C binding 
Box 2. Examples of germ-
line VHL-mutations and 
disease class correlations 
Mutation Cases Class 
Y98H 21 Type 2A 
Y112H 4 Type 2A 
Y112N 1 Type 2B 
F119L 5 Type 2B 
R167W 21 Type 2B 
F119S 1 Type 2C 
L188V 5 Type 2C 
V84L 1 Type 2C 
- Type 1 disease is associated generally 
with deletions and truncations which 
include both frameshift and nonsense 
mutations. 
Figure 2. Distribution of VHL-
mutations are concentrated in 
the HIFα and Elongin C binding 
domains. Red bars highlight the 
ten most frequent mutations as 
outlined in box 2. Below is the 
VHL protein structure illustrating 
the acidic N-terminal region and 
internal methionine at position 54 
which gives rise to the second 
protein product, pVHL19. pVHL is 
divided into an α- and β-domain. 
The α-domain is responsible for 
binding elongin C, and consists of 
3 α-helices. The β-domain is 
defined as the substrate 
recognition domain of pVHL and 
consists of a β-sandwich located 
between residues 63-154, and an 
α-helix between residues 193-204. 
Noteworthy, residues 88-111 
constitutes the pVHL- Hyp564 
interacting interface which 
harbours the frequently mutated 
residue Y98, the ‘black forest’ 
founder  mutation. Some 823 
germ-line and somatic mutations 
have been collected so far 
(www.umd.be) [2, 8, 9]. 
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type 2 disease, whereas gross deletions or mutations that lead to truncated versions of pVHL are 
primarily associated with the development of 
type 1 disease. Moreover, as outlined in box 2, 
specific point mutations in VHL predispose to 
distinct clinical sub-classifications of disease. 
For example, Y98H predisposes to type 2A 
disease while R167W gives rise to type 2B 
[2]. Thus, the type of germ-line mutation 
strongly determines the clinical manifestation 
of VHL disease, suggesting that VHL may 
have multiple and tissue-specific tumour 
suppressor functions. 
 
Importantly, sporadic forms of the same 
tumour types that are common in familial 
VHL disease display bi-allelic somatic 
inactivation of the VHL gene through a variety 
of mechanisms including mutation, deletion 
and hypermethylation [144]; [124]; [123]; 
[125]; [122]; [126]; [95]. For example, 
inactivation of VHL has been demonstrated in 
70-80% of all sporadic clear cell RCC, the 
major form of RCC, which accounts for 
approximately 2% of all cancer deaths 
worldwide [51]. In addition, almost half the 
number of patients diagnosed with RCC have 
Figure 3. pHIF-1α domains and regulation through post-
translational modification. Ac – acetylation; N/C-TAD – 
transactivation domains; ID – inhibitory domain containing 
the oxygen dependent domain (ODD) which harbours both 
VHL binding prolines; bHLH – basic helix-loop-helix 
domain; PAS – Per/Amt/sim 
Box 3. HIF control by post-translational 
modification 
 
Hydroxylation at two proline residues mediates interactions
with the β-domain of pVHL [7, 8]. Each site can interact 
independently with pVHL, potentially contributing to the
extremely rapid proteolysis of HIF-α that is observed under 
normoxic conditions. These sites contain a conserved
LxxLAP motif and are targeted by proline hydroxylases that 
in mammalian cells are provided by three isoforms termed
PHD 1–3 [11-13]. In a second hydroxylation-dependent 
control, β-hydroxylation of an asparaginyl residue in the C-
terminal activation domain of HIF-α, Asn803 in human HIF-
1α, is regulated by a HIF asparaginyl hydroxylase called FIH 
(factor inhibiting HIF) [17]; [19]. Hydroxylation at this site 
prevents binding of the transcriptional co-activators 
p300/CBP. Under normoxic conditions, these hydroxylation
reactions provide a dual mechanism of HIF inactivation that
involves proteolytic destruction and inhibition of 
transcriptional activity [20]. These hydroxylases are all
Fe(II)- and 2-oxoglutarate-dependent dioxygenases that
require molecular oxygen. HIFα therefore becomes stabilised 
under hypoxic conditions where oxygen availability is low. 
Furthermore, an acetyltransferase, ARD1, acetylates Lys532,
a residue previously shown to effect HIFα stability, thereby 
negatively regulating it [23]; [27]. Jab1, a transcriptional co-
activator, has been shown to positively regulate HIFα [28]. 
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metastatic disease on presentation. Metastatic RCC has an extremely poor prognosis, with a 
median survival of less than 1 year. Therefore, the need to understand how pVHL normally effects 
its tumour suppressor activity is essential if we are to appreciate the pathological consequence of 
its mutational deregulation and subsequent role in tumourigenesis. This review details the 
advances that have been made in this regard, and addresses questions that remain to be answered. 
 
Functional analysis of pVHL  
The VHL gene located on chromosome 3p25-p26 [80, 147] encodes a single 4.7 kb mRNA which 
gives rise to two protein products; a polypeptide of 213 amino acids (pVHL30) and, resulting from 
internal initiation of translation, a second polypeptide of 180 amino acids (pVHL19) [102, 120]. 
VHL mRNA and protein are ubiquitously expressed [94] [95] [90] [3], implying that tissue-
specific expression cannot account for the complex tumour pattern observed in VHL disease. 
pVHL30 is distinguished from pVHL19 by the presence of eight acidic N-terminal pentameric 
amino acid repeats. Both protein products are detected in vivo.  While the functional distinction 
between pVHL30 and pVHL19 remains elusive to date, they have been shown to exhibit different 
sub-cellular localisations in that pVHL19 is predominantly nuclear, while pVHL30 localises to both 
nuclear and cytoplasmic compartments, and when cytoplasmic, can associate with the microtubule 
network [107]. This implies that functional differences may exist. Noteworthy, all known 
inactivating mutations reside within a region of the VHL gene common to both protein products, 
arguing that the development of VHL tumours may require simultaneous inactivation of both 
pVHL30− and pVHL19−associated functions. VHL knockout studies in mice revealed an essential 
role for pVHL in development [261]. Homozygous VHL-/- embryos die between E10.5 to E12.5 
due to lack of placental vasculogenesis. Furthermore, efforts to develop in vivo models of VHL 
disease have shown that VHL+/- heterozygote mice develop blood vessel tumours of the liver [269] 
and further studies have also confirmed the finding that VHL heterozygosity could predispose 
mice to a vascular phenotype which appears consistent with the ability of pVHL to control the 
CHAPTER 8 – Discussion and Future Perspective 
 181
expression of genes whose products participate in angiogenesis, a critical stage in tumour 
progression [5, 272]. 
 
The most established function of pVHL to date has been as a substrate recognition 
component of an E3 ubiquitin protein ligase complex comprising pVHL, Elongin C, Elongin B, 
Cullin 2 and the RING finger protein, Rbx1, referred to as the VCB-Cul2 complex [184, 185]. In 
this setting, pVHL targets the α-subunits of HIF for ubiquitin-mediated proteolysis under normal 
oxygen conditions [114]. This suppresses a transcription programme normally engaged by HIF as 
part of the cell’s adaptive response to low oxygen (hypoxia) such as the activation of vascular 
endothelial growth factor (VEGF), a potent angiogenic factor [401] [20]. The stabilisation of HIF 
in response to hypoxia involves the inactivation of prolylhydroxylases that modify HIF at specific 
proline residues in an oxygen-dependent manner. Proline hydroxylation marks HIF for 
degradation by the VCB-Cul2 E3 ligase complex (Figure 3; Box 3). Noteworthy, naturally 
occurring mutations cluster in hotspots and predominantly affect elongin C and HIF-α interface 
regions of pVHL (see Figure 3) [109]; [2].  
 
While biochemical and genetic evidence clearly demonstrate that pVHL regulates HIFα 
degradation to mediate normal cellular responses to changing oxygen concentration, it remains 
unclear whether deregulation of HIFα has a causal role for tumour formation when VHL is 
mutated. Studies investigating the tumour growth of RCC cell lines in nude mouse models support 
the idea of HIF-dependent tumour suppressor activities of pVHL. Inhibition of HIF-2α expression 
by siRNA inhibits growth of VHL negative tumours [278], while re-introduction of a degradation-
resistant mutant of HIF-2α abolishes the ability of VHL to suppress growth of these cell lines 
[279]. While these studies display the importance of HIF-2α in the growth of established tumour 
cell lines in vivo, they do not demonstrate that deregulation of HIF degradation is sufficient to 
induce de novo tumour formation. Importantly, VHL ablation in mouse embryonic stem cells 
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results in smaller tumour formation than controls, in spite of displaying maximal HIF activity 
[280]. This observation suggests that loss of VHL may actually cause a growth disadvantage in an 
otherwise normal genetic background and implies that malignancies associated with inactivation 
of the VHL tumour suppressor may manifest only in the background of other genetic alterations, 
and are perhaps not solely attributable to loss of VHL. Therefore, in this setting, HIF activity 
alone is not capable of driving tumour progression. Furthermore, as already mentioned, while re-
introduction of VHL into RCC cells eliminated tumour growth, these cells are known to harbour 
alternative genetic abnormalities [121, 263, 281] . Defining molecular mechanisms with respect to 
VHL alone in an already effected background is therefore difficult and requires caution. 
Moreover, several lines of evidence suggest that VHL has HIF-independent tumour suppressor 
functions, namely, a subclass of VHL mutations that retain the ability to induce HIFα degradation 
still predispose to phaeochromocytoma-only (type 2C) VHL disease. These findings raise 
interesting questions as to whether VHL-related tumours are a consequence of aberrant VHL 
control of HIFα or rather a means of promoting growth advantage within a given genetic 
background.  
 
VHL as a multi-faceted tumour suppressor 
Development of malignancy requires that tumour cells undergo biological changes allowing them 
to proliferate, escape apoptosis, form new blood supplies, invade surrounding tissue and 
metastasise to distant sites. Recent evidence now suggest that VHL loss-of-function results in the 
deregulation of a number of signalling pathways that play key roles in one or more of the above-
noted biological processes.  
 
A number of polypeptide growth factors that stimulate proliferation of normal cells have 
pathological consequences in tumourigenesis when deregulated.  RCC cells lacking functional 
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pVHL over-express various growth factors including PDGFβ, VEGF and transforming growth 
factor (TGF)-α. The latter is a bona fide renal cell mitogen that activates the Ras-Raf-MAP kinase 
signalling cascade through its cognate EGF cell-surface receptor [301]. Overproduction of TGF-α 
in RCC cells, at least in part, is HIF-dependent and a major contributory event that confers growth 
advantage to these cells [302, 303]. Indeed, transgenic expression of TGF-α in mice leads to the 
formation of multiple renal cysts reminiscent of pre-neoplastic lesions of the human kidney [33, 
304, 305]. These findings highlight a direct link between pVHL loss-of-function, activation of 
HIF and the ensuing deregulated production of a potent growth factor of renal epithelial cells.  
 
Several studies have associated loss of VHL function to decreased susceptibility of cells to 
undergo apoptosis and promote cell survival [200, 236, 306, 307]. Interestingly, while the 
molecular pathway(s) is unclear, tumour necrosis factor (TNF)-α has been shown to promote HIF-
1α accumulation and this may involve a VHL-dependent step [308-311]. TNF-α, a pro-
inflammatory cytokine, is an endogenous mediator of inflammation and apoptotic cell death 
[312]. Jung et al. recently investigated TNF-α-induced HIF-1α accumulation and demonstrated 
that an NFκB-mediated event normally associated with inflammation and cell survival, caused 
protein accumulation in normoxic cells [313]. While the report fails to identify the mechanism of 
HIF-1α accumulation, it is suggested that this might interfere with the pVHL-mediated HIF-1α 
degradation process. Further studies support the concept of a pVHL-dependent cytotoxicity in 
RCC cells to TNF-α [314, 315]. In particular it has been reported that RCC cells can be sensitised 
to TNF-α induced cytotoxicity by re-introducing wild-type VHL [315]. Interestingly, the authors 
highlight the fact that TNF-receptor engagement by TNF-α triggers the activation of atypical PKC 
(aPKC), which, through phosphorylation of IKKβ phosphorylation, liberates NFκB thereby 
initiating transcription of genes involved in apoptosis. pVHL has been shown to directly bind 
various aPKC isoforms and to target aPKCλ for ubiquitin-mediated degradation [245, 316]. 
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Deregulation of this process may therefore have significant impact on NFκB transcriptional 
activity, and ultimately represents a means of promoting a selective pressure for populations of 
cells lacking functional pVHL to survive under adverse environmental conditions. 
pVHL has also been implicated in tumour invasion and metastasis, which represent 
complex multi-step processes requiring the proteolytic degradation of the basement membrane and 
tissue matrix, changes in cell polarity and motility, and the attachment and detachment of cells to 
extracellular matrix (ECM) [283]; [284]. pVHL-dependent remodelling of the ECM can be 
inferred by its link to fibronectin [318]. Fibronectin has the ability to decrease the metastatic 
behaviour of malignant cells by increasing the interaction between tumour cells and their micro-
environment via the integrin receptor family [319]. Several reports have demonstrated that 
inactivation of pVHL tumour suppressor function is linked to abnormal extra-cellular fibronectin 
arrays in RCC cells lacking functional pVHL and in VHL-/- mouse fibroblasts [134]; [320]; [250]; 
[402]. However, the exact nature of such an association and the mechanism by which VHL 
regulates the assembly of this ECM remain poorly understood. Nevertheless, the restored ability 
of pVHL-positive transfectants to assemble extracellular fibronectin was shown to be mediated by 
β1 integrins implying that pVHL controls ECM assembly, at least in part, via integrin signalling 
[250]. A recent development has demonstrated that an ubiquitin-like molecule, NEDD8, 
covalently modifies pVHL, and that a non-neddylateable pVHL mutant, while retaining its ability 
to degrade HIF, fails to promote the assembly of a fibronectin matrix. Furthermore, expression of 
the neddylation defective pVHL in RCC cells, while restoring the regulation of HIF, was 
insufficient to suppress the formation of tumours in nude mice models. These results suggest an 
important role for NEDD8 modification of pVHL in the assembly of a fibronectin matrix, and that 
in this context HIF control is not sufficient to prevent VHL-associated tumourigenesis. 
 
Emerging evidence indicates an inhibitory role for pVHL in the regulation of components 
that have been implicated in establishing/maintaining cell polarity and directed cell migration, in 
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particular protein kinase C (PKC) isoforms. Regulation of insulin growth factor (IGF)-I-mediated 
cell invasion of RCC cells appears to be dependent upon PKCδ inhibition by pVHL. This 
inhibition is mediated through protein-protein interaction involving a domain of pVHL which 
shows similarity to protein kinase inhibitor (PKI), a natural inhibitor of cAMP-dependent protein 
kinase (PKA) [322]. In contrast to protein-binding inhibition, evidence has shown that pVHL 
binds both atypical PKC isoforms λ and ζ through it’s β-domain, and in the case of activated 
aPKCλ, mediates it’s turnover as part of pVHL’s function as an E3 ligase [245, 316]. While the 
functional significance of this inhibition remains elusive, given the central role for atypical 
PKC’s, namely aPKCζ, in establishing cell polarity in conjunction with PAR6 and the GTPase 
CDC42 [323], one could envisage a scenario whereby loss of pVHL leads to altered cell polarity, 
and by extension, aberrant cell migration.  
 
Consistent with this above-noted view, pVHL30 has been shown to co-localise with the 
microtubule network in vivo and to promote microtubule stabilisation [107]. Since microtubule 
dynamics have been intimately linked to the process of directed cell migration [323], this 
functional association may be an additional element of pVHL’s tumour suppressing activity. 
Indeed, the microtubule stabilising function of pVHL is specifically disrupted by type 2A disease 
mutants that predispose to a defined tumour spectrum of haemangioblastoma and 
phaeochromocytoma with a low predisposition to develop RCC. It is certainly tempting to draw 
parallels between the tumour suppressor pathways regulated by pVHL and that by the 
adenomatosis polyposis tumour suppressor (APC) gene product, whose inactivation is the most 
frequently observed in hereditary and sporadic colon cancers [324]. Analogous to VHL, APC also 
binds to microtubules [323], and it has been shown that for APC this association culminates in 
cytoskeletal rearrangements and changes in cell polarity upon activation of the CDC42-PAR6-
aPKCζ pathway. Studies aimed at pVHL’s role with respect to cell polarity and directed cell 
migration are therefore clearly warranted.  
CHAPTER 8 – Discussion and Future Perspective 
 186
 
Recently, important mediators of cell invasion and metastasis were shown to be regulated 
by the pVHL tumour suppressor and these include hepatocyte growth factor (HGF) acting through 
the Met tyrosine kinase receptor and the chemokine receptor CXCR4, implicated in organ-specific 
metastasis [136, 321]. Koochekpour et al. examined the HGF responsiveness of VHL-negative 
RCC cells and found that certain VHL-negative RCC cells were highly invasive and exhibited an 
extensive branching morphogenesis phenotype in response to HGF when compared to their wt-
VHL expressing isogenic counterparts [136]. This same study demonstrated that VHL loss-of-
function negatively regulates tissue inhibitor of metalloproteinase 2 (TIMP-2), resulting in the up-
regulation of matrix metalloproteinases 2 and 9 (MMP2/9), thereby implicating pVHL in the 
control of these molecules. Matrix metalloproteinases (MMPs) are responsible for the degradation 
of ECM and have been associated with cellular invasiveness [330]. Importantly, it has been 
recently shown that hypoxia promotes tumour cell invasion by inducing the expression of the Met 
receptor [331]. This establishes a mechanism whereby transformed cells can be spurred to exit a 
hypoxic microenvironment and invade surrounding tissues, which provide more favourable 
growth conditions. Given the fact that HIF-1α has been shown to be involved in Met gene 
expression, constitutive HIF-1α activation as a consequence of pVHL deregulation provides a 
mechanism explaining the observation that expression of HGF and Met receptor is associated with 
genetic alterations of VHL in primary RCC. Hypoxic cell-sensitisation to HGF has therefore been 
proposed as an ‘invasive switch’ which facilitates cell movement away from an area of low 
oxygen availability, and is dependent on pVHL’s ability to degrade HIFα. 
 
The gene encoding the chemokine receptor CXCR4 has been discovered as a novel HIF 
target based on microarray comparison of genetic profiles derived from VHL null RCC cells and 
their isogenic wild type VHL-expressing counterparts [321]. CXCR4 has been previously 
implicated in directing malignant breast cancer cells to specific target organs, thereby fulfilling 
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the chemoattraction theory of tumour metastasis [6] [332]. Interestingly, CXCR4 is highly 
expressed in malignant breast cancer cells but not in normal breast epithelial cells [6]. The fact 
that CXCR4 is a hypoxia-inducible gene provided a potential mechanistic explanation for CXCR4 
up-regulation during tumour cell evolution. CXCR4-induced surface expression due to VHL loss-
of-function confers enhanced migratory potential to RCC cells in response to its cognate ligand 
stromal-derived factor 1  (SDF1). In addition, CXCR4 might be needed to promote the survival of 
tumour cells in a hypoxic environment. Thus, the ability of a cell to generate genetic programmes 
capable of evading unfavourable growth conditions is reflected at least in part by the up-
regulation of CXCR4 in response to a hypoxic microenvironment. However, unlike the Met 
receptor, and perhaps other hypoxic responsive factors that promote cell motility and invasion, 
CXCR4, due to its chemotactic responsiveness to SDF1, might confer not only a migratory 
potential but also the possibility of targeting migrating cells to specific secondary sites.  
Interestingly, strong CXCR4 expression can be correlated to poor tumour-specific survival in 
clear cell RCC, reflecting the metastatic potential of these tumours. This further implies that 
CXCR4 expression levels may influence the metastatic behaviour of these cells. The question 
remains however, whether CXCR4 up-regulation is a result of a cell’s ability to metastasise, or 
whether this up-regulation itself primes the cell to metastasise. What ever this may represent, a 
cell’s ability to migrate to specific target sites may therefore be determined, in part, by loss of 
VHL, suggesting that these cells may be primed from an early stage to spread to other sites in the 
body. CXCR4 could represent a novel target site for therapeutic intervention in the prevention of 
cancer metastasis, the major cause of death in RCC patients and of many other solid tumours. 
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Concluding Remarks 
Research to date shows that pVHL functions in the correct orchestration of cell proliferation, 
survival and angiogenesis through the control of the HIF pathway. However, VHL has also been 
linked to the regulation of cell polarity and directed cell migration in part through its association 
with aPKC and the microtubule network. Finally, intimate mechanistic linkages have been 
established between loss-of-function of pVHL and the processes of invasion and metastasis. Thus, 
a deeper appreciation of the many aspects of VHL biology and their deregulation within a 
pathological setting will help us to understand the molecular details pertaining to these pathways 
and key processes of the cancer phenotype. 
Figure 4. The role of HIF in conferring tumour growth potential. In solid tumours, HIFα is stabilised under 
conditions of low oxygen due to lack of vascularisation and the subsequent evolution of a hypoxic 
microenvironment. In a VHL null tumour, HIFα is constitutively active, and can initiate genetic programmes 
within the entire population of cells that would normally be activated only under hypoxic conditions. 
Inappropriate up-regulation of genes is, in the case of VHL null tumours, independent of oxygen status. This 
may help explain, in part, why VHL-/- RCC exhibits an aggressive phenotype. 
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Part II 
Discussion and Future Perspectives 
 
The identification of novel pVHL interactions helps us to understand the physiological 
role of pVHL and allows us to propose models of how inappropriate pVHL function can 
result in a pathological consequence.  Part I of chapter 7 outlined a novel approach for 
identifying pVHL interactions. By immuno-precipitating endogenous pVHL on a large 
scale, followed by proteomic identification of co-precipitating proteins, new pVHL 
interactions have been isolated. This section briefly discusses the proteins found in this 
proteomics approach, the results obtained to date, and future perspectives concerning 
these interactions. 
 
8.1 p97 in HIF regulation 
 
The finding that pVHL interacts with a member of the AAA ATPase family, p97, 
has highlighted the importance of energy dependency in pVHL mediated events. This is 
not the first evidence that an ATPase can bind an E3 ubiquitin ligase. In yeast, it has 
recently been shown that UBR1 and UFD4, two E3 ubiquitin ligases of Saccharomyces 
Cerevisiae, interact with RPT4 and RPT6, two ATPases of the 19S proteasome [403]. 
The data presented in this thesis provide evidence for an endogenous interaction 
between a component of an E3 ubiquitin ligase, pVHL, and an ATPase, which can 
associate with the 26S proteasome in mammalian cells in vivo, p97. Interestingly, during 
the course of this work, another already mentioned study emerged demonstrating the 
interaction of an ATPase with a component of an E3 ubiquitin ligase, namely Tat-binding 
protein-1 with pVHL. This study has demonstrated the importance of an energy 
dependent chaperone activity that facilitates Hif-1α presentation to the proteasome and 
subsequent proteolytic degradation. This study supports a concept whereby p97, an 
ATPase of the same family as TBP-1, may participate in a similar process to ensure 
efficient Hif-α degradation in normoxic cells.  
 
Although reduction in p97 expression using siRNA did not result in detectable 
levels of Hif-1α, there are three possible explanations for this. First, despite the efficacy 
of the p97 siRNA, it was only possible to achieve a partial knockdown of p97 expression. 
This is probably due to variable transfection efficiencies for the RNAi oligo in different cell 
lines or the partial efficiency of siRNA to completely inhibit p97 expression. Therefore, in 
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assays for Hif-1α degradation in cells treated with p97 siRNA, there was always some 
residual p97 present in the cell. The presence of even low levels of endogenous wild-
type p97 might also explain why over-expression of p97QQ, an ATPase mutant p97, did 
not result in elevated levels of Hif-1α in normoxia. Therefore, it is predicted that a cell line 
with a complete knockout of p97 (as with a somatic knockout or embryonic stem cell 
knockout) might show higher normoxic levels of Hif-1α than observed with cells having 
only a partial knockout of p97 using siRNA. Second, other proteins besides p97 might 
regulate the pVHL-mediated degradation of Hif-1α. Certainly the presence or absence of 
pVHL is the most important factor for clearing Hif-1α, as p97 does not promote Hif1α 
degradation in pVHL-deficient cells. The possibility of additional chaperones implies that 
even with a complete loss of p97, pVHL might still be able to degrade Hif1α, albeit less 
efficiently. Certainly in light of the finding that TBP-1 facilitates Hif-1α degradation, it 
seems that there may be various energy-dependent chaperone-like proteins with similar 
functions. The third reason, and something under active investigation, is that unlike TBP-
1, p97 functions seem to be dictated according to the adaptor protein(s) that it complexes 
with. We have already discussed in chapter 7 that p47 directs p97 to act in the post-
mitotic fusion of Golgi membranes. Furthermore other accessory components, namely a 
complex of Ufd1-Npl4, have been shown to direct p97 to function in the retrotranslocation 
pathway. In yeast, the Cdc48-Ufd1-Npl4 complex has been shown to move poly-
ubiquitinated polypeptides from the ER membrane into the cytosol for their subsequent 
degradation by the proteasome. Given the fact that adaptor proteins direct p97 function, 
it seems logical that targeting these proteins by RNAi may render more telling results 
than p97 itself because p97 is so abundant, representing some 1% of the total cytosol 
making efficient depletion by RNAi difficult. Further experimentation is required to 
investigate the role of Ufd1 and Npl4 in the process of Hif-α degradation, and current 
work involves the targeting of both of these adapter proteins by siRNA in an attempt to 
up-regulate Hif-α in normoxic cells. 
 
It remains to be seen upon re-oxygenation after hypoxic stress, whether the 
pVHL-p97 interaction can be enhanced, and also whether other ligase components co-
precipitate with p97. This would further support a role for p97 involvement in Hif-α 
degradation. It would also be very interesting to reinvestigate the kinetics of p97 
degradation following endogenous depletion of Ufd1 and/or Npl4. Evidence that these 
proteins might interfere with Hif-α degradation would further implicate p97 in Hif-α 
regulation. Taken together, it seems plausible that aberrations in the pVHL-p97 
interaction may provide a novel mechanism for Hif-1α stabilisation in some pVHL-
deficient tumours and further define a role for derangements of proteasome function in 
human cancer. A simplified model of the involvement of p97 in Hifα degradation is 
schematically depicted in figure 90. 
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8.2 p97 and the malfolded protein response 
 
p97 has also been shown to be involved in 
retrotranslocation of proteins form the ER. 
Newly synthesised proteins in the ER of 
eukaryotic cells are subject to rigorous quality 
control, which consists of a sophisticated 
protein proofreading and elimination 
mechanism. When misfolded or improperly 
assembled proteins emerge in the lumen of the 
ER, they are exported back to the cytosolic side 
of the ER (an event called retrotranslocation), 
conjugated with poly-ubiquitin and subsequently 
degraded by the 26S proteasome (Fig.91). This 
process, named ERAD (ER-associated 
degradation), is capable of destroying both 
Figure 90. Proposed model for p97 involvement in pVHL-mediated Hifα proteolytic degradation. Endogenous 
p97 interacts with pVHL and ubiquitin, and this interaction may facilitate a p97 interaction with ubiquitinated and 
modified Hifα. In a fashion analogous to TBP-1, an energy dependent step might allow p97 to chaperone Hifα to the 
proteosome where it is subsequently degraded. Unlike TBP-1 however, adapter proteins may facilitate p97 
recognition of modified and ubiquitinated Hifα. Identification of these species would prove important. 
Figure 91. p97 involvement in ER associated 
degradation (ERAD). A misfolded polypeptide is 
poly-ubiquitinated and retrotranslocated to the 
cytosolic side of the ER where it is recognised by 
p97 (yellow). This interaction then facilitates the 
poly-ubiquitinated (red) misfolded polypeptide to be 
presented to the proteasome in an ATP-dependent 
manner for subsequent degradation.  
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integral membrane proteins and lumenal proteins. In the past, a series of efforts have 
shown that p97 is required in ERAD and acts as a molecular chaperone that extracts the 
ubiquitinated proteins from the ER membrane before their final degradation by the 
proteasome [347, 349, 350, 363, 364, 404].  This may, at least in part, explain the 
accumulation of ubiquitinated proteins when p97 is inactivated [347]. This is interesting 
for two reasons. Firstly, RCC cells lacking functional pVHL exhibit deposition of misfolded 
fibronectin resulting in an aberrant fibronectin matrix assembly. This inappropriate 
deposition is corrected upon reintroduction of wild-type, but not mutant, pVHL [134]. It 
would seem therefore, at least in the case of fibronectin, pVHL might also be involved in 
protein proofreading and the misfolded protein response. Secondly, as already 
mentioned in section 7.4.4.5, pVHL has been shown to bind HDAC6, albeit in vitro. 
HDAC6 has been shown to be a component of the aggresome and exhibits the capacity 
to bind both poly-ubiquitinated misfolded proteins and dynein motors, thereby acting to 
recruit misfolded protein cargo to dynein motors for transport to aggresomes [375]. 
Indeed, cells deficient in HDAC6 fail to clear misfolded protein aggregates from the 
cytoplasm, cannot form aggresomes properly, and are hypersensitive to the 
accumulation of misfolded proteins. These findings identify HDAC6 as a crucial player in 
the cellular management of misfolded protein-induced stress. For these reasons, a role 
for pVHL, HDAC6 and p97 in the context of controlling protein folding seems plausible 
and merits further attention. As no yeast VHL homologue exists, it is difficult to 
investigate as most studies to date regarding retrotranslocation and ERAD have been 
performed in yeast. Nonetheless, targeted inactivation of p97 and/or HDAC6 in RCC 
cells with and without re-introduced wild-type VHL could offer some interesting insights. 
For example, it would be interesting to see whether the restored extracellular fibronectin 
matrix assembly observed when wild-type VHL is re-introduced in 786-0 cells can be 
reversed upon inactivation of p97 and/or HDAC6 in these cells by RNAi or introduction of 
a dominant-negative version of either protein. This would clearly indicate that they are 
functioning together in a pathway that facilitates deposition of correctly folded fibronectin, 
and that aberrations in this interaction may account for the incorrect extracellular matrix 
assembly, a characteristic of cancer cells, and an event which facilitates tumour invasion 
and metastasis. 
 
8.3 A potential role for pVHL in the critical methylation of tRNAimet 
 
In addition to p97, the novel proteomics approach to find new pVHL interactions identified 
a protein complex which demonstrates structural homology to the yeast tRNA (1-
methyladenosine) methyltransferase, Gcd10p/Gcd14p. This finding would be the first 
evidence linking pVHL to RNA methylation activity. The consequence, if any, of this 
interaction is unclear, though in vitro and in vivo evidence demonstrate that the complex 
forms, and that pVHL binds this complex in mammalian cells. In collaboration with 
another doctoral student, P.Ballschmieter, efforts are currently being made to investigate 
whether this homologous human complex is capable of exhibiting methyltransferase 
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activity as has already been shown for Gcd10p/Gcd14p in the critical methylation event 
at position 58 in the TΨC loop of yeast initiator methionine tRNA. With both components 
cloned and antibodies raised against them, it is now possible to address the question of 
whether this mammalian complex can exhibit methyltransferase activity, and whether it is 
the true mammalian orthologue of Gcd10p/Gcd14p. If this is the case, it will be 
interesting to investigate the effect that naturally occurring mutants of pVHL might have 
on this activity. Such functional studies may expose a sub-class of VHL mutants that 
could be linked to a particular VHL disease type. Efforts are being made to investigate 
whether other VCB-Cul2 ligase components co-precipitate with the complex, which might 
indicate whether this potential methyltransferase is targeted by pVHL for proteolytic 
degradation.  However, sequence analysis has revealed no evidence in either protein 
that might suggest that either could be bound by pVHL in a manner similar to Hifα. 
 
One problem that remains unclear for the yeast Gcd10p/GCD14p is how this 
complex exercises substrate specificity. All yeast tRNAs where the sequence has been 
determined contain adenine at position 58, but only 21 of 32 sequenced tRNAs contain 
m1A (methyladenosine) at this position [380]. Thus, it is important to determine how the 
Gcd10p/Gcd14p complex discriminates against the subset of tRNAs that lack m1A. One 
suggestion is that Gcd10p specifically binds only those nascent tRNA transcripts 
destined for m1A methylation and presents them to Gcd14p for modification. An 
alternative possibility is that Gcd10p contributes only non-specific RNA binding affinity to 
the complex and that Gcd14p imposes tRNA-substrate specificity at the step of methyl 
group transfer. This would be akin to certain aminoacyl-tRNA synthetases that 
distinguish cognate from noncognate tRNAs primarily at the catalytic step rather than at 
the tRNA binding step [405]. In mammalian cells however, it is tempting to suggest that 
substrate specificity might be conferred by pVHL, which through its interaction with the 
methyltransferase complex, facilitates specific substrate methylation. This is purely 
speculative, and no evidence exists which suggests that pVHL can exhibit any RNA 
binding ability, but a theory certainly interesting to test. 
 
Protein kinases that phosphorylate the alpha subunit of eukaryotic initiation factor 
2 (eIF2α) are activated in stressed cells and negatively regulate protein synthesis. 
Phenotypic analysis of targeted mutations in murine cells reveals a novel role for eIF2α 
kinases in regulating gene expression in the malfolded protein response and in amino 
acid starved cells. When activated by their cognate upstream stress signals, the 
mammalian eIF2 kinases PERK and GCN2 repress translation of most mRNAs but 
selectively increase translation of Activating Transcription Factor 4 (ATF4), resulting in 
the induction of the downstream gene CHOP (GADD153) (Fig.92). This is the first 
example of a mammalian signalling pathway homologous to the well studied yeast 
general control response in which eIF2α phosphorylation activates the transcriptional 
activator GCN4 whose translation in yeast has been shown to be increased upon amino 
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acid starvation resulting in transactivation of many genes involved in amino acid 
biosynthesis. Mammalian cells thus utilise an ancient pathway to regulate gene 
expression in response to diverse stress signals [406]. Interestingly, Gcd10p and Gcd14p 
were first identified genetically as repressors of GCN4 mRNA translation in S.Cerevisiae, 
linking this complex to a general stress control pathway, which seems to be conserved in 
mammalian cells. [377]. 
 
Hypoxia profoundly influences tumour development and response to therapy. 
While progress has been made in identifying individual gene products whose synthesis is 
altered under hypoxia, little is known about the mechanism by which hypoxia induces a 
global down-regulation of protein synthesis. A critical step in the regulation of protein 
synthesis in response to stress is the phosphorylation of translation initiation factor eIF2α 
on Ser51, which leads to inhibition of new protein synthesis. Koumenis et al. reported 
that exposure of human diploid fibroblasts and transformed cells to hypoxia led to 
phosphorylation of eIF2α, a modification that was readily reversed upon reoxygenation 
[407]. Expression of a transdominant, nonphosphorylatable mutant allele of eIF2α 
attenuated the repression of protein synthesis under hypoxia. The endoplasmic reticulum 
(ER)-resident eIF2α kinase PERK was hyperphosphorylated upon hypoxic stress, and 
overexpression of wild-type PERK increased the levels of hypoxia-induced 
phosphorylation of eIF2α. Cells stably expressing a dominant-negative PERK allele and 
mouse embryonic fibroblasts with a homozygous deletion of PERK exhibited attenuated 
phosphorylation of eIF2α and reduced inhibition of protein synthesis in response to 
Figure 92. Comparison of genes in the yeast general control response and the homologous mammalian 
stress response pathway described in the text. The mode by which each gene is regulated is indicated in 
parenthesis. PEPCK refers to gluconeogenic enzyme phosphoenolpyruvate carboxykinase, activated by ATF4. 
HIS3 is representative of the genes activated by yeast Gcn4p. 
Adapted from Harding et al. 2000 
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hypoxia. PERK-/- mouse embryo fibroblasts failed to phosphorylate eIF2α and exhibited 
lower survival after prolonged exposure to hypoxia than did wild-type fibroblasts. These 
results indicate that adaptation of cells to hypoxic stress requires activation of PERK and 
phosphorylation of eIF2α and suggest that the mechanism of hypoxia-induced 
translational attenuation may be linked to ER stress and the malfolded-protein response. 
 
We have already seen in chapter 7, part II, that stress signals can render pVHL 
intra-cellular localisation changes. It seems therefore that pVHL sub-cellular localisation 
can reflect the cellular microenvironment, and that under sub-optimal conditions, or 
conditions which induce a stress response, pVHL re-localises to the nucleus, an event 
exemplified by the fact that drug-induced disruption of microtubules causes pVHL30 to 
accumulate in the nucleus. Interestingly, the Gcd10p/Gcd14p complex has been shown 
to complex within the nucleus.  Also of interest is the fact that the ability of 786-0 cells to 
exit the cell cycle upon serum deprivation is achieved only when wild type-pVHL is 
reintroduced into these cells, further supporting a role for pVHL in nutrient signalling 
[137]. In a manner analogous to Gcd10p/Gcd14p inhibition of GCN4, one could envisage 
a scenario whereby, stress signalling which results in phophorylation of eIF2α, could 
render a nuclear accumulation of pVHL, which in turn would negatively regulate the 
methyltransferase complex (protein A/B complex) identified by proteomics, thereby 
relieving the inhibitory effect this complex might have on ATF4, the mammalian GCN4 
counterpart. While the link is of course tenuous, given the fact that pVHL is a central 
component of oxygen signalling, and that hypoxia results in activation of eIF2α, it is 
plausible to suggest a role of pVHL in the context of protein synthesis regulation within 
the mammalian stress-response pathway, and that this role could be to mediate a critical 
methyltransferase activity.  
 
Figure 93. Model proposed regarding the involvement of pVHL and Gcd10p/Gcd14p homologous 
complex (protein A/B complex) identified in a proteomics approach to identify novel pVHL interacting 
proteins. As Gcd10p/Gcd14p have been shown to repressGCN4 in yeast, an analogous situation is proposed 
for mammalian cells where pVHL functions to positively regulate ATF4 translation by suppressing the protein 
A/B complex upon appropriate stimuli. 
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Finally, given the fact that eIF2 has also been implicated in the malfolded protein 
response further implies a functional significance of pVHL involvement in this signalling 
cascade. Considering the involvement of p97 in retrotranslocation and ERAD, the role of 
HDAC6 in transport of malfolded proteins, and the fact that pVHL is involved in correctly 
folded fibronectin deposition, one must assume that pVHL’s role in the malfolded 
response is somewhat unappreciated. Current research in our laboratory is emerging 
that might suggest that post-translational modification of pVHL could be involved in 
regulating fibronectin deposition (Frew and Krek). Given the implications of an aberrant 
extracellular matrix assembly in tumour growth and progression clearly justifies further 
studies of pVHL in the malfolded protein response, and may be in part be explained by 
its potential role in the regulation of protein synthesis. 
 
 
8.4 pVHL intracellular dynamics 
 
Part II of chapter 7 demonstrated work which contributed to published data pertaining to 
the ability of pVHL30 to protect microtubules from depolymerisation (for further discussion 
please refer to Hergovich et al. 2003 [107]). The experiments demonstrated differential 
localisation of ectopically expressed GFPVHL30 and GFPVHL19, with GFPVHL30 residing 
predominantly in the cytoplasm, and GFPVHL19 in the nucleus. This observation was 
confirmed by endogenous localisation of pVHL30 to the cytoplasm. In addition, it was 
shown that cytoplasmic pVHL30 can associate with the microtubule network, disruption of 
which resulted in pVHL30 accumulating in the nucleus. It is believed that this translocation 
facilitates a more efficient, nuclear targeting of Hifα for proteolytic degradation following 
an hypoxic insult, or other, alternative signals that induce Hifα accumulation. This 
hypothesis is supported by literature that emerged during the course of this work [208, 
391]. 
 
Interestingly, Schraml et al. have investigated the relevance of nuclear and 
cytoplasmic VHL expression in renal carcinoma progression [408]. The authors observed 
that combined nuclear and cytoplasmic pVHL expression was associated with low 
histological grade, early tumour stage, and better prognosis, suggesting that the ability of 
pVHL to localise to both the nucleus and the cytoplasm may have potential relevance for 
the biological behaviour of clear-cell RCC. This is the first evidence linking VHL shuttling 
to a pathological consequence if deregulated. Taken together it seems plausible to 
suggest that pVHL30 localisation reflects its functional activity, and factors affecting the 
stability of the microtubule cytoskeleton result in intracellular alterations in pVHL30 
dynamics which, when deregulated, may result in a pathological phenotype. 
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8.5 VHL RNA interference 
 
Endogenous depletion of pVHL by RNAi rendered no HIF response, nor were the kinetics 
of Hifα degradation affected upon VHL siRNA treatment of cells. These results, as 
discussed in part III of chapter 7, might be explained in two ways. Either residual 
amounts of pVHL that remain following RNAi treatment are sufficient to regulate Hifα, or 
that compensatory mechanisms are activated upon pVHL depletion which target Hifα for 
degradation in the absence of pVHL. Given the importance of HIF control, the latter 
would not be surprising. Hifα regulation is known to be controlled at many levels (see 
chapter 4), and while pVHL is considered the principle ligase for Hifα, other means of 
Hifα regulation may be activated in the absence of pVHL. As mentioned in chapter 7, to 
date, no VHL RNAi has been published, and peers in the field have communicated 
similar results regarding Hifα status following VHL RNAi. Furthermore, while published 
VHL-/- MEFs have been shown to exhibit up-regulated Hifα levels, similar targeting of 
VHL by CRE-lox recombinase technology in our own laboratory, has not demonstrated 
any up-regulation in Hifα (Frew and Krek). It would seem therefore that the depletion of 
pVHL and the consequence this may have on Hifα is more complicated than thought. 
While VHL-/- tumours are highly vascularised owing, at least in part, to the HIF-induced 
up-regulation of potent angiogenic factors like VEGF, the discrepancy still remains with 
the fact that VHL-/- mice die due to a lack of placental vasculogenesis. If VHL RNAi is 
reflecting a similar situation as that observed for the trophoblast cells in VHL-/- mice, then 
this may represent a system that could be used to delineate the molecular mechanism 
underlying this embryonic lethality. 
 
Finally, confirmation of the role of pVHL in the phosphorylation status of cofilin has 
further implicated pVHL in cofilin-mediated cell shape changes and may help to explain 
the highly migratory phenotype of VHL-/- RCC cells. Lim kinase-1 (LIMK1) knockout mice 
have recently been developed in the laboratory (Sayi, Lehembre and Krek). As LIMK is 
the established kinase demonstrated to phosphorylate cofilin, and also a pVHL binding 
partner (Lisztwan and Krek, unpublished), these mice will prove important in studying the 
implication of pVHL in LIMK-cofilin mediated actin cytoskeleton rearrangements. 
 
 
8.6 Therapeutic intervention in VHL disease 
 
Current surgical techniques aim to reduce morbidity and mortality in VHL patients are 
limited in their effectiveness, and the generation of specific biological and/or chemical 
therapies for VHL tumours would be beneficial. This is the reason why understanding the 
molecular basis of VHL disease is so important. Experimental investigations like those 
outlined in this thesis, help to identify pathways in which the VHL tumour suppressor is 
implicated, and ultimately may expose areas of potential therapeutic intervention. 
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When considering therapeutic intervention in VHL disease, it is important to 
appreciate that VHL is a multi-functional tumour suppressor, resulting in a vast array of 
different cellular consequences. Interfering with one aspect of VHL biology, may 
therefore have more serious repercussions elsewhere. For this reason, it is suggested 
that therapeutic intervention should be devised to target several aspects involved in VHL 
disease. Box 20 outlines potential sites of therapeutic intervention, already being 
targeted in the clinics, or currently under investigation. 
 
 
 Clinical trials of specific VEGF inhibitors are underway in VHL patients with kidney 
and CNS tumours, and many other anti-angiogenic drugs are under evaluation in other 
cancer patients [45, 409, 410]. If effective, these might inhibit the growth of hypervascular 
VHL tumours. Attempts are also being made to develop gene therapy for treatment of 
VHL tumours (and sporadic RCC in which pVHL function has been lost), initially using 
recombinant adenovirus to express the normal VHL gene [411]. Such methods are in 
their infancy, but there is hope that further advances in understanding the function of the 
pVHL tumour suppressor will lead ultimately to effective therapies for the prevention or 
treatment of VHL tumours.  
Box 21. Sites for therapeutic consideration in VHL disease 
Negative regulation by VHL Examples of Inhibitors   Studies 
pHIFα Histone deacetylase inhibitors  Kim et al. 2001 
 Nitric oxide releasing compounds  Semenza et al. 2001
 Non-steroidal anti-inflammatory drugs Jones et al. 2002 
 
Growth factors + Receptors Synthetic antagonists 
e.g. VEGF e.g. SU5416    Aiello et al. 2002 
 
Additional receptor molecules Receptor signalling blockade 
- Integrin receptors e.g. β1-blocking antibodies   Esteban et al. 2002 
- Chemokine receptors e.g. CXCR4-blocking antibodies  Muller et al. 2001[6] 
- Cytokine receptors e.g. EGFR tyrosine kinase inhibitors  Sweeney et al. 2003 
- IGF1 receptor e.g. antisense IGF-IR oligonucleotides Chernicky et al. 2002
- aPKC  Isoform specific PKC inhibitors   Saraiva et al. 2003 
 e.g. xanthonolignoids     
  
 
Scatter factor signalling HGF competitor inhibitors   Kuba et al. 2000 
 
Metalloproteinases IGF-IR kinase inhibitor   Zhang et al. 2003 
 
Positive regulation by VHL Effector     Studies 
Re-introduction of VHL wild-type VHL    Kamada et al. 2001 
Introduction of VHL peptide  Residues 104-123    Datta et al. 2001 
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Concluding Remarks 
 
It is clear that inactivation of the VHL gene is a key event in the development of tumours 
in VHL disease and also in the development of a large proportion of sporadic tumours of 
the same tissue types as those found in this cancer syndrome. Wild-type pVHL has 
multiple interactions with other cellular proteins and elicits multiple effects on target 
genes. The major finding to date in VHL biology is the fact that pVHL constitutes an E3 
ligase and targets hypoxia inducible factor α for proteolytic degradation. This discovery 
has lead to a molecular mechanism that helps, at least in part, explain the role of pVHL in 
tumourigenesis. Loss of pVHL leads to increased levels of Hifα under normoxic 
conditions, resulting in over-expression of hypoxia-inducible genes such as VEGF. This 
is likely to be one of the key events that results in tumour growth. However, other pVHL 
functions also are important, most notably the role of pVHL in fibronectin assembly. 
Therefore, there is still considerable work to do to elucidate clearly the key functions of 
pVHL that are critical for tumour suppression. For example, little is known about how 
expression of VHL is regulated and experiments are needed to identify the transcription 
factors that control VHL mRNA expression. Similarly, analysis of pVHL is required to 
determine whether its levels are regulated under different conditions, and whether its 
function is controlled by post-translational modifications such as phosphorylation. Our 
laboratory is currently studying the significance of a potential post-translational 
modification of pVHL that may help explain its interaction with the microtubule network. 
Similar studies may also help clarify the role of pVHL in fibronectin deposition, a function 
believed to be independent from its HIF activity. 
 
Analysis of many different VHL mutations is under way to determine whether the 
different VHL phenotypes are related to the ability of the mutant proteins to retain certain 
protein-binding functions. Much of the research to date has concentrated on RCC 
(because of the availability of cell lines), but it is likely that there might be tissue-specific 
functions that relate to phaeochromocytoma, haemangioblastoma or other tumours 
related to VHL disease that have yet to be identified.  
 
Finally, continued efforts in delineating VHL biology and the pathological 
consequence of its deregulation are crucial if we are to understand the physiological 
function of the von Hippel-Lindau tumour suppressor, and its role in tumourigenesis. Only 
by detailing the molecular mechanism of VHL function can we begin to propose effective 
therapeutic strategies that could combat this life threatening condition and offer hope to 
those who suffer from VHL disease and VHL disease-related cancer. 
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